The invention is directed to physiologically active compounds of the general formula (Ix) [structure] and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Description

121 parts

›This application is entitled to the benefit of…

This application is entitled to the benefit of earlier filed French Application No. 0113868 filed Oct. 26, 2001, British Application No. 0206893.0 filed Mar. 22, 2002, British Application No. 0206895.5 filed Mar. 22, 2002, U.S. Provisional Application No. 60/395,060 filed Jul. 11, 2002, and U.S. Provisional Application No. 60/395,151 filed Jul. 11, 2002.

This invention is directed to benzimidazoles of formula (Ix), their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the protein kinases. Such protein kinases belong especially to the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2, VEGFR, ITK and SYK.

Protein kinases are a family of enzymes that participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the environment. In general, these kinases fall into several groups; those which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues and those which preferentially catalyse the phosphorylation of hydroxy groups of tyrosine residues [S. K. Hanks and T. Hunter, FASEB. J., 1995, 9, pages 576-596]. Such phosphorylations may greatly modify the function of the proteins; thus, protein kinases play an important role in regulating a wide variety of cell processes including, especially, metabolism, cell proliferation, cell differentiation or cell survival. Among the various cellular functions in which the activity of a kinase protein is involved, certain processes represent attractive targets for treating certain diseases. As an example, mention may be made especially of angiogenesis and the control of the cell cycle, in which kinase proteins can play an essential role. These processes are essential for the growth of solid tumours and also for other diseases.

Angiogenesis or the formation of new blood vessels by sprouting from the preexisting vasculature is of central importance for embryonic development and organogenesis. Should the need arise, the vascular system has the potential to generate a network of new vessels so as to maintain the correct functioning of the tissues and organs. Angiogenesis is a complex multistage process which includes activation, migration, proliferation and survival of endothelial cells. In adults, angiogenesis is fairly limited, appearing mainly only in the processes of repair after an injury or of vascularization of the endometrium. (Merenmies et al., Cell Growth & Differentiation, 8, 3-10, 1997). However, uncontrolled angiogenesis is found in certain pathologies such as retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration or cancer (solid tumours) (Folkman, Nature Med., 1, 27-31, 1995). The kinase proteins whose involvement it has been possible to demonstrate in the angiogenesis process include three members of the family of growth factor receptor tyrosine kinases: VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR, kinase insert domain receptor, or FLK-1), FGF-R (fibroblast growth factor receptor) and TEK (also known as Tie-2).

In conjunction with other systems, the Vascular Endothelial Growth Factor receptors (VEGFRs) transmit signals involved in the migration, proliferation and survival of endothelial cells. The family VEGFR includes VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR3 (Flt4). The receptor VEGF-R2, which is expressed only in the endothelial cells, binds to the angiogenic growth factor VEGF, and thus serves as a transduction signal mediator via the activation of its intracellular kinase domain. Thus, the direct inhibition of the kinase activity of VEGF-R2 makes it possible to reduce the phenomenon of angiogenesis in the presence of exogenous VEGF (Strawn et al., Cancer Research, 56, 3540-3545, 1996), this process being demonstrated especially with the aid of VEGF-R2 mutants (Millauer et al., Cancer Research, 56, 1615-1620, 1996). The VEGF-R2 receptor appears to have no other function in adults than that associated with the angiogenic activity of VEGF. Thus, a selective inhibitor of the kinase activity of VEGF-R2 should show only little toxicity.

In addition to this central role in the dynamic angiogenic process, recent results suggest that the expression of VEGF contributes towards the survival of tumoral cells after chemotherapy and radiotherapy, underlining the potential synergism of KDR inhibitors with other agents (Lee C. G., Heijn M. et al., (2000), Cancer Research, 60 (19), 5565-70). The KDR inhibitors thus especially constitute anti-angiogenic agents and such agents might be used as a first line treatment against the emergence or regrowth of malignant tumours. The inhibition or regulation of VEGFR-2 (KDR) thus provides a powerful new mechanism of action for the treatment of a large number of solid tumours.

Extensive studies in the field of tumor angiogenesis in the past two decades have identified a number of therapeutic targets including kinases, proteases and integrins resulting in the discovery of many new anti-angiogenic agents, including KDR inhibitors some of which are currently under clinical evaluation (Jekunen, et al Cancer Treatment Rev. 1997, 23, pages 263-286.).

The present patent application thus relates particularly to novel inhibitors of the VEGFR-2 (KDR) receptor that may be used especially for anti-angiogenic treatment in oncology.

The protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include for example, protein kinase C isoforms [A. C. Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cyclin-dependent kinases such as cdk2 [J. Pines, Trends in Biochemical Sciences, 1995, 18, pages 195-197]. The protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include membrane-spanning growth factor receptors such as the epidermal growth factor receptor [S. Iwashita and M. Kobayashi, Cellular Signalling, 1992, 4, pages 123-132], and cytosolic non-receptor kinases such as p56lck, p59fYn, ZAP-70 and csk kinases [C. Chan et. al., Ann. Rev. Immunol., 1994, 12, pages 555-592].

›Inappropriately high protein kinase activity has been implicated…

Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly, for example by failure of the proper control mechanisms for the kinase, related for example to mutation, over-expression or inappropriate activation of the enzyme; or by over- or underproduction of cytokines or growth factors also participating in the transduction of signals upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.

SYK (Spleen Tyrosine Kinase) is a 72-kDa cytoplasmic protein tyrosine kinase that is expressed in a variety of hematopoietic cells and is an essential element in several cascades that couple antigen receptors to cellular responses. Thus, SYK plays a pivotal role in signalling of the high affinity IgE receptor, FcεR1, in mast cells and in receptor antigen signalling in T and B lymphocytes. The signal transduction pathways present in mast, T and B cells have common features. The ligand binding domain of the receptor lacks intrinsic tyrosine kinase activity. However, they interact with transducing subunits that contain immunoreceptor tyrosine based activation motifs (ITAMs) [M. Reth, Nature, 1989, 338, pages 383-384]. These motifs are present in both the β and γ subunits of the FcεR1, in the ξ-subunit of the T cell receptor (TCR) and in the IgGα and IgG β subunits of the B cell receptor (BCR). [N. S. van Oers and A. Weiss, Seminars in Immunology, 1995, 7, pages 227-236] Upon binding of antigen and multimerization, the ITAM residues are phosphorylated by protein tyrosine kinases of the Src family. SYK belongs to a unique class of tyrosine kinases that have two tandem Src homology 2 (SH2) domains and a C terminal catalytic domain. These SH2 domains bind with high affinity to ITAMs and this SH2-mediated association of SYK with an activated receptor stimulates SYK kinase activity and localises SYK to the plasma membrane.

In SYK deficient mice, mast cell degranulation is inhibited, suggesting that this is an important target for the development of mast cell stabilising agents [P. S. Costello, Oncogene, 1996, 13, pages 2595-2605]. Similar studies have demonstrated a critical role for SYK in BCR and TCR signalling [A. M. Cheng, Nature, 1995, 378, pages 303-306, (1995) and D. H. Chu et al., Immunological Reviews, 1998, 165, pages 167-180]. SYK also appears to be involved in eosinophil survival in response to IL-5 and GM-CSF [S. Yousefi et al., J. Exp. Med., 1996, 183, pages 1407-1414]. Despite the key role of SYK in mast cell, BCR and T cell signalling, little is known about the mechanism by which SYK transmits downstream effectors. Two adaptor proteins, BLNK (B cell Linker protein, SLP-65) and SLP-76 have been shown to be substrates of SYK in B cells and mast cells respectively and have been postulated to interface SYK with downstream effectors [M. Ishiai et al., Immunity, 1999, 10, pages 117-125 and L. R. Hendricks-Taylor et al., J. Biol. Chem, 1997, 272, pages 1363-1367]. In addition SYK appears to play an important role in the CD40 signalling pathway, which plays an important role in B cell proliferation [M. Faris et al., J. Exp. Med., 1994, 179, pages 1923-1931].

SYK is further involved in the activation of platelets stimulated via the low-affinity IgG receptor (Fc gamma-RIIA) or stimulated by collagen [F. Yanaga et al., Biochem. J., 1995, 311, (Pt. 2) pages 471-478].

ITK, is a T cell specific tyrosine kinase of the Tec family that is required for normal Th2 function. Asthma is a disease characterised by increased Th2 cytokine production including IL-4. An inhibitor of ITK should therefore have an impact on disease progression in asthma through inhibition of Th2 cytokine production.

We have now found a novel group of benzimidazoles, which have valuable pharmaceutical properties, in particular, the ability to inhibit protein kinases, more particularly, the ability to inhibit the protein kinase SYK, the protein kinase KDR, the protein kinase tie2 or the protein kinase ITK.

Thus, in one aspect, the present invention is directed to pharmaceutical compositions comprising compounds of general formula (Ix):—

wherein, for the purposes of (Ix):—

X represents C—R 2 and W, Y and Z, which may be identical or different, represent CH or CR 3 ; or W represents CH, X represents N, Y represents CH or CR 3 , and Z represents CH or CR 3 ; or W represents N, X represents CH or CR 2 , Y represents CH and CR 3 , and Z represents CH or CR 3 ; or W represents N, X represents CH or CR 2 , Y represents N, and Z is CH or CR 3 ; or W represents N, X represents CH or CR 2 , Y represents CH or CR 3 , and Z represents N; or W represents N, X represents N, Y represents CH or CR 3 , and Z represents CH or CR 3 ; A 5 represents H or alkyl; R 1 represents aryl or heteroaryl, each optionally substituted by one or more groups selected from carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )SO 2 NY 1 Y 2 , —NY 1 Y 2 , —OR 4 , —OCF 2 H, —OCF 3 , —OC(═O)R 4 , —OC(═O)NY 1 Y 2 , —OS(O) n R 4 , —S(O) n R 4 , —S(O) n NY 1 Y 2 and —S(O) n OR 4 ; R 2 and R 3 are such that: R 2 and R 3 , which may be identical or different, represent H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —NY 1 Y 2 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )SO 2 NY 1 Y 2 , —OR 4 , —OCF 2 H, —OCF 3 , —OC(═O)R 4 , —OC(═O)NY 1 Y 2 , —S(O) n R 4 , —S(O) n NY 1 Y 2 or —S(O) n OR 4 ; or R 2 represents H, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —NY 1 Y 2 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )SO 2 NY 1 Y 2 , —OR 4 , —OCF 2 H, —OCF 3 , —OC(═O)R 4 , —OC(═O)NY 1 Y 2 , —S(O) n R 4 , —S(O) n NY 1 Y 2 or —S(O) n OR 4 and R 3 represents alkyl, haloalkyl, halogen and OR 6 ; or R 2 and R 3 groups on adjacent carbon atoms may form a 5- to 6-membered carbon-based ring containing one or more heteroatoms, which may be identical or different, chosen from O, N and S, and which may be optionally substituted by alkyl [examples include those where R 2 and R 3 form a group selected from —O—CH 2 —O—, —O—CH 2 —CH 2 —O—; —CH 2 —O—CH 2 —, —CH 2 —N(R 14 )—CH 2 —, —CH 2 —CH 2 —CH 2 —, —CH 2 —C(CH 3 ) 2 —CH 2 —, —CH 2 —O—CH 2 —CH 2 —, —CH 2 —N(R 14 )—CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —CH 2 —, —CH 2 —C(CH 3 ) 2 —CH 2 —CH 2 —, —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH— or —CH═CH—CH═N, in which R 14 is H or alkyl)]; R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each optionally substituted with one or more substituents selected from alkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, halo, hydroxy, hydroxyalkyl, —C(═O)NY 3 Y 4 , —C(═O)OR 6 , —N(R 6 )C(═O)NY 1 Y 2 , —NY 1 Y 2 , —OR 5 or alkyl substituted by —NY 3 Y 4 ; R 5 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R 6 is chosen from the values of R 5 ; n is zero or an integer 1 or 2; Y 1 and Y 2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, heterocycloalkylalkyl or alkyl optionally substituted by one or more groups selected from cyano, aryl, heteroaryl, hydroxy, —C(═O)OR 6 , —C(═O)NY 3 Y 4 , —NY 3 Y 4 or —OR 5 , or the group —NY 1 Y 2 may form a cyclic amine; Y 3 and Y 4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group —NY 3 Y 4 may form a cyclic amine; all the alkyl (or alk, which represents alkyl), alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino(NH—COalk), —C(═O)OR 6 , —C(═O)R 6 , hydroxyalkyl, carboxyalkyl, S(O) n -alk S(O) n —NH 2 , S(O) n —NH(alk), S(O) n —N(alk) 2 , CF 3 , OCF 3 , NO 2 , arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, —C(═O)—NY 3 Y 4 and NY 3 Y 4 radicals, the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH—C(O)R 5 ;

›and their corresponding N-oxides, and their prodrugs, and…

and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and their prodrugs, and their acid bioisosteres; together with one or more pharmaceutically acceptable carriers or excipients.

In another aspect, the invention concerns the compounds of formula (Ix) as defined above wherein R 1 is a pyrazolyl moiety

in which R 7 is hydrogen or alkyl, and R 8 and R 9 are independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )SO 2 NY 1 Y 2 , —NY 1 Y 2 , —OR 4 , —OC(═O)R 4 , —OC(═O)NY 1 Y 2 , —S(O) n R 4 and —S(O) 2 NY 1 Y 2 ; or R 8 and R 9 together with the carbon atoms to which they are attached form (i) a 5 to 8 membered carbocyclic ring optionally substituted by one or more carbocyclic ring substituents; (ii) a phenyl ring optionally substituted by one or more aryl group substituents; (iii) a 5 or 6 membered heteroaromatic ring in which one or more of the ring members is/are nitrogen, oxygen or sulfur (examples of such groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups) and which is optionally substituted by one or more groups selected from haloalkyl, hydroxy, halo, cyano, nitro, R 4 , —C(═O)NY 1 Y 2 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )SO 2 R 4 , —NY 1 Y 2 and —OR 5 ; or (iv) a 5 or 6 membered heterocyclic ring optionally substituted by alkyl or oxo, and containing a heteroatom-containing group selected from O, S, SO 2 , or NY 5 (where Y 5 is hydrogen, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 or —SO 2 R 4 ); but excluding the compounds: 2-(2H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-methyl-2H-pyrazol-3-yl)-1H-benzoimidazole; 5-methyl-6-[2-(2H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-[2-(2H-pyrazol-3-yl)-1H-benzoimidazol-4-yl]4,5-dihydro-2H-pyridazin-3-one; 3,5-bis(benzimidazol-2-yl)-1H-pyrazole; 5,6-dimethyl-2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 6-methyl-2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 5,6-dichloro-2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5-nitro-2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole-5-carboxylic acid; 2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5,6-dimethyl-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5-methyl-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 6-chloro-2-(5-methyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5-chloro-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; 5,6-dichloro-2-(5-phenyl-1H-pyrazole-3-yl)-1H-benzoimidazole; N-[2-(5-isoquinolin-4-yl-1H-indazol-3-yl)-3H-benzoimidazol-5-yl]-methanesulfonamide; 3-(1H-benzoimidazol-2-yl)-5-(1H-indazol-4-yl)-1H-indazole, 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-2-methoxyphenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-5-yl]isoquinoline; 4-{3-[6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-indazol-5-yl}-isoquinoline; 4-[3-(4-chloro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-isoquinoline; 4-[2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-phenol; 3-[5-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-[5-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-[5-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-1H-indazole; 3-(1H-benzoimidazol-2-yl)-5-phenyl-1H-indazole; 2-(4-bromo-1-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-tert-butyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 3-(1H-benzoimidazol-2-yl)-6-(3-methoxy-phenyl)-1H-indazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid; 5-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-2-hydroxy-benzoic acid methyl ester; 5-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-furan-2-carboxylic acid methyl ester; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-4-methoxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (5-hydroxy-1H-pyrazol-3-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-pyrazol-3-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (9H-purin-6-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid dimethylamide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-morpholin-4-yl-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyrazin-2-ylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid cyclohexylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-indazol-5-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-pyrrolidin-1-yl-methanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (1H-indazol-5-yl)-amide; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-[4-(furan-2-carbonyl)-piperazin-1-yl]-methanone; [3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-(4-methyl-piperazin-1-yl)-methanone; 1-{4-[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-piperazin-1-yl}-ethanone; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (6-methoxy-pyridin-3-yl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyridin-4-ylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (2-hydroxy-ethyl)-methyl-amide; 3-{[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-amino}-butyric acid ethyl ester; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-hydroxy-propyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid phenylamide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid pyridin-3-ylamide; 3-(6-methoxy-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-6-pyridin-4-yl-1H-indazole; 3-(5-chloro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5-fluoro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6-tert-butyl-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(6,7-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(5,6-difluoro-1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (3-fluoro-4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-2,3-dimethyl-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-2-methyl-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid (4-hydroxy-phenyl)-amide; 3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carboxylic acid cyclopropylamide; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-sulfonic acid amide; 4-[3-(6-dimethylamino-1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-carboxylic acid methylamide; 3-methoxy-4-{3-[6-(4-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-indazol-6-yl}-phenol; 2-[6-(4-hydroxy-2-methoxy-phenyl)-1H-indazol-3-yl]-3H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 4-[3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-2-methoxy-phenol; 3-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3,5-dimethyl-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-phenoxy-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-benzene-1,3-diol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-3-methoxy-phenol; 4-[3-(1H-benzoimidazol-2-yl)-1H-indazol-6-yl]-2-methoxy-phenol; N-{3-[3-(1H-benzoimidazol-2-yl)-1H-indazole-6-carbonyl]-phenyl}-benzamide; 6-[2-(1,5-dimethyl-1H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-[2-(1-methyl-1H-pyrazol-3-yl)-3H-benzoimidazol-5-yl]-4,5-dihydro-2H-pyridazin-3-one; 8-(1,5-dimethyl-1H-pyrazol-3-yl)-7H-purine; 2-(1,5-dimethyl-1H-pyrazol-3-yl)-1H-imidazo[4,5-b]pyridine and 2-(5-methyl-1H-pyrazol-3-yl)-1H-imidazo[4,5-b]pyridine.

›In the present specification, the term “compounds of…

In the present specification, the term “compounds of the invention”, and equivalent expressions, are meant to embrace compounds of general formula (Ix) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

As used above for compounds of formula (Ix), and throughout the description of the invention hereinafter, the following terms unless otherwise indicated, shall be understood to have the following meanings:—

“Patient” includes both human and other mammals.

“Acid bioisostere” means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986, 21, p283 “Bioisosterism In Drug Design”; Yun, Hwahak Sekye, 1993, 33, pages 576-579 “Application Of Bioisosterism To New Drug Design”; Zhao, Huaxue Tongbao, 1995, pages 34-38 “Bioisosteric Replacement And Development Of Lead Compounds In Drug Design”; Graham, Theochem, 1995, 343, pages 105-109 “Theoretical Studies Applied To Drug Design: ab initio Electronic Distributions In Bioisosteres”). Examples of suitable acid bioisosteres include: —C(═O)—NHOH, —C(═O)—CH 2 OH, —C(═O)—CH 2 SH, —C(═O)—NH—CN, sulfo, phosphono, alkylsulfonylcarbamoyl, tetrazolyl, arylsulfonylcarbamoyl, heteroarylsulfonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydoxy-1-methylpyrazolyl.

“Acyl” denotes a radical R—C(═O)— in which R represents a radical chosen from a hydrogen atom, linear or branched alkyl radicals containing not more than 6 carbon atoms; optionally substituted amino; aryl, heteroaryl, cycloalkyl or heterocycloalkyl radicals, for example phenyl or pyrrolidinyl radicals: the term “acyl” thus especially denotes, for example, formyl radicals and acetyl, propionyl, butanoyl, pentanoyl, hexanoyl, benzoyl and pyrrolidinylcarbonyl radicals.

“Acylamino” denotes —C(═O)—NH 2 , —C(O)—NH(alk) and —C(O)—N(alk)(alk) radicals: in these radicals, NH(alk) and N(alk)(alk) have the meanings given hereinafter defined.

“Alkenyl” means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain and containing one or more double bonds. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. “Branched,” as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. “Lower alkenyl” means about 2 to about 4 carbon atoms in the chain, which may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl, decenyl, and 3,7-dimethyl-octa-2,6-dienyl.

“Alkoxy” means an alkyl-O— group in which the alkyl group is as described herein. Exemplary alkoxy groups include difluoromethoxy, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, pentoxy, hexoxy and heptoxy, and also the linear or branched positional isomers thereof.

“Alkoxycarbonyl” means an alkyl-O—CO— group in which the alkyl group is as described herein. Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.

“Alkyl” means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched chain having about 1 to about 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. “Lower alkyl” as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be a straight or branched chain having 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl and dodecyl, and also the linear or branched positional isomers thereof. Exemplary alkyl groups substituted by one or more halogen atoms include trifluoromethyl, difluoromethyl, trifluoroethyl and difluoroethyl.

“Alkylene” means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.

“Alkylenedioxy” means an —O-alkylene-O— group in which alkylene is as defined above. Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.

“Alkylsulfinyl” means an alkyl-SO— group in which the alkyl group is as previously described. Preferred alkylsulfinyl groups are those in which the alkyl group is C 1-4 alkyl.

“Alkylsulfonyl” means an alkyl-SO 2 — group in which the alkyl group is as previously described. Preferred alkylsulfonyl groups are those in which the alkyl group is C 1-4 alkyl.

“Alkylsulfonylcarbamoyl” means an alkyl-SO 2 —NH—C(═O)— group in which the alkyl group is as previously described. Preferred alkylsulfonylcarbamoyl groups are those in which the alkyl group is C 1-4 alkyl.

“Alkylthio” means an alkyl-S— group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, hexylthio, isohexylthio and heptylthio, and also the linear or branched positional isomers thereof. Preferred alkylthio groups have not more than 4 carbon atoms.

›“Alkynyl” means an aliphatic hydrocarbon group containing a…

“Alkynyl” means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which group may be a straight or branched chain having about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.

“Aroyl” means an aryl-CO— group in which the aryl group is as described herein. Exemplary aroyl groups include-benzoyl and 1- and 2-naphthoyl.

“Aroylamino” is an aroyl-NH— group wherein aroyl is as previously defined.

“Aryl” as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which a monocyclic aromatic carbocyclic moiety and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Except where otherwise defined, aryl groups may be substituted with one or more aryl group substituents, which may be the same or different, where “aryl group substituent” includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, —C(═O)NY 1 Y 2 , —NY 1 —C(═O)alkyl, —NY 1 SO 2 alkyl, —NY 1 Y 2 , —SO 2 NY 1 Y 2 or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, —C(═O)OR 6 , —C(═O)NY 1 Y 2 , —NY 1 Y 2 or —OR 5 .

“Arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C 1-4 alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.

“Arylalkyloxy” means an arylalkyl-O— group in which the arylalkyl group is as previously described. Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.

“Arylalkyloxycarbonyl” means an arylalkyl-O—CO— group in which the arylalkyl group is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.

“Arylalkylthio” means an arylalkyl-S— group in which the arylalkyl group is as previously described. An exemplary arylalkylthio group is benzylthio.

“Aryloxy” means an aryl-O— group in which the aryl group is as previously described. Exemplary aryloxy groups include phenoxy and naphthoxy, each optionally substituted.

“Aryloxycarbonyl” means an aryl-O—C(═O)— group in which the aryl group is as previously described. Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

“Arylsulfinyl” means an aryl-SO— group in which the aryl group is as previously described.

“Arylsulfonyl” means an aryl-SO 2 — group in which the aryl group is as previously described.

“Arylsulfonylcarbamoyl” means an aryl-SO 2 —NH—C(═O)— group in which the aryl group is as previously described.

“Arylthio” means an aryl-S— group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio.

“Carbocyclic” means a saturated ring system comprising carbon atoms.

“Carbocyclic group substituent” includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, —C(═O)NY 1 Y 2 , —NY 1 —C(═O)alkyl, —NY 1 SO 2 alkyl, —NY 1 Y 2 , —SO 2 NY 1 Y 2 or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, —C(═O)OR 6 , —C(═O)NY 1 Y 2 , —NY 1 Y 2 or —OR 5 .

“Cyclic amine” means a 3 to 8 membered monocyclic cycloalkyl ring system wherein one of the ring carbon atoms is replaced by nitrogen and which (i) may also contain a further heteroatom-containing group selected from O, S, SO 2 , or NY 6 (where Y 6 is hydrogen, alkyl, aryl, arylalkyl, —C(═O)R 5 , —C(═O)OR 5 , —C(—O)NY 1 Y 2 or —SO 2 R 5 ); and (ii) may be fused to additional aryl (e.g. phenyl), heteroaryl (e.g. pyridyl), heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system. Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline, pyrindoline, tetrahydroquinoline and the like groups.

“Cycloalkenyl” means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl and cycloheptenyl.

“Cycloalkyl” means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms, optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C 3-8 cycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.

“Cycloalkylalkyl” means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

“Halo” or “halogen” means fluoro, chloro, bromo, or iodo. Preferred are fluoro, bromo and chloro.

“Haloalkyl” means an alkyl group having about 1 to about 6 carbon atoms in the chain and substituted by one or more halo atoms. Exemplary haloalkyl groups include trifluoromethyl.

›“Heteroaroyl” means a heteroaryl-C(═O)— group in which the…

“Heteroaroyl” means a heteroaryl-C(═O)— group in which the heteroaryl group is as described herein. Exemplary heteroaryl groups include pyridylcarbonyl.

“Heteroaroylamino” means a heteroaroyl-NH— group in which the heteroaryl moiety is as previously described.

“Heteroaryl” as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzoimidazolyl, benzothiazolyl, furyl, imidazolyl, indazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above except where otherwise defined); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a monocyclic heteroaromatic moiety and a cycloalkyl, cycloalkenyl or heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include tetrahydro-indazole, tetrahydro-pyrazolopyridine, 5-oxo-1,4,5,6,7,8,9,9a-octahydro-1,2,4,5a-tetraza-cyclopenta[a]naphthyl, optionally substituted by one or more “aryl group substituents” as defined above, except where otherwise defined). Optional substituents include one or more “aryl group substituents” as defined above, except where otherwise defined. When R 1 is heteroaryl this may particularly represent pyrazolyl, triazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, imidazolyl, pyrrolyl, furanyl, thiophenyl, phenyl, pyridinyl, oxodihydropyridinyl, pyrimidinyl, indolyl, indazolyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetahydropyridinopyrazolyl, or oxodihydropyridinopyrazolyl.

“Heteroarylalkyl” means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C 1-4 alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.

“Heteroarylalkyloxy” means an heteroarylalkyl-O— group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.

“Heteroaryloxy” means an heteroaryl-O— group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.

“Heteroarylsulfonylcarbamoyl” means a heteroaryl-SO 2 —NH—C(═O)— group in which the heteroaryl group is as previously described.

“Heterocycloalkyl” means: (i) a cycloalkyl group of about 3 to 10 ring members which contains one or more heteroatoms or heteroatom-containing groups selected from O, S and NY 6 and may be optionally substituted by oxo (examples of such groups include hexahydropyran, pyrrolidinyl, piperidinyl, tetrahydropyranyl and octahydro-pyrido[1,2-c]pyrimidin-1-one); (ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl) ring, each optionally substituted by one or more “aryl group substituents,” and a heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).

“Heterocycloalkylalkyl” means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.

“Hydroxyalkyl” means an alkyl group substituted by one or hydroxy groups.

“NH(alk)” and “N(alk)(alk)” denote an amino radical substituted, respectively, with one or two alkyl radicals, such alkyl radicals being linear or branched and chosen from alkyl radicals as defined above, preferably containing not more than 4 carbon atoms.

“Prodrug” means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (Ix), including N-oxides thereof. For example an ester of a compound of formula (Ix) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule. Alternatively, an ester of a compound of formula (Ix) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.

Suitable esters of compounds of formula (Ix) containing a hydroxy group are, for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-p-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.

Suitable esters of compounds of formula (Ix) containing a carboxy group are, for example, those described by F. J. Leinweber, Drug Metab. Res., 1987, 18, page 379.

An especially useful class of esters of compounds of formula (Ix) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32, pages 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

Where the compound of the invention of formula (Ix) contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

›Some of the compounds of the present invention…

Some of the compounds of the present invention of formula (Ix) are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.

Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulfates, phosphates, nitrates, sulfamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methane-sulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.

As well as being useful in themselves as active compounds, salts of compounds of the invention of compounds of formula (Ix) are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

It will be appreciated that compounds of the present invention of formula (Ix) may contain asymmetric centres. These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (Ix) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates. Additionally, tautomers of the compounds of formula (Ix) are possible, and the present invention is intended to include all tautomeric forms of the compounds.

One subject of the present invention is thus the compounds of formula (I):

in which:

X represents C—R 2 and W, Y and Z, which may be identical or different, represent CH or CR 3 ; R 1 represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno-pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydropyridinopyrazolyl radicals, all these radicals being optionally substituted with one or more radicals X 1 , X 2 or X 3 chosen from H, halogen, haloalkyl, OH, R 4 , NO 2 , CN, S(O) n R 4 , OR 4 , NY 1 Y 2 , COR 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —C(═O)OH, —N(R 6 )C(═O)R 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR, —S(O)nOR 4 , —S(O) n NY 1 Y 2 , —OC(═O)NY 1 Y 2 , —OS(O) n R 4 , —OC(═O)R 4 and optionally substituted thienyl, R 2 and R 3 are such that: either R 2 and R 3 , which may be identical or different, represent H, R 4 , halogen, haloalkyl, OH, NO 2 , CN, OR 4 , COR 4 , S(O) n R 4 —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —C(═O)OH, —NY 1 Y 2 , —N(R 6 )C(═O)R 4 , —N(R 6 )SO 2 R, —N(R)C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —S(O) n OR 4 , —S(O) n NY 1 Y 2 , —OC(═O)NY 1 Y 2 and —OC(═O)R 4 or R 2 represents H, R 4 , halogen, haloalkyl, OH, NO 2 , CN, OR 4 , COR 4 S(O) n R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —C(═O)OH, —NY 1 Y 2 , —N(R 6 )C(═O)R 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —S(O) n OR 4 , —S(O) n NY 1 Y 2 , —OC(═O)NY 1 Y 2 and —OC(═O)R 4 and R 3 represents alkyl, haloalkyl, halogen and OR 6 or R 2 and R 3 together form a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S, R 4 represents alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl (optionally substituted), halogen, alkyl, hydroxyalkyl, OH, OR 5 , C(═O)NY 3 Y 4 , NY 3 Y 4 , alk-NY 3 Y 4 and C(═O)OR 6 , R 5 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl. Y 1 and Y 2 are such that: either Y 1 and Y 2 , which may be identical or different, represent H and optionally substituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, or Y 1 and Y 2 form, together with the nitrogen atom to which they are attached, a cyclic amino radical, Y 3 and Y 4 are such that: either Y 3 and Y 4 , which may be identical or different, represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y 3 and Y 4 form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical, A 5 represents H or alkyl, R 6 is chosen from the values of R 5 , all the alkyl (or alk, which represents alkyl), alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino(NH—COalk), —C(═O)OR 6 , acyl —C(═O)R 6 , hydroxyalkyl, carboxyalkyl, S(O) n -alk, S(O) n —NH 2 , S(O) n —NH(alk), S(O), —N(alk) 2 , CF 3 , OCF 3 , NO 2 , arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, —C(═O)—NY 3 Y 4 and NY 3 Y 4 radicals, the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH—C(O)R 5 , the phenyl radicals furthermore being optionally substituted with a dioxole radical, n represents an integer from 0 to 2, it being understood that when R 1 represents an indazolyl radical to give the compounds of formula (F) below:

›with X representing H, R 2 or R…

with X representing H, R 2 or R 3 as defined above, then W necessarily represents H or unsubstituted alkyl,

the said compounds of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compoundss of formula (I) as defined above corresponding to the formula (Ia):

in which:

Xa represents C—R 2 a and Wa, Ya and Za, which may be identical or different, represent CH or CR 3 a; R 1 a represents aryl or heteroaryl chosen from pyrazolyl, triazolyl and indazolyl radicals, all these radicals being optionally substituted with one or more radicals X 1 a, X 2 a or X 3 a chosen from H, halogen, OH, R 4 a, OR 4 a, NY 1 aY 2 a, S(O) n Ra, —C(═O)NY 1 aY 2 a, —C(═O)OR 4 a, —N(R 6 a)C(═O)R 4 a, —N(R 6 a)SO 2 R 4 a, —N(R 6 a)C(═O)NY 1 aY 2 a, —N(R 6 a)C(═O)OR 4 a, —OC(═O)NY 1 aY 2 a, —OC(═O)R 4 a, —OS(O) n R 4 a and thienyl optionally substituted with an alkyl radical, R 2 a and R 3 a are such that: either R 2 a and R 3 a, which may be identical or different, represent H, R 4 a, halogen, OH, OR 4 a, C(═O)NY 1 aY 2 a, —C(═O)OR 4 a and —C(═O)OH, and R 3 a represents alkyl, halogen and OR 6 a, or R 2 a represents H, R 4 a, halogen, OH, OR 4 a, C(═O)NY 1 aY 2 a, —C(═O)OR 4 a and —C(═O)OH, and R 3 a represents alkyl, halogen and OR 6 a, or R 2 a and R 3 a together form an —O—CH 2 —O— or —O—CH 2 —CH 2 —O— ring, R 4 a represents alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl (optionally substituted), halogen, alkyl, hydroxyalkyl, OH, OR 5 a, C(═O)NY 3 aY 4 a, NY 3 aY 4 a, alk-NY 3 aY 4 a and C(═O)OR 6 a, R 5 a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl, all these radicals being optionally substituted, Y 1 a and Y 2 a are such that: either Y 1 a and Y 2 a, which may be identical or different, represent H, alkyl, alkoxyalkyl, aryloxyalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkyl, aryl and heteroaryl, all these radicals being optionally substituted, or Y 1 a and Y 2 a form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical, Y 3 a and Y 4 a are such that: either Y 3 a and Y 4 a, which may be identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl, or Y 3 a and Y 4 a form, together with the nitrogen atom to which they are attached, a cyclic amino radical, A 5 represents H or alkyl, all the alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl radicals present in the above radicals furthermore being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, acylamino(NH—C(O)R 6 a), —C(═O)OR 6 a, acyl —C(═O)R 6 a, hydroxyalkyl, carboxyalkyl, S(O) n -alk, S(O) n —NH 2 , S(O), —NH(alk), S(O) n —N(alk) 2 , CF 3 , OCF 3 , NO 2 , arylalkoxy, aryl, heteroaryl, aryloxy, aryloxyalkyl, —C(═O)—NY 3 aY 4 a and NY 3 aY 4 a radicals, the latter radicals containing alkyl, aryl and heteroaryl themselves being optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, alkoxy radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH—C(O)R 6 a, the phenyl radicals furthermore being optionally substituted with a dioxole radical, R 6 a is chosen from the values of R 5 a, n represents an integer from 0 to 2, the said compounds of formula (Ia) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compounds of formula (I):

in which:

X represents C—R 2 and W, Y and Z, which may be identical or different, represent CH or CR 3 ; R 1 represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno-pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydro-pyridinopyrazolyl radicals, all these radicals optionally being substituted with one or more radicals X 1 , X 2 or X 3 chosen from H, halogen, haloalkyl, OH, R 4 , NO 2 , CN, S(O) n R, OR 4 , NY 1 Y 2 , COR 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —C(═O)OH, —N(R 6 )C(═O)R 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —S(O) n OR 4 , —S(O) n NY 1 Y 2 , —OC(═O)NY 1 Y 2 , —OS(O) n R 4 , —OC(═O)R 4 and optionally substituted thienyl, R 2 and R 3 are such that: either R 2 and R 3 , which may be identical or different, represent H, R 4 , halogen, haloalkyl, OH, NO 2 , CN, OR 4 , COR 4 , S(O) n R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —C(═O)OH, —NY 1 Y 2 , —N(R 6 )C(═O)R 4 , —N(R6)SO2R4, —N(R6)C(═O)NY1Y2, —N(R6)C(═O)OR4, —S(O)nOR4, —S(O)nNY1Y2, —OC(═O)NY 1 Y 2 and —OC(═O)R 4 or R 2 represents H, R 4 , halogen, haloalkyl, OH, NO 2 , CN, OR 4 , COR 4 , S(O) n R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —C(═O)OH, —NY 1 Y 2 , —N(R 6 )C(═O)R 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —S(O) n OR 4 , S(O) n NY 1 Y 2 , —OC(═O)NY 1 Y 2 and —OC(═O)R 4 and R 3 represents alkyl, haloalkyl, halogen and OR 6 or R 2 and R 3 together form a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S, R 4 represents alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, hetero-arylalkyl and arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl, OH, OR 5 , C(═O)NY 3 Y 4 , NY 3 Y 4 and C(═O)OR 6 , R 5 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl. R 6 represents H and C1-C4 alkyl, n represents an integer from 0 to 2 Y 1 and Y 2 are such that: either Y 1 and Y 2 , which may be identical or different, represent H, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, all these radicals being optionally substituted with one or more radicals chosen from hydroxyl, —C(═O)—NY 3 Y 4 , —C(═O)OR 6 and NY 3 Y 4 , or Y 1 and Y 2 form, together with the nitrogen atom to which they are attached, a cyclic amino radical, Y 3 and Y 4 are such that: either Y 3 and Y 4 , which may be identical or different, represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y 3 and Y 4 form, together with the nitrogen atom to which they are attached, a cyclic amino radical, A 5 represents H or alkyl, it being understood that when R 1 represents an indazolyl radical

›to give the compounds of formula (F) below…

to give the compounds of formula (F) below:

with X representing H, R 2 or R 3 as defined above, then W necessarily represents H or unsubstituted alkyl,

the said compounds of formula (F) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

It is obvious that, according to the ring represented by R 1 and its number of members, R 1 can comprise one, two or three substituents represented by X 1 , X 2 and X 3 .

One subject of the present invention is thus the compounds of formula (I) as defined above corresponding to the formula (Ia):

in which:

Xa represents C—R 2 a and Wa, Ya and Za, which may be identical or different, represent CH or CR 3 a; R 1 a represents aryl or heteroaryl chosen from pyrazolyl, triazolyl or indazolyl radicals, all these radicals being optionally substituted with one or more radicals X 1 a, X 2 a or X 3 a chosen from H, halogen, OH, R 4 a, OR 4 a, NY 1 aY 2 a, S(O) n R 4 a, —C(═O)NY 1 aY 2 a, —C(═O)OR 4 a, —N(R 6 a)C(═O)R 4 a, —N(R 6 a)SO 2 R 4 a, —N(R 6 a)C(═O)NY 1 aY 2 a, —N(R 6 a)C(═O)OR 4 a, —OC(═O)NY 1 aY 2 a and —OC(═O)R 4 a, —OS(O) n R 4 a and thienyl optionally substituted with an alkyl radical, R 2 a and R 3 a are such that: either R 2 a and R 3 a, which may be identical or different, represent H, R 4 a, halogen, OH, OR 4 a, C(═O)NY 1 aY 2 a, —C(═O)OR 4 a, —C(═O)OH, and R 3 a represents alkyl, halogen and OR 6 a, or R 2 a represents H, R 4 a, halogen, OH, OR 4 a, C(═O)NY 1 aY 2 a, —C(═O)OR 4 a, —C(═O)OH, and R 3 a represents alkyl, halogen and OR 6 , or R 2 a and R 3 a together form an —O—CH 2 —O or —O—CH 2 —CH 2 —O— ring, R 4 a represents alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, heteroarylalkyl or arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl, OH, OR 5 a, C(═O)NY 3 aY 4 a, NY 3 aY 4 a and C(═O)OR 6 a, R5a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl, R 6 a represents H and C1-C4 alkyl, n represents an integer from 0 to 2, Y 1 a and Y 2 a are such that: either Y 1 a and Y 2 a, which may be identical or different, represent H, alkyl, cycloalkyl, aryl and heteroaryl, all these radicals being optionally substituted with one or more radicals chosen from hydroxyl, —C(═O)—NY 3 Y 4 , —C(═O)OR 6 and NY 3 Y 4 , or Y 1 a and Y 2 a form, together with the nitrogen atom to which they are attached, a cyclic amino radical, Y 3 a and Y 4 a are such that: either Y 3 a and Y 4 a, which may be identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl, or Y 3 a and Y 4 a form, together with the nitrogen atom to which they are attached, a cyclic amino radical, A 5 represents H or alkyl, the said compounds of formula (Ia) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.

One subject of the present invention is thus the compounds of formula (I) as defined above corresponding to the formula (IA):

in which A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from O, N and S, this heterocycle A being optionally substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from the values indicated hereinabove for the radicals X 1 , X 2 or X 3 ,

A 1 , A 2 , A 3 and A 4 , which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, aryl, heteroaryl and aryloxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 A 7 such that either A 6 and A 7 , which may be identical or different, are chosen from a hydrogen atom and optionally substituted alkyl, alkoxyalkyl, phenoxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl radicals, or A 6 and A 7 form, together with the nitrogen atom to which they are attached, an optionally substituted 5- or 6-membered cyclic radical,

it being understood that two consecutive radicals among A 1 , A 2 , A 3 and A 4 can form, with the benzimidazole radical to which they are attached, a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S,

A 5 represents a hydrogen atom or an alkyl radical,

R 6 b represents hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl and cycloalkylalkyl,

all the alkyl, alkenyl, aryl, heteroaryl, aryloxy, cycloalkyl and heterocycloalkyl radicals present in the above radicals being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino(NH—COR 6 ), —C(═O)OR 6 b, acyl —C(═O)R 6 b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, S(O) n -alk, S(O) n —NH 2 , S(O) n —NH(alk), S(O) n —N(alk) 2 , CF 3 , OCF 3 , NO 2 , CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, —C(═O)—NH 2 , —C(═O)—NH(alk) and C(═O)—N(alk) 2 radicals,

all the above alkyl, alkenyl, alkoxy and alkylthio radicals being linear or branched and containing not more than 4 carbon atoms,

all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

n represents an integer from 0 to 2,

the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

›A subject of the present invention is thus…

A subject of the present invention is thus the compounds of formula (I) as defined above, corresponding to the formula (IAa):

in which Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from the values indicated hereinabove for the radicals X 1 , X 2 or X 3 ,

A 1 a, A 2 a, A 3 a and A 4 a, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 aA 7 a such that either A 6 a and A 7 a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A6a and A7a form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl or phenyl radical, which are themselves optionally substituted, it being understood that two consecutive radicals from among A 1 a, A 2 a, A 3 a and A 4 a may form, with the benzimidazole radical to which they are attached, an optionally substituted 5- to 6-membered carbon-based ring containing one or two oxygen atoms, A 5 a represents a hydrogen atom or an alkyl radical, the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms,

the said compounds of formula (IAa) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAa).

The substituents X 1 , X 2 and X 3 as defined above are in particular such that one represents a hydrogen atom and the other two, which may be identical or different, are chosen from halogen atoms and OH, R 4 a, OR 4 a, CF 3 , OCF 3 , NO 2 , CN, NY 1 aY 2 a, acylamino(NH—COR 6 b), S(O) n -alk, S(O) n —NH 2 , S(O) n —NH(alk), S(O) n —N(alk) 2 , —C(═O)—NH 2 , —C(═O)—NH(alk), C(═O)—N(alk) 2 , —C(═O)OR 4 a, —N(R 6 b)C(═O)R 4 a, —N(R 6 b)SO 2 R 4 a, —N(R 6 b)C(═O)NY 1 aY 2 a, —N(R 6 b)C(═O)OR 4 a, —OC(═O)NY 1 aY 2 a and thienyl radicals, the thienyl radical being optionally substituted with an alkyl radical,

R 4 a, Y 1 a, Y 2 a and R 6 b having the values defined above and alk representing a linear or branched alkyl radical including not more than 6 carbon atoms and optionally substituted as indicated above.

All the alkylthio radicals are such that the sulfur atom is optionally oxidized to sulfone or sulfoxide with one or two oxygen atoms.

Tables I, II and III described below give examples of compounds illustrating the present invention, with in particular substituents chosen from the values of X 1 , X 2 and X 3 as defined above.

with X represents hydrogen, halogen or alkoxy as defined above.

in which NR′R represents NY 1 Y 2 as defined above.

in which X represents hydrogen, alkynyl or NHCOCH 2 Ph which is optionally substituted.

The subject of the present invention is thus the compounds of formula (I) as defined above in which the substituents of the said compounds of formula (I) have the any of the values indicated as defined hereinabove and in which the aryl radicals represent the phenyl and naphthyl radicals; the heteroaryl radicals represent the furyl, thienyl, benzothienyl, thianthrenyl, pyridyl, pyrazolyl, benzimidazolyl, benzofuran, isobenzofuran and dihydrobenzofuran radicals; the cycloalkyl radicals represent a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical; the heterocycloalkyl radicals represent the hexahydropyran, piperidyl or morpholino radicals; the heterocycloalkylalkyl radicals represent the hexahydropyranylalkyl, piperidylalkyl and morpholinoalkyl radicals; the arylalkyl radicals represent the phenylalkyl, ethylenedioxyphenylalkyl and naphthylalkyl radicals; the heteroarylalkyl radicals represent the thienylalkyl, pyridylalkyl, furylalkyl, pyrazolylalkyl, benzothienylalkyl, dihydrobenzofuranylalkyl and benzimidazolylalkyl radicals; the aryloxy radicals represent the phenoxy and naphthyloxy radicals; the arylalkoxy radicals represent the phenylalkoxy and naphthylalkoxy radicals; and the aryloxyalkyl radicals represent the phenoxyalkyl radical; all these radicals being optionally substituted as indicated hereinabove.

One subject of the present invention is, more particularly, the compounds of formula (I) as defined above corresponding to the formula (IA):

in which A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from O, N and S, this heterocycle A optionally being substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals or thienyl radicals optionally substituted with an alkyl radical,

A 1 , A 2 , A 3 and A 4 , which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 A 7 such that either A 6 and A 7 , which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and heteroarylalkyl radicals, or A 6 and A 7 form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical, it being understood that two consecutive radicals among A 1 , A 2 , A 3 and A 4 can form, with the benzimidazole radical to which they are attached, a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S, A 5 represents a hydrogen atom or an alkyl radical, all the phenyl, phenoxy, cycloalkyl and heteroarylalkyl radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms, the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

›A subject of the present invention is also…

A subject of the present invention is also, more particularly, the compounds of formula (D) as defined above, corresponding to the formula (IAb):

in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or two radicals chosen from halogen atoms and OH, alkyl, alkynyl, —OR 6 b (including alkoxy), —COR 6 b, —O—COR 6 b, —OS(O) n R 6 b, —O(CH 2 ) n —CO—R 6 b, phenyl, phenylalkyl, CF 3 , OCF 3 , NO 2 , CN, NY 1 bY 2 b, —NH—C(═O)NY 1 bY 2 b, acylamino(NH—CO—R 6 b), S(O) n -alk, S(O) n —NY 1 bY 2 b, —C(═O)—NY 1 bY 2 b, —C(═O)OR 6 b, —NH—C(═O)R 6 b, —NH—S(O) n R 6 b, —NH—C(═O)OR 6 b, —N(R 6 b)C(═O)NY 1 bY 2 b, —OC(═O)NY 1 bY 2 b and thienyl radicals, all these radicals being optionally substituted,

with NY 1 bY 2 b such that either Y 1 b and Y 2 b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y 1 b and Y 2 b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,

A 1 b, A 2 b, A 3 b and A 4 b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, —OR 6 b (including alkoxy), —CO—R 6 b, —O—COR 6 b, —OS(O) n R 6 b, —O(CH 2 ) n —CO—R 6 b, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A 6 b and A 7 b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benzimidazolylalkyl radicals, all these radicals being optionally substituted, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted, it being understood that two consecutive radicals among A 1 b, A 2 b, A 3 b and A 4 b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimid-azole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical, A 5 b represents a hydrogen atom,

all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino(NH—COR 6 b), —C(═O)OR 6 b, acyl —C(═O)R 6 b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, S(O) n -alk, S(O) n —NH 2 , S(O) n —NH(alk), S(O) n —N(alk) 2 , CF 3 , OCF 3 , NO 2 , CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, —C(═O)—NH 2 , —C(═O)—NH(alk) and C(═O)—N(alk) 2 radicals, with n representing an integer from 0 to 2, and R 6 b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, —NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF 3 , OCF 3 , alkyl, phenyl-S(O) n -alk-phenyl, alkoxy, NH 2 , NHalk, N(alk) 2 , SO 2 NH 2 , SO 2 Nalk or SO 2 N(alk) 2 radical,

all the alkyl, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 10 carbon atoms, all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

One subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or two radicals chosen from halogen atoms and OH, alkyl, alkynyl, alkoxy, phenyl, phenylalkyl, CF 3 , OCF 3 , NO 2 , CN, NY 1 bY 2 b, —NH—C(═O)NY 1 bY 2 b, acylamino (NH—CO—R 6 b), S(O) n -alk, S(O) n —NY 1 bY 2 b, —C(═O)—NY 1 bY 2 b, —C(═O)OR 6 b, —NH—C(═O)R 5 b, —NH—S(O) n R 6 b, —NH—C(═O)OR 6 b, —N(R 6 b)C(═O)NY 1 bY 2 b, —OC(═O)NY 1 bY 2 b and thienyl radicals which are optionally substituted,

A 1 b, A 2 b, A 3 b and A 4 b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A 6 b and A 7 b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benzimidazolylalkyl radicals, all these radicals being optionally substituted, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted, it being understood that two consecutive radicals among A 1 b, A 2 b, A 3 b and A 4 b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical, A 5 b represents a hydrogen atom,

›all the above radicals containing alkyl, alkenyl, phenyl…

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl radical substituted with one or two radicals such that one is chosen from hydrogen, halogen atoms and alkyl, alkynyl, —COR 6 b, phenyl, phenylalkyl, CF 3 , NO 2 , CN, NY 1 bY 2 b, —NH—C(═O)NY 1 bY 2 b, NH—CO—R 6 b, S(O) n -alk, S(O) n —NY 1 bY 2 b, —C(═O)—NY 1 bY 2 b, —C(═O)OR 6 b, —NH—C(═O)R 6 b, —NH—S(O) n R 6 b, —NH—C(═O)OR 6 b, —N(R 6 b)C(═O)NY 1 bY 2 b and thienyl radicals, all these radicals being optionally substituted,

and the other is chosen from OH, —OR 6 b, —O—COR 6 b, —OS(O) n R 6 b, —O(CH 2 ) n —CO—R 6 b and —OC(═O)NY 1 bY 2 b radicals, all these radicals being optionally substituted, with NY 1 bY 2 b such that Y 1 b and Y 2 b, which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y 1 b and Y 2 b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,

A 1 b, A 2 b, A 3 b and A 4 b, which may be identical or different, are such that two of them represent hydrogen and the other two, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, —OR 6 b (including alkoxy), —CO—R 6 b, —O—COR 6 b, —OS(O) n R 6 b, —O(CH 2 ) n —CO—R 6 b, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A 6 b and A 7 b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benzimidazolylalkyl radicals, all these radicals being optionally substituted, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical itself optionally substituted, A 5 b represents a hydrogen atom,

all the above radicals containing alkyl, alkenyl, phenyl, phenoxy, furyl, thienyl, piperidyl, pyridyl, pyrazolyl and benzimidazolyl being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, acylamino(NH—COR 6 b), —C(═O)OR 6 b, acyl —C(═O)R 6 b, hydroxyalkyl, carboxyalkyl, phenoxyalkyl, S(O) n -alk, S(O) n —NH 2 , S(O), —NH(alk), S(O) n —N(alk) 2 , CF 3 , OCF 3 , NO 2 , CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, —C(═O)—NH 2 , —C(═O)—NH(alk) and C(═O)—N(alk) 2 radicals, with n representing an integer from 0 to 2, and R 6 b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, —NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF 3 , OCF 3 , alkyl, phenyl-S(O)n-alk-phenyl, alkoxy, NH 2 , NHalk, N(alk) 2 , SO 2 NH 2 , SO 2 Nalk or SO 2 N(alk) 2 radical,

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals,

A 1 b, A 2 b, A 3 b and A 4 b, which may be identical or different, are chosen from a hydrogen atom; halogen atoms; radicals of the following types: hydroxyl, alkyl, alkenyl optionally substituted with phenyl itself optionally substituted with one or more halogen atoms, alkoxy, nitro, cyano, furyl, thienyl optionally substituted with acyl COalk, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy which are optionally substituted; and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A 6 b and A 7 b, which may be identical or different, are chosen from hydrogen and radicals of the following types: alkyl, alkoxyalkyl containing not more than 6 carbon atoms, phenoxyalkyl optionally substituted with acylamino NH—C(O)alk, phenyl, optionally substituted phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl optionally substituted with one or more alkyl radicals, naphthylalkyl, thienylalkyl optionally substituted with alkyl or thienyl, piperidylalkyl optionally substituted with a carboxyl radical which is free, salified or esterified with an alkyl radical, pyridylalkyl optionally substituted with one or more radicals chosen from halogen and CF3, benzothienylalkyl, pyrazolylalkyl optionally substituted with one or more alkyl radicals, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl, and benzimidazolylalkyl optionally substituted with one or more alkyl radicals, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical, it being understood that two consecutive radicals among A 1 b, A 2 b, A 3 b and A 4 b can form, with the benzimidazole radical to which they are attached, an optionally substituted 4,5-ethylenedioxybenzimidazole radical or an optionally substituted 4,5-methylenedioxybenzimidazole radical, A 5 a represents a hydrogen atom,

›the phenyl, phenoxy and phenylalkyl radicals above being…

the phenyl, phenoxy and phenylalkyl radicals above being optionally substituted with one or more radicals chosen from halogen atoms, hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino and NH—COalk radicals, a carboxyl radical which is free, salified or esterified with an alkyl radical, and hydroxyalkyl, carboxyalkyl, phenoxyalkyl, alkylthio, SO 2 alk, SO 2 NH 2 , SO 2 —NH(alk), SO 2 —N(alk) 2 , CF 3 , OCF 3 , NO 2 , CN, phenyl, itself optionally substituted with one or more halogen atoms, thienyl, phenoxy, phenylalkoxy, —C(═O)—NH 2 , —C(═O)—NH(alk), C(═O)—N(alk) 2 and C(O)CH 3 radicals,

all the alkyl or alk, alkenyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 4 carbon atoms,

all the phenyl radicals of the above radicals furthermore being optionally substituted with a dioxole radical,

A subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab, A 1 b, A 2 b, A 3 b, A 4 b and A 5 b have any of the meanings indicated hereinabove,

and when one of A 1 b, A 2 b, A 3 b and A 4 b represents a carboxyl radical amidated with a radical NA 6 bA 7 b, then either one of A 6 b and A 7 b represents a hydrogen atom or an alkyl radical and the other of A 6 b and A 7 b is chosen from the values defined for A 6 b and A 7 b, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical, the other substituents of the said compounds of formula (I) having the any of the values indicated hereinabove,

A subject of the present invention is thus in particular the compounds of formula (I) as defined above in which X, W, Y and Z are such that two or three of them represent CH and the others are chosen from the values of CR 2 or CR 3 and, if appropriate, i.e., when two of them represent CH and CR 2 and CR 3 are adjacent to each other, can form a dioxole radical,

R 2 , R 3 and the other substituents of the said compounds of formula (I) having any of the values as defined hereinabove, the said compounds of formula (I) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (I).

The present invention thus relates in particular to the compounds of formula (IA) as defined above in which A 1 , A 2 , A 3 and A 4 are such that two or three of them represent a hydrogen atom and the others are chosen from the values of A 1 , A 2 , A 3 and A 4 and, if appropriate, i.e., when two of them represent a hydrogen atom and the other two are on adjacent carbons, can form a dioxole radical,

the other substituents of the compounds of formula (IA) having any of the values as defined hereinabove, the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).

A subject of the present invention is also, more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAa):

in which Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals and thienyl radicals optionally substituted with an alkyl radical,

A 1 a, A 2 a, A 3 a and A 4 a, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 aA 7 a such that either A 6 a and A 7 a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A 6 a and A 7 a form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl or phenyl radical, which are themselves optionally substituted, it being understood that two consecutive radicals from among A 1 a, A 2 a, A 3 a and A 4 a may form, with the benzimidazole radical to which they are attached, an optionally substituted 5- to 6-membered carbon-based ring containing one or two oxygen atoms, A5a represents a hydrogen atom or an alkyl radical, the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms, the said compounds of formula (IAa) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAa).

One subject of the present invention is, more particularly, the compounds of formula (I) as defined above in which R 1 represents a pyrazolyl or indazolyl radical, the other substituents having the values indicated above or below.

›Among the preferred compounds that are particularly noted…

Among the preferred compounds that are particularly noted are the compounds of formula (I) in which Aa represents a pyrazolyl or indazolyl radical optionally substituted as indicated above and below, A 1 a, A 2 a, A 3 a and A 4 a are chosen from the following values:

A 1 a represents hydrogen or carboxyl or forms a ring with

the adjacent member A 2 a

A 4 a represents hydrogen or carboxyl or forms a ring with the adjacent member A 3 a A 2 a represents a carboxyl radical that is free, salified, esterified with an optionally substituted alkyl radical or an amidated carboxyl as indicated above or below, A 2 a and A 3 a represent two optionally substituted alkyl radicals,

A 5 a represents hydrogen.

One subject of the present invention is, even more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAb):

in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals,

A 1 b, A 2 b, A 3 b and A 4 b, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl and alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical that is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A 6 b and A 7 b, which may be identical or different, are chosen from alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and furylalkyl radicals, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl radical,

it being understood that two consecutive radicals from among A 1 b, A 2 b, A 3 b and A 4 b may form, with the benzimidazole radical to which they are attached, an optionally substituted

4,5-ethylenedioxybenzimidazole radical or 4,5-methylenedioxybenzimidazole radical,

A 5 b represents a hydrogen atom,

the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino and free, salified or esterified carboxyl radicals,

all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 4 carbon atoms,

the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer from, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).

With reference to formula (Ix) above, the following are particular and preferred groupings:

R 1 may particularly represent optionally substituted heteroaryl. Exemplary optionally substituted heteroaryls include dihydrofuropyrazolyl, imidazolyl, indazolyl, indolyl, isoxazolyl, oxodihydropyridazinyl, oxodihydropyridinopyrazolyl, oxodihydropyridinyl, oxotetrahydropyrrolopyrazolyl, pyrazolyl, thiazolyl, thienopyrazolyl, tetrahydrocyclopentapyrazolyl, tetrahydroindazolyl, tetrahydropyranopyrazolyl, tetahydropyridinopyrazolyl, tetrahydropyrrolopyrazolyl or triazolyl. Optional substituents include one or more groups selected from carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —N(R 6 SO 2 R 4 , —N(R 6 )SO 2 NY 1 Y 2 , —NY 1 Y 2 , —OR 4 , —OCF 2 H, —OCF 3 , —OC(═O)R 4 , —OC(═O)NY 1 Y 2 , —S(O) n R 4 and —S(O) 2 NY 1 Y 2 . R 1 more preferably represents a heteroaryl moiety

in which R 7 , R 8 and R 9 are as hereinbefore defined. It will be appreciated that compounds of formula (Ix) in which R 1 represents a heteroaryl moiety

and R 7 is hydrogen can exist in the tautomeric forms

W may particularly represent CH when X is CR 2 , Y is CH or CR 3 and Z are CH or CR 3 .

W may also particularly represent CH when X is N, Y is CH or CR 3 and Z is CH or CR 3 .

W may also particularly represent N when X is CH or CR 2 , Y is CH or CR 3 and Z is CH or CR 3 .

W may also particularly represent N when X is CH or CR 2 , Y is CH or CR 3 and Z is N.

It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

A particular group of compounds of the invention are compounds of formula (Ixa):—

in which W, X, Y, Z and R 7 are as hereinbefore defined for compounds of formula (Ix), and R 8 and R 9 are independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —N(R 6 )SO 2 R 4 , —NY 1 Y 2 , —OR 4 , —OC(═O)R 4 , —OC(═O)NY 1 Y 2 , —S(O) n R 4 and —S(O) 2 NY 1 Y 2 ; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Y represents CH and Z represents CH or C—CH 3 are preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Z represents CH and Y represents:

are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents C—CH 3 , C—CH 2 CH 3 , C—CH(CH 3 ) 2 , C—OCH 3 , C—OCH 2 CH 3 , C—Br or C—Cl, Y represents C—CH 3 , C—CH 2 CH 3 , C—OCH 3 ,

and Z represents CH are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Y represents C—CH 3 and Z represents C—CH 3 are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also preferred.

›Compounds of formula (Ixa) in which R 7…

Compounds of formula (Ixa) in which R 7 represents hydrogen are preferred.

Compounds of formula (Ixa) in which R 8 represents:

are preferred.

Compounds of formula (Ixa) in which R 9 represents:

are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixa) in which:—W represents CH; X represents CH; Y represents CH; Z represents CH or C—CH 3 ; R 7 represents hydrogen; R 8 represents

and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:—W represents CH; X represents CH; Z represents CH; Y represents

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:—W represents CH; X represents

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:—W represents CH; X represents CH; Y represents C—CH 3 ; Z represents C—CH 3 ; R 7 represents hydrogen; R 8 represents

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:—W represents CH; X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —; Z represents CH; R 7 represents hydrogen; R 8 represents

A further preferred group of compounds of the invention are compounds of formula (Ixa) in which:—W represents CH; X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —; Z represents CH; R 7 represents hydrogen; R 8 represents

Compounds of formula (Ixa) in which R 8 is hydrogen or —CH 3 and R 9 is

are particularly preferred.

Compounds of formula (Ixa) in which R 9 represents hydrogen and R 8 represents

are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is CH, Y is

and Z is CH are particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C—CH 3 or C—CH 2 CH 3 , Y is

and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C—OCH 3 , Y is CH, C—CH 3 , C—CH 2 CH 3 , C—Cl or C—OCH 3 and Z is CH are also particularly-preferred.

Compounds of formula (Ixa) in which W is CH, X is C—OCH 2 CH 3 , Y is C—F and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 atoms form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also particularly preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also particularly preferred.

Compounds of formula (Ixa) in which R 8 is hydrogen or —CH 3 and R 9 is

are especially preferred.

Compounds of formula (Ixa) in which W is CH, X is CH, Y is

and Z is CH are especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C—CH 3 or C—CH 2 CH 3 , Y is C—CH 3 or C—CH 2 CH 3 , C—Cl or C—F and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C—OCH 3 , Y is C—CH 3 , C—CH 2 CH 3 , C—Cl, C—F or C—OCH 3 and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W is CH, X is C—OCH 2 CH 3 , Y is C—Cl or C—F and Z is CH are also especially preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also especially preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also especially preferred.

Another particular group of compounds of the invention are compounds of formula (Ix) wherein R 1 is a heteroaryl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form an optionally substituted phenyl ring, i.e. compounds of formula (Ixb):—

in which W, X, Y, Z and R 7 are as hereinbefore defined for compounds of formula (Ix); R 10 is carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 , —N(R 6 )C(═O)R 4 , —N(R 6 )C(═O)NY 1 Y 2 , —N(R 6 )C(═O)OR 4 , —N(R 6 )SO 2 R 4 , —N(R 6 )SO 2 NY 1 Y 2 , —NY 1 Y 2 , —OR 4 , —OCF 2 H, —OCF 3 , —OC(═O)R 4 , —OC(═O)NY 1 Y 2 , —S(O) n R 4 or —S(O) 2 NY 1 Y 2 ; and p is zero, or an integer 1; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Y represents CH and Z represents CH or C—CH 3 are preferred.

›Compounds of formula (Ixb) in which W represents…

Compounds of formula (Ixb) in which W represents CH, X represents CH, Z represents CH and Y represents:

are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents

and Z represents CH are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CH, Y represents C—CH 3 and Z represents C—CH 3 are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also preferred.

Compounds of formula (Ixb) in which R 7 represents hydrogen are preferred.

Compounds of formula (Ixb) in which p is zero or one are preferred.

Compounds of formula (Ixb) in which R 10 represents:

(i) cyano (ii) halo [e.g. chloro, fluoro]; (iii) C 1-4 alkyl [e.g. methyl, (iv) —OR 4 [e.g. —OCH 3 , —OCH 2 CH 3 ]; or (v) —C(═O)NY 1 Y 2 [e.g. —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 , —C(═O)—N(CH 3 ) 2 are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixb) in which:—W represents CH; X represents CH; Y represents CH; Z represents CH or C—CH 3 ; R 7 represents hydrogen; R 10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C 1-4 alkyl [e.g. methyl], (iv) —OR 4 [e.g. —OCH 3 or —OCH 2 CH 3 ] or (v) —C(═O)NY 1 Y 2 [e.g. —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 or —C(═O)—N(CH 3 ) 2 ]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:—W represents CH; X represents CH; Z represents CH; Y represents

represents hydrogen; p is zero or one; R 10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C 1-4 alkyl [e.g. methyl], (iv) —OR 4 [e.g. —OCH 3 or —OCH 2 CH 3 ] or (v) —C(═O)NY 1 Y 2 [e.g. —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 or —C(═O)—N(CH 3 ) 2 ]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:—W represents CH; X represents C—CH 3 , C—CH 2 CH 3 , C—CH(CH 3 ) 2 , C—OCH 3 , C—OCH 2 CH 3 , C—Br or C—Cl; Y represents C—CH 3 , C—CH 2 CH 3 ,

Z represents CH; R 7 represents hydrogen; p is zero or one; R 10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C 1-4 alkyl [e.g. methyl], (iv) —OR 4 [e.g. —OCH 3 or —OCH 2 CH 3 ] or (v) —C(═O)NY 1 Y 2 [e.g. —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 or —C(═O)—N(CH 13 ) 2 ]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:—W represents CH; X represents CH; Y represents C—CH 3 ; Z represents C—CH 3 ; R 7 represents hydrogen; p is zero or one; R 10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C 1-4 alkyl [e.g. methyl], (iv) —OR 4 [e.g. —OCH 3 or —OCH 2 CH 3 ] or (v) —C(═O)NY 1 Y 2 [e.g. —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 or —C(═O)—N(CH 3 ) 2 ]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:—W represents CH; X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —; Z represents CH; R 7 represents hydrogen; p is zero or one; R 10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C1-4alkyl [e.g. methyl], (iv) —OR 4 [e.g. —OCH 3 or —OCH 2 CH 3 ] or (v) —C(═O)NY 1 Y 2 [e.g. —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 or —C(═O)—N(CH 3 ) 2 ]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixb) in which:—W represents CH; X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —; Z represents CH; R 7 represents hydrogen; p is zero or one; R 10 represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C 1-4 alkyl [e.g. methyl], (iv) —OR 4 [e.g. —OCH 3 or —OCH 2 CH 3 ] or (v) —C(═O)NY 1 Y 2 [e.g. —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 or —C(═O)—N(CH 3 ) 2 ]; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixb) in which R 7 represents hydrogen and p is zero are particularly preferred.

Compounds of formula (Ixb) in which R 7 represents hydrogen; p is one and R 10 represents cyano, chloro, fluoro, methyl, —OCH 3 , —OCH 2 CH 3 , —C(═O)—NH 2 , —C(═O)—NHCH(CH 3 ) 2 or —C(═O)—N(CH 3 ) 2 are also particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is

and Z is CH are particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is C—CH 3 or C—CH 2 CH 3 , Y is

and Z is CH are also particularly preferred.

Compounds of formula (Ixb) in which W is CH, X is C—OCH 3 , Y is CH, C—CH 3 , C—CH 2 CH 3 , C—Cl or C—OCH 3 and Z is CH are also particularly preferred.

›Compounds of formula (Ixb) in which W is…

Compounds of formula (Ixb) in which W is CH, X is C—OCH 2 CH 3 , Y is C—F and Z is CH are also particularly preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also particularly preferred.

Compounds of formula (Ixb) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also particularly preferred.

Compounds of formula (Ixb) in which R 7 represents hydrogen and p is zero are especially preferred.

Compounds of formula (Ixb) in which R 7 represents hydrogen; p is one and R 10 represents —OCH 3 , —OCH 2 CH 3 or —C(═O)—NHCH(CH 3 ) 2 attached to position 5 of the indazolyl ring are also especially preferred.

Compounds of formula (Ixb) in which W is CH, X is C—CH 3 or C—CH 2 CH 3 , Y is C—CH 3 or C—CH 2 CH 3 and Z is CH are also especially preferred.

Another particular group of compounds of the invention are compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form an optionally substituted C 5-8 cycloalkyl ring, i.e. compounds of formula (Ixc):—

in which W, X, Y, Z, X and p are as hereinbefore defined for compounds of formula (Ix),

is a C 5-8 cycloalkyl ring and R 12 is acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl, —C(═O)NY 1 Y 2 , —NY 1 —C(═O)alkyl, —NY 1 SO 2 alkyl, —NY 1 Y 2 , —SO 2 NY 1 Y 2 or alkyl, alkenyl or alkynyl each optionally substituted with aryl, cycloalkyl, heteroaryl, hydroxy, —C(═O)OR 6 , —C(═O)NY 1 Y 2 , —NY 1 Y 2 or —OR 5 ; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Y represents CH and Z represents CH or C—CH 3 are preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Z represents CH and Y represents:

are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents C—CH 3 , C—CH 2 CH 3 , C—CH(CH 3 ) 2 , C—OCH 3 , C—OCH 2 CH 3 , C—Br or C—Cl, Y represents

and Z represents CH are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CH, Y represents C—CH 3 and Z represents C—CH 3 are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also preferred.

Compounds of formula (Ixc) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also preferred.

Compounds of formula (Ixc) in which R 7 represents hydrogen are preferred.

Compounds of formula (Ixc) in which

represents a cyclopentyl, cyclohexyl and cycloheptyl, especially cyclohexyl, ring are preferred.

Compounds of formula (Ixc) in which q is zero are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixc) in which:—W represents CH; X represents CH; Y represents CH; Z represents CH or C—CH 3 ; R 7 represents hydrogen;

represents a cyclopentyl, cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:—W represents CH; X represents CH; Z represents CH; Y represents

R 7 represents hydrogen;

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:—W represents CH; X represents C—CH 3 , C—CH 2 CH 3 , C—CH(CH 3 ) 2 , C—OCH 3 , C—OCH 2 CH 3 , C—Br or C—Cl; Y represents

Z represents CH; R 7 represents hydrogen;

A further preferred group of compounds of the invention are compounds of formula (Ixc) in which:—W represents CH; X represents CH; Y represents C—CH 3 ; Z represents C—CH 3 ; R 7 represents hydrogen;

›A further preferred group of compounds of the…

Compounds of formula (Ixc) in which R 7 represents hydrogen and p is zero are particularly preferred.

Compounds of formula (Ixc) in which W is CH, X is C—CH 3 , Y is C—CH 3 and Z is CH are also particularly preferred.

Compounds of formula (Ixc) in which

is a cyclopentyl ring are particularly preferred.

Another particular group of compounds of the invention are compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form an optionally substituted heterocycloalkyl ring, i.e. compounds of formula (Ixd):—

in which W, X, Y, Z and X are as hereinbefore defined for compounds of formula (Ix), X 1 is O, S, SO 2 , or NY 5 (where Y 5 is hydrogen, R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 or —SO 2 R 4 ), r is zero or an integer one or two and R 13 is alkyl or two R 13 groups attached to the same carbon atom form an oxo group; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

Compounds of formula (Ixd) in which W represents CH, X represents CH, Y represents CH and Z represents CH or C—CH 3 are preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CH, Z represents CH and Y represents:

are also preferred.

Compounds of formula (Ixd) in which W represents CH, X represents C—CH 3 , C—CH 2 CH 3 , C—CH(CH 3 ) 2 , C—OCH 3 , C—OCH 2 CH 3 , C—Br or C—Cl, Y represents

and Z represents CH are also preferred.

Compounds of formula (Ixa) in which W represents CH, X represents CH, Y represents C—CH 3 and Z represents C—CH 3 are also preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also preferred.

Compounds of formula (Ixd) in which R 7 represents hydrogen are preferred.

Compounds of formula (Ixd) in which X 1 is:

are preferred.

Compounds of formula (Ixd) in which r is zero are preferred.

A preferred group of compounds of the invention are compounds of formula (Ixd) in which:—W represents CH; X represents CH; Y represents CH; Z represents CH or C—CH 3 ; R 7 represents hydrogen; X 1 is

and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:—W represents CH; X represents CH; Z represents CH; Y represents

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:—W represents CH; X represents C—CH 3 , C—CH 2 CH 3 , C—CH(CH 3 ) 2 , C—OCH 3 , C—OCH 2 CH 3 , C—Br or C—Cl; Y represents

Z represents CH; R 7 represents hydrogen; X 1 is

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:—W represents CH; X represents CH; Y represents C—CH 3 ; Z represents C—CH 3 ; R 7 represents hydrogen; X 1 is

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:—W represents CH; X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —; Z represents CH; R 7 represents hydrogen; X 1 is

A further preferred group of compounds of the invention are compounds of formula (Ixd) in which:—W represents CH; X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —; Z represents CH; R 7 represents hydrogen; X 1 is

Compounds of formula (Ixd) in which X 1 is

N—C(═O)OCH 3 or N—C(═O)OCH 2 CH 3 and r is zero are particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is CH, Y is

and Z is CH are particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is C—CH 3 or C—CH 2 CH 3 , Y is

›and Z is CH are also particularly preferred…

and Z is CH are also particularly preferred.

Compounds of formula (Ixa) in which W is CH, X is C—OCH 3 , Y is CH, C—CH 3 , C—CH 2 CH 3 , C—Cl or C—OCH 3 and Z is CH are also particularly preferred.

Compounds of formula (Ixd) in which W is CH, X is C—OCH 2 CH 3 , Y is C—F and Z is CH are also particularly preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —CH 2 —CH 2 —, and Z represents CH are also particularly preferred.

Compounds of formula (Ixd) in which W represents CH, X represents CR 2 and Y represents CR 3 where R 2 and R 3 form the group —CH 2 —O—CH 2 —, and Z represents CH are also particularly preferred.

Compounds of formula (Ixd) in which X 1 is

and r is zero are especially preferred.

Compounds of formula (Ixd) in which W represents CH, X represents C—CH 3 , Y represents C—CH 3 or C—Cl and Z represents CH are especially preferred.

Particular compounds of the invention of formula (Ix) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the heteroaryl moiety of one of the fragments (B1 to B168) shown in Table 2.

Particular compounds of the invention of formula (Ixa) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the pyrazole ring of one of the fragments (B1 to B48, B74 to B107, B124 to B127, 130 to 142 or 144 to 150) shown in Table 2.

Particular compounds of the invention of formula (Ixb) are also selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B63 to B73, B108 to B114, B128 or B151) shown in Table 2.

Particular compounds of the invention of formula (Ixc) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B56, B59 or B129) shown in Table 2.

Particular compounds of the invention of formula (Ixd) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (A1 to A110) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B115 to B123 or B157) shown in Table 2.

Particular compounds of the invention of formula (Ix) denoted as the product of the combination of group A1 to A110 in Table 1 with B1 to B169 in Table 2 are illustrated below:

Thus, for example, in the above list the compound denoted as A9-B9 is the product of the combination of group A9 in Table 1 and B9 in Table 2, namely

›Examples47

›Example 230(a) hereinafter described · 1 of 19

Particular compounds of the invention of formula (Ix) for the inhibition of SYK are:

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide; 5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole; 2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole; 2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole; 2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole; 5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole; 5-fluoro-2-[5-methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole; 5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 5,6-dimethyl-2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 6-chloro-5-methyl-2-(5-morpholin-4-yl-1H-pyrazol-3-yl)-1H-benzoimidazole; 5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole; 2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole hydrochloride; 5-methyl-2-(5-methylsulfanyl-4-propyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-(4-methoxy-benzylsulfanyl) 4 -propyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole; 2-(5-benzylsulfanyl-4-isopropyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole; 2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole; 2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole; 3-(5-chloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 2-(4-amino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester; 3-(1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanone; 2-(1H-indazol-3-yl)-3H-benzoimidazol-4-ol; 2-phenyl-1H-imidazol[4,5-b]pyrazine; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine; 2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine; 2-(1H-pyrazol-3-yl)-1H-benzoimidazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole; 5,6-dimethyl-2-(4-phenyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-bromo-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole; 3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(5,6-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(2-methoxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(4-chloro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(4-methyl)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(4,5-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile; 3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrazole-4-carboxylic acid ethyl ester; 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid ethyl ester; 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide; 3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide; 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile; 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide; 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide; 3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile; 2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-ethoxy-1H-pyrazol-3-yl)-1H-benzoimidazole; 2-(5-methylsulfanyl-isoxazol-3-yl)-1H-benzoimidazole; 5-chloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 5,6-dichloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; (benzoimidazol-2-yl)-5-methylthio-3-pyrazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole; 2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole; 2-(5-ethyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole; 5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole; 4-chloro-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazol-5-ol; 3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide; 3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide; [2-indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide; 1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethylethyl)-amide; 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide; 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide; 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide; 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide; 2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid; 3-(5,6-dimethyl-1H-benzoimidazol-5-yl)-pyrazole-4-carboxylic acid; 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide; cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea; cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide; cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]4-methyl-benzamide; 5,6-dimethyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 5-ethyl-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 6-chloro-5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 5-fluoro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethoxy-1H-benzoimidazole; 2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole; 5-chloro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide; cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone; isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine; 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine; 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine; 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester; 5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 5-ethoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester; 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole; 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide; 2-dimethylamino-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide; 2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea; 1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide; cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide; 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-ylamine; 4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide; 1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea; cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide; tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide; morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide; piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide; 3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea; 5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole; morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide; 3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea; piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide; morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide; piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea; piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea; morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpbolin-4-yl-methanone; 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [2-(2H-tetrazol-5-yl)ethyl]-amide; 1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; 1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea; 4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea; morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; 1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea; 4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea; 4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; 1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea; 1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea; 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid; 2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid; 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea; 3-(5-nitro-1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide; 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide; 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide; N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide; N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide; 2-(1H-indazol-3-yl)-3H-benzoimidazol-5-amine; piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 2 of 19

Preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:—

›Example 230(a) hereinafter described · 3 of 19

Particularly preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:—

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide, Example 1; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide, Example 2; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide, Example 3; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide, Example 4; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide, Example 5; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide, Example 6 5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole, (compound denoted as A9-B9), Example 230(a); 6-chloro-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole, (compound denoted as A12-B9), Example 230(b); 6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole, (compound denoted as A12-B10), Example 230(c); 2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole, (compound denoted as A4-B9), Example 230(d); 2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole, (compound denoted as A9-B11), Example 230(e); 2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole, (compound denoted as A9-B10), Example 230(f); 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah); 3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide, Example 235(ak); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide, Example 235(al); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am); 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ao); 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ap); 3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(aq); 2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole, (compound denoted as A9-B83), Example 241 (b); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, (compound denoted as A9-B106), Example 246(g); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethylethyl)-amide, (compound denoted as A9-B25), Example 246(h); 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, (compound denoted as A40-B106), Example 246(i); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide, (compound denoted as A9-B105), Example 246(j); 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide, (compound denoted as A17-B106), Example 246(k); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 246(w); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide, Example 246(x); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide, Example 246(y); 2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide, Example 246(aa); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, (compound denoted as A9-B85), Example 248(a); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide, (compound denoted as A9-B86), Example 248(b); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide, (compound denoted as A9-B36), Example 248(c); cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B89), Example 248(d); methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B94), Example 248(e); cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B87), Example 248(f); trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B88), Example 248(g); tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B90), Example 248(h); butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B91), Example 248(i); isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B96), Example 248(j); S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B93), Example 248(k); cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A55-B89), Example 248(l); piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(m); 3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea, Example 248(n); cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(o); cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(p); cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(q); cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(r); cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(s); N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, Example 248(t); cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(u); 3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(v); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide, Example 248(w); furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(x); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide, Example 248(y); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide, (compound denoted as A9-B99), Example 253; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide, (compound denoted as A9-B97), Example 254(a); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide; Example 254(b); 2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; Example 254(c); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, (compound denoted as A9-B38), Example 255(a); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea, (compound denoted as A9-B103), Example 255(b); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea, (compound denoted as A9-B40), Example 255(c); 1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, (compound denoted as A9-B39), Example 255(d); cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a); 4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 256(c); 1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d); cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(a); tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide, Example 257(b); morpholine-4-arboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(c); piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d); 3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e); morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide, Example 257(g); 3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h); piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i); cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(a); cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b); morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(c); piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d); 3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(e); piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f); 3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(g); morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(h); morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(n); piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o); 1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a); 1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(b); 4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(c); piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d); 1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(e); morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(f); 4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(g); 1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(h); 1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(i); 4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(j); 1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea, Example 260(l); 4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(m); 1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n); 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea, Example 260(p); 1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q); 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(r); 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide, Example 246(ab); 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide, Example 246(ac); N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide, Example 253(c); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 4 of 19

Especially preferred compounds of formula (Ixa), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:—

3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah); 3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide, Example 235(ak); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide, Example 235(al); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am); 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ao); 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ap); 3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(aq); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, (compound denoted as A9-B106), Example 246(g); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide, (compound denoted as A9-B25), Example 246(h); 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, (compound denoted as A40-B106), Example 246(i); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide, (compound denoted as A9-B105), Example 246(j); 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide, (compound denoted as A17-B106), Example 246(k); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 246(w); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide, Example 246(x); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide, Example 246(y); 2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide, Example 246(aa); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, (compound denoted as A9-B85), Example 248(a); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide, (compound denoted as A9-B86), Example 248(b); cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B89), Example 248(d); methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B94), Example 248(e); cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B87), Example 248(f); trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B88), Example 248(g); tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B90), Example 248(h); butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B91), Example 248(i); isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B96), Example 248(j); S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A9-B93), Example 248(k); cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, (compound denoted as A55-B89), Example 248(l); piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(m); 3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea, Example 248(n); cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(o); cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(p); cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(q); cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(s); N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide, Example 248(t); cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(u); 3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(v); furan-3-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 248(x); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide, (compound denoted as A9-B99), Example 253; N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide, (compound denoted as A9-B97), Example 254(a); N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide; Example 254(b); 2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide; Example 254(c); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, (compound denoted as A9-B38), Example 255(a); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea, (compound denoted as A9-B103), Example 255(b); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea, (compound denoted as A9-B40), Example 255(c); 1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, (compound denoted as A9-B39), Example 255(d); cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a); 4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 256(c); 1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d); cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(a); tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide, Example 257(b); morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(c); piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d); 3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e); 3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h); piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i); cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(a); cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b); morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(c); piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d); 3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(e); piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f); 3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(g); morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(h); morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(n); piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o); 1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a); 1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(b); 4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(c); piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d); 1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(e); morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(f); 1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(h); 1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea, Example 260(i); 4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(j); 1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea, Example 260(l); 4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(m); 1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n); 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea, Example 260(p); 1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q); 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, (compound denoted as A9-B142), Example 258(r); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 5 of 19

More especially preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:—

3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide, Example 235(ai); 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide, Example 235(ah); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide, Example 235(am); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide, Example 246(v); cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 256(a); 1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea, Example 256(d); piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide, Example 257(d); 3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethylurea, Example 257(e); 3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 257(h); piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 257(i); cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide, Example 258(b); piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(d); piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(f); piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 258(o); 1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(a); piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide, Example 260(d); 1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(k); 1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(n); 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea, Example 260(o); 1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea, Example 260(q); 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea, Example 258(r); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixb) of the invention for the inhibition of SYK are:—

3-(1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanone; 2-(1H-indazol-3-yl)-3H-benzoimidazol-4-ol; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine; 2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole; 3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-bromo-1H-benzoimidazol-2-yl 1H-indazole; 3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole; 3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(5,6-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(2-methoxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(4-chloro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-(4-methyl)phenyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile; 3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole; 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole; 3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide; 3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide; 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid; 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 6 of 19

Particularly preferred compounds of formula (Ixb), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:—

3-(1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A1-B63), Example 234(a); 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A6-B63), Example 234(b); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A9-B63), Example 234(f); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole, (compound denoted as A9-B68), Example 235(b); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole, (compound denoted as A9-B70), Example 235(d); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole, (compound denoted as A9-B71), Example 235(e); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole, (compound denoted as A9-B64), Example 235(f); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole, (compound denoted as A9-B69), Example 235(g); 3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A27-B63), Example 235(i); 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A55-B63), Example 235(j); 3-(5-isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A54-B63), Example 235(k); 3-(5-bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A58-B63), Example 235(l); 3-(5-bromo-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A32-B63), Example 235(m); 3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A68-B63), Example 235(n); 3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A69-B63), Example 235(o); 3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A57-B63), Example 235(p); 3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A60-B63), Example 235(q); 3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A65-B63), Example 235(r); 3-(5-(3,4-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A66-B63), Example 235(s); 3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A74-B63), Example 235(w); 3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A22-B63), Example 235(x); 3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A23-B63), Example 235(y); 3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A56-B63), Example 235(z); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile, (compound denoted as A33-B63), Example 235(ab); 3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A35-B63), Example 235(ac); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole, (compound denoted as A9-B63), (compound denoted as A9-B112), Example 235(ad); 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole, Example 235(aj); 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile, Example 235(an); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile, Example 235(ar); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl) 4 -fluoro-1H-indazole, (compound denoted as A9-B110), Example 242(a); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole, (compound denoted as A9-B109), Example 242(c); 3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A28-B63), Example 244(a); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide, Example 244(b); 3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole; Example 244(c) [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol, (compound denoted as A34-B63), Example 245; [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, ethylamide, (compound denoted as A36-B63), Example 246(a); [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide, (compound denoted as A15-B63), Example 246(b); [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide, (compound denoted as A16-B63), Example 246(d); [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide, (compound denoted as A17-B63), Example 246(e); [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide, (compound denoted as A52-B63), Example 246(f); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide, Example 246(m); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide, Example 246(n); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide, Example 246(o); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide, Example 246(p); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide, Example 246(q); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide, Example 246(r); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide, Example 246(s); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide, Example 246(t); 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide, Example 246(u), 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide, Example 246(x); [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, (compound denoted as A14-B63), Example 247(a); 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride, Example 262; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Especially preferred compounds of formula (Ixb) of the invention for the inhibition of SYK are:—

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole, (compound denoted as A9-B68), Example 235(b); 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A55-B63), Example 235(j); 3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole, (compound denoted as A56-B63), Example 235(z); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide, Example 246(x); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 7 of 19

Preferred compounds of formula (Ixc) of the invention for the inhibition of SYK are:—

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole; 5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixc), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:—

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole, (compound denoted as A9-B59), Example 241(a); 5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole, (compound denoted as A9-B56), Example 241(d); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixd) of the invention for the inhibition of SYK are:—

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide; cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone; isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-methyl-propan-1-one; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-3-methyl-butan-1-one; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone; 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-(propane-2-sulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particularly preferred compounds of formula (Ixd), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:—

3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide, (compound denoted as A9-B121), Example 250(a); cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone, (compound denoted as A9-B122); isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone; 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide; 26(e) prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone; [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone; 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide; 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid dimethylamide, (compound denoted as A9-B119); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-methyl-propan-1-one, (compound denoted as A9-B117); 3-(5,6-dimethyl-1H-benzoimidazol-2-yl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester, (compound denoted as A9-B120); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-3-methyl-butan-1-one, (compound denoted as A9-B118); 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one, (compound denoted as A9-B123); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 8 of 19

Especially preferred compounds of formula (Ixd), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of SYK are:—

Particular compounds of formula (Lx) of the invention for the inhibition of KDR are:—

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N—(N′-methylpiperazino)amide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide; methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate; 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole; 5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole; 2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid; 5-bromo 2-(1H-indazol-3-yl)-3H-benzimidazole; 2-(5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid; 5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole; 5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole; 2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole; 2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole; 2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole; 2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole; 2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole. 2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide; 4-({[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-1H-pyrazol-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid ([2,2′]bithiophenyl-5-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-chloro-benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-benzoimidazol-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide; 2-(1H-indazol-3-yl) 3 H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (3-ethoxy-propyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-bromo-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (naphthalen-1-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-dimethylamino-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-nitro-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-bromo-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-phenoxy-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethoxy-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-trifluoromethyl-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-chloro-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenethyl-amide; 3-(6-phenyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(2,4-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-(6-naphthalen-1-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3-chloro-4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3,5-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-(6-thianthren-1-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-biphenyl-4-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-p-tolyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-m-tolyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-o-tolyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(3-trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-trifluoromethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3,5-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3,4-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-(6-benzo[1,3]dioxol-5-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(4-tert-butyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-(6-hex-1-enyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(3,4-dimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol; 4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol; 3-[6-(3,4-dichloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 1-{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone; 3-(6-benzo[b]thiophen-2-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(3,4,5-trimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 1-{5-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl}-ethanone; 1-{3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-ethanone; 3-[6-(4-benzyloxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(2-fluoro-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-(6-benzo[b]thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole; {3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol; 3-[6-(4-ethylsulfanyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(2,4-difluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3-trifluoromethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-fluoro-2-methyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-{6-[2-(4-fluoro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole; 3-{6-[2-(4-chloro-phenyl)-vinyl]-1H-benzoimidazol-2-yl}-2H-indazole; 3-{4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-propionic acid; {4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol; 3-(6-furan-2-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(3-benzyloxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-isopropyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-methanesulfonyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-acetylamino-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid isopropylamide; [2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-morpholin-4-yl-methanone; [2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-(4-methyl-piperazin-1-yl)-methanone; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzyl-methyl-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-nitro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-difluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4-difluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4,5-trifluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4′-chloro-biphenyl-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3′,5′-dichloro-biphenyl-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (4′-fluoro-biphenyl-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-3-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2′-chloro-biphenyl-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-trifluoromethyl-pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-pyridin-2-yl-thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide; 4-[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide; 2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3-phenyl-allyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(2-methyl-allyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3,7-dimethyl-octa-2,6-dienyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3-bromo-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 3-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxymethyl]-benzonitrile; 2-[5-(4-trifluoromethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3,4-dichloro-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-pentafluorophenylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(4-tert-butyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(2-benzenesulfonylmethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 4-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxymethyl]-benzonitrile; 2-[5-(biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2,3-dichloro-benzenesulfonic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 2-[5-(2-morpholin-4-yl-ethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(2-piperidin-1-yl-ethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3-methoxy-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-p-tolyl-ethanone; 1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3,4,4,4-pentafluoro-butan-2-one; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-biphenyl-4-yl-ethanone; 1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-butan-2-one; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-dimethylamino-phenyl)-ethanone; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(3-phenyl-isoxazol-5-yl)-ethanone; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-N-phenyl-acetamide; 1-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-3,3-dimethyl-butan-2-one; 1-adamantan-1-yl-2-[5-(1H-benzoimidazol-2-yl 1H-pyrazol-3-yloxy]-ethanone; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-naphthalen-2-yl-ethanone; 4-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-benzonitrile; 6-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-3,4-dihydro 1H-quinolin-2-one; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-trifluoromethoxy-phenyl)-ethanone; 5-{2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-acetyl}-2-chloro-benzenesulfonamide; 2-[5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-(4-methoxy-phenyl)-ethanone; 2-[5 (1H-benzoimidazol-2-yl)-1H-pyrazol-3-yloxy]-1-cyclopropyl-ethanone; isonicotinic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 2,2-dimethyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; benzyloxy-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester, benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 4-methoxy-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester, phenyl-acetic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 2,3,4,5,6-Pentafluoro-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; cyclopropanecarboxylic acid 5-(1H-benzoimidazol-2-yl 1H-pyrazol-3-yl ester; 2,2,3,3,4,4,4-heptafluoro-butyric acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; cyclopentanecarboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 3-phenyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester, biphenyl-4-carboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 3,5-bis-trifluoromethyl-benzoic acid 5-(H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 4-trifluoromethyl-benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; thiophene-2-carboxylic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 9 of 19

Preferred compounds of formula (Ixa), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of KDR are:—

2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole, (compound denoted as A9-B3); 2-(5-methyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole (compound denoted as A9-B2); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Preferred compounds of formula (Ixb), denoted as the product of the combination of group A1 in Table 1 and B1 in Table 2, of the invention for the inhibition of KDR are:—

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide, (compound denoted as A17-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide, (compound denoted as A15-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide, (compound denoted as A36-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide, (compound denoted as A37-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide, (compound denoted as A52-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide, (compound denoted as A51-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide, (compound denoted as A92-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N—(N′-methylpiperazino)amide, (compound denoted as A93-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide, (compound denoted as A91-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide, (compound denoted as A82-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide, (compound denoted as A83-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide, (compound denoted as A84-B63); 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide, (compound denoted as A90-B63); 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-ethoxy-propyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (naphthalen-1-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-trifluoromethyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-dimethylamino-benzylamide; 4-({[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-bromo-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1,3-dimethyl-1H-pyrazol-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-trifluoromethyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-phenoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-trifluoromethoxy-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-isopropoxy-propyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-isopropyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,5-dimethyl-furan-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(3-acetylamino-phenoxy)-propyl]-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid ([2,2′]bithiophenyl-5-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-cyano-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (furan-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-nitro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,5-dimethyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (1-methyl-1H-benzoimidazol-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 4-sulfamoyl-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3-methoxy-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid (furan-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-nitro-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 3,5-dimethyl-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid phenylamide; 3-[6-(4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3-chloro-4-fluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-(6-m-tolyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-o-tolyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-thiophen-3-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(3-chloro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3-methoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(3,5-dimethyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-(6-benzo[1,3]dioxol-5-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-(6-hex-1-enyl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(3,4-dimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol; 4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenol; 3-[6-(3,4,5-trimethoxy-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 1-{5-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-thiophen-2-yl}-ethanone; {3-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol; 3-[6-(2,4-difluoro-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 3-[6-(4-fluoro-2-methyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; {4-[2-(2H-indazol-3-yl)-3H-benzoimidazol-5-yl]-phenyl}-methanol; 3-(6-furan-2-yl-1H-benzoimidazol-2-yl)-2H-indazole; 3-[6-(4-isopropyl-phenyl)-1H-benzoimidazol-2-yl]-2H-indazole; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-acetylamino-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid isopropylamide; [2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-morpholin-4-yl-methanone; [2-(1H-indazol-3-yl)-1H-benzoimidazol-5-yl]-(4-methyl-piperazin-1-yl)-methanone; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzyl-methyl-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-nitro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-difluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4-difluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3,4,5-trifluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,6-difluoro-3-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2′-chloro-biphenyl-4-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-trifluoromethyl-pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (5-pyridin-2-yl-thiophen-2-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide; 4-[2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide; 2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3-phenyl-allyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3,7-dimethyl-octa-2,6-dienyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3-bromo-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3,4-dichloro-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(2-benzenesulfonylmethyl-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(biphenyl-4-ylmethoxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; 2-[5-(3-methoxy-benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole; isonicotinic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; benzoic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester; 3-phenyl-propionic acid 5-(1H-benzoimidazol-2-yl)-1H-pyrazol-3-yl ester, methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate; 5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole; 5-bromo 2-(1H-indazol-3-yl)-3H-benzimidazole, (compound denoted as A32-B63); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

›Example 230(a) hereinafter described · 10 of 19

Particularly preferred compounds of formula (Ixb) of the invention for the inhibition of KDR are:—

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-cyclohexylmethyl)amide; 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methanesulfonyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-nitro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-chloro-pyridin-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,3-dihydro-benzofuran-5-ylmethyl)-amide; 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2-methylsulfanyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (benzo[b]thiophen-3-ylmethyl)-amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-chloro-benzylamide; 2-(1H-indazol-3-yl)-3H-benzoimidazole-4-carboxylic acid 2-methylsulfanyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-bromo-2-fluoro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 2,4-dichloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-chloro-2-methyl-benzylamide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,6-difluoro-4-chloro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2,4-dichloro-6-fluoro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-fluoro-4-chloro-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-fluoro-4-chloro-6-methyl-benzyl)amide; 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (6-methoxy-pyridin-3-ylmethyl)-amide; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Particular compounds of formula (Ix) of the invention for the inhibition of ITK are:—

2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide, Example 246(ab); 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide, Example 246(ac); 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide, Example 246(ad); N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide, Example 246(ae) N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide, Example 253(c) and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

The compounds of formula (Ix) of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of formula (Ix) of the invention and compositions containing compounds of formula (Ix) of the invention for use in therapy.

Compounds of formula (Ix) within the scope of the present invention block kinase catalytic activity according to tests described in the literature and in vitro procedures described hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of formula (Ix) of the invention and compositions containing compounds of formula (Ix) of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of protein kinase inhibitors (e.g. Syk, KDR, tie2 or ITK). For example, compounds of formula (Ix) of the present invention are useful in the treatment of inflammatory diseases, for example asthma: atopic dermatitis, inflammatory dermatoses (e.g. psoriasis, dematitis herpetiformis, eczema, necrotizing and cutaneous vasculitis, bullous disease, acute and chronic urticaria,); allergic rhinitis and allergic conjunctivitis; joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. The compounds of formula (Ix) are also useful in the treatment of Chronic Obstructive Pulmonary Disease (COPD), adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, collitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, restenosis, myocarditis, B cell lymphomas, systemic lupus erythematosus, viral infections, bacterial infections, parasitic infections, graft v host disease and other transplant associated rejection events, reperfusion injury, Crohn's disease and ulcerative colitis, cancers and tumours (such as colorectal, prostate, breast, thyroid, colon and lung cancers), atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis, fibrotic diseases of the viscera, and inflammatory bowel disease.

The products of the present patent application as SYK inhibitors may be used for the treatment of diseases chosen from the following: asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, acute and chronic urticaria, cutaneous and systemic anaphylaxis, endotoxemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, diabetes, multiple sclerosis, systemic lupus erythromatosis, viral infections, bacterial infections, parasitic infections, graft vs. host disease, organ transplant rejection, reperfusion injury, Crohn's disease and ulcerative colitis.

›Example 230(a) hereinafter described · 11 of 19

The products of the present patent application as KDR inhibitors may be used especially for the treatment or prevention of diseases chosen from the following group: cancers, especially breast, colon, lung and prostate cancer, atherosclerosis, degenerative muscle diseases, obesity, conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis and fibrotic diseases of the viscera.

A special embodiment of the therapeutic methods of the present invention is the treating of asthma.

Another special embodiment of the therapeutic methods of the present invention is the treating of psoriasis.

Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.

Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.

Another special embodiment of the therapeutic methods of the present invention is the treating of cancers and tumours.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of a protein kinase inhibitor (e.g. Syk, KDR, tie2 or ITK) for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention. “Effective amount” is meant to describe an amount of compound of the present invention effective in inhibiting the catalytic activity a protein kinase, such as. Syk, KDR, tie2 or ITK, and thus producing the desired therapeutic effect.

References herein to treatment should be understood to include prophylactic therapy as well as treatment of established conditions.

The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of formula (Ix) of the invention, as defined above, or a pharmaceutically acceptable salt or a prodrug, in association, where appropriate, with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical compositions of the present invention for the treatment of KDR or tie2 associated disease states can also, where appropriate, contain active principles of other antimitotic medicinal products such as, in particular, those based on taxol, cis-platin, DNA-intercalating agents and the like.

Compounds of formula (Ix) of the invention may be administered by any suitable means. In practice compounds of formula (Ix) of the present invention may generally be administered parenterally, locally by topical application to the skin and mucous membranes, rectally, orally, by inhalation, or by intravenous or intramuscular injection, especially by the oral route.

Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilised by heating, irradiation or microfiltration.

For topical administration, gels (water or alcohol based), creams or ointments containing compounds of formula (Ix) of the invention may be used. Compounds of formula (Ix) of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.

For administration by inhalation compounds of formula (Ix) of the invention may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

›Example 230(a) hereinafter described · 12 of 19

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The compounds of formula (Ix) according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.

Compounds of formula (Ix) of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R. C. Larock in Comprehensive Organic Transformations, VCH publishers, 1989.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T. W. Greene and P. G. M. Wuts in “Protective Groups in Organic Chemistry” John Wiley and Sons, 1991.

Compounds of formula (Ix) wherein W, X, Y, Z and R 1 are as hereinbefore defined for compounds of formula (Ix) and A 5 is H, may be prepared by reaction of compounds of formula (IIx):—

in which W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), with acids of formula (IIIx):—

R 1 —CO 2 H (IIIx)

in which R 1 is as hereinbefore defined for compounds of formula (Ix), at a temperature at about 160° C. Alternatively the reaction may (i) be carried in the presence of hydrochloric acid at about reflux temperature, or polyphosphoric acid at a temperature at about 160° C. or (ii) be carried out in a microwave oven.

Compounds of formula (Ix) wherein W, X, Y, Z and R 1 are as hereinbefore defined and A 5 is H, may be prepared by reaction of compounds of formula (IIx) in which W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), with aldehydes of formula (IVx):—

R 1 CHO (IVx)

in which R 1 is as hereinbefore defined for compounds of formula (Ix), in the presence of in inert solvent, such as dimethylformamide or nitrobenzene, and at a temperature up to about 145° C. Alternatively the reaction may (i) be carried in the presence of sodium bisulfite at a temperature at about reflux temperature or (ii) be carried out in a microwave oven at a temperature up to about 200° C.

Compounds of formula (Ix) wherein W, X, Y, Z and R 1 are as hereinbefore defined for compounds of formula (Ix) and A 5 is H, may be prepared by cyclisation of compounds of formula (Vx):—

wherein W, X, Y, Z and R 1 are as hereinbefore defined for compounds of formula (Ix). The cyclisation may be carried out by heating in the presence of an acid catalyst, such as acetic acid, and at a temperature up to about 120° C.

Compounds of formula (Ixa) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and R 1 is

in which R 9 is as hereinbefore defined for compounds of formula (Ix), R 7 is hydrogen and R 8 is SR 4 , i.e. compounds of formula (Ixaa), may be prepared as shown in scheme 1.

For example diamines of formula (IIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may be treated, in Step 1, with formic acid in the presence of hydrochloric acid at a temperature at about 50° C. The imino group of the resulting compounds of formula (VIx) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may then be protected, in Step 2, with a suitable protecting group, for example when this is a 2-(trimethylsilanyl)ethoxymethyl group the protection is conveniently carried out by (i) reaction with sodium hydride in dimethylformamide then (ii) reaction with 2-(trimethylsilanyl)ethoxymethyl chloride. The resulting compounds of formula (VIIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and R 11 is a suitable protecting group, such as a 2-(trimethylsilanyl)ethoxymethyl group, may then be treated, in Step 3, with (i) lithium diisopropylamide, in an inert solvent, such as tetrahydrofuran, and at a temperature at about −78° C., then (ii) acetamides of formula R 9 —C(═O)—N(CH 3 ) 2 [in which R 9 is as hereinbefore defined for compounds of formula (Ix)]. The resulting compounds of formula (Xx), wherein W, X, Y, Z, R 9 and R 11 are as hereinbefore defined for compounds of formula (Ix), [alternatively prepared by (i) reaction of diamines of formula (IIx) with β-hydroxy-acids of formula R 9 CH 2 CH(OH)CO 2 H [in which R 9 is as hereinbefore defined for compounds of formula (Ix)], in Step 1a, at a temperature at about 70° C., (ii) oxidation, in Step 2a, of the resulting compounds of formula (VIIIx) with manganese dioxide in an inert solvent, such as chloroform, and at a temperature at about 60° C. and (iii) protection of the imino group, in Step 3a, as described in Step 2 above)] may then be treated, in Step 4, with (i) sodium tertiary butoxide, in an inert solvent, such as benzene or tetrahydrofuran, at −5° C., then (ii) carbon disulfide and then (iii) compounds of formula R 4 —X 1 [in which R 4 is as hereinbefore defined for compounds of formula (Ix)] and X 1 is halo. The resulting compounds of formula (XIx), wherein W, X, Y, Z, R 4 , R 9 and R 11 are as hereinbefore defined for compounds of formula (Ix), may then be treated, in Step 5, with hydrazine, in an inert solvent, such as ethanol, and at a temperature from about room temperature to about reflux temperature. The resulting compounds of formula (XIIx), wherein W, X, Y, Z, R 4 , R 9 and R 11 are as hereinbefore defined for compounds of formula (Ix), may then be deprotected {for example when R 11 is a 2-(trimethylsilanyl)ethoxymethyl group by treatment with hydrochloric acid in an inert solvent, such as ethanol, and at a temperature from about room temperature to about reflux temperature}, in Step 6, to liberate the pyrazoles of general formula (Ixaa), wherein W, X, Y, Z, R 4 and R 9 are as hereinbefore defined for compounds of formula (Ix). Compounds of formula (XIx) in which R 11 is a tetrahydropyran-2-yl protecting group may be deprotected by treatment with an acid, such as p-toluenesulfonic acid, in water at reflux temperature and subsequently treated with hydrazine, in an inert solvent, such as ethanol, and at a temperature from about room temperature to about reflux temperature to give pyrazoles of general formula (Ixaa), wherein W, X, Y, Z, R 4 and R 9 are as hereinbefore defined for compounds of formula (Ix).

›Example 230(a) hereinafter described · 13 of 19

Compounds of formula (Ix) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and A 5 is H, and R 1 is

in which R 9 is as hereinbefore defined for compounds of formula (Ix), R 7 is hydrogen and R 8 is OR 4 , i.e. compounds of formula (Ixab), may be prepared as shown in scheme 2.

For example compounds of formula (XIx), wherein W, X, Y, Z, R 9 , R 11 are as hereinbefore defined for compounds of formula (Ix), and R 4 is lower alkyl, may be treated, in Step 1, with the sodium salt of an alcohol of formula R 4 —OH (in which R 4 is lower alkyl), such as sodium ethoxide, followed by treatment with hydrazine as described hereinabove for scheme 1. The resulting compounds of formula (XIIIx), wherein W, X, Y, Z, R 4 , R 9 and R 11 are as hereinbefore defined for compounds of formula (Ix), may then be deprotected [for example when R 11 is a 2-(trimethylsilanyl)ethoxymethyl group by treatment with trifluoroacetic acid at about 50° C.], in Step 2, to liberate the pyrazoles of general formula (Ixab).

Compounds of formula (Ix) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and A 5 is H, and R 1 is

in which R 9 is as hereinbefore defined for compounds of formula (Ix), R 7 is hydrogen and R 8 is —NY 1 Y 2 , i.e. compounds of formula (Ixac), may be prepared as shown in scheme 3.

For example compounds of formula (XIx), wherein W, X, Y, Z, R 9 and R 11 are as hereinbefore defined for compounds of formula (Ix), and R 4 is lower alkyl, may be treated, in Step 3, with an amine of formula HNY 1 Y 2 [in which Y 1 and Y 2 are as hereinbefore defined for compounds of formula (Ix)], e.g. morpholine. The resulting compounds of formula (XIVx), wherein W, X, Y. Z. R 9 , R 11 , Y 1 and Y 2 are as hereinbefore defined for compounds of formula (Ix), and R 4 is lower allyl, may then be treated, in step 2, with hydrazine as described hereinabove for scheme 1. The resulting compounds of formula (XVx), wherein W, X, Y, Z, R 9 , R 11 , Y 1 and Y 2 are as hereinbefore defined for compounds of formula (Ix), may then be deprotected as described hereinabove, in Step 3, to liberate the pyrazoles of general formula (Ixac).

Compounds of formula (Ix) wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix) and A 5 is H, and R 1 is

i.e. compounds of formula (Ixad), may be prepared as shown in scheme 4.

For example compounds of formula (XIx), wherein W, X, Y, Z, R 9 and R 11 are as hereinbefore defined for compounds of formula (Ix), and R 4 is lower alkyl, may be treated, in Step 1, with hydroxylamine in the presence of sodium methoxide and in methanol at reflux temperature. The resulting compounds of formula (XVIx), wherein W, X, Y, Z, R 4 , R 9 and R 11 are as hereinbefore defined for compounds of formula (Ix), may then be deprotected as described hereinabove, in Step 2, to liberate the isoxazoles of general formula (Ixad).

Compounds of the invention of formula (Ix) may also be prepared by interconversion of other compounds of the invention.

Thus, for example, compounds of formula (Ix) containing a carboxy group may be prepared by hydrolysis of the corresponding esters. The hydrolysis may conveniently be carried out by alkaline hydrolysis using a base, such as an alkali metal hydroxide, e.g. lithium hydroxide, or an alkali metal carbonate, e.g. potassium carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature from about ambient to about reflux. The hydrolysis of the esters may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50° C. to about 80° C.

As another example compounds of formula (Ix) containing a carboxy group may be prepared by acid catalysed removal of the tert-butyl group of the corresponding tert-butyl esters using standard reaction conditions, for example reaction with trifluoroacetic acid at a temperature at about room temperature.

As another example compounds of formula (Ix) containing a carboxy group may be prepared by hydrogenation of the corresponding benzyl esters. The reaction may be carried out in the presence of ammonium formate and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol and at a temperature at about reflux temperature. The reaction may alternatively be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

As another example compounds of formula (Ix) containing a carboxy group may be prepared by treatment of compounds of formula I(x) containing a cyano group with hydrochloric acid in acetic acid at a temperature at about 100° C.

As another example of the interconversion process, compounds of formula (Ix) containing a —C(═O)—NY 1 Y 2 group may be prepared by reaction of compounds of formula (Ix) containing a carboxy group with an amine of formula HNY 1 Y 2 to give an amide bond using standard peptide coupling procedures, for example coupling in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, hydroxybenzotriazole and di-isopropylethylamine in an inert solvent, such as dimethylformamide and a temperature up to about 80° C. The reaction may alternatively be carried out in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tetrahydrofuran (or dimethylformamide) at room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a —NH—C(═O)—R 4 group may be prepared by: (i) coupling compounds of formula (Ix) containing an amino group with acids of formula R 4 —CO 2 H using standard coupling conditions as described above; or (ii) by reaction of compounds of formula (Ix) containing an amino group with acid chlorides of formula R 4 —C(═)O—Cl in the presence of a tertiary base, such as di-isopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature. In some instances a bis-acylated derivative is obtained by reaction of compounds of formula (Ix) containing an amino group and in which A 5 is H, with acid chlorides of formula R 4 —C(═)O—Cl. These bis-acylated derivatives may be converted to compounds of formula (Ix) containing a —NH—C(═O)—R 4 group and in which A 5 is H, by treatment with potassium hydroxide in aqueous methanol at a temperature at about 60° C.

›Example 230(a) hereinafter described · 14 of 19

As another example of the interconversion process, compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is —C(═O)R 4 ) may be prepared by reaction of compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is hydrogen) with acid chlorides of formula R 4 —C(═O)—Cl in the presence of a tertiary base, such as di-isopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is —C(═O)NY 1 Y 2 ) may be prepared by reaction of compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is hydrogen) with carbamoyl chlorides of formula Y 1 Y 2 N—C(═O)—Cl in the presence of a tertiary base, such as diisopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is —C(═O)OR 4 ) may be prepared by reaction of compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is hydrogen) with chloroformates of formula R 4 O—C(═O)—Cl in the presence of a tertiary base, such as diisopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is —SO 2 R 4 ) may be prepared by reaction of compounds of formula (Ix) wherein R 1 is a pyrazolyl moiety

in which R 8 and R 9 together with the carbon atoms to which they are attached form a 5 or 6 membered heterocyclic ring containing a NY 5 group (where Y 5 is hydrogen) with sulfonyl chlorides of formula R 4 SO 2 —Cl in the presence of a tertiary base, such as diisopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a —NH—C(═O)—R 4 group, in which R 4 is alkyl substituted by NY 1 Y 2 , may be prepared by (i) coupling compounds of formula (Ix) containing an amino group with the appropriate chloroalkyl acid chloride, in the presence of a tertiary base, such as di-isopropylethylamine, in an inert solvent, such a dichloromethane, and at a temperature at about room temperature, followed by (ii) reaction with an amine of formula HNY 1 Y 2 .

As another example of the interconversion process, compounds of formula (Ix) containing a —N(R 6 )C(═O)NY 1 Y 2 group [in which R 6 is hydrogen, Y 1 is hydrogen and Y 2 is alkenyl, aryl, cycloalkyl, heteroaryl, or optionally substituted alkyl] may be prepared by reaction of compounds of formula (Ix) containing an amino group with isocyanates of formula Y 2 N═C═O [in which Y 2 is alkenyl, aryl, cycloalkyl, heteroaryl, or optionally substituted alkyl], in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a —N(R 6 )C(═O)NY 1 Y 2 group [in which R 6 is hydrogen] may be prepared by reaction of compounds of formula (Ix) containing an amino group with 1,1-carbonyldiimidazole in an inert solvent such as tetrahydrofuran and at a temperature at about 60° C. followed by reaction with an amine of formula HNY 1 Y 2 .

As another example of the interconversion process, compounds of formula (Ix) containing an amino group may be prepared by reduction of the corresponding compounds of formula (Ix) containing a nitro group. For example, the reduction may conveniently be carried out by hydrogenation in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol. The reduction may also conveniently be carried out by means of reaction with tin chloride, in an inert solvent, such as methanol or ethanol, and at a temperature at about reflux temperature. Alternatively the reaction with tin chloride may be carried out in a microwave oven at a temperature at about 140° C.

As another example of the interconversion process, compounds of formula (Ix) containing a —CH 2 OH group may be prepared by the reduction of corresponding compounds of formula (Ix) containing a —CHO or —CO 2 lower alkyl group. For example, the reduction may conveniently be carried out by means of reaction with lithium aluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature from about room temperature to about reflux temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a —CH(OH)R 4 group may be prepared by treating compounds of formula (Ix) containing a —C(═O)R 4 group with diisobutylaluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature from about −78° C. to about room temperature.

›Example 230(a) hereinafter described · 15 of 19

As another example of the interconversion process, compounds of formula (Ix) in which R 1 is aryl or heteroaryl substituted by hydroxy may be prepared by reaction of the corresponding compounds of formula (Ix) in which R 1 is aryl or heteroaryl substituted by methoxy with a Lewis acid, such as boron tribromide, in an inert solvent, such as dichloromethane, and at a temperature from about 0° C. to about room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing sulfoxide linkages may be prepared by the oxidation of corresponding compounds containing —S— linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulfate in a medium such as aqueous methanol, buffered to about pH 5, at temperatures between about 0° C. and room temperature. This latter method is preferred for compounds containing an acid-labile group.

As another example of the interconversion process, compounds of formula (Ix) containing sulfone linkages may be prepared by the oxidation of corresponding compounds containing —S— or sulfoxide linkages. For example, the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a cyano group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a —C(═O)—NH 2 group with phosphorus pentachloride in the presence of triethylamine. The reaction may conveniently be carried out in an inert solvent, such as tetrahydrofuran, and at a temperature at about reflux temperature.

As another example of the interconversion process, compounds of formula (Ix) containing a —C(═O)NH 2 group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a cyano group with hydrogen peroxide in the presence of sodium hydroxide. The reaction may conveniently be carried out in methanol at a temperature at about room temperature. Alternatively compounds of formula (Ix) containing a —C(═O)—NH 2 group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a cyano group with hydrochloric acid in acetic acid at a temperature from about 80° C. to about 100° C.

As another example of the interconversion process, compounds of formula (Ix) containing a tetrazolyl group may be prepared by reaction of the corresponding compounds of formula (Ix) containing a cyano group with azidotributyltin. The reaction may conveniently be carried out in an inert solvent, such as toluene, and at a temperature at about reflux temperature.

According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

Compounds of this invention can be regenerated from their acid addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.

The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.

Intermediates of formula (IIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may be prepared by reduction of the corresponding nitro compounds of formula (1):

wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix). For example, the reduction may conveniently be carried out by means of reaction with tin chloride, in an inert solvent, such as methanol or ethanol, and at a temperature at about reflux temperature. Alternatively the reaction may be carried out in a microwave oven at a temperature at about 140° C.

Intermediates of formula (IIx), wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), may also be prepared by reduction of the corresponding dinitro compounds of formula (2):

›Example 230(a) hereinafter described · 16 of 19

wherein W, X, Y and Z are as hereinbefore defined for compounds of formula (Ix), with tin chloride as above.

Nitro compounds of formula (1), wherein W is CH, X is C—R 2 , Y is C—R 3 and Z is CH [in which R 3 is as hereinbefore defined for compounds of formula (Ix)], may be prepared from the corresponding anilines of formula (3)

wherein X is C—R 2 and Y is C—R 3 [in which R 3 is as hereinbefore defined for compounds of formula (Ix)], by (i) reaction with acetic anhydride in the presence of triethylamine, in an inert solvent, such as dichloromethane, and at a temperature from about 0° C. to about room temperature, (ii) reaction with nitric acid in the presence of acetic acid and acetic anhydride at a temperature at about −5° C. and (iii) reaction with an alkali metal alkoxide, such as sodium methoxide, in methanol and at room temperature.

Nitro compounds of formula (1), wherein W is CH, X is C—R 2 (in which R 2 is alkyl), Y is C—R 3 (in which R 3 is an aryl or heteroaryl group) and Z is CH may be prepared by reaction of compounds of formula (4):

wherein X is C—R 2 (in which R 2 is alkyl) and X 2 is bromo or iodo, with an aryl (or heteroaryl) boronic acid in the presence of a suitable catalyst, such as tetrakis(triphenylphosphine)palladium, in an inert solvent, such as tetrahydrofuran, and at a temperature at about 85° C.

Intermediates of formula (IIIx), wherein R 1 is

in which R 7 is hydrogen, R 8 is alkyl and R 9 is hydrogen or alkyl may be prepared by reaction of compounds of formula (5):

wherein R 8 is alkyl and R 9 is hydrogen, with hydrazine in the presence of acetic acid at reflux temperature, followed by hydrolysis.

Intermediates of formula (IIIx), wherein R 1 is

in which R 7 is hydrogen and R 8 and R 9 together with the carbon atoms to which they are attached form a 5, 6 or 7 membered carbocyclic ring may be similarly prepared by reaction of compounds of formula (5) wherein R 8 and R 9 together with the carbon atoms to which they are attached form a 5, 6 or 7 membered carbocyclic ring, with hydrazine, followed by hydrolysis.

Intermediates of formula (IIIx), wherein R 1 is

in which R 7 is hydrogen, R 13 is alkyl and X 1 is O, S, SO 2 , or NY 5 (where Y 5 is R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 or —SO 2 R 4 ) may be similarly prepared by reaction of compounds of formula (6):

wherein R 13 is alkyl and X 1 is O, S, SO 2 , or NY 5 (where Y 5 is R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 or —SO 2 R 4 ), with hydrazine, followed by hydrolysis.

Compounds of formula (5), wherein R 8 is alkyl and R 9 is hydrogen, may be prepared by reaction of compounds of formula (7):

wherein R 8 is alkyl, with diethyl oxalate, in the presence of an alkali metal alkoxide, such as sodium ethoxide, in an inert solvent, such as ethanol, and at a temperature at about 60° C.

Compounds of formula (5), wherein R 8 and R 9 together with the carbon atoms to which they are attached form a 5, 6 or 7 membered carbocyclic ring may be similarly prepared by reaction of cyclopentanone, or cyclohexanone, with diethyl oxalate.

Compounds of formula (6), wherein R 13 is alkyl and X 1 is O, S, SO 2 , or NY 5 (where Y 5 is R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 or —SO 2 R 4 ) may be similarly prepared by reaction of compounds of formula (8):

wherein R 13 is alkyl and X 1 is O, S, SO 2 , or NY 5 (where Y 5 is R 4 , —C(═O)R 4 , —C(═O)NY 1 Y 2 , —C(═O)OR 4 or —SO 2 R 4 ), with diethyl oxalate.

Intermediates of formula (IVx), wherein R 1 is as hereinbefore defined for compounds of formula (Ix), may be prepared by oxidation of compounds of formula (9):

R 1 —CH 2 OH (9)

wherein R 1 is as hereinbefore defined for compounds of formula (Ix). The oxidation may conveniently be carried out with manganese dioxide, or pyridinium chlorochromate, in an inert solvent, such as chloroform, or dichloromethane, and at a temperature at about 60° C. This procedure is particularly suitable for intermediates of formula (IVx) wherein R 1 is

(in which R 10 and p are as hereinbefore defined).

Compounds of formula (9), wherein R 1 is as hereinbefore defined for compounds of formula (Ix), may be prepared by reduction of acids of formula (10):

R 1 —CO 2 H (10)

wherein R 1 is as hereinbefore defined for compounds of formula (Ix). The reduction may conveniently be carried out with lithium aluminium hydride, in an inert solvent, such as tetrahydrofuran, and at a temperature at about room temperature.

Compounds of formula (9), wherein R 1 is as hereinbefore defined for compounds of formula (Ix), may be prepared by reduction of alkyl esters of formula (10a):

R 1 —CO 2 alkyl (10a)

Acids of formula (10), wherein R 1 is

(in which R 10 and p are as hereinbefore defined), may be prepared by reaction of indole-diones of formula (11):

wherein R 10 and p are as hereinbefore defined, with (i) sodium hydroxide at 50° C., (ii) sodium nitrite then sulfuric acid at 5° C. and (iii) tin (II) chloride.

Indole-diones of formula (11), wherein R 10 is as hereinbefore defined and p is one, may be prepared by reaction of compounds of formula (12):

wherein R 10 is as hereinbefore defined, with polyphosphoric acid at a temperature at about 80° C.

Compounds of formula (12), wherein R 10 is as hereinbefore defined, may be prepared by reaction of anilines of formula (13):

wherein R 10 is as hereinbefore defined, with chloral hydrate and hydroxylamine in the presence of hydrochloric acid at a temperature at about 80° C.

Intermediates of formula (Vx), wherein W, X, Y, Z and R 1 are as hereinbefore defined for compounds of formula (Ix), may be prepared by reaction of compounds of formula (1) with acid chlorides of formula R 1 —C(═O)—Cl, optionally in the presence of a tertiary base, such as pyridine, and in an inert solvent, such as dichloromethane, at a temperature at about room temperature.

›Example 230(a) hereinafter described · 17 of 19

The following references are also cited, which may be used for the preparation of benzimidazoles, pyrazoles or indazoles in the context of the present invention:

G. R. Newkome, W. W. Paudler, Comtemporary Heterocyclic Chemistry, Syntheses, Reactions and Applications, J. Wiley, 1982 Preston, Heterocyclic Compounds, Benzimidazoles and congeneric tricyclic compounds, J. Wiley, 1981 Behr, Fusco, Jarboe, Heterocyclic Compounds, Pyrazoles, Pyrazolines, Pyrazolidines, indazoles and condensed rings, J. Wiley, 1967.

The following schemes, schemes 5 to 13, illustrate the synthesis of specific examples within the specification using the processes hereinbefore described with the use of appropriate protecting groups where necessary.

The present invention is further exemplified but not limited by the following illustrative Examples and Reference Examples.

400M Hz 1 H nuclear magnetic resonance spectra (NMR) were recorded on a Varian Unity INOVA machine. In the nuclear magnetic resonance spectra (NMR) the chemical shifts (δ) are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances: s=singlet; d=doublet; t=triplet; m=multiplet; q=quartet; dd=doublet of doublets; ddd=doublet of double doublets.

The thin layer chromatography (TLC) R F values were determined using Merck silica plates.

High Pressure Liquid Chromatography-Mass Spectrometry (LC-MS) conditions for determination of retention times (R T ) and associated mass ions were as follows:—

Method A:

Mass Spectrometer (MS)—LCT Time-of-Flight (Micromass UK Ltd) Serial No. KA014 [Ionization Mode: Electrospray (Positive Ion); Scan: Tof MS (Full Scan m/z 100-1200, sum for 0.4 s @ 50 us/scan) Centroid Mode]. Liquid Chromatograph (LC): Hewlett Packard HP1100 Series Binary Pump (Serial # US80301343)& Degasser (serial # JP73008973). Hypersil BDS C-18, 3μ (4.6 mm×50 mm), Reverse Phase Column operated under gradient elution conditions using (A) water containing 0.05% trifluoroacetic acid and (B) acetonitrile containing 0.05% trifluoroacetic acid as the mobile phase (gradient: 0.00 minutes, 100% A; linear gradient to 100% B at 2 minutes; then hold until 1.5 minutes); flow rate 1 ml/minute to column & to UV detector, flow split after UV detector such that 0.75 ml/minute to ELS detector and 0.25 ml/minute to mass spectrometer; injection volume 10 μl; Auxiliary Detectors: (i) Hewlett Packard Model BP1100 Series UV detector (serial # JP73704703) wavelength=220 nm; (ii) Sedere (France) Model SEDEX 75 Evaporative Light Scattering (ELS) detector (serial #9970002A); temperature=46° C., Nitrogen pressure=4 bar; Autosampler/Injector: Gilson Model 215 Liquid Handler with Model 819 injection valve (serial #259E8280).

Method B:

Waters Symmetry C8 3.5 μm HPLC column operated under gradient conditions with mixtures of (A) water containing 0.1% formic and (B) acetonitrile containing 0.1% formic acid as the mobile phase (gradient: 0.00 minutes, 95% A:5% B; 0.75 minutes, 95% A:5% B; 3.00 minutes 100% B; 4.00 minutes 100% B; 4.25 minutes 95% A:5% B); flow rate 1.5 ml/minute with approximately 200 μl/minute split to the Mass Spectrometer; injection volume 20 μl; in line Diode Array (210-300 nm), in line Evaporative light scattering (ELS) detection ELS—temperature 40° C., Gain 7-1.5 m/minute; Source temperature 150° C.

Method C:

Waters Symmetry C8 3.5 μm HPLC column operated under gradient conditions with mixtures of (A) water containing 10 mM ammonium acetate and (B) methanol containing 10 mM ammonium acetate as the mobile phase (gradient: 0.00 minutes, 95% A:5% B; 0.75 minutes, 95% A:5% B; 3.00 minutes 100% B; 4.00 minutes 100% B; 4.25 minutes 95% A:5% B); flow rate 1.5 mL/minute with approximately 200 μl/minute split to the Mass Spectrometer; injection volume 20 μl; in line Diode Array (210-300 nm), in line Evaporative light scattering (ELS) detection ELS—temperature 40° C., Gain 7-1.5 ml/minute; Source temperature 150° C.

Method D:

C8 Phenomenex Luna 5 μm (250×4.6 mm) HPLC column operated under gradient conditions with mixtures of (A) methanol containing 10 mM ammonium acetate and (B) water containing 10 mM ammonium acetate as the mobile phase (gradient: 0 to 2 minutes 10% A:90% B; 2 to 23 minutes ramp up to 100% A; 23 to 30 minutes 100% A; 30 to 37 minutes 10% A:90% B); flow rate 1 ml/minute.

Method E:

Mass Spectrometer (MS)—LCT Time-of-Flight (Micromass UK Ltd) Serial No. KA014 [Ionization Mode: Electrospray (Positive Ion); Scan: Tof MS (Full Scan m/z 100-1200, sum for 0.4 s @ 50 us/scan) Centroid Mode]. Liquid Chromatograph (LC): Hewlett Packard HP1100 Series Binary Pump (Serial # US80301343)& Degasser (serial # JP73008973). Synergi 2U Hydro reverse phase 20×4 mm column. solvent A 0.1% trifluoroacetic acid in water, Solvent B 0.1% trifluoroacetic acid in acetonitrile. Gradient 5% B at time 0 to 90% B at time 2 minutes to 100% B at 5 minutes; flow rate 1 ml/minute to column & to UV detector, flow split after UV detector such that 0.75 m/minute to ELS detector and 0.25 ml/minute to mass spectrometer; injection volume 10 μl; Auxiliary Detectors: (i) Hewlett Packard Model HP1100 Series UV detector (serial # JP73704703) wavelength=220 nm; (ii) Sedere (France) Model SEDEX 75 Evaporative Light Scattering (ELS) detector (serial #9970002A); temperature=46° C., Nitrogen pressure=4 bar; Autosampler/Injector: Gilson Model 215 Liquid Handler with Model 819 injection valve (serial #259E8280).

Method F:

Agilent 1100 Series HPLC with a YMC CombiScreen Pro C18 5.5 μm 4.6 mm by 33 mm reverse phase column using gradient elution with a mixture of (A) acetonitrile/0.1% trifluoroacetic acid and (B) water/0.1% trifluoroacetic acid (5% A:95% B to 95% A:5% B over 5.1 minutes) with a 1.2 mL/minute flow rate; Agilent 1100 Series wellplate autosampler with 2 μL injection; Agilent 1100 Series diode array detector with 215, 254 and 300 nM wavelength detection; Hewlett Packard 1100 Series mass spectrometer with electrospray and positive ionisation.

Method G:

Rainin HPXL dual pump HPLC system with a Rainin Dynamax UV-D II detector for 254 nM wavelength, C18 Metachem Monochrom 10 μM (100×4.6 mm) column using gradient elution with a mixture of (A) water with 0.1% trifluoroacetic acid and (B) acetonitrile as the mobile phase (90% A:10% B to 0% A in 12 minutes) with a flow rate of 1.0 ml/minute

›Example 230(a) hereinafter described · 18 of 19

C18 Phenomenex Luna 5 μM (150×4.6 mm) column using gradient elution with a mixture of (A) methanol and (B) water with 10 mM ammonium acetate as the mobile phase (0-2 minutes 10% A:90% B; 2-25 minutes ramp up to 100% A; 25-32 minutes 100% A; 32-33 minutes 10% A:90% B) with a flow rate of 1.0 ml/minute.

Method H:

Waters Symmetry C8 3.5 μM Column (50×4.6 mm) using gradient elution with a mixture of (A) water/0.1% formic acid and (B) acetonitrile/0.1% formic acid (5% B:95% A to 100% B in 3.5 min, 100% B for 1 min, 100% B to 5% B:95% A in 0.1 min, Equilibrate 5% B:95% A 0.49 minutes, Total run time 5 min) with a flow rate of 1.5 mL/minute; Detection 210-300 nM, 2 nM range interval; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 140 to 850 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method J:

Waters Symmetry C8 3.5 μM Column (50×4.6 mm) using gradient elution with a mixture of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile (5% B:95% A 0.75 minutes to 100% B in 4 minutes, 100% B for 0.5 minutes, 100% B to 5% B:95% A in 1 minute, Total run time 5 minutes with a flow rate of 1.5 mL/minute; Detection 210-300 nM, 2 nM range interval; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 140 to 850 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method K:

Waters Symmetry C8 3.5μ Column (50×4.6 mm) using gradient elution with a mixture of (A) 10 mM ammonium acetate in water and (B) 10 mM ammonium acetate in methanol (5% B:95% A 0.75 minutes to 100% B in 4 minutes, 100% B for 0.5 minutes, 100% B to 5% B:95% A in 1 minute, Total run time 5 min) with a flow rate of 1.5 mL/minute; Detection 210-300 nM, 2 nm range interval; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 140 to 850 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method L:

Phenomenex Luna C18(2) 3 μM Column (150×4.6 mm) using gradient elution with a mixture of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile (20% B:80% A to 100% B in 10 minutes, 100% B for 2 minutes, 100% B to 20% B:80% A in 0.5 minutes, 20% B:80% A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0 mL/minute; 210-300 nM, 220 and 254 nM extracted and ELSD; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 100 to 900 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method M:

Phenomenex Luna C18(2) 3 μM Column (150×4.6 mm) using gradient elution with a mixture of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile (5% B:95% A to 60% B:40% A in 10 minutes, 60% B:40% A for 2 minutes, 60% B:40% A to 5% B:95% A in 0.5 minutes, 5% B:95% A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0 mL/minute; 210-300 nM, 220 and 254 nM extracted and ELSD; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 100 to 900 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method N:

Waters Symmetry C8 3.5 μM Column (50×4.6 mm) using gradient elution with a mixture of (A) 10 mM ammonium acetate in water and (B) 10 mM ammonium acetate in methanol (5% B:95% A to 100% B in 3.5 minutes, 100% B for 1 minute, 100% B to 5% B:95% A in 0.1 minute, Equilibrate 5% B:95% A 0.49 minutes, Total run time 5 minutes) with a flow rate of 1.5 mL/minute; Detection 210-300 nM, 2 nM range interval; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 140 to 850 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method P:

Phenomenex Luna C18(2) 3 μM Column (150×4.6 mm) using gradient elution with a mixture of (A) 10 mm ammonium acetate in water and (B) 10 mm ammonium acetate in methanol (5% B:95% A to 60% B:40% A in 10 minutes, 60% B:40% A for 2 minutes, 60% B:40% A to 5% B:95% A in 0.5 minutes, 5% B:95% A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0 mL/minute; 210-300 nM, 220 and 254 nM extracted and ELSD; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 100 to 900 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method Q:

Phenomenex Luna C18(2) 3 μM Column (150×4.6 mm) using gradient elution with a mixture of (A) 10 mm ammonium acetate in water and (B) 10 mm ammonium acetate in methanol (20% B:80% A to 100% B in 10 minutes, 100% B for 2 minutes, 100% B to 20% B:80% A in 0.5 minutes, 20% B:80% A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0 mL/minute; 210-300 nM, 220 and 254 nM extracted and ELSD; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 100 to 900 Da, 0.6 sec scan, 0.4 sec inter scan delay.

Method R:

Phenomenex Luna C18(2) 5 μM Column (150×4.6 mm) using gradient elution with a mixture of (A) 10 mm ammonium acetate in water and (B) 10 mm ammonium acetate in methanol (40% B:60% A to 100% B in 10 minutes, 100% B for 2 minutes, 100% B to 40% B:60% A in 0.5 minutes, 40% B:60% A for 3.5 minutes, Total run time 16 minutes with a flow rate of 1.0 mL/minute; 210-300 nM, 220 and 254 nM extracted and ELSD; Column Temp 30° C.; Mass Spec Quadrupole, Electrospray, cone voltage 25V, +/−ion switching, centroid data, 100 to 900 Da, 0.6 sec scan, 0.4 sec inter scan delay.

High Pressure Liquid Chromatography conditions for determination of retention times (R T ) were as follows:—

Method A1:

YMC ODS-AQ (2×50 mm) column using gradient elution conditions with mixtures of acetonitrile, water and formic acid as the mobile phase [95/5/0.1% to 5/95/0.1%] and a flow rate of 0.4 mL/minute.

Method B1:

C18 Phenomenex Luna 5 μM (150×4.6 mm) column using gradient elution with a mixtures of (A) acetonitrile containing 0.1% formic acid and (B) water containing 0.1% formic acid as the mobile phase (gradient: 0-2 minutes 10% A:90% B; 2-25 minutes ramp up to 100% A; 25-32 minutes 100% A; 32-33 minutes 10% A:90% B) with a flow rate of 1.0 ml/minute.

›Example 230(a) hereinafter described · 19 of 19

Method C1:

Method D1:

C18 Phenomenex Luna 3 μM (150×4.6 mm) column using gradient elution with a mixture of (A) acetonitrile containing 0.1% formic acid and (B) water containing 0.1% formic acid with a flow rate of 1.0 ml/minute

Method E1:

C18 Phenomenex Luna 3 μM (150×4.6 mm) column using gradient elution with a mixture of (A) methanol and (B) water with 10 mM ammonium acetate as the mobile phase (20% A:80% B to 100% A in 10 minutes; 100% A for 2 minutes; 100% Ato 20% A:80% B in 0.5 minutes; 20% A:80% B for 3.5 minutes) with a flow rate of 1.0 ml/minute.

Method F1:

C18 Phenomenex Luna 3 μM (150×4.6 mm) column using gradient elution with a mixture of acetonitrile and water with 0.1% formic acid.

Method G1:

C18 Phenomenex Luna 3 μM (150×4.6 mm) column using gradient elution with a mixture of (A) methanol and (B) water with 10 mM ammonium acetate as the mobile phase (5% A; 95% B to 60% A:40% B in 10 minutes; 60% A:40% B for 2 minutes; 60% A:40% B to 5% A:95% B in 0.5 minutes; 5% A:95% B for 3.5 minutes) with a flow rate of 1.5 ml/minute.

Gas Chromatography-Mass Spectrometry (GC-MS) conditions for determination of retention times (R T ) and associated mass ions were as follows:

Varian 3800 Gas Chromatograph with Chrompack 0.25 mm diameter fused silica 30 m column using a 20 minute elution with 25° C./minute gradient from 50 to 300° C. from time 1 to 11 minute; helium mobile phase with 1.2 mL/minute flow rate; 3-8 μL injection volume with 50:50 injection split ratio; Varian 2000R mass spectrometer with electron impact detection for ions 40 to 650 m/z.

General method of LC-MS purification of examples 1 to 229: a Waters Fraction Lynx system is used, and the separations were carried out on a Waters Symmetry column (C18, 5 μM, 19×50 mm, catalogue number 186000210), eluting with a linear gradient of acetonitrile containing 0.07% trifluoroacetic acid (v/v) in water containing 0.07% trifluoroacetic acid (v/v), gradient rising from 5% to 95% (v/v) of acetonitrile/trifluoroacetic acid over 8 minutes, and then 2 minutes at 95% acetonitrile/trifluoroacetic acid at a flow rate of 10 ml/minute. The products are injected in solution in dimethylsulfoxide, and collected according to the detection of their molecular weight.

Compound names were generated using an auto-nom plug in for ISIS2.3 or ISIS2.4.

›EXAMPLE 1

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide may be prepared in the following manner.

A solution of 27.3 mg of HBTU in 0.2 ml of dimethylformamide is added, at a temperature in the region of 20° C., to a solution of 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid in 0.42 ml of anhydrous dimethylformamide. After stirring at a temperature in the region of 20° C. for one hour, 15.7 ml of benzylamine are added, followed by addition of 12.4 ml of N,N-diisopropylethylamine dissolved in 0.32 ml of dimethylformamide. After 20 hours, at a temperature in the region of 20° C., the reaction medium is concentrated under reduced pressure, at a temperature in the region of 40° C. The crude residue obtained is dissolved in DMSO and purified by preparative LC-MS. The fractions containing the desired product are combined and concentrated under reduced pressure at a temperature in the region of 40° C. 20 mg of 21H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid benzylamide are thus obtained in the form of a cream-coloured powder, the characteristics of which are as follows:

LC-MS retention time=2.86 minutes

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid may be prepared in the following manner: 1.3 g of sodium metabisulphite and 1.04 g of 3,4-diaminobenzoic acid are added, at a temperature in the region of 20° C., to a solution of 1 g of 1H-indazole-3-carboxaldehyde in 10 ml of dimethylformamide. The reaction mixture is refluxed for one hour and then cooled to a temperature in the region of 20° C. and diluted with dichloromethane, and the mixture is filtered. The collected filtrate is concentrated under reduced pressure. The brown lacquer obtained (340 mg) is purified by preparative LC-MS. 138.8 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid are thus obtained in the form of a beige-coloured powder.

1H-Indazole-3-carboxaldehyde may be prepared in the following manner:

A solution of 2.27 g of (1H-indazol-3-yl)methanol in 220 ml of 1,2-dimethoxyethane is added to 13.32 g of manganese dioxide. After one hour at a temperature in the region of 20° C., the reaction mixture is refluxed for 15 minutes. After cooling to a temperature in the region of 20° C., the reaction medium is filtered through a sinter funnel packed with Celite. The collected filtrate is concentrated under reduced pressure at a temperature in the region of 40° C. 2.02 g of 1H-indazole-3-carboxaldehyde are thus obtained in the form of a yellow powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 7.40 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.75 ppm (doublet, 1H); 8.18 ppm (doublet, 1H); 10.23 ppm (singlet, 1H); 14.2 ppm (multiplet, 1H).

(1H-Indazol-3-yl)methanol may be prepared in the following manner:

3.2 g of lithium aluminium hydride are added portionwise to a solution of 7.08 g of methyl 3-indazolecarboxylate in 80 ml of tetrahydrofuran, cooled to a temperature in the region of 0° C. by an ice bath. After 4 hours at a temperature in the region of 0° C., 1.6 g of lithium aluminium hydride are added. After 2 hours at a temperature in the region of 0° C., the reaction medium is treated successively with 6 ml of water and then 6 ml of aqueous 1N sodium hydroxide solution and finally 18 ml of water. The reaction mixture is filtered through paper and the aqueous filtrate is then extracted with dichloromethane. The collected organic fractions are combined, dried over magnesium sulphate and concentrated under reduced pressure at a temperature in the region of 40° C. 3.15 g of (1H-indazol-3-yl)methanol are obtained in the form of an off-white powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 4.80 ppm (doublet, 21); 5.25 ppm (triplet, 1H); 7.15 ppm (triplet, 1H); 7.35 ppm (triplet, 1H); 7.51 ppm (doublet, 1H); 7.87 ppm (doublet, 1H); 12.81 ppm (multiplet, 1H).

Methyl 3-indazolecarboxylate may be prepared in the following manner:

0.5 ml of concentrated sulphuric acid (95%) is added dropwise, at a temperature in the region of 20° C., to a solution of 9.13 g of 3-indazolecarboxylic acid in 100 ml of methanol. After refluxing for 20 hours, the reaction medium is concentrated under reduced pressure at a temperature in the region of 40° C. The aqueous residue obtained is extracted with dichloromethane. The organic phases are combined, washed with water until neutral, dried over magnesium sulphate and then concentrated under reduced pressure at a temperature in the region of 40° C. The yellow powder obtained is washed with ethyl ether. A white powder is obtained. The filtrate is concentrated under reduced pressure until a yellow powder is obtained. This yellow powder is washed again with ethyl ether until a white powder is obtained. The yellow filtrate is concentrated a third time under reduced pressure and the yellow powder collected is itself also washed with ethyl ether. All the fractions of white powder are combined. 7.08 g of methyl 3-indazolecarboxylate are thus obtained in the form of a white powder.

›EXAMPLE 2

2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-methylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 71.8 μl of a methylamine solution (2M in tetrahydrofuran), 14.8 mg of expected product are obtained.

›EXAMPLE 3

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 19.4 ml of an ethylamine solution (33% in water) 14.8 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-ethylamide are obtained.

›EXAMPLE 4

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 12.3 ml of isopropylamine, 16.5 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-isopropylamide are obtained.

›EXAMPLE 5

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 13.1 ml of aniline, 14.1 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenylamide are obtained in the form of a white powder.

›EXAMPLE 6

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 18 ml of phenethylamine, 17.7 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-phenethylamide are obtained in the form of a white powder.

›EXAMPLE 7

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 12.5 ml of morpholine, 18.6 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-morpholinoamide are obtained in the form of a pale yellow powder.

›EXAMPLE 8

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N—(N′-methyl-piperazino)amide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N—(N′-methyl-piperazino)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 15.9 ml of N-methylpiperazine, 16.1 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N—(N′-methyl-piperazino)amide are obtained in the form of a yellow oil.

›EXAMPLE 9

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 12 ml of pyrrolidine, 17.7 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-pyrrolidinoamide are obtained in the form of a pale yellow powder.

›EXAMPLE 10

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 14.6 ml of isobutylamine, 7.6 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(isobutyl)amide are obtained in the form of a pale yellow powder.

›EXAMPLE 11

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(cyclohexylmethyl)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 18.7 ml of cyclohexylmethylamine, 16.1 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-cyclohexylmethyl)amide are obtained in the form of a white powder.

›EXAMPLE 12

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 13.3 ml of 2-furfurylamine, 14.8 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-(2-furfuryl)amide are obtained in the form of a white powder.

›EXAMPLE 13

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide

2-(1H-Indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide may be prepared by following the procedure for the preparation of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzylamide (Example 1):

Starting with 20 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid and 18.6 ml of N-methylbenzylamine, 7.3 mg of 2-(1H-indazol-3-yl)-1H-benzimidazole-5-carboxylic acid N-benzyl-N-methylamide are obtained in the form of a pale yellow powder.

›EXAMPLE 14

Methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate

Methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate may be prepared in the following manner:

A mixture of 0.1 g of 1H-indazole-3-carboxaldehyde and 113.7 mg of methyl 3,4-diaminobenzoate in 10 ml of nitrobenzene is maintained at a temperature in the region of 145° C. for 3 hours and 45 minutes. After cooling to a temperature in the region of 20° C., the reaction mixture is purified on SPE (5 g of SCX phase, processing and washing with methanol, extraction with a 2N ammoniacal methanol solution). The ammoniacal solution collected during the detachment is then concentrated under reduced pressure at a temperature in the region of 40° C. 198.3 mg of an orange lacquer are obtained and are purified by preparative LC-MS. 42.7 mg of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate are thus obtained in the form of a beige-coloured powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 3.95 ppm (singlet, 3H); 7.40 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.75 ppm (doublet, 1H); 7.77 ppm (doublet, 1H); 7.95 ppm (doublet, 1H); 8.57 ppm (doublet, 1H); 13.85 ppm (multiplet, 1H).

›EXAMPLE 15

5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole

5,6-Dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole may be prepared by following the procedure for the preparation of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate (Example 14):

Starting with 200 mg of 1H-indazole-3-carboxaldehyde and 177 mg of 4,5-dimethyl-1,2-phenylenediamine in 10 ml of nitrobenzene, 15.9 mg of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole are obtained in the form of a dark red powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 2.60 ppm (singlet, 6H); 7.42 ppm (triplet, 1H); 7.53 ppm (singlet, 2H); 7.58 ppm (triplet, 1H); 7.78 ppm (doublet, 1H); 8.52 ppm (doublet, 1H); 14.05 ppm (multiplet, 1H).

5,6-Dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole may also be prepared according to the following procedure:

389 mg of sodium metabisulphite are added, at a temperature in the region of 20° C., to a solution of 300 mg of 1H-indazole-3-carboxaldehyde and 279 mg of 4,5-dimethyl-1,2-phenylenediamine in 3 ml of dimethylformamide. The reaction mixture is refluxed for 4 hours and then cooled to a temperature in the region of 20° C. and filtered through paper. The collected filtrate is concentrated under reduced pressure. The brown lacquer obtained (340 mg) is purified by preparative LC-MS. 138.8 mg of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole are thus obtained in the form of a beige-coloured powder.

›EXAMPLE 16

5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole

5-Methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole may be prepared by following the procedure for the preparation of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate (Example 14):

Starting with 200 mg of 1H-indazole-3-carboxaldehyde and 274.4 mg of 4-methoxy-1,2-phenylenediamine dihydrochloride in 10 ml of nitrobenzene, 45.6 mg of 5-methoxy-2-(1H-indazol-3-yl)-1H-benzimidazole are obtained in the form of a light brown powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 3.90 ppm (singlet, 3H); 7.00 ppm (doublet, 1H); 7.18 ppm (doublet, 1H); 7.40 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.64 ppm (doublet, 1H); 7.73 ppm (doublet, 1H); 8.52 ppm (doublet, 1H); 13.91 ppm (multiplet, 1H).

›EXAMPLE 17

2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid

2-(1H-Indazol-3-yl)-3H-benzimidazole-4-carboxylic acid may be prepared by following the procedure for the preparation of methyl 2-(1H-indazol-3-yl)-3H-benzimidazole-5-carboxylate (Example 14):

Starting with 237 mg of 1H-indazole-3-carboxaldehyde and 305.5 mg of 2,3-diaminobenzoic acid hydrochloride in 10 ml of nitrobenzene, 20.5 mg of 2-(1H-indazol-3-yl)-3H-benzimidazole-4-carboxylic acid are obtained in the form of a beige-coloured powder, the characteristics of which are as follows:

1H NMR, DMSO d6, 400 MHz: 7.40 ppm (triplet, 1H); 7.42 ppm (triplet, 1H); 7.55 ppm (triplet, 1H); 7.72 ppm (doublet, 1H); 7.90 ppm (doublet, 1H); 8.02 ppm (doublet, 1H); 8.52 ppm (doublet, 1H); 13.68 ppm (multiplet, 1H).

›EXAMPLE 18

5-bromo-2-(1H-indazol-3-yl)-3H-benzimidazole

5-Bromo-2 (1H-indazol-3-yl)-3H-benzimidazole may be prepared by following the procedure for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 643 mg of 1H-indazole-3-carboxaldehyde, 816 mg of 4-bromo-1,2-phenylenediamine, and 836.5 mg of sodium metabisulphite in 15 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica, 939 mg of 5-bromo-2-(1H-indazol-3-yl)-3H-benzimidazole are obtained in the form of a brick-red powder.

›EXAMPLE 19

2-(5-Ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid

2-(5-Ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid may be obtained from 2-(2-benzyl-5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid by deprotection of the benzyl group in the presence of hydrogen and a catalyst such as palladium.

2-(2-Benzyl-5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid may be prepared by following the procedure for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 21.6 mg of 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxaldehyde, and 17.7 mg of 3,4-diaminobenzoic acid hydrochloride in 1 ml of nitrobenzene, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 50.9 mg of 2-(2-benzyl-5-ethoxy-2H-pyrazol-3-yl)-1H-benzimidazole-4-carboxylic acid are obtained in the form of a yellow lacquer.

2-Benzyl-5-ethoxy-2H-pyrazole-3-carboxaldehyde may be prepared in the following manner:

4 Å molecular sieves are added to a solution of 45.7 mg of (2-benzyl-5-ethoxy-2H-pyrazol-3-yl)methanol in 0.5 ml of dichloromethane, followed by addition of 43.1 mg of pyridinium chlorochromate. After 20 hours at a temperature in the region of 20° C., the reaction mixture is filtered through Celite. The insoluble material formed is rinsed with ethyl acetate and then with dichloromethane. The filtrate is washed with water. After separation of the phases by settling, the aqueous phase is re-extracted with dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated under reduced pressure. 21.6 mg of 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxaldehyde are thus obtained in the form of a brown lacquer, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 1.35 ppm (triplet, 3H); 4.25 ppm (quartet, 2H); 5.30 ppm (singlet, 2H); 6.30 ppm (singlet, 1H); 7.25-7.40 ppm (multiplet, 5H); 9.72 ppm (singlet, 1H).

(2-Benzyl-5-ethoxy-2H-pyrazol-3-yl)methanol may be prepared in the following manner:

11.1 mg of lithium aluminium hydride are added to a solution of 76 mg of methyl 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxylate in 0.75 ml of tetrahydrofuran, cooled to a temperature in the region of 0° C. by an ice bath. After 3 hours at a temperature in the region of 0° C., 22.2 mg of lithium aluminium hydride are added and the reaction medium is allowed to warm to a temperature in the region of 20° C. After 30 minutes at a temperature in the region of 20° C., 10 ml of ice-cold water are added and the reaction mixture is then filtered through Celite. After separation of the phases by settling, the aqueous phase is extracted with ethyl acetate. The organic phases are combined, dried over magnesium sulphate and concentrated under reduced pressure. 45.7 mg of (2-benzyl-5-ethoxy-2H-pyrazol-3-yl)methanol are thus obtained in the form of a brown lacquer, the characteristics of which are as follows:

1 HNMR (DMSO d6, 400 MHz): 1.35 ppm (triplet, 3H); 4.15 ppm (quartet, 2H); 4.30 ppm (doublet, 2H); 5.00 ppm (triplet, 1H); 5.08 ppm (singlet, 2H); 5.70 ppm (singlet, 1H); 7.20-7.40 ppm (multiplet, 5H).

Methyl 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxylate may be prepared in the following manner:

5 mg of sodium iodide, 36 μl of bromoethane and 70 mg of potassium carbonate are added, at a temperature in the region of 20° C., to a solution of 100 mg of methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate in 1 ml of acetone. The reaction mixture is refluxed for 9 hours, cooled to a temperature in the region of 20° C. and filtered. The filtrate is concentrated under reduced pressure. 76 mg of methyl 2-benzyl-5-ethoxy-2H-pyrazole-3-carboxylate are thus obtained in the form of a solid, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 1.35 ppm (triplet, 3H); 3.50 ppm (singlet, 3H); 4.22 ppm (quartet, 2H); 5.22 ppm (singlet, 2H); 6.28 ppm (singlet, 1H); 7.20-7.40 ppm (multiplet, 5H).

Methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate may be prepared in the following manner:

1.72 ml of dimethylacetylene dicarboxylate are added, at a temperature in the region of 20° C., to a solution of 2.73 g of benzylhydrazine dihydrochloride in 45 ml of glacial acetic acid. The reaction mixture is refluxed for 3 hours, cooled to a temperature in the region of 20° C. and then concentrated under reduced pressure. After filtering off the insoluble material formed, 252 mg of methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate are collected in the form of a white powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 400 MHz): 3.76 ppm (singlet, 3H); 5.19 ppm (singlet, 2H); 5.85 ppm (singlet, 1H); 7.25-7.45 ppm (multiplet, 5H); 11.69 ppm (multiplet, 1H).

The filtrate may be purified by flash chromatography on 400 g of 20-45 μm silica (applied in a 25/75 ethyl acetate/cyclohexane mixture; eluant: 25/75 and then 40/60 ethyl acetate/cyclohexane) to give an additional batch of methyl 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylate in the form of a white powder.

›EXAMPLE 20

5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole

5,6-Dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 53.3 mg of 5-methyl-2H-pyrazole-3-carboxaldehyde, 65.9 mg of 4,5-dimethyl-1,2-phenylenediamine, and 92 mg of sodium metabisulphite, in 0.5 ml of ethanol and 1.5 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica, 20.8 mg of 5,6-dimethyl-2-(5-methyl-2H-pyrazol-3-yl)-1H-benzimidazole are obtained in the form of a white powder.

5-Methyl-2H-pyrazole-3-carboxaldehyde may be prepared from commercial ethyl 5-methyl-2H-pyrazole-3-carboxylate by following the procedure described for the preparation of 1H-indazole-3-carboxaldehyde, starting with methyl 3-indazolecarboxylate.

›EXAMPLE 21

5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole

5,6-Dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 16.2 mg of 5-thiophen-2-yl-2H-pyrazole-3-carboxaldehyde, 12.4 mg of 4,5-dimethyl-1,2-phenylenediamine, and 17.3 mg of sodium metabisulphite, in 0.2 ml of ethanol and 0.6 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica and a purification by LC-MS, 5,6-dimethyl-2-(5-thiophen-2-yl-2H-pyrazol-3-yl)-1H-benzimidazole is obtained in the form of a white powder.

5-Thiophen-2-yl-2H-pyrazole-3-carboxaldehyde may be prepared from commercial ethyl 5-thiophen-2-yl-2H-pyrazole-3-carboxylate by following the procedure described for the preparation of 1H-indazole-3-carboxaldehyde starting with methyl 3-indazolecarboxylate.

›EXAMPLE 22

2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole

2-(4-Bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of commercial 4-bromo-2H-pyrazole-3-carboxaldehyde, 77.8 mg of 4,5-dimethyl-1,2-phenylenediamine, and 108.6 mg of sodium metabisulphite, in 1 ml of ethanol and 2 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a chromatography under pressure on silica, 143.2 mg of 2-(4-bromo-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole are obtained in the form of a yellow foam.

›EXAMPLE 23

2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole

2-(5-Ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 110 mg of 4,5-dimethyl-1,2-phenylenediamine, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm C18 phase, dimensions 100×25 mm, flow rate 20 m/min, elution gradient acetonitrile/0.07% TFA—water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 82 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-5,6-dimethyl-1H-benzimidazole are obtained in the form of a beige-coloured powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 300 MHz): 1.26 (t, J=7 Hz: 3H); 2.31 (s: 6H); 2.70 (broad q, J=7 Hz: 2H); 6.60 (broad s: 1H); 7.22 (mult: 1H); 7.36 (mult: 1H); 12.37 (mult: 1H); 12.92 (mult: 1H).

5-Ethyl-2H-pyrazole-3-carboxaldehyde may be prepared from ethyl 5-ethyl-2H-pyrazole-3-carboxylate by following the procedure described for the preparation of 1H-indazole-3-carboxaldehyde starting with methyl 3-indazolecarboxylate.

Ethyl 5-ethyl-2H-pyrazole-3-carboxylate may be prepared according to the general procedure in the following reference: Kunio Seki et al., Chem. Pharm. Bull., 32(4), 1568-1577 (1984).

›EXAMPLE 24

2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole

2-(5-Ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 134 mg of 3,4-ethylenedioxy-1,2-phenylenediamine, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm, C18 phase, dimensions 100×25 mm, flow rate 20 m/min, elution gradient acetonitrile/0.07% TFA-water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 60 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-4,5-ethylenedioxy-1H-benzimidazole are obtained in the form of a brown lacquer, the characteristics of which are as follows:

1 H NMR (DMSO d6, 300 MHz): 1.27 (t, J=7 Hz: 3H); 2.70 (broad q, J=7 Hz: 2H); from 4.20 to 4.45 (mt: 4H); 6.61 (broad s: 1H); 6.72 (d, J=8 Hz: 1H); 6.88 (broad d, J=8 Hz: 1H); 12.50 (mult: 1H); 12.94 (mult: 1H).

›EXAMPLE 25

2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole

2-(5-Ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 138 mg of 4-methoxy-1,2-phenylenediamine, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm C18 phase, dimensions 100×25 mm, flow rate 20 ml/min, elution gradient: acetonitrile/0.07% TFA—water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 61 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-5-methoxy-1H-benzimidazole are obtained in the form of a brown lacquer, the characteristics of which are as follows:

1 H NMR (DMSO d6 with addition of a few drops of CD 3 COOD, 300 MHz): 1.26 (t, J=7 Hz: 31); 2.70 (q, J=7 Hz: 2H); 3.79 (s: 3H); 6.61 (s: 1H); 6.81 (dd, J=8.5 and 2.5 Hz: 1H); 7.03 (broad s: 1H); 7.42 (d, J=8.5 Hz: 1H).

›EXAMPLE 26

2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole

2-(5-Ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15): Starting with 100 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 100 mg of 2,3-diaminophenol, and 153 mg of sodium metabisulphite, in 1 ml of ethanol and 3 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm, C18 phase, dimensions: 100×25 mm, flow rate 20 ml/min, elution gradient: acetonitrile/0.07% TFA—water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 16 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-4-hydroxy-1H-benzimidazole are obtained in the form of a brown lacquer, the characteristics of which are as follows:

1 H NMR (DMSO d6 with addition of a few drops of CD 3 COOD, 300 MHz): 1.26 (t, J=7 Hz: 3H); 2.70 (q, J=7 Hz: 2H); 6.55 (t, J=4.5 Hz: 1H); 6.66 (s: 1H); 6.96 (broad d, J=4.5 Hz: 2H).

›EXAMPLE 27

2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole

2-(5-Ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole may be prepared by following the procedure described for the preparation of 5,6-dimethyl-2-(1H-indazol-3-yl)-1H-benzimidazole (Example 15):

Starting with 20 mg of 5-ethyl-2H-pyrazole-3-carboxaldehyde, 30 mg of 4-bromo-1,2-phenylenediamine and 30 mg of sodium metabisulphite, in 1 ml of ethanol and 2 ml of dimethylformamide, and after purification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol) followed by a reverse-phase HPLC (5 mm C18 phase, dimensions: 100×25 mm, flow rate 20 ml/min, elution gradient: acetonitrile/0.07% TFA-water/0.07% TFA from 5-95 to 95-5 (v/v)), and desalification by SPE (SCX phase, washing with methanol, extraction with 2N ammoniacal methanol), 21 mg of 2-(5-ethyl-2H-pyrazol-3-yl)-5-bromo-1H-benzimidazole are obtained in the form of a yellow powder, the characteristics of which are as follows:

1 H NMR (DMSO d6, 300 MHz): 1.28 (t, J=7 Hz: 3H); 2.71 (q, J=7 Hz: 2H); 6.67 (s: 1H); 7.30 (dd, J=8.5 and 2.5 Hz: 1H); 7.49 (mt: 1H); 7.712 (broad s: 1H); from 12.5 to 13.5 (broad mult: 2H).

The products of formula (I) of the present application can also be prepared according to the following process:

The products of Examples 97 to 145 of the present application represented in the TABLE 3 below can be prepared according to the schemes indicated above and in particular according to the procedures indicated below.

›EXAMPLE 97

3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole

›Step 1: Synthesis of 3-(6-bromo-1H-benzimidazol-2-yl)-2H-indazole (other preparation of example 18)

4.25 g of 1-hydroxybenzotriazole and 4.3 g of calcium sulphate are added at ambient temperature to a solution of 4.6 g of indazole-3-carboxylic acid in 50 ml of dimethylformamide. The reaction mixture is cooled to approximately 0° C. and then 4.9 ml of N,N-diisopropylcarbodiimide are slowly added. After stirring for 2 hours at ambient temperature, 5.9 g of 4-bromo-o-phenylenediamine are added. After stirring for 60 hours at ambient temperature, the reaction mixture is concentrated to dryness under reduced pressure. The brown oil obtained is taken up in 50 ml of water and extracted 3 times with 50 ml of ethyl acetate. The organic phases are combined, dried over magnesium sulphate and then concentrated to dryness under reduced pressure. 18 g of a brown oil are thus obtained, which oil is taken up in 100 ml of a 20% solution of hydrochloric acid in ethanol. The mixture is brought to reflux for 4 hours and then concentrated to dryness, the brown oil obtained is taken up in 20 ml of water, and an aqueous ammonia solution is run in until a pH of the mixture of about 8-9 is obtained. The aqueous phase is then extracted 3 times with 30 ml of ethyl acetate and the organic phases are combined, dried over magnesium sulphate and concentrated to dryness under reduced pressure. After purification by chromatography under pressure on silica (eluent water/acetonitrile), 5 g of 3-(6-bromo-1H-benzimidazol-2-yl)-2H-indazole are thus obtained.

IR spectrum (KBr): characteristic bands at 1621, 1570, 1441, 1344, 1324, 1273, 1239, 1135, 1042, 914, 804, 774 and 746 cm −1

›Step 2: Synthesis of 1-[2-(1-acetyl-1H-indazol-3-yl)-5-bromobenzimidazol-1-yl]ethanone

5 g of 3-(6-bromo-1H-benzimidazol-2-yl)-2H-indazole are charged to a solution of 40 ml of acetic anhydride and 40 ml of pyridine. The mixture is brought to reflux for 4 hours and then concentrated to dryness after returning to ambient temperature. The brown solid obtained is taken up in 50 ml of ethyl acetate and washed with 50 ml of a saturated sodium hydrogencarbonate solution until a pH of 7-8 is obtained. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure. The light brown solid obtained is triturated in 20 ml of ethyl acetate and then filtered off on a sintered glass funnel. 1.5 g of the compound 1-[2-(1-acetyl-1H-indazol-3-yl)-5-bromobenzimidazol-1-yl]ethanone are thus obtained. A second crop is obtained by chromatographing the filtrate obtained above under pressure on silica (eluent cyclohexane/ethyl acetate), i.e. 1.3 g of the same compound.

Characteristics of the Compound:

1 H NMR spectrum (300 MHz, (CD 3 ) 2 SO d6, δ in ppm).

The mixture of the two positional isomers in the proportions 50/50 is observed.

2.61 and 2.62 (2 s, 3H in all); 2.80 (s, 3H); 7.62 (broad t, J=7.5 Hz, 1H); 7.68 and 7.71 (2 dd, J=9 and 2 Hz, 1H in all); 7.80 (ddd, J=8.5, 7.5 and 0.5 Hz, 1H); 7.91 and 8.01 (2 d, J=9 Hz, 1H); 8.18 and 8.20 (2 d, J=2 Hz, 1H in all); 8.27 and 8.30 (2 d, J=7.5 Hz, 1H in all); 8.46 (d, J=8.5 Hz, 1H)

IR spectrum (KBr): characteristic bands at 1727, 1610, 1450, 1405, 1374, 1326, 1290, 1198, 1176, 964 and 760 cm −1

›Step 3: Synthesis of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole · 1 of 4

40 mg of sodium carbonate, 7 mg of dihydrogendichlorobis(di-tert-butylphosphonite-κP)palladate(2-) (POPd[0]) and 46 mg of phenylboronic acid are added under an argon atmosphere to a solution of 50 mg of 1-[2-(1-acetyl-1H-indazol-3-yl)-5-bromobenzimidazol-1-yl]ethanone in 800 μl of anhydrous tetrahydrofuran. The reaction mixture is brought to reflux for 3 hours and then cooled to ambient temperature. The mixture is then diluted with 3 ml of ethyl acetate and then washed with 2 times 2 ml of water. The organic phase is dried over magnesium sulphate and then concentrated to dryness under reduced pressure. 48 mg of a brown solid are obtained, which solid is dissolved in 500 μl of tetrahydrofuran, to which 500 μl of diethylamine are added. The reaction mixture is heated at 60° C. for 4 hours and then allowed to return to ambient temperature. The mixture is then concentrated to dryness and then the brown solid obtained is purified by LC-MS to produce 12.5 mg of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole (6); analytical retention time 3.10, MS 311 [M+H] + .

The products of formula (I) of the present application and in particular examples 98 to 145 can be prepared according to the following process:

The synthesis of examples 98 to 145 is carried out in a similar way to the synthesis of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole (example 97) but replacing phenylboronic acid with boronic acids of formula RB(OH) 2 .

Products of formula (I) of the present application which constitute Examples 28 to 96 and 146 to 180 of the present application are represented in Table 3: these products can be prepared according to the schemes indicated above and in particular as indicated above for the product of Example 1.

MFCD00013005

C22H18N6O3S

446.49

447

[M + H] +

2.77

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2,4- dichloro-benzylamide

MFCD00008221

C20H21N5O2

363.42

364

[M + H] +

2.8

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (3- ethoxy-propyl)-amide

MFCD00047931

C22H16BrN5O

446.31

447

[M + H] +

3.35

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- bromo-benzylamide

MFCD000216491

C23H19N5O3S

445.50

446

[M + H] +

2.81

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- methanesulfonyl- benzylamide

MFCD00004048

C26H19N5O

417.47

418

[M + H] +

3.38

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (naphthalen-1- ylmethyl)-amide

chemistry 6

MFCD00010220

C23H16F3N5O

435.41

436

[M + H] +

3.41

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- trifluoromethyl- benzylamide

chemistry 7

MFCD00005460

C20H15N5OS

373.44

374

[M + H] +

3.01

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (thiophen-2- ylmethyl)-amide

MFCD00012862

C24H22N6O

410.48

411

[M + H] +

2.49

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- dimethylamino- benzylamide

MFCD01076207

C26H30N6O3

474.56

475

[M + H] +

3.31

4-({[2-(1H-Indazol- 3-yl)-1H- benzoimidazole-5- carbonyl]-amino}- methyl)-piperidine-1- carboxylic acid tert- butyl ester

MFCD00012863

C22H16N6O3

412.41

413

[M + H] +

3.14

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- nitro-benzylamide

MFCD00006412

C21H16N6O

368.40

369

[M + H] +

2.39

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (pyridin-3-ylmethyl)- amide

chemistry 12

MFCD01026119

C22H16BrN5O

446.31

447

[M + H] +

3.36

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3- bromo-benzylamide

chemistry 16

MFCD00008115

C23H19N5O2

397.44

398

[M + H] +

3.1

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3- methoxy- benzylamide

chemistry 18

MFCD00005840

C23H17N5O3

411.42

412

[M + H] +

3.07

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (benzo[1,3]dioxol-5- ylmethyl)-amide

chemistry 19

MFCD00176440

C24H17N5OS

423.50

424

[M + H] +

3.42

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (benzo[b]thiophen-3- ylmethyl)-amide

chemistry 20

MFCD02055709

C21H19N7O

385.43

386

[M + H] +

2.59

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (1,3-dimethyl-1H- pyrazol-4-ylmethyl)- amide

MFCD00085176

C23H16F3N5O2

451.41

452

[M + H] +

3.44

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carobyxlic acid 2- trifluoromethoxy- benzylamide

chemistry 54

MFCD00008112

C23H19N5O

381.44

382

[M + H] +

3.21

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2- methyl-benzylamide

MFCD02093988

C21H17N5OS

387.46

388

[M + H] +

3.16

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (3- methyl-thiophen-2- ylmethyl)-amide

MFCD00010297

C23H16F3N5O

435.41

436

[M + H] +

3.38

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2- trifluoromethyl- benzylamide

MFCD01310836

C28H21N5O2

459.51

460

[M + H] +

3.56

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- phenoxy- benzylamide

MFCD00061267

C23H16F3N5O2

451.41

452

[M + H] +

3.46

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3- trifluoromethoxy- benzylamide

MFCD00008220

C21H23N5O2

377.45

378

[M + H] +

2.94

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (3- isopropoxy-propyl)- amide

chemistry 29

MFCD02090924

C20H17N7O

371.40

372

[M + H] +

2.56

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic aicd (1- methyl-1H-pyrazol-4- ylmethyl)-amide

MFCD00025580

C25H23N5O

409.49

410

[M + H] +

3.51

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- isopropyl- benzylamide

MFCD02677701

C22H19N5O2

385.43

386

[M + H] +

3.19

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (2,5-dimethyl-furan- 3-ylmethyl)-amide

MFCD00965305

C24H17N5OS

423.50

424

[M + H] +

3.38

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (benzo[b]thiophen-2- ylmethyl)-amide

MFCD00277760

C26H24N6O3

468.52

469

[M + H] +

2.92

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid [3- (3-acetylamino- phenoxy)-propyl]- amide

MFCD00673153

C21H15ClN6O

402.84

403

[M + H] +

2.92

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (6- chloro-pyridin-3- ylmethyl)-amide

MFCD00110111

C24H17N5OS2

455.56

456

[M + H] +

3.47

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid ([2,2′]bithiophenyl-5- ylmethyl)-amide

chemistry 40

MFCD00728869

C24H19N5O2

409.45

410

[M + H] +

3.07

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (2,3-dihydro- benzofuran-5- ylmethyl)-amide

›Step 3: Synthesis of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole · 2 of 4

chemistry 41

MFCD01861472

C23H16N6O

392.42

393

[M + H] +

3.03

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- cyano-benzylamide

chemistry 42

MFCD02677713

C24H16ClN5OS

457.94

458

[M + H] +

3.55

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (5-chloro- benzo[b]thiophen-3- ylmethyl)-amide

MFCD00008117

C23H16F3N5O

435.41

436

[M + H] +

3.41

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3- trifluoromethyl- benzylamide

MFCD00831039

C23H19N5OS

413.50

414

[M + H] +

3.26

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2- methylsulfanyl- benzylamide

chemistry 46

MFCD00176440

C24H17N5OS

423.50

424

[M + H] +

3.38

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (benzo[b]thiophen- 3-ylmethyl)-amide

MFCD02179435

C21H21N5O2

375.43

376

[M + H] +

2.65

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (tetrahydro-pyran-4- ylmethyl)-amide

chemistry 48

MFCD00203985

C24H19N5O3

425.45

426

[M + H] +

3.28

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (2,3-dihydro- benzo[1,4]dioxin-2- ylmethyl)-amide

chemistry 49

MFCD02681983

C20H15N5O2

357.37

358

[M + H] +

2.92

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (furan-3-ylmethyl)- amide

chemistry 50

MFCD00136280

C22H16N6O3

412.41

413

[M + H] +

3.14

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2- nitro-benzylamide

chemistry 51

MFCD01529872

C20H15N5OS

373.44

374

[M + H] +

3.03

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (thiophen-3- ylmethyl)-amide

chemistry 52

MFCD00040753

C24H21N5O

395.47

396

[M + H] +

3.37

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3,5-dimethyl- benzylamide

chemistry 53

MFCD00457746

C24H19N7O

421.46

422

[M + H] +

2.61

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (1-methyl-1H- benzoimidazol-2- ylmethyl)-amide

chemistry 54

MFCD00008118

C23H19N5O

381.44

382

[M + H] +

3.24

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3- methyl-benzylamide

chemistry 55

MFCD00040752

C22H16ClN5O

401.86

402

[M + H] +

3.29

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3- chloro-benzylamide

MFCD00013005

C22H18N6O3S

446.49

447

[M + H] +

3.07

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 4- sulfamoyl- benzylamide

chemistry 57

MFCD00008221

C20H21N5O2

363.42

364

[M + H] +

3.45

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (3- ethoxy-propyl)-amide

chemistry 58

MFCD00047931

C22H16BrN5O

446.31

447

[M + H] +

4.38

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 4- bromo-benzylamide

MFCD00004048

C26H19N5O

417.47

418

[M + H] +

4.4

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (naphthalen-1- ylmethyl)-amide

MFCD00005460

C20H15N5OS

373.44

374

[M + H] +

3.93

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (thiophen-2- ylmethyl)-amide

MFCD00012862

C24H22N6O

410.48

411

[M + H] +

2.93

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 4- dimethylamino- benzylamide

MFCD00012863

C22H16N6O3

412.41

413

[M + H] +

3.87

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 4- nitro-benzylamide

MFCD00006412

C21H16N6O

368.40

369

[M + H] +

2.4

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (pyridin-3-ylmethyl)- amide

chemistry 65

MFCD01026119

C22H16BrN5O

446.31

447

[M + H] +

4.18

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 3- bromo-benzylamide

MFCD00008115

C23H19N5O2

397.44

398

[M + H] +

3.95

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 3- methoxy- benzylamide

MFCD00176440

C24H17N5OS

423.50

424

[M + H] +

4.68

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (benzo[b]thiophen-3- ylmethyl)-amide

MFCD01310836

C28H21N5O2

459.51

460

[M + H] +

4.55

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 4-phenoxy- benzylamide

MFCD00061267

C23H16F3N5O2

451.41

452

[M + H] +

4.43

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 3- trifluoromethoxy- benzylamide

MFCD00673153

C21H15ClN6O

402.84

403

[M + H] +

3.9

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (6- chloro-pyridin-3- ylmethyl)-amide

MFCD00728869

C24H19N5O2

409.45

410

[M + H] +

3.9

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (2,3-dihydro- benzofurna-5- ylmethyl)-amide

MFCD00008117

C23H16F3N5O

435.41

436

[M + H] +

4.3

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 3- trifluoromethyl- benzylamide

chemistry 73

MFCD00831039

C23H19N5OS

413.50

414

[M + H] +

3.98

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 2- methylsulfanyl- benzylamide

MFCD02681983

C20H15N5O2

357.37

358

[M + H] +

3.68

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid (furan-3-ylmethyl)- amide

chemistry 75

MFCD00136280

C22H16N6O3

412.41

413

[M + H] +

3.95

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 2- nitro-benzylamide

MFCD00040753

C24H21N5O

395.47

396

[M + H] +

4.45

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 3,5-dimethyl- benzylamide

MFCD00040752

C22H16ClN5O

401.86

402

[M + H] +

5.03

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid 3- chloro-benzylamide

MFCD00007629

C21H15N5O

353.38

354

[M + H] +

4.27

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid phenylamide

MFCD00008106

C22H17N5O

367.41

368

[M + H] +

3.94

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid benzylamide

chemistry 54

MFCD00008184

C23H19N5O

381.44

382

[M + H] +

4.01

2-(1H-Indazol-3-yl)- 3H-benzoimidazole- 4-carboxylic acid phenethyl-amide

chemistry 121

MFCD00002103

C20H14N4

310.36

311

[M + H]+

3.14

3-(6-Phenyl-1H- benzoimidazol-2- yl)-2H-indazole

chemistry 124

MFCD00013930

C20H12Cl2N4

379.25

379

[M + H]+

3.63

3-[6-(2,4-Dichloro- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

chemistry 125

MFCD00019722

C24H16N4

360.42

361

[M + H]+

3.51

3-(6-Naphthalen-1- yl-1H-benzoimidazol- 2-yl)-2H-indazole

100

chemistry 126

MFCD00039136

C20H13FN4

328.35

329

[M + H]+

3.21

3-[6-(4-Fluoro- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

101

chemistry 127

MFCD00039137

C20H13ClN4

344.805

345

[M + H+

3.44

3-[6-(4-Chloro- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

102

chemistry 128

MFCD00039139

C21H16N4O

340.386

341

[M + H]+

3.14

3-[6-(4-Methoxy- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

103

chemistry 129

MFCD00051800

C20H12ClFN4

362.795

362

[M + H]+

3.51

3-[6-(3-Chloro-4- fluoro-phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

›Step 3: Synthesis of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole · 3 of 4

104

chemistry 130

MFCD00051935

C20H12Cl2N4

379.25

[378- 380]

[M + H]+

3.81

3-[6-(3,5-Dichloro- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

105

chemistry 132

MFCD00093039

C26H16N4S2

448.57

449

[M + H]+

3.91

3-(6-Thianthren-1-yl- 1H-benzoimidazol-2- yl)-2H-indazole

106

chemistry 133

MFCD00093311

C26H18N4

386.458

387

[M + H]+

3.78

3-(6-Biphenyl-4-yl- 1H-benzoimidazol-2- yl)-2H-indazole

107

chemistry 137

MFCD00039138

C21H16N4

324.387

324

[M]

3.38

3-(6-p-Tolyl-1H- benzoimidazol-2-yl)- 2H-indazole

108

chemistry 138

MFCD00040198

C21H16N4

324.387

324

[M + H]+

3.41

3-(6-m-Tolyl-1H- benzoimidazol-2-yl)- 2H-indazole

109

chemistry 139

MFCD00093526

C21H16N4

324.387

325

[M + H]+

3.41

3-(6-o-Tolyl-1H- benzoimidazol-2-yl)- 2H-indazole

110

chemistry 140

MFCD00151851

C18H12N4S

316.386

317

[M + H]+

3.13

3-(6-Thiophen-3-yl- 1H-benzoimidazol-2-yl yl)-2H-indazole

111

chemistry 141

MFCD00151854

C21H13F3N4

378.357

379

[M + H]+

3.65

3-[6-(3- Trifluoromethyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

112

chemistry 142

MFCD00151855

C21H13F3N4

378.357

379

[M + H]+

3.68

3-[6-(4- Trifluoromethyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

113

chemistry 143

MFCD00161354

C20H13ClN4

344.805

345

[M + H]+

3.55

3-[6-(3-Chloro- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

114

chemistry 144

MFCD00161359

C21H16N4O

340.386

341

[M + H]+

3.41

3-[6-(3-Methoxy- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

115

chemistry 145

MFCD00185689

C22H18N4

338.414

339

[M + H]+

3.39

3-[6-(3,5-Dimethyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

116

chemistry 146

MFCD01009694

C22H18N4

338.414

339

[M + H]+

3.55

3-[6-(3,4-Dimethyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

117

chemistry 147

MFCD01009695

C21H14N4O2

354.369

354

[M]

3.18

3-(6- Benzo[1,3]dioxol- 5-yl-1H- benzoimidazol- 2-yl)-2H-indazole

118

chemistry 148

MFCD01009697

C24H22N4

366.468

367

[M + H]+

3.95

3-[6-(4-tert-Butyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

119

chemistry 149

MFCD01074553

C20H20N4

316.408

317

[M + H]+

3.72

3-(6-Hex-1-enyl-1H- benzoimidazol-2-yl)- 2H-indazole

120

chemistry 150

MFCD01074574

C22H18N4O2

370.412

371

[M + H]+

3.00

3-[6-(3,4-Dimethoxy- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

121

chemistry 152

MFCD01074603

C20H14N4O

326.359

327

[M + H]+

2.92

3-[2-(2H-Iindazol-3- yl)-3H- benzoimidazol-5-yl]- phenol

122

chemistry 153

MFCD01074628

C20H14N4O

326.359

327

[M + H]+

2.84

4-[2-(2H-Indazol-3- yl)-3H- benzoimidazol-5-yl]- phenol

123

chemistry 154

MFCD01074646

C20H12Cl2N4

379.25

378

[M + H]+

3.82

3-[6-(3,4-Dichloro- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

124

chemistry 157

MFCD01074648

C21H13F3N4O

394.356

395

[M + H]+

3.72

3-[6-(4- Trifluoromethoxy- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

125

chemistry 159

MFCD01074667

C22H16N4O

352.397

353

[M + H]+

3.08

1-{4-[2-(2H-Indazol- 3-yl)-3H- benzoimidazol-5-yl]- phenyl}-ethanone

126

chemistry 160

MFCD01075674

C22H14N4S

366.446

367

[M + H]+

3.82

3-(6- Benzo[b]thiophen-2- yl-1H-benzoimidazol- 2-yl)-2H-indazole

127

chemistry 161

MFCD01075676

C23H20N4O3

400.438

401

[M + H]+

3.02

3-[6-(3,4,5- Trimethoxy-phenyl)- 1H-benzoimidazol-2- yl]-2H-indazole

128

chemistry 162

MFCD01075681

C20H14N4OS

358.423

359

[M + H]+

3.09

1-{5-[2-(2H-Indazol- 3-yl)-3H- benzoimidazol-5-yl]- thiophen-2-yl}- ethanone

129

chemistry 163

MFCD01074678

C22H16N4O

352.397

353

[M + H]+

3.05

1-{3-[2-(2H-Indazol- 3-yl)-3H- benzoimidazol-5-yl]- phenyl}-ethanone

130

MFCD01075705

C27H20N4O

416.484

417

[M + H]+

3.75

3-[6-(4-Benzyloxy- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

131

chemistry 165

MFCD01075707

C26H17FN4

404.448

405

[M + H]+

4.02

3-[6-(2-Fluoro- biphenyl-4-yl)-1H- benzoimidazol-2-yl]- 2H-indazole

132

chemistry 167

MFCD01114669

C22H14N4S

366.446

367

[M + H]+

3.55

3-(6- Benzo[b]thiophen-3- yl-1H-benzoimidazol- 2-yl)-2H-indazole

133

chemistry 168

MFCD01317846

C21H16N4O

340.386

341

[M + H]+

2.79

{3-[2-(2H-Indazol-3- yl)-3H- benzoimidazol-5-yl]- phenyl}-methanol

134

chemistry 171

MFCD01318146

C22H18N4S

370.478

371

[M + H]+

3.62

3-[6-(4-Ethylsulfanyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

135

chemistry 176

MFCD01318998

C20H12F2N4

346.34

347

[M + H]+

3.29

3-[6-(2,4-Difluoro- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

136

chemistry 178

MFCD01320697

C21H13F3N4O

394.356

395

[M + H]+

3.66

3-[6-(3- Trifluoromethoxy- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

137

chemistry 183

MFCD02093072

C21H15FN4

342.377

343

[M + H]+

3.36

3-[6-(4-Fluoro-2- methyl-phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

138

chemistry 184

MFCD02093725

C22H15FN4

354.388

355

[M + H]+

3.49

3-{6-[2-(4-Fluoro- phenyl)-vinyl]-1H- benzoimidazol-2-yl}- 2H-indazole

139

chemistry 185

MFCD02093767

C22H15ClN4

370.843

371

[M + H]+

3.76

3-{6-[2-(4-Chloro- phenyl)-vinyl]-1H- benzoimidazol-2-yl}- 2H-indazole

140

chemistry 188

MFCD01318119

C23H18N4O2

382.423

383

[M + H]+

3.03

3-{4-[2-(2H-Indazol- 3-yl)-3H- benzoimidazol-5-yl]- phenyl}-propionic acid

141

chemistry 190

MFCD00792672

C21H16N4O

340.386

341

[M + H]+

2.72

{4-[2-(2H-Indazol-3- yl)-3H- benzoimidazol-5-yl]- phenyl}-methanol

142

chemistry 191

MFCD00799544

C18H12N4O

300.321

301

[M + H]+

3.02

3-(6-Furan-2-yl-1H- benzoimidazol-2-yl)- 2H-indazole

143

MFCD02093063

C27H20N4O

416.484

417

[M + H]+

3.93

3-[6-(3-Benzyloxy- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

144

chemistry 194

MFCD01074614

C23H20N4

352.441

353

[M + H]+

3.88

3-[6-(4-Isopropyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

145

chemistry 195

MFCD01630820

C21H16N4O2S

388.449

389

[M + H]+

3.03

3-[6-(4- Methanesulfonyl- phenyl)-1H- benzoimidazol-2-yl]- 2H-indazole

146

chemistry 84

MFCD00223987

C22H17N5O4

415.409

415

,[M]

2.31

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (tetrahydro-pyran-4- ylmethyl)-amide

147

chemistry 85

MFCD01861391

C24H20N6O2

424.464

424

,[M]

2.58

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- acetylamino- benzylamide

148

chemistry 88

H 2 N— MFCD00008104

C16H13N5O

291.314

291

,[M]

2.22

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid methylamide

149

chemistry 89

MFCD00008082

C18H17N5O

319.368

319

,[M]

2.63

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid isopropylamide

150

chemistry 90

MFCD00005972

C19H17N5O2

347.378

347

,[M]

2.23

[2-(1H-Indazol-3-yl)- 1H-benzoimidazol-5- yl]-morpholin-4-yl- methanone

151

MFCD00005966

C20H20N6O

360.421

361

[M + H] +

1.94

[2-(1H-Indazol-3-yl)- 1H-benzoimidazol-5- yl]-(4-methyl- piperazin-1-yl)- methanone

152

chemistry 96

MFCD00008289

C23H19N5O

381.439

381

,[M]

3.45

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid benzyl-methyl-amide

›Step 3: Synthesis of 3-(6-phenyl-1H-benzimidazol-2-yl)-2H-indazole · 4 of 4

153

chemistry 97

MFCD00012858

C22H16N6O3

412.409

412

,[M]

3.32

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3- nitro-benzylamide

154

chemistry 98

MFCD00008107

C22H16FN5O

385.402

385

,[M]

2.96

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2- fluoro-benzylamide

155

chemistry 99

MFCD00010142

C22H15F2N5O

403.392

403

,[M]

3.26

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2,4- difluoro-benzylamide

156

chemistry 100

MFCD00010144

C22H15F2N5O

403.392

403

,[M]

2.93

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2,6- difluoro-benzylamide

157

chemistry 101

MFCD00143266

C22H15BrFN5O

464.303

464

,[M]

3.34

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- bromo-2-fluoro- benzylamide

158

chemistry 102

MFCD00143286

C22H15ClFN5O

419.847

419

,[M]

3.21

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- chloro-2-fluoro- benzylamide

159

chemistry 103

MFCD00153076

C22H15BrFN5O

464.303

464

,[M]

3.31

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- bromo-2-fluoro- benzylamide

160

chemistry 104

MFCD00010145

C22H15F2N5O

403.392

403

,[M]

3.64

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3,4- difluoro-benzylamide

161

chemistry 105

MFCD00236318

C22H14F3N5O

421.382

421

,[M]

3.35

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 3,4,5-trifluoro- benzylamide

162

chemistry 107

MFCD02089424

C28H20ClN5O

477.955

477

,[M]

3.89

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (4′- chloro-biphenyl-4- ylmethyl)-amide

163

chemistry 108

MFCD02089425

C28H19Cl2N5O

512.4

512

,[M]

4.36

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (3′,5′-dichloro- biphenyl-4-ylmethyl)- amide

164

chemistry 109

MFCD02089427

C28H20FN5O

461.5

461

,[M]

3.6

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (4′- fluoro-biphenyl-4- ylmethyl)-amide

165

chemistry 110

MFCD01566531

C22H16FN5O

385.402

385

,[M]

2.94

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2- fluoro-benzylamide

166

chemistry 111

MFCD01631410

C23H17F2N5O

417.419

417

,[M ]

3.14

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2,6- difluor-3-methyl- benzylamide

167

chemistry 112

MFCD00008109

C22H15Cl2N5O

436.302

436

,[M]

3.48

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 2,4- dichloro-benzylamide

168

chemistry 113

MFCD00008121

C22H16ClN5O

401.857

401

,[M]

3.73

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- chloro-benzylamide

169

chemistry 114

MFCD00047932

C23H18ClN5O

415.884

385

,[M]

3.52

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- chloro-2-methyl- benzylamide

170

chemistry 115

MFCD00008120

C22H16FN5O

385.402

385

,[M]

3.09

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid 4- fluoro-benzylamide

171

chemistry 116

MFCD02089431

C28H20ClN5O

477.955

477

,[M]

3.9

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (2′- chloro-biphenyl-4- ylmethyl)-amide

172

chemistry 117

MFCD01862649

C22H15F3N6O

436.397

436

,[M]

2.93

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (6- trifluoromethyl- pyridin-3-ylmethyl)- amide

173

chemistry 118

MFCD02681984

C25H18N6OS

450.524

450

,[M]

2.67

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (5- pyridin-2-yl-thiophen- 2-ylmethyl)-amide

174

chemistry 119

MFCD00009819

C21H19N7O

385.431

385

,[M]

2.11

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (3- imidazol-1-yl-propyl)- amide

175

MFCD00075265

C24H26N6O3

446.511

447

[M + H] +

3.11

4-[2-(1H-Indazol- 3-yl)-1H- benzoimidazole-5- carbonyl]-piperazine- 1-carboxylic acid tert-butyl ester

176

chemistry 121

438

[M + H] +

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (2,6-difluoro-4- chloro-benzyl)amide

177

chemistry 122

437

[M + H] +

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (2,4-dichloro-6- fluoro-benzyl)amide

178

chemistry

420

[M + H] +

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (3- fluoro-4-chloro- benzyl)amide

179

chemistry 124

434

[M + H] +

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (2- fluoro-4-chloro-6- methyl-benzyl)amide

180

chemistry 125

399

[M + H] +

2-(1H-Indazol-3-yl)- 1H-benzoimidazole- 5-carboxylic acid (6- methoxy-pyridin-3- ylmethyl)-amide

The products of formula (I) of the present application can also be prepared according to the following process:

In the above scheme, the values of Z3 and Z4 are chosen from the values of R2 and R3 as defined above and the values of Z1 and —OZ2 are chosen from the values of X1, X2 or X3 with R1 representing a pyrazole radical,

When Z1, Z3 and Z4 represent a hydrogen atom, it is possible in particular to prepare products of formula (I) of the present application according to the following synthesis scheme:

Products of formula (I) of the present application which constitute Examples 181 to 228 of the present application are represented in the table 4 hereinbelow: these products can be prepared according to the schemes indicated above and in particular the product of Example 181 can be prepared according to the procedure indicated below. The products of Examples 182 to 228 can be prepared like the product of Example 181.

›Examples49

›EXAMPLE 181

2-[5-(benzyloxy)-2H-pyrazol-3-yl]-1H-benzoimidazole

Step 1: the cyclization is performed as in: Chem. Pharm. Bull., 31(4), 1228-1234 (1983); J. Org. Chem., 47(2), 214-221 (1982).

Step 2: To the crude ester 1.015 g in 50 ml of MeOH, was added 5.5 ml of 6N NaOH and the mixture is heated to reflux during 2 h. After evaporation of most of the methanol, the medium is cooled and conc. HCl is carefully added until pH=2. After further evaporation to dryness, the solid is triturated three times with 30 ml of MeOH/AcOEt 1/1 and the filtrate evaporated to give 0.875 g of light brown solid after desiccation.

LC-MS: [gradient acetonitrile/water 0.1% HCOOH; Xterra RP18 2.1×50 mm] retention time 0.53 minutes, MH+=129, 95% pure

Step 3: To 3.5 g of PPA (polyphosphoric acid) were added 0.701 g of 1,2-phenylenediamine and 0.87 g of the step 2 acid. The mixture is heated to 150° C. during 1.5 h. After cooling, conc NH4OH was added until pH=3. The green precipitate is filtered, washed with water and then with acetone. After one night drying under vacuum at 50° C., 2.1 g of solid remains containing around 50% of mineral salts.

MS: EI M+=200.

Step 4: Ex. 181: To 80 mg of the step 3 solid in 4 ml of NMP were added caesium carbonate 137 mg and benzyl bromide 72 mg. After 2 h the mixture is hydrolysed with saturated KH2PO4 and extracted with AcOEt. After evaporation, the crude mixture was submitted to preparative LC-MS to give 8 mg of pure compound:

LC-MS: [gradient acetonitrile/water 0.1% HCOOH; Xterra RP18 2.1×50 mm] retention time 3.17 minutes, MH+=291.97% pure

In the same way, the step 4 is carried out with 15 benzyl or allyl bromides, 15 α-bromocarbonyl compounds and 15 acid chlorides in either DMF or NMP to give the expected compounds of TABLE 4. Examples 181 to 228 of the present application are represented in TABLE 4.

›EXAMPLE 229

Pharmaceutical Composition

Tablets corresponding to the formula below were prepared:

Product of Example 1 . . . 0.2 g Excipient for a finished tablet containing . . . 1 g (details of the excipient: lactose, talc, starch, magnesium stearate).

Example 1 is taken as pharmaceutical preparation example, it being possible for this preparation to be produced, if desired, with other products in examples in the present application.

›EXAMPLE 230

(a) 5,6-Dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole

A mixture of 5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [90 mg, Reference Example 1(a)], hydrochloric acid (2 mL, 4N) and ethanol (4 mL) was heated at reflux temperature for 16 hours then cooled to room temperature. The pH of the reaction mixture was adjusted to 7 by addition of saturated sodium bicarbonate solution. The resulting solid was filtered, then washed with water and then dried in a vacuum oven to give 5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole (38 mg). LC-MS (METHOD A): R T =2.22 minutes; 259 (M+H) + .

(b) 6-Chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(b)] there was prepared 6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole.

By proceeding in a similar manner to Example 230(a) above but using 6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(c)] there was prepared 6-chloro-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole.

(d) 2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(d)] there was prepared 2-(5-methylsulfanyl-1H-pyrazol-3-yl-5-trifluoromethyl-1H-benzoimidazole.

(e) 2-(5-Cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(e)] there was prepared 2-(5-cyclopropylmethylsulfanyl-1-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole. LC-MS (METHOD A): R T =2.47 minutes; 299 (M+H) + .

(f) 2-(5-Ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 5,6-dimethyl-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(f)] there was prepared 2:5-ethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole. LC-MS (METHOD A): R T =2.32 minutes; 273 (M+H) + .

(g) 5,6-Dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 5,6-dimethyl-2-[5-(pyridin-3-yl)methylsulfanyl-1H-pyrazol-3-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(g)] there was prepared 5,6-dimethyl-2-[5-(pyridin-3-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole as a colourless solid.

(h) 5-Fluoro-2-[5-methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 5-fluoro-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(h)] there was prepared 5-fluoro-2-[5-methylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole. MS: 249 (M+H) + .

(i) 5,6-Dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(i)] there was prepared 5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole.

(j) 4-Methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(j)] there was prepared 4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole. MS: 245 (M+H) + .

(k) 5,6-Dimethyl-2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(k)] there was prepared 5,6-dimethyl-2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-1H-benzoimidazole.

(l) 6-Chloro-5-methyl-2-(5-morpholin-4-yl-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 6-chloro-5-methyl-2-(5-morpholin-4-yl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(l)] there was prepared 6-chloro-5-methyl-2-(5-morpholin-4-yl-1H-pyrazol-3-yl)-1H-benzoimidazole.

(m) 5,6-Dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole

By proceeding in a similar manner to Example 230(a) above but using 5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 1(m)] there was prepared 5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1H-benzoimidazole.

›EXAMPLE 231

(2-(5-Ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole hydrochloride

A mixture of 3,3-bis-ethylsulfanyl-1-[5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone [˜0.78 mmole, Reference Example 2(j)] and hydrazine hydrate (500 μL) in ethanol (6 mL) was heated at reflux temperature for 18 hours, then evaporated. The residue was purified on the Flashmaster to give 2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole which was treated with ethanol (6 mL) and hydrochloric acid (3 mL). This mixture was heated at reflux temperature for 18 hours and then evaporated to give 2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole hydrochloride. LC-MS (METHOD A): R T =2.17 minutes; 275 (M+H) + .

›EXAMPLE 232

(a) 5-Methyl-2-(5-methylsulfanyl-4-propyl-1H-pyrazol-3-yl)-1H-benzoimidazole

A mixture of 2-(bis-methylsulfanyl-methylene)-1-(5-methyl-1H-benzoimidazol-2-yl)-pentan-1-one [˜0.49 mmole, Reference Example 2(l)] and hydrazine hydrate (200 μL) in ethanol (6 mL) was heated at reflux temperature for 2 days, then evaporated. The mixture was then treated with hydrochloric acid (4 mL, 4N) and heating was continued at reflux temperature for a further 24 hours. The reaction mixture was cooled, then neutralised by addition of sodium hydroxide solution (4N) and then extracted with dichloromethane. The extract was evaporated to give 5-methyl-2-(5-methylsulfanyl-4-propyl-1H-pyrazol-3-yl)-1H-benzoimidazole. MS: 287 (M+H) + .

(b) 2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole

By proceeding in a similar manner to Example 233(a) above but using 2-[bis-(4-methoxy-benzylsulfanyl)-methylene]-1-(5-methyl-1H-benzoimidazol-2-yl)-pentan-1-one [Reference Example 2(m)] there was prepared 2-(5-(4-methoxy-benzylsulfanyl)-4-propyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole. MS: 393 (M+H) + .

By proceeding in a similar manner to Example 232(a) above but using 2-(bis-benzylsulfanyl-methylene)-3-methyl-1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-butan-1-one [Reference Example (2n)] there was prepared 2-(5-benzylsulfanyl-4-isopropyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole. MS: 363 (M+H) + .

(d) 2-(5-Methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole

By proceeding in a similar manner to Example 232(a) above but using 1-[5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-2-methyl-3-(bis-methanesulfanyl)-1-propenone [Reference Example 2(r)] there was prepared 2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methoxy-1H-benzoimidazole.

(e) 2-(5-Methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole

By proceeding in a similar manner to Example 232(a) above but using 1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-2-methyl-3-bis-methanesulfanyl)-1-propenone [Reference Example 2(t)] there was prepared 2-(5-methylsulfanyl-4-methyl-1H-pyrazol-3-yl)-5-methyl-1H-benzoimidazole.

›EXAMPLE 233

(a) 3-(5-Chloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

A solution of 5-chloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [91 mg, Example 239(a)] in ethanol (40 mL), under nitrogen, was treated with palladium on carbon (spatula tip, 5%). The mixture was stirred under hydrogen for 3 hours and then filtered through Celite. The filter pad was washed well with dichloromethane. The combined filtrate and washings were evaporated to give 3-(5-chloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine (116 mg). LC-MS (METHOD A): R T =2 minutes; 234 (M+H) + .

(b) 3-(5,6-Dichloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a similar manner to Example 233(a) above but using 5,6-dichloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [Example 239(b)] there was prepared 3-(5,6-dichloro-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine. LC-MS (METHOD A): R T =2.37 minutes; 268 (M+H) + .

By proceeding in a similar manner to Example 233(a) above but using 5,6-dimethyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [Example 249(a)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine as a brown solid. LC-MS (METHOD B): R T =2.29 minutes; 228.25 (M+H) + .

(d) 3-(5-Ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a similar manner to Example 233(a) above but using 5-ethyl-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [Example 249(b)] there was prepared 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine as a brown solid. LC-MS (METHOD B): R T =2.14 minutes, 242.20 (M+H) + .

(e) 3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a similar manner to Example 233(a) above but using 6-chloro-5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [0.7 g, Example 249(c)] there was prepared 3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine (0.54 g) as a brown foam. MS 264 (M+H) + .

(f) 3-(5-Methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a similar manner to Example 233(a) above but using 5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [373 mg, Example 257(f)] there was prepared 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine (257 mg) as a dark brown solid. LC-MS (Method H): R T =1.23 minutes, 230.25 (M+H) + , 228.25 (M−H) − .

(g) 3-(5-Ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a manner similar to Example 233(a) above but using 5-ethoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [407 mg, Example 252(c)] there was prepared 3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine (375 mg) as a dark brown oil. LC-MS (Method H): R T =1.43 minutes, 244.26 (M+H) + , 242.28 (M−H) − .

(h) 3-(5-Fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a manner similar to Example 233(a) above but using 5-fluoro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [Example 249(d)] there was prepared 3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine (0.590 g) as a brown solid. LC-MS (METHOD J): R T =2.25 minutes, MS: 232.29 (M+H) + .

(i) 3-(5-Trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a manner similar to Example 233(a) above but using 5-trifluoromethoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [Example 249(e)] there was prepared 3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine (0.920 g) as a brown solid. LC-MS (METHOD J): R T =2.76 minutes, 284.23 (M+H) + .

(j) 3-(5-Trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a manner similar to Example 233(a) above but using 5-trifluoromethyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [Example 249(f)] there was prepared 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine (0.150 g) as a brown solid. LC-MS (METHOD B): R T =3.00 minutes, 268.16 (M+H) + .

(k) 2-(4-Amino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester

By proceeding in a manner similar to Example 233(a) above but using 2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester [Example 249(h)] there was prepared 2-(4-amino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester (1.10 g) as an off-white solid. LC-MS (METHOD B): R T =2.40 minutes, 258.17 (M+H) + .

›EXAMPLE 234

(a) 3-(1H-Benzoimidazol-2-yl)-1H-indazole

A mixture of 1,2-diaminobenzene (108 mg), indazole-3-carboxylic acid (118 mg) and polyphosphoric acid (1 mL) was heated at 150-160° C. for 24 hours. The mixture was cooled, then diluted with ice water (10 mL) and then treated with ethyl acetate (10 mL). The aqueous layer was basified by addition of solid potassium carbonate. The layers were separated and the aqueous layer was extracted with ethyl acetate (10 mL). The combined organic phases were dried and then evaporated. The residue was subjected to chromatography on silica eluting with a mixture of heptane and ethyl acetate to give 3-(1H-benzoimidazol-2-yl)-1H-indazole (78 mg). LC-MS (METHOD A): R T =1.28 minutes; 235 (M+H) + .

(b) 3-(5-Methoxy-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a similar manner to Example 234(a) above but using 4-methoxy-1,2-diaminobenzene hydrochloride there was prepared 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-indazole as a solid.

LC-MS (METHOD A): R T =1.28 minutes; 265 (M+H) + .

By proceeding in a similar manner to Example 234(a) above but using 3,4-diaminobenzophenone there was prepared [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanone as a solid.

LC-MS (METHOD A): R T =1.73 minutes; 339 (M+H) + .

(d) 2-(1H-Indazol-3-yl)-3H-benzoimidazol-4-ol

By proceeding in a similar manner to Example 234(a) above but using 2,3-diaminophenol there was prepared 2-(1H-indazol-3-yl)-3H-benzoimidazol-4-ol as a solid. LC-MS (METHOD A): R T =1.63 minutes; 251 (M+H) + .

(e) 2-Phenyl-1H-imidazol[4,5-b]pyrazine

By proceeding in a similar manner to Example 234(a) above but using 2,3-diaminopyrazine [Reference Example 9] and benzoic acid there was prepared 2-phenyl-1H-imidazol[4,5-b]pyrazine as a pale brown solid, mp 239-240° C. HPLC (METHOD A1): R T =10.18 minutes.

(f) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a similar manner to Example 234(a) above but using 1,2-diamino-4,5-dimethylbenzene there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole (28 mg). LC-MS (METHOD A): R T =1.34 minutes; 263 (M+H) + .

(g) 2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine

By proceeding in a similar manner to Example 234(a) above but using 3,4-diaminopyridine there was prepared 2-(1H-indazol-3-yl)-3H-imidazo[4,5-c]pyridine as a solid. MS: 236 (M+H) + . HPLC (METHOD A): R T =2.48 minutes.

(h) 2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine

By proceeding in a similar manner to Example 234(a) above but using 2,3-diaminopyridine there was prepared 2-(1H-indazole-3-yl)-3H-imidazo[4,5-b]pyridine as a solid. MS: 236 (M+H) + . HPLC (METHOD A): R T =2.49 minutes.

›EXAMPLE 235 · 1 of 3

(a) 2-(1H-Pyrazol-3yl)-1H-benzoimidazole

A mixture of 1H-pyrazole-3-carbaldehyde (0.961 g, Reference Example 10), o-phenylenediamine (0.973 g), sodium bisulfite (1.898 g) and dry dimethylformamide (10 mL) was stirred at reflux for 2 hours, then cooled to room temperature and then poured onto cracked ice (35 g). The mixture was filtered and the solid was washed with aqueous sodium bicarbonate and then with water. The solid was vacuum dried at 70° C. and then recrystallised from ethanol to give 2-(1H-pyrazol-3yl)-1H-benzoimidazole (0.645 g) as a pale yellowish solid, mp 335-338° C. [Elemental analysis:—C, 62.56%; H, 4.04%; N, 29.14%. Calculated for C 10 H 8 N 4 :—C, 65.19%; H, 4.39%; N, 30.42%].

(b) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole

By proceeding in a similar manner to Example 235(a) above but using 3-formyl-5-methoxy-indazole-1-carboxylic acid tert-butyl ester [Reference Example 20(a)] and 4,5-dimethylbenzene-1,2-diamine there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole as a white solid.

LC-MS (METHOD B): R T =2.35 minutes; 289 (M+H) + .

By proceeding in a manner similar to Example 235(a) above but using 3-formyl-5-methoxy-indazole-1-carboxylic acid tert-butyl ester [Reference Example 20(a)] and 4-ethyl-5-methyl phenylene diamine [Reference Example 30], and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of ethyl acetate and 40-60 petrol (1:1, v/v), there was prepared, 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole as a pale yellow solid.

LC-MS (METHOD B): R T =2.48 minutes; 307 (M+H) + .

(d) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole

By proceeding in a manner similar to Example 235(a) above but using 5-fluoro-1H-indazole-3-carbaldehyde [Reference Example 6(c)] and 4,5-dimethylbenzene-1,2-diamine there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-fluoro-1H-indazole as a brown solid.

LC-MS (METHOD B): R T =2.41 minutes; 281 (M+H).

(e) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole

By proceeding in a manner similar to Example 235(a) above but using 6-fluoro-1H-indazole-3-carbaldehyde [Reference Example 6(d)] and 4,5-dimethylbenzene-1,2-diamine there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-fluoro-1H-indazole (0.104 g) as a brown solid. MS: 281 (M+H) + . HPLC (METHOD B1): R T =23.6 minutes.

(f) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole

By proceeding in a manner similar to Example 235(a) above but using 5-methyl-1H-indazole-3-carbaldehyde [Reference Example 6(e)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-indazole as a brown solid. LC-MS (METHOD B): R T =2.35 minutes; 277 (M+H) + .

(g) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole

By proceeding in a manner similar to Example 235(a) above but using 6-methoxy-1H-indazole-3-carbaldehyde [Reference Example 6(f)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methoxy-1H-indazole as a pale orange solid. LC-MS (METHOD B): R T =2.52 minutes; 293 (M+H) + .

(h) 5,6-Dimethyl-2-(4-phenyl-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a manner similar to Example 235(a) above but using 4-phenyl-1H-pyrazole-3-carbaldehyde [Reference Example 6(g)] there was prepared 5,6-dimethyl-2-(4-phenyl-1H-pyrazol-3-yl)-1H-benzoimidazole as a white solid. LC-MS (METHOD B): R T =2.35 minutes; 289 (M+H) + .

(i) 3-(5-Ethyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(a) above but using 4-ethyl-phenylene diamine [Reference Example 29(a)], a reaction temperature of 160° C. and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of ethyl acetate and hexane (2:1) there was prepared 3-(5-ethyl-1H-benzoimidazol-2-yl)-1H-indazole as an off-white solid. LC-MS (Method D): R T =23.13 minutes, 263.3 (M+H) + .

(j) 3-(5-Ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-ethyl-5-methyl-phenylene diamine [Reference Example 30(a)] there was prepared 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl-1H-indazole as an off-white solid. LC-MS (Method D): R T =23.79 minutes, 277.3 (M+H) + .

(k) 3-(5-Isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-isopropyl-5-methyl-phenylene diamine [Reference Example 30(b)] there was prepared 3-(5-isopropyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole as an off-white solid. MS: 291.03 (N+H) + . HPLC (METHOD B1): R T =23.39 minutes.

(l) 3-(5-Bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-bromo-5-methyl-phenylene diamine [Reference Example 30(c)] there was prepared 3-(5-bromo-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole as an off-white solid. MS: 329.09 (M+H) + . HPLC (METHOD B1): R T =22.74 minutes.

(m) 3-(5-Bromo-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-bromo-phenylene diamine [Reference Example 30(e)] there was prepared 3-(5-bromo-1H-benzoimidazol-2-yl)-1H-indazole as a brown solid. LC-MS (Method D): R T =23.46 minutes, 315.15 (M+1) + .

(n) 3-(5-(3-Cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 3′,4′-diaminobiphenyl-3-carbonitrile [Reference Example 30(f)] there was prepared 3-(5-(3-cyano)phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 335.3 (M+H) + . HPLC (METHOD B1): R T =21.47 minutes.

(o) 3-(5-(Pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-(pyridine-3-yl) benzene-1,2-diamine [Reference Example 30(g)] there was prepared 3-(5-(pyrid-3-yl)-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 312.2 (M+H) + . HPLC (METHOD B1): R T =8.58 minutes.

(p) 3-(6-Methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole

›EXAMPLE 235 · 2 of 3

By proceeding in a manner similar to Example 235(i) above but using 6-methylbiphenyl-3,4-diamine [Reference Example 30(h)] there was prepared 3-(6-methyl-5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 325.3 (M+H) + . HPLC (METHOD B1): R T 14.48 minutes.

(q) 3-(5-Phenyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-biphenyl-3,4-diamine [Reference Example 30(i)] there was prepared 3-(5-phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 311.2 (M+H) + . HPLC (Method D): R T =24.54 minutes.

(r) 3-(5-(2-Fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 2′-fluorobiphenyl-3,4-diamine diamine [Reference Example 30(j)] there was prepared 3-(5-(2-fluoro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 329.2 (M+H) + . HPLC (METHOD B1): R T =22.54 minutes.

(s) 3-(5-(3,4-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-benzo[1,3]dioxol-5-ylbenzene-1,2-diamine [Reference Example 30(k)] there was prepared 3-(5-(5,6-methylenedioxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 355.2 (M+H) + . HPLC (METHOD B1): R T =22.04 minutes.

(t) 3-(5-(2-Methoxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 2′-methoxybiphenyl-3,4-diamine [Reference Example 30(l)] there was prepared 3-(5-(2-methoxy)phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 341.2 (M+H) + . HPLC (METHOD B1): R T =22.09 minutes.

(u) 3-(5-(4-Chlorophenyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4′-chlorobiphenyl-3,4-diamine [Reference Example 30(m)] there was prepared 3-(5-(4-chloro)phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 345.2 (M+H) + . HPLC (METHOD B1): R T =23.71 minutes.

(v) 3-(5-(4-Methyl)phenyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4′-methylbiphenyl-3,4-diamine diamine [Reference Example 30(n)] there was prepared 3-(5-(4-methyl)phenyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 325.1 (M+H) + . HPLC (METHOD C1): R T =15.22 minutes.

(w) 3-(5-Benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-benzyloxybenzene-1,2-diamine [Reference Example 30(o)] there was prepared 3-(5-benzyloxy-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. MS: 339.3 (M+H) + . HPLC (METHOD B1): R T =22.32 minutes.

(x) 3-(5,6-Methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using benzo[1,3]dioxole-5,6-diamine [Reference Example 30(p)] there was prepared 3-(5,6-methylenedioxy-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. LC-MS (METHOD B): R T =2.25 minutes; 279.22 (M+H) + .

(y) 3-(5,6-Dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4,5-dimethoxybenzene-1,2-diamine [Reference Example 30(q)] there was prepared 3-(5,6-dimethoxy-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. LC-MS (METHOD B): R T =2.16 minutes; 295.26 (M+H) + .

(z) 3-(5,6-Diethyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4,5-diethylbenzene-1,2-diamine [Reference Example 30(r)] there was prepared 3-(5,6-diethyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. LC-MS (METHOD B): R T =2.49 minutes; 291.32 (M+H) + .

(aa) 3-(4,5-Dimethyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 3,4-dimethylbenzene-1,2-diamine there was prepared 3-(4,5-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. LC-MS (METHOD B): R T =2.31 minutes; 263.24 (M+H) + .

(ab) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carbonitrile

By proceeding in a manner similar to Example 235(i) above but using 3,4-diaminobenzonitrile amine there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carbonitrile as a white solid.

LC-MS (Method D): R T =21.81 minutes, MS: 260.10 (M+H) + .

(ac) 3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 3,4-diaminobenzoic acid, methyl ester there was prepared 3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole as a white solid. LC-MS (Method D): R T =22.13 minutes, 293.16 (M+H) + .

(ad) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole

By proceeding in a manner similar to Example 235(a) above but using 5-ethoxy-3-formyl-indazole-1-carboxylic acid tert-butyl ester [Reference Example 20(d)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-ethoxy-1H-indazole as a pale orange solid. MS: 307 (M+H) + . HPLC (METHOD B1): R T =13.58 minutes.

(ae) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-pyrazole-4-carboxylic acid ethyl ester

By proceeding in a manner similar to Example 235(a) above but using 3-formyl-pyrazole-4-carboxylic acid ethyl ester [Reference Example 6(i)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl-pyrazole-4-carboxylic acid ethyl ester as a pale brown solid. LC-MS (METHOD B): 2.56 minutes; 285 (M+H) + .

(af) 2-(4-Isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester

By proceeding in a manner similar to Example 235(a) above but using 3-formyl-pyrazole-4-carboxylic acid isopropylamide [Reference Example 6(j)] and methyl-3,4-diamino benzoate there was prepared 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester as a yellow solid. LC-MS (METHOD B): 2.99 minutes; 328 (M+H) + .

(ag) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid ethyl ester

By proceeding in a manner similar to Example 235(a) above but using 3-formyl-5-methyl-pyrazole-4-carboxylic acid ethyl ester [Reference Example 6(k)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid ethyl ester as a white solid. LC-MS (METHOD B): R T =2.59 minutes; 299 (M+H) + .

›EXAMPLE 235 · 3 of 3

(ah) 3-(1,5,6,7-Tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide

By proceeding in a manner similar to Example 235(a) above but using indane-5,6-diamine (130 mg) and 3-formyl-1H-pyrazole-4-carboxylic acid cyclopropylamide [150 mg, Reference Example 6(q)] and subjecting the reaction product to chromatography on silica [eluting with ethyl acetate/gradient 75 to 0% heptane] followed by trituration with acetone, there was prepared 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide (31 mg) as a white solid. LC-MS (Method A): R T =2.85 minutes, 308 (M+H) + .

(ai) 3-(5-Methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide

By proceeding in a manner similar to Example 235(a) above but using 3-formyl-pyrazole-4-carboxylic acid-isopropylamide [198 mg, Reference Example 60)] and 4-methoxy-5-methyl-benzene-1,2-diamine [166 mg, Reference Example 29(b)] and subjecting the reaction product to flash chromatography on silica eluting with dichloromethane/methanol (95:5) followed by recrystallisation from a mixture of ethyl acetate and n-pentane there was prepared 3-(5-methoxy-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide (145 mg) as a white solid. LC-MS (Method H): R T =2.09 minutes, 314.27 (M+H) + , 312.29 (M−H) − .

(aj) 3-[5-(2-Morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole

By proceeding in a manner similar to Example 235(i) above but using 4-(2-morpholin-4-yl-ethoxy)-benzene-1,2-diamine [Reference Example 29(c)] and subjecting the reaction product to preparative LC-MS there was prepared 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1H-indazole (25 mg) as a white solid. MS: 364 (M+H) + . HPLC (METHOD B1): R T =19.38 minutes.

(ak) 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide

By proceeding in a manner similar to Example 235(i) above but using 4,5-dimethylbenzene-1,2-diamine and 3-formyl-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide [Reference Example 6(n)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide (87 mg) as a cream solid. LC-MS (METHOD L): R T =4.23 minutes, 314.2 (M+H) + .

(al) 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide

By proceeding in a manner similar to Example 6(i) above but using 4,5-dimethylbenzene-1,2-diamine and 3-formyl-1H-pyrazole-4-carboxylic acid propylamide [Reference Example 6(o)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid propylamide (73 mg) as a pale yellow solid. LC-MS (METHOD L): R T =4.94 minutes, 298.29 (M+H) + .

(am) 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide

By proceeding in a manner similar to Example 235(i) above but using 4,5-dimethyl-1,2-phenylenediamine and 3-formyl-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide [Reference Example 6(p)] and recrystallising the reaction product from methanol there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (tetrahydro-pyran-4-yl)-amide (228 mg) as a white solid. LC-MS (METHOD R): R T =9.40 minutes, 360 (M+H) + .

(an) 3-(5-Ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile

By proceeding in a manner similar to Example 235(i) above but using 4-ethyl-5-methyl-phenylene diamine [Reference Example 30(a)] and 3-formyl-1H-indazole-5-carbonitrile [Reference Example 68] there was prepared 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile (133 mg) as a pale yellow solid. MS: 302 (M+H) + . HPLC (METHOD B1): R T =16.45 minutes.

(ao) 3-(5-Difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide

By proceeding in a manner similar to Example 235(i) above but using 4-difluormethoxy-benzene-1,2-diamine [Reference Example 30(y)] and 3-formyl-pyrazole-4-carboxylic acid isopropylamide [Reference Example 6(j)] there was prepared 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide (118 mg) as a white solid. LC-MS (METHOD L): R T =10.46 minutes, 336.19 (M+H) + .

(ap) 3-(5-Difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide

By proceeding in a manner similar to Example 235(ao) above but using 3-formyl-1H-pyrazole-4-carboxylic acid cyclopropylamide [Reference Example 6(q)] there was prepared 3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylamide (63 mg) as a white solid. LC-MS (METHOD L): R T =10.18 minutes, 334.17 (M+H) + .

(aq) 3-(6-Ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide

By proceeding in a manner similar to Example 235(i) but using 4-ethyl-5-methoxy-benzene-1,2-diamine [200 mg, Reference Example 30(z)] and 3-formyl-pyrazole-4-carboxylic acid isopropylamide [Reference Example 6(j)] there was prepared 3-(6-ethyl-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide (115 mg) as an off-white solid. LC-MS (METHOD L): R T =11.34 minutes, 328.24 (M+H) + .

(ar) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile dihydrochloride

By proceeding in a manner similar to Example 235(i) above but (i) using 4,5-dimethyl-phenylene diamine and 3-formyl-1H-indazole-5-carbonitrile [Reference Example 68] (ii) treating a suspension of the reaction product in methanol with a solution of hydrochloric acid (4M) in 1,4-dioxane followed by evaporation of the mixture (iii) trituration of the residue with methanol and (iv) recrystallisation from diethyl ether, there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile dihydrochloride (133 mg) as an off-white solid. LC-MS (METHOD B): R T =2.32 minutes. MS: 288 (M+H) + .

(as) 3-(5-nitro-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 235(a) above but using 4-nitrophenylenediamine there was prepared 3-(5-nitro-1H-benzoimidazol-2-yl)-1H-indazole as red solid. MS: 280.17 (M+H) + . HPLC (Method B1): R T =3.00 minutes.

›EXAMPLE 236

2-(5-Methyl-1H-pyrazol-3-yl)-1H-benzoimidazole

A mixture of o-phenylenediamine (1.08 g) and 5-methylpyrazole-3-carboxylic acid (1.266 g) was finely ground and the finely ground material was heated at 160° C. for 3 hours and then cooled to ambient temperature. The reaction mixture was recrystallised from ethyl alcohol (50 mL) to give a light blue solid (0.27 g). The filtrate gave another crop (0.1 g) on standing. The combined solids were recrystallised from ethyl alcohol to give 2-(5-methyl-1H-pyrazol-3-yl)-1H-benzoimidazole (223 mg) as a lilac coloured solid, mp 322-324° C. [Elemental analysis:—C, 66.54%; H, 4.80%; N, 28.14%. Calculated for C 11 H 10 N 4 :—C, 66.64%; H, 5.09%; N, 28.27%].

›EXAMPLE 237

2-(5-Ethoxy-1H-pyrazol-3-yl)-1H-benzoimidazole

A mixture of trifluoroacetic acid (6 mL) and 2-(5-ethoxy-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole (300 mg, Reference Example 11) was stirred at 50° C. for 1.5 hours. The reaction mixture was evaporated and the residue was partitioned between ethyl acetate and water (pH 10). The organic layer was dried and then evaporated. The residue was subjected to chromatography on silica eluting with a mixture of dichloromethane and methanol (9:1, v/v) and then recrystallised from toluene to give 2-(5-ethoxy-1H-pyrazol-3-yl)-1H-benzoimidazole (0.1 g) as a colourless solid, mp 217-219.5° C. [Elemental analysis:—C, 62.26%; H, 5.23%; N, 23.44%. Calculated for C 12 H 12 N 4 O:—C, 63.15%; H, 5.30%; N, 24.55%].

›EXAMPLE 238

2-(5-Methylsulfanyl-isoxazol-3-yl)-1H-benzoimidazole

A mixture of 2-(5-methylsulfanyl-isoxazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole (160 mg, Reference Example 12), methanol (12 mL) and concentrated aqueous hydrochloric acid (2.45 mL) were heated at reflux for four hours, then cooled and then evaporated. The residue was treated with aqueous sodium bicarbonate and the mixture was extracted with ethyl acetate. The extracts were dried and then evaporated to give 2-(5-methylsulfanyl-isoxazol-3-yl)-1H-benzoimidazole (96 mg) as an off white solid, mp 179-181° C. 1 H-NMR [(CD 3 ) 2 SO]: δ 4.65 (s, 3H), 9.00 (s, 1H), 9.15-9.6 (m, 4H).

›EXAMPLE 239

(a) 5-Chloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

A solution of 4-chloro-benzene-1,2-diamine (500 mg) in hydrochloric acid (4N) was treated with 4-nitro-pyrazole-3-carboxylic acid (826 mg) then heated at reflux temperature, under nitrogen. The reaction mixture was cooled to room temperature when the pH was adjusted to 8 by addition of ammonium hydroxide and the mixture was extracted with ethyl acetate. The extracts were evaporated to give 5-chloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole.

(b) 5,6-dichloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a similar manner to Example 239(a) above but using 4,5-dichloro-1,2-diaminobenzene there was prepared 5,6-dichloro-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole.

›EXAMPLE 240

(Benzoimidazol-2-yl)-5-methylthio-3-pyrazole

A mixture of 1-[(3,3-bis(methylthio))benzoimidazol-2-yl]propen-2-one [5.5 g, Reference Example 15], hydrazine hydrate (1.02 g) and acetonitrile (50 mL) was stirred at reflux for 18 hours. The reaction mixture was cooled, and the precipitate was isolated by filtration. Recrystallisation from aqueous ethanol provided (benzoimidazol-2-yl)-5-methylthio-3-pyrazole (3.36 g) as a beige crystalline solid, m.p. 242° C. [Elemental analysis: Found: C, 57.8; H, 4.5; N, 24.0. Calculated for C 11 H 10 N 4 S: C, 57.37; H, 4.38; N, 24.33].

›EXAMPLE 241

(a) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole

4,5-Dimethylbenzene-1,2-diamine (90 mg) and 4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid [110 mg, Reference Example 17(a)] were mixed in a glass vial then subjected to microwave radiation (900 W, domestic oven) twice for two minutes. The resulting solid was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and hexane (85:15, v/v) to give 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-indazole (30 mg) as a pale brown solid. LC-MS (METHOD B): R T =2.28 minutes; 267 (M+H) + .

(b) 2-(5-Isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole

By proceeding in a manner similar to Example 241 (a) above, but using 5-isopropyl-1H-pyrazole-3-carboxylic acid [Reference Example 17(b)] there was prepared 2-(5-isopropyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole (80 mg) as a brown solid. LC-MS (METHOD B): R T =2.27 minutes; 255 (M+H) + .

By proceeding in a manner similar to Example 241(a) above but using 5-ethyl-1H-pyrazole-3-carboxylic acid [Reference Example 17(c)], and triturating the brown solid reaction product with a mixture of ethyl acetate and hexane (1:1, v/v), there was prepared 2-(5-ethyl-1H-pyrazol-3-yl)-5,6-dimethyl-1H-benzoimidazole as a light brown solid. LC-MS (METHOD B): R T =2.22 minutes; 241 (M+H) + .

(d) 5,6-Dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole

By proceeding in a manner similar to Example 214(a) above but using 1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid [Reference Example 17(f)] and triturating the reaction product with ethyl acetate, ether and methanol, there was prepared 5,6-dimethyl-2-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl)-1H-benzoimidazole (50 mg) as an off-white solid. MS: 253 (M+H) + . HPLC (METHOD B1): R T =11.17 minutes.

›EXAMPLE 242

(a) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole

A mixture of 4,5-dimethylbenzene-1,2-diamine (70 mg) and 4-fluoro-1H-indazole-3-carbaldehyde [80 mg, Reference Example 20(b)] in dimethylformamide (8 ml) was heated to 120° C. for 30 minutes and then at 100° C. for 16 hours. The reaction mixture was cooled, then diluted with ethyl acetate and then washed five times with brine. The organic phase was dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of 40/60 petrol and ethyl acetate (1:5, v/v) to give 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4-fluoro-1H-indazole (104 mg) as a light brown solid. MS: 281 (M+H) + . HPLC (METHOD B1): R T =10.08 minutes.

(b) 4-Chloro-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole

By proceeding in a manner similar to Example 242(a) above but using 4-chloro-3-formyl-indazole-1-carboxylic acid tert-butyl ester [Reference Example 20(c)] there was prepared 4-chloro-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole (25 mg) as an off-white solid. MS: 299 (M+H) + . HPLC (METHOD B1): R T =10.59 minutes.

By proceeding in a manner similar to Example 242(a) above but using 5-chloro-1H-indazole-3-carbaldehyde [Reference Example 6(h)] there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-chloro-1H-indazole (25 mg) as a pale brown solid. LC-MS (METHOD D): R T =24.24 minutes, 299 (M+H) + .

›EXAMPLE 243

3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-indazol-5-ol

A solution of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methoxy-1H-indazole [34 mg, Example 235(b)] at 0° C. was treated with a solution of boron tribromide in dichloromethane (0.30 mL, 1M). The mixture was then heated at reflux temperature for 4 hours, then cooled and then treated dropwise with water. The pH was adjusted to between 7 and 8 by the addition of saturated aqueous sodium bicarbonate solution and this mixture was then extracted twice with ethyl acetate. The combined extracts were washed with brine, then dried over magnesium sulfate and then evaporated. The pale yellow solid residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and triethylamine (99:1, v/v) to yield 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazol-5-ol (23 mg) as a white solid. LC-MS (METHOD B): R T =2.19 minutes; 279 (M+H) + .

›EXAMPLE 244

(a) 3-(5-n-Propyl-1H-benzoimidazol-2-yl)-1H-indazole

A stirred solution of 4-propyl-benzene-1,2-diamine [57 mg, Reference Example 30(d)] and sodium bisulfite (40 mg) in dimethylformamide (2 ml) was treated with indazole-3-carboxaldehyde [Reference Example 6(l)]. The reaction mixture was heated in a Smith Creator microwave at 200° C. for 13 minutes then partitioned between ethyl acetate and water. The organic layer was washed with brine, then dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and hexane (3:1) to give 3-(5-n-propyl-1H-benzoimidazol-2-yl)-1H-indazole (74 mg) as a pale brown solid. MS: 277.3 (M+H) + . HPLC (METHOD B1): R T =12.81 minutes.

(b) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide

By proceeding in a manner similar to Example 244(a) above but using 3,4-diamino-N-benzyl-benzenesulfonamide[Reference Example 30(x)] and heating at 230° C. there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-sulfonic acid benzylamide (235 mg) as a white solid. LC-MS (METHOD L): R T =6.35 minutes, 404.20 (M+H) + .

By proceeding in a manner similar to Example 244(a) above but using 4-methanesulfonyl-benzene-1,2-diamine [Reference Example 49(f)] and heating at 210° C. there was prepared 3-(5-methanesulfonyl-1H-benzoimidazol-2-yl)-1H-indazole (105 mg) as a white solid. LC-MS (METHOD L): R T =5.71 minutes, 313.23 (M+H) + .

›EXAMPLE 245

[2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol

A stirred solution of [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanone [200 mg, Example 234(c)] in tetrahydrofuran (10 mL), at −78° C. and under an atmosphere of nitrogen, was treated dropwise with a solution of diisobutylaluminium hydride in tetrahydrofuran (1.18 mL, 1N). The reaction mixture was warmed to ambient temperature, then stirred for 16 hours and then partitioned between ether and sodium hydroxide solution (2N). The organic phase was washed with water, then with brine, then dried over magnesium sulfate and then evaporated. The residue was subjected to flash column chromatography on silica eluting with a mixture of ethyl acetate and hexane (3:1, v/v) to give [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-phenyl-methanol (161 mg) as a white solid. LC-MS (Method D): R T =21.89 minutes, 341.3 (M+H) + .

›EXAMPLE 246 · 1 of 3

(a) [2-(Indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, ethylamide

A stirred solution of [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid [130 mg, Example 247(a)], hydroxybenzatriazole (189 mg) and diisopropyl ethylamine (732 μL) in dimethylformamide (3 mL) was treated with ethylamine and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (267 mg). The reaction mixture was heated at 80° C. overnight and then partitioned between ethyl acetate and 5% citric acid. The aqueous layer was re-extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium hydrogen carbonate solution, then with brine, then dried over magnesium sulfate and then evaporated. The residual oil was subjected to preparative HPLC to give [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, ethylamide as a white solid. LC-MS (METHOD B): R T =2.37 minutes; 306.27 (M+H) + .

(b) [2-(Indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide

By proceeding in a manner similar to Example 246(a) above but using methylamine, there was prepared [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, methylamide as a white solid.

LC-MS (METHOD B): R T =2.28 minutes; 292.30 (M+H) + .

By proceeding in a manner similar to Example 246(a) above but using dimethylamine, there was prepared [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, dimethylamide as a white solid. LC-MS (METHOD B): R T =2.38 minutes; 306.27 (M+H) + .

(d) [2-(Indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide

By proceeding in a manner similar to Example 246(a) above but using isopropylamine, there was prepared [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, isopropylamide as a white solid.

LC-MS (METHOD B): R T =2.48 minutes; 320.30 (M+H) + .

(e) [2-(Indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide

By proceeding in a manner similar to Example 246(a) above but using benzylamine, there was prepared [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzylamide as a white solid.

LC-MS (METHOD B): R T =2.68 minutes; 368.27 (M+H) + .

(f) [2-(Indazol-3-yl-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide

By proceeding in a manner similar to Example 246 (a) above but using aniline, there was prepared [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid, benzamide as a white solid.

LC-MS (METHOD B): R T =2.73 minutes; 354.26 (M+H) + .

(g) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide

By proceeding in a manner similar to Example 246(a) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrazole-4-carboxylic acid [Example 247(b)] and isopropylamine, and subjecting the reaction product to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (19:1, v/v), there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide as an off-white solid. LC-MS (METHOD B): R T =2.67 minutes; 298 (M+H) + .

(h) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrazole-4-carboxylic acid [Example 247(b)] and 2-amino-2-methyl-1-propanol, and subjecting the reaction product to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (19:1, v/v), there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide as a pale yellow solid.

LC-MS (METHOD B): R T =2.63 minutes; 328 (M+H) + .

(i) 2-(4-Isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [Example 247(c)] and 3-aminomethyl)pyridine there was prepared 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide as a white solid. LC-MS (METHOD B): R T =2.49 minutes; 404 (M+H) + .

(j) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide

By proceeding in a manner similar to Example 246(a) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid [Example 247(d)] and cyclopropylamine, and subjecting the reaction product to flash chromatography on silica eluting with a mixture of dichloromethane and methanol (119:1, v/v), there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid cyclopropylamide as a white solid. LC-MS (METHOD B): R T =2.67 minutes; 310 (M+H) + .

(k) 2-(4-Isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide

By proceeding in a manner similar to Example 246(a) above but using 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [Example 247(c)] and benzylamine there was prepared 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid phenylmethyl-amide as a pale yellow solid. LC-MS (METHOD B): R T =3.17 minutes; 403 (M+H) + .

(l) 2-(4-Isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [Example 247(c)] and 2-(aminomethyl)pyridine there was prepared 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide as an off-white solid. LC-MS (Method D): R T =9.33 minutes, 367.28 (M+H) + .

(m) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 3-(aminomethyl)pyridine there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-3-ylmethyl)-amide (42.2 mg) as an off white solid. LC-MS (Method L): R T =4.96 minutes, 367.19 (M−H) − .

›EXAMPLE 246 · 2 of 3

(n) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide

By proceeding in a manner similar to Example 246(a) above but using 3-methylbenzylamine there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 3-methyl-benzylamide (33.4 mg) as a white solid. MS: 382.52 (M+H) + . HPLC (Method B1): R T =16.22 minutes.

(o) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide

By proceeding in a manner similar to Example 246(a) above but using 4-methylbenzylamine there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid 4-methyl-benzylamide (63.5 mg) as a white solid. MS: 382.54 (M+H) + . HPLC (Method B1): R T =16.14 minutes.

(p) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide

By proceeding in a manner similar to Example 246(a) above but using 1-(3-aminopropyl)-2-pyrrolidinone there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide (68.1 mg) as a white solid. MS: 401.13 (M−H) − . HPLC (Method B1): R T =11.29 minutes.

(q) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 4-(2-aminoethyl)morpholine there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-morpholin-4-yl-ethyl)-amide (70.8 mg) as a white solid. MS: 389.12 (M−H) − . HPLC (Method B1): R T =8.51 minutes.

(r) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 2-methoxyethylamine there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-methoxy-ethyl)-amide (55.2 mg) as a white solid. MS: 336.52 (M+H) + . HPLC (Method B1): R T =11.30 minutes.

(s) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide

By proceeding in a manner similar to Example 246(a) above but heating the reaction at 50° C. and using 3-aminopropionitrile there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide (15.4 mg) as a white solid. MS: 331.15 (M+H) + , 329.17 (M−H) − . HPLC (Method B1): R T =12.72 minutes.

(t) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide

By proceeding in a manner similar to Example 246(a) above but heating the reaction at 50° C. and using 2-amino-2-methyl-1-propanol there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl)-amide (29.6 mg) as a brown oil. LC-MS (Method L): R T =10.57 minutes, 350.16 (M+H) + , 348.18 (M−H) − .

(u) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 1-(3-aminopropyl)imidazole there was prepared 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (3-imidazol-1-yl-propyl)-amide (31.9 mg) as a white solid. LC-MS (Method B): R T =8.45 minutes, 386.22 (M+H) + , 384.26 (M−H) − .

(v) 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide

By proceeding in a manner similar to Example 246(g) above but using isobutylamine there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl-amide (101 mg) as a white solid. LC-MS (METHOD M): R T =9.38 minutes, 312 (M+H) + .

(w) 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide

By proceeding in a manner similar to Example 246(g) above but using isopropylamine there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid isopropylamide (100 mg) as a white solid. LC-MS (METHOD L): R T =7.21 minutes, 298 (M+H) + .

(x) 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide

By proceeding in a manner similar to Example 246(g) above but using (aminomethyl)cyclopropane there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid cyclopropylmethyl-amide (105 mg) as a white solid. LC-MS (METHOD M): R T =8.77 minutes, 310 (M+H) + .

(y) 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide

By proceeding in a manner similar to Example 246(j) above but using tert-butylamine there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid tert-butylamide (57 mg) as an off-white solid. LC-MS (METHOD M): R T =13.86 minutes, 326 (M+H) + .

(z) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide dihydrochloride

By proceeding in a manner similar to Example 246(j) above, but (i) using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid [97 mg, Example 263] and dimethylamine hydrochloride (23 mg), (ii) carrying out the reaction at ambient temperature overnight, and (iii) subjecting the reaction product to flash column chromatography [eluting with ethyl acetate to ethyl acetate/methanol (97:3, v/v)] followed by treatment with 4M hydrogen chloride in 1,4-dioxane and trituration with dichloromethane and diethyl ether there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid dimethylamide dihydrochloride (8 mg) as a white solid. LC-MS (METHOD M): R T =9.37 minutes, 320 (M+H) + .

(aa) 2-(4-Isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide

By proceeding in a manner similar to Example 246(a) above but using 2-(4-isobutylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [Reference Example 35] and benzylamine there was prepared 2-(4-Isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid benzylamide (17 mg) as a white solid. LC-MS (METHOD L): R T =11.00 minutes, 403 (M+H) + .

(ab) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide

By proceeding in a manner similar to Example 246(a) above but using 1-(2-aminoethyl)piperidine, and heating the reaction mixture at 50° C. for 6 hours, there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-piperidin-1-yl-ethyl)-amide as an oil. MS: 387.22 (M−H) − . HPLC (Method L): R T =5.03 minutes.

›EXAMPLE 246 · 3 of 3

(ac) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide

By proceeding in a manner similar to Example 246(ab) above but using (2-aminomethyl)pyridine there was prepared 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (pyridin-2-ylmethyl)-amide as an off-white solid. MS: 367.28 (M+H) + . HPLC (Method B1): R T =9.33 minutes.

(ad) 2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide

By proceeding in a manner similar to Example 246(ab) above but using 443-(aminopropyl))-1-methyl piperazine there was prepared 2-(4H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide as an oil. MS: 416.21 (M+H) + . HPLC (Method L): R T =4.46 minutes.

(ae) N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide

By proceeding in a manner similar to Example 246(ab) above but using isobutyric acid and 2-(1H-indazol-3-yl)-3H-benzoimidazol-5-amine [Example 265] there was prepared N-[2-(1H-Indazol-3-yl)-1H-benzoimidazol-5-yl]-isobutyramide as an off-white solid. MS: 320.23 (M+H) + . HPLC (Method B1): R T =19.28 minutes.

›EXAMPLE 247

(a) [2-(Indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid

A stirred solution of 3-(5-methoxycarbonyl-1H-benzoimidazol-2-yl)-1H-indazole [84.5 mg, Example 235(ac)] and sodium hydroxide (74 mg) in tetrahydrofuran (4 mL) and water (2 mL) was heated at 75° C. overnight. The reaction mixture was evaporated and the oily residue was partitioned between ethyl acetate and water. The aqueous layer was acidified to pH 6 and extracted with ethyl acetate. The organic layers was dried over magnesium sulfate and then evaporated to give [2-(indazol-3-yl)-1H-benzoimidazol-5-yl]-carboxylic acid (80 mg) as an oil. MS: 279.14 (M+H) + . HPLC (METHOD H): R T =2.81 minutes.

(b) 3-(5,6-Dimethyl-1H-benzoimidazol-5-yl)-pyrazole-4-carboxylic acid

By proceeding in a manner similar to Example 247(a) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-pyrazole-4-carboxylic acid ethyl ester [Example 235(ae)] and carrying out the reaction at 60° C. there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-5-yl)-pyrazole-4-carboxylic acid as a white solid. LC-MS (METHOD B): R T =2.17 minutes; 257 (M+H) + .

By proceeding in a manner similar to Example 247(a) above but using 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester [Example 235(af)], replacing the tetrahydrofuran with methanol and carrying out the reaction at 65° C., there was prepared 2-(4-isopropylcarbamoyl-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid as a pale brown solid which was used without further purification. LC-MS (METHOD B): R T =2.67 minutes; 314 (M+H) + .

(d) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid

By proceeding in a manner similar to Example 247(a) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid ethyl ester [Example 235(ag)], replacing the tetrahydrofuran with methanol and carrying out the reaction at 65° C., there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-5-methyl-pyrazole-4-carboxylic acid as a white solid. LC-MS (METHOD B): R T =2.75 minutes; 271 (M+H) + .

›EXAMPLE 248 · 1 of 2

(a) N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide

A stirred solution of 5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [83 mg, Example 233(c)] and diisopropylethylamine (256 μL) in dichloromethane (4 mL) was treated with isobutyryl chloride (115 μL). The reaction mixture was stirred for 30 minutes at room temperature then treated with piperidine (500 μL) and stirring was continued for a further hour. The reaction mixture was partitioned between 5% citric acid. The organic layer was dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of hexane and ethyl acetate to give N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide (49 mg) as a white solid. MS: 298.28 (M+H) + . HPLC (METHOD B1): R T =14.66 minutes.

(b) N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide

By proceeding in a manner similar to Example 248(a) above but using isovaleryl chloride there was prepared N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-butyramide as a white solid. MS: 312.28 (M+H) + . HPLC (METHOD B1): R T =15.28 minutes.

By proceeding in a manner similar to Example 248(a) above but using phenylacetyl chloride there was prepared N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-phenyl-acetamide as a white solid. LC-MS (METHOD B): R T =2.83 minutes, 346.18 (M+H) + .

(d) Cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using cyclopropanecarbonyl chloride, there was prepared cyclopropanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 296.28 (M+H) + . HPLC (METHOD B1): R T =13.50 minutes.

(e) Methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using methoxyacetyl chloride, there was prepared methoxyacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 300.33 (M+H) + . HPLC (METHOD C1): R T =14.25 minutes.

(f) Cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using cyclopentylcarbonyl chloride, there was prepared cyclopentanecarboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 324.39 (M+H) + . HPLC (METHOD B1): R T =17.64 minutes.

(g) Trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using trimethylacetyl chloride, there was prepared trimethylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 312.39 (M+H) + . HPLC (METHOD B1): R T =19.52 minutes.

(h) tert-Butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using tert-butylacetyl chloride, there was prepared tert-butylacetic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 326.29 (M+H) + . HPLC (METHOD B1): R T =19.52 minutes.

(i) Butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using butyryl chloride, there was prepared butanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 298.34 (M+H) + . HPLC (METHOD B1): R T =15.07 minutes.

(j) Isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using isoxazole-5-carbonyl chloride, there was prepared isoxazole-5-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 323.16 (M+H) + . HPLC (METHOD B1): R T =10.01 minutes.

(k) S(+)-2-Methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using S(+)-2-methyl butyryl chloride, there was prepared S(+)-2-methylbutanoic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 312.18 (M+H) + . HPLC (METHOD B1): R T =11.15 minutes.

(l) Cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(d)] and cyclopropanecarbonyl chloride, there was prepared cyclopropanecarboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide as a white solid. MS: 310.32 (M+H) + . HPLC (METHOD B1): R T =8.88 minutes.

(m) Piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but (i) treating a solution of 3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [0.2 g, Example 233(e)] and diisopropylethylamine (392 mg, 4 eq) in tetrahydrofuran (25 mL) with piperidinecarbonyl chloride (450 mg, 4 eq), stirring overnight at ambient temperature, and evaporating the reaction mixture, (ii) triturating the reaction product with water (30 mL) and ethyl acetate (50 mL) and extracting with aqueous layer with ethyl acetate, (iii) combining the organic phases, drying over magnesium sulfate, then evaporating (iv) chromatographing the residue on silica gel (ethyl acetate), (v) triturating the partially purified material with ethyl acetate (15 mL) for 1.5 hours and filtering, and (vi) evaporating the filtrate and chromatographing the residue on silica gel (ethyl acetate/heptane gradient of 20-0%) there was prepared piperidine-1-carboxylic acid[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (50 mg) as a yellow solid, mp>310° C. LC-MS (Method E) R T =3.25 minutes, 374 (M+H) + .

›EXAMPLE 248 · 2 of 2

(n) 3-[3-(6-Chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea

By proceeding in a similar manner to Example 248(m) above but using N,N-dimethylcarbamyl chloride there was prepared 3-[3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethylurea as a yellow solid, mp>300° C. LC-MS (Method E): R T =2.4 minutes, 335 (M+H) + .

(o) Cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [282 mg, Example 233(f)] and cyclopropanecarbonyl chloride (0.558 ml) there was prepared cyclopropanecarboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (76 mg) as an off-white solid. LC-MS (Method L): R T =5.25 minutes, 298.26 (M+H) + .

(p) Cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(o) above but using 3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [187 mg, Example 233(g)] there was prepared cyclopropanecarboxylic acid [3-(5-ethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (112 mg) as a pale yellow solid. LC-MS (Method H): R T =2.26 minutes, 312.23 (M+H) + , 310.30 (M−H) − .

(q) Cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using 3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(h)] and cyclopropanecarbonyl chloride there was prepared cyclopropanecarboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (135 mg) as a white solid. LC-MS (METHOD M): R T =11.31 minutes, 300.31 (M+H) + .

(r) Cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using 3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(i)] and cyclopropanecarbonyl chloride there was prepared cyclopropanecarboxylic acid [3-(5-trifluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (275 mg) as a white solid. LC-MS (METHOD M): R T =13.57 minutes, 352.22 (M+H) + .

(s) Cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(j)] and cyclopropanecarbonyl chloride there was prepared cyclopropanecarboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (88 mg) as a white solid. LC-MS (METHOD M): R T =13.62 minutes, 338.12 (M+H) + .

(t) N-[3-(5-Trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide

By proceeding in a manner similar to Example 248(s) above but using isobutyryl chloride there was prepared N-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isobutyramide (71 mg) as a white solid. LC-MS (METHOD M): R T =10.11 minutes, 336.12 (M+H) + .

(u) Cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 261] and cyclopropanecarbonyl chloride there was prepared cyclopropanecarboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (46 mg) as a white solid. LC-MS (METHOD L): R T =7.06 minutes, MS: 316.26 (M+H) + .

(v) 3,5-Dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248(a) above but using 3,5-dimethylisoxazole-4-carbonyl chloride there was prepared 3,5-dimethyl-isoxazole-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (62 mg) as a white solid. LC-MS (METHOD L): R T =8.45 minutes, 351.32 (M+H) + .

(w) N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide

By proceeding in a manner similar to Example 248(a) above but using acetyl chloride there was prepared N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide (25 mg) as a white solid. LC-MS (METHOD L): R T =6.34 minutes, 270.14 (M+H) + .

(x) Furan-3-carboxylic acid [3-(5,6-dimethylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 248 (a) above but using 3-furoylchloride there was prepared furan-3-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (80 mg) as a white solid. LC-MS (METHOD L): R T =7.10 minutes, 322.31 (M+H) + .

(y) N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide

By proceeding in a manner similar to Example 248(a) above but using p-toluoyl chloride there was prepared N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-4-methyl-benzamide (42 mg) as a white solid. LC-MS (METHOD L): R T =12.24 minutes, 346 (M+H) + .

›EXAMPLE 249

(a) 5,6-Dimethyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

A stirred solution of 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-4,5-dimethylphenyl)amide [5.7 g, Reference Example 36(a)] in acetic acid (100 mL) was heated at 120° C. for 1 hour, then cooled to ambient temperature and then evaporated. The oily residue was partitioned between ethyl acetate and water. The organic layer was dried over magnesium sulfate and then evaporated to give 5,6-dimethyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole (5.70 g) as an orange solid. LC-MS (METHOD B): R T =2.30 minutes, 258.11 (M+H) + .

(b) 5-Ethyl-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a manner similar to Example 249(a) above but using 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-4-ethyl-5-methylphenyl)amide [Reference Example 36(b)] there was prepared 5-ethyl-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole as a yellow solid. LC-MS (METHOD B): R T =2.61 minutes, 272.23 (M+H) + .

By proceeding in a manner similar to Example 249(a) above but using 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-5-chloro-4-methoxyphenyl)amide [1.5 g, Reference Example 36(c)] there was prepared 6-chloro-5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole (0.7 g) as a dark solid. MS: 294 (M+H) + .

(d) 5-Fluoro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a manner similar to Example 249(a) above but using 4-Nitro-1H-pyrazole-3-carboxylic acid (2-amino-4-fluoro-5-methyl-phenyl)-amide [Reference Example 36(f)] there was prepared 5-fluoro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole (0.730 g) as a red solid. LC-MS (METHOD J): R T =2.76 minutes, 262.21 (M+H) + .

(e) 2-(4-Nitro-1H-pyrazol-3-yl)-5-trifluoromethoxy-1H-benzoimidazole

By proceeding in a manner similar to Example 249(a) above but using 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-4-trifluoromethoxy-phenyl)-amide [Reference Example 36(g)] there was prepared 2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethoxy-1H-benzoimidazole (1.02 g) as a red solid. LC-MS (METHOD J): R T =3.32 minutes, 314.19 (M+H) + .

(f) 2-(4-Nitro-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole

By proceeding in a manner similar to Example 249(a) above but using 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-4-trifluoromethyl-phenyl)-amide [Reference Example 36(h)] there was prepared 2-(4-nitro-1H-pyrazol-3-yl)-5-trifluoromethyl-1H-benzoimidazole (0.195 g) as an orange solid. MS: 298.07 (M+H) + . HPLC (METHOD B): R T =3.50 minutes.

(g) 5-Chloro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a manner similar to Example 249(a) above but using 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-4-chloro-5-methyl-phenyl)-amide [Reference Example 36(i)] there was prepared 5-chloro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole (0.320 g) as an orange solid. LC-MS (METHOD C): R T =3.36 minutes, 314.19 (M+H) + .

(h) 2-(4-Nitro-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester

By proceeding in a manner similar to Example 249(a) above but using 3-amino-4-[(4-nitro-1H-pyrazole-3-carbonyl)-amino]-benzoic acid methyl ester [Reference Example 36(j)] there was prepared 2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester (2.50 g) as a yellow solid. LC-MS (METHOD B): R T =2.76 minutes, 288.12 (M+H) + .

›EXAMPLE 250

(a) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide

A solution of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine [0.150 g, Example 251(a)] in dimethyl formamide (4 ml) was treated with diisopropylethylamine (0.54 ml) and then with dimethyl carbamyl chloride (0.122 ml). After stirring for 1 hour the reaction mixture was quenched by the addition of methanol (0.1 ml) and then diluted with ethyl acetate. This mixture was washed five times with brine and then evaporated. The residue was treated with tetrahydrofuran (9 ml) and methanol (3 ml) and the resulting solution was then treated with potassium hydroxide (50 mg). This mixture was stirred for 1 hour, then acidified by addition of hydrochloric acid (1M) and then extracted three times with ethyl acetate. The aqueous layer was basified by addition of sodium carbonate and the resulting suspension was filtered, then washed with water, then dried in air and then azeotroped with toluene to yield 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide as a pale brown solid. MS: 339 (M+H) + . HPLC (METHOD F1): R T =8.67 minutes.

(b) Cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone

By proceeding in a manner similar to Example 250(a) above, but using cyclopropanecarbonylchloride and stirring the reaction mixture for 16 hours, there was prepared cyclopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone (68 mg) as a pale yellow solid. LC-MS (METHOD M): R T =10.57 minutes, 336 (M+H) + .

By proceeding in a manner similar to Example 250(b) above, but using isopropylcarbonyl chloride, cyclopropylcarbonylchloride there was prepared isopropyl-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-methanone (68 mg) as a white solid. LC-MS (METHOD M): R T =9.28 minutes, 338 (M+H) + .

(d) 1-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one

By proceeding in a manner similar to Example 250(b) above, but using trimethylacetyl chloride and filtering the precipitate formed upon basification with sodium carbonate, followed by azeotroping with toluene there was prepared 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2-dimethyl-propan-1-one (49 mg) as a pale yellow solid. LC-MS (METHOD M): R T =11.39 minutes, 352 (M+H) + .

(e) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester

By proceeding in a manner similar to Example 250(b) above but using methylchloroformate there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid methyl ester (89 mg) as a pale brown solid. LC-MS (METHOD M): R T =8.95 minutes, 326 (M+H) + .

›EXAMPLE 251

(a) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine

A solution of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester [1.014 g, Example 252(a)] in methanol (20 ml) was treated with a solution of hydrogen chloride in dioxane (5 ml, 4M). After stirring for 16 hours the reaction mixture was evaporated. The resulting beige solid was triturated with methanol to yield 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (0.523 g) as a pale yellow solid. LC-MS (METHOD B): R T =0.63 minutes; 268 (M+H) + .

(b) 3-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine

By proceeding in a manner similar to Example 251(a) above, but using 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester [Example 252(d)] there was prepared 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (223 mg) as a white solid. LC-MS (METHOD K): R T =3.91 minutes, 288/290 (M+H) + .

By proceeding in a manner similar to Example 251(a) above, but using 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester [Example 252(e)] there was prepared 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (200 mg) as an off-white solid. LC-MS (METHOD N): R T =2.55 minutes, 369.19 (M+H) + .

(d) 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine

By proceeding in a manner similar to Example 251(a) above but using 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester [Example 252(g)] there was prepared 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (500 mg) as an off-white solid. LC-MS (METHOD N): R T =3.21 minutes, 308.17 (M+H) + .

›EXAMPLE 252

(a) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester

A suspension of 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-3,5-dicarboxylic acid, 3-(2-amino-4,5-dimethylphenyl)amide, 5-tert-butyl ester [1.091 g, Reference Example 39(a)] in acetic acid (5 ml) was heated to 100° C. for 12 minutes in a Smith Creator Microwave. The mixture was neutralised with care by addition of solid sodium hydrogen carbonate and then extracted twice with ethyl acetate. The combined extracts were evaporated to yield 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. LC-MS (METHOD B): R T =2.79 minutes; 368 (M+H) + .

(b) 5-Methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a manner similar to Example 252(a) above but (i) using 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-4-methoxy-phenyl)-amide [410 mg, Reference Example 36(d)] and heating at 120° C. for 5 minutes, (ii) pouring the reaction mixture into water, adjusting to pH14 with 2N sodium hydroxide and filtering, and (iii) adjusting the pH of the filtrate to 6 with 2N hydrochloric acid and collecting the precipitate by filtration, there was prepared 5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole (327 mg) as a yellow powder. LC-MS (Method H): R T =1.61 minutes, 260.25 (M+H) + , 258.26 (M−H) − .

By proceeding in a manner similar to Example 252(b) above but using 4-nitro-1H-pyrazole-3-carboxylic acid (2-amino-4-ethoxy-phenyl)-amide [824 mg, Reference Example 36(e)] there was prepared 5-ethoxy-2-(4-nitro-1H-pyrazol-3-yl-1H-benzoimidazole (407 mg) as a light brown powder. LC-MS (Method H): R T =1.82 minutes, 274.26 (M+H) + , 272.30 (M−H) − .

(d) 3-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester

By proceeding in a manner similar to Example 252(b) above, but using 3-(2-amino-4-chloro-5-methyl-phenylcarbamoyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester [Reference Example 39(c)] and heating at 110° C. for 15 minutes, there was prepared 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (391 mg) as a brown solid. LC-MS (METHOD J): R T =3.53 minutes, 388 (M+H) + .

(e) 3-[5-(2-Morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester

By proceeding in a manner similar to Example 252(b) above, but using 3-[2-amino-4-(2-morpholin-4-yl-ethoxy)-phenylcarbamoyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester [Reference Example 39(d)] there was prepared 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (350 mg) as a brown solid. LC-MS (METHOD N): R T =3.53 minutes, 469.24 (M+H) + .

(f) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole

By proceeding in a manner similar to Example 252(a) above but using 1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole-3-carboxylic acid (2-amino-4,5-dimethyl-phenyl)-amide [Reference Example 39(e)] and beating at 120° C. for 3 minutes there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrano[4,3-c]pyrazole (49 mg) as a pale brown solid. MS: 269 (M+H) + . HPLC (METHOD C1): R T =19.68 minutes.

(g) 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester

By proceeding in a manner similar to Example 252(a) above but using 3-(2-amino-4-trifluoromethyl-phenylcarbamoyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester [Reference Example 39(f)] there was prepared 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (950 mg) was prepared as a brown solid. LC-MS (METHOD N): R T =3.90 minutes, 408 (M+H) + .

›EXAMPLE 253

(a) N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide

A stirred solution of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [100 mg, Example 233(c)] and diisopropylethylamine (307 μl) in dichloromethane (10 ml) was treated with chloroacetyl chloride (105 μl). The reaction mixture was stirred for 30 minutes at room temperature, then treated with morpholine (575 μl), then kept at room temperature overnight and then evaporated. The oily residue was partitioned between ethyl acetate and water and the organic phase was washed with water, then dried over magnesium sulfate and then evaporated. The residue was subjected to flash chromatography on silica eluting with ethyl acetate to give the N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-morpholin-4-yl-acetamide (49.9 mg) as an off-white solid. MS: 355.68 (M+H) + . HPLC (METHOD B1): R T =8.28 minutes.

(b) 2-Dimethylamino-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide

By proceeding in a manner similar to Example 253(a) above but using dimethylamine hydrochloride there was prepared 2-dimethylamino-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide (52 mg) as a white solid. LC-MS (METHOD M): R T =8.28 minutes, 355.68 (M+H) + .

By proceeding in a manner similar to Example 253(a) above but using piperidine there was prepared N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-piperidin-1-yl-acetamide (4 mg) as a white solid. LC-MS (METHOD M): R T =7.69 minutes, 353.68 (M+H) + .

›EXAMPLE 254

(a) N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide

A stirred solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (295.7 mg) and diisopropylethylamine (269 μl) in dimethylformamide (10 ml) were treated with 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [100 mg, Example 233(c)] and 2-(1H-1,2,3,4-tetraazol-1-yl) acetic acid (197.8 mg). The reaction mixture was stirred for 72 hours then treated further with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (295.7 mg), diisopropylethylamine (269 μl) and 2-(1H-1,2,3,4-tetraazol-1-yl) acetic acid (197.8 mg). Stirring was continued for a further 48 hours then the reaction mixture was partitioned between ethyl acetate and water. The organic phase was evaporated and the residue was treated with 1N potassium hydroxide in a mixture of methanol and tetrahydrofuran (1:4, 8 ml). After 1 hour this mixture was extracted with ethyl acetate. The extract was washed with brine, then dried over magnesium sulfate and then evaporated to dryness. The residue was subjected to preparative HPLC to give N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-2-(1H-1,2,3,4-tetraazol-1-yl)-acetamide (13.7 mg) as an off-white solid. MS: 338.14 (M+H) + . HPLC (METHOD B1): R T =7.26 minutes.

(b) N-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide

By proceeding in a manner similar to Example 254(a) above but using isonicotinic acid there was prepared N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-isonicotinamide (9 mg) as a white solid. LC-MS (METHOD L): R T =8.71 minutes, 331.21 (M+H) + .

By proceeding in a manner similar to Example 254(a) above but using cyclopropylacetic acid there was prepared 2-cyclopropyl-N-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-acetamide (98 mg) as a light pink solid. LC-MS (METHOD M): R T =11.04 minutes, MS: 310 (M+H) + .

›EXAMPLE 255

(a) 1-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea

A solution of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [0.500 g, Example 233(c)] in tetrahydrofuran (5 ml) was treated with methyl isocyanate (0.502 ml) and the mixture stirred at ambient temperature for 16 hours. The mixture was then concentrated in vacuo and the residue was redissolved in 1N potassium hydroxide in a mixture of methanol and tetrahydrofuran (1:3, 5 ml). The mixture was stirred for a further 1 hour, then concentrated and then partitioned between ethyl acetate and water. The aqueous layer was extracted three times with ethyl acetate and the combined organic extracts were washed with brine, then dried over magnesium sulfate, and then evaporated. The residue was subjected to flash column chromatography on silica eluting initially with a mixture of ethyl acetate and hexane (1:1, v/v) and then with ethyl acetate to afford 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl-1H-pyrazol-4-yl]-3-methyl-urea (230 mg) as a white solid. MS: 269 (M+H) + . HPLC (METHOD D1): R T =5.97 minutes.

(b) 1-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea

By proceeding in a manner similar to Example 255(a) above but using isopropyl isocyanate there was prepared 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isopropyl-urea as a white solid. MS: 313 (M+H) + . HPLC (METHOD D1): R T =10.94 minutes.

By proceeding in a manner similar to Example 255(a) above but using phenyl isocyanate there was prepared 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-phenyl-urea as a white solid. MS: 347 (M+H) + . HPLC (METHOD B1): R T =16.16 minutes.

(d) 1-Benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea

By proceeding in a manner similar to Example 255(a) above but using benzyl isocyanate there was prepared 1-benzyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea as a white solid. MS: 361 (M+H) + . HPLC (METHOD D1): R T =7.78 minutes.

(e) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide

By proceeding in a manner similar to Example 255(a) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine [Example 251(a)] and isopropylisocyanate, and subjecting the reaction product to flash column chromatography eluting with ethyl acetate/methanol (19:1, v/v), there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid isopropylamide (93.3 mg) as an off-white solid. LC-MS (METHOD M): R T =10.15 minutes, 353 (M+H) + .

›EXAMPLE 256

(a) Cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide

A solution of cyclopropanecarboxylic acid [3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-yl]amide [0.3 g, Reference Example 48(a)] and p-toluenesulfonic acid hydrate (1.2 g) in ethanol (25 mL) was heated in an 80° C. in an oil bath for 1 hour, then cooled, and then poured into aqueous sodium bicarbonate solution. The aqueous mixture was extracted twice with ethyl acetate (75 mL). The combined extracts were evaporated and the residue was redissolved in a mixture of methylene chloride (100 mL) and methanol (10 mL). This solution was washed with aqueous sodium bicarbonate, to remove some residual p-toluenesulfonic acid, then evaporated to give cyclopropanecarboxylic acid[3-(5-ethoxy-6-ethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]amide (120 mg) as a white solid. LC-MS (Method E): R T =2.36 minutes, 340 (M+H) + .

(b) 3-(1,5,6,7-Tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-ylamine

By proceeding in a similar manner to Example 256(a) but using 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-ylamine [0.9 g, Reference Example 49(d)] and p-toluenesulfonic acid (1.0 g) in ethanol (100 mL) and carrying out the reaction at 55° C. for 2 hours, there was prepared 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-ylamine (800 mg) as a brown solid. LC-MS (Method G): R T =2.68 minutes, 240 (M+H) + .

By proceeding in a similar manner to Example 256(a) but (i) using 4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-yl]amide [171 mg, Reference Example 48(b)], (ii) carrying out the reaction at 55° C. for 1.5 hours, then at 70° C. for 1 hour, and (iii) subjecting the reaction product to chromatography on silica gel (ethyl acetate/gradient 0 to 20% methanol), there was prepared 4-methylpiperazine-1-carboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide (55 mg) as a white solid. LC-MS (Method E): R T =1.53 minutes, 366 (M+H) + .

(d) 1,1-Dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea

By proceeding in a similar manner to Example 256(c) but using 1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-yl]urea (230 mg) and p-toluenesulfonic acid hydrate [40 mg, Reference Example 48(c)] there was prepared 1,1-dimethyl-3-[3-(1,5,6,7-tetrahydro-s-indacen-2-yl)-1H-pyrazol-4-yl]urea (106 mg) as a tan solid. LC-MS (Method E): R T =1.97 minutes, 311 (M+H) + .

›EXAMPLE 257

(a) Cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide

A solution of cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-yl]amide [90 mg, Reference Example 48(d)] in a 1/1 mixture of trifluoroacetic acid and dichloromethane (30 mL) was stirred for 5 hours and then evaporated. The residue was mixed with ethyl acetate (30 mL) and aqueous sodium bicarbonate (30 mL). The organic layer was evaporated to give cyclopropanecarboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide (44 mg). LC-MS (Method E): R T =2.34 minutes, 330 (M+H) + .

(b) Tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide

By proceeding in a similar manner to Example 257(a) but using tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazole-4-yl]amide [120 mg, Reference Example 48(e)] there was prepared tetrahydropyran-4-carboxylic acid [3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazole-4-yl]amide (65 mg). LC-MS (Method E) R T =2.17 minutes, 374 (M+H) + .

By proceeding in a similar manner to Example 257(a) but using morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-yl]amide [140 mg, Reference Example 48(f)] there was prepared morpholine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide (65 mg). LC-MS (Method E): R T =2.62 minutes, 375 (M+H) + .

(d) Piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide

By proceeding in a similar manner to Example 257(a) but using piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-yl]amide [127 mg, Reference Example 48(g)] there was prepared piperidine-4-carboxylic acid[3-(6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]amide (65 mg). LC-MS (Method E): R T =3.15 minutes. MS 373 (M+H) + .

(e) 3-[6-Ethoxy-5-fluoro-1H-benzimidazol-2-yl-1H-pyrazol-4-yl]-1-diethylurea

By proceeding in a similar manner to Example 257(a) but using 3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-pyrazol-4-yl)-1,1-diethylurea (110 mg, Reference Example 48(h)] there was prepared 3-[6-ethoxy-5-fluoro-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-1H-diethylurea (65 mg). LC-MS (Method E): R T =3.13 minutes, 361 (M+H) + .

(f) 5-Methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole

By proceeding in a similar manner to Example 257(a) but using 5-methoxy-2-[4-nitro-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-3-yl]-1H-benzoimidazole (282 mg, Reference Example 50(d) there was prepared 5-methoxy-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole (373 mg) as a red powder. LC-MS (Method H): R T =1.60 minutes, 260.22 (M+H) + , 258.23 (M−H) − .

(g) Morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide

By proceeding in a similar manner to Example 257(a) but using morpholine-4-carboxylic acid (2,4-dimethoxy-benzyl)-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-ylmethyl]-amide (Reference Example 59), subjecting the reaction product to flash chromatography on silica [eluting with dichloromethane to dichloromethane/methanol (9:1)] and recrystallising from water/acetonitrile followed by trituration with diethyl ether there was prepared morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylmethyl]-amide (16.5 mg) as a white solid. LC-MS (Method M): R T =6.97 minutes, MS: 355.36 (M+H) + , 353.39 (M−H) − .

(h) 3-[3-(5-Difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea

By proceeding in a manner similar to Example 257(a) above but using 3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea [Reference Example 48(j)] there was prepared 3-[3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea (60 mg) as a white solid. LC-MS (METHOD L): R T =10.61 minutes. 1 H NMR(CD 3 OD): δ 1.24 (t, 6H), 3.43 (q, 4H), 6.72 (bt, 1H), 6.98 (d, 1H), 7.26 (s, 1H), 7.47 (d, 1H), 7.91 (s, 1H).

(i) Piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 257(a) above but using piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-amide [Reference Example 48(k)], there was prepared piperidine-1-carboxylic acid [3-(5-difluoromethoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (52 mg) as a white solid. HPLC (METHOD E1): R T =10.78 minutes. 1 H NMR(CD 3 OD): δ 1.69 (bm, 6H), 3.64 (bm, 4H), 6.82 (bt, 1H), 7.09 (bm, 1H), 7.39 (bm, 1H), 7.61 (bm, 1H), 8.05 (bm, 1H).

›EXAMPLE 258 · 1 of 2

(a) Cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

A solution of 3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [50 mg, Example 233(e)] and diisopropylethylamine (40 μL) in dichloromethane (20 mL), stirred at room temperature, was treated with cyclopropanecarbonyl chloride (51 μL, 3 eq). After stirring for a further 20 hours the reaction mixture was evaporated and the residue was subjected to chromatography on silica gel (ethyl acetate/heptane 1/1) to give the bis-acylated product (60 mg) as an orange solid. MS 400 (M+H) + . The bis-acylated product was dissolved in methanol (5 mL), then treated with potassium hydroxide solution (0.5 mL, 5N), then stirred at 60° C. for 1 hour, then cooled and then evaporated. The residue was treated with water (15 mL) and the pH of the aqueous mixture was adjusted to 5 and then extracted twice with ethyl acetate (25 mL). The combined extracts were dried with magnesium sulfate, then evaporated and the residue was triturated with diisopropyl ether, filtered and the precipitate was vacuum dried at 60° C. to give cyclopropanecarboxylic acid [3-(6-chloro-5-methoxy-1H-benzoimidazol-2-yl-1H-pyrazol-4-yl]-amide (11 mg) as an off-white solid, mp 225-226° C. LC-MS (Method E): R T =2.92 minutes, 332 (M+H) + .

(b) Cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide

By proceeding in a similar manner to Example 258(a) above but (i) treating a solution of 3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-ylamine [310 mg, Example 256(b)] and triethylamine (4 eq) in tetrahydrofuran (15 mL) with cyclopropanecarbonyl chloride (4 eq), (ii) stirring the reaction mixture at 60° C. for 2 hours, (iii) treating the resulting bis-acylated product with methanolic potassium hydroxide (20 mL, 10.05 g KOH) at 40° C. for 1 hour followed by treatment with aqueous ammonium chloride (200 mL), (iii) extracting this mixture three times with ethyl acetate (100 mL), (iv) evaporating the combined extracts and (v) chromatographing the residue on silica gel (ethyl acetate/gradient of 50-0% heptane) there was prepared cyclopropanecarboxylic acid [3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]amide (50 mg) as a yellow solid. LC-MS (Method E) R T =2.05 minutes, 308 (M+H) + .

By proceeding in a similar manner to Example 258(b) above but using morpholine-4-carbonyl chloride there was prepared morpholine-4-carboxylic acid[3-(1,5,6,7-tetrahydro-1,3-diaza-s-indacen-2-yl)-1H-pyrazol-4-yl]-amide as an orange solid. LC-MS (Method E) R T =2.45 minutes, 353 (M+H) + .

(d) Piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a similar manner to Example 258(a) above treating 3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [257 mg, Example 233(f)] with 1-piperidine-carbonyl chloride in the presence of diisopropylethylamine and using tetrahydrofuran as the solvent there was prepared piperidine-1-carboxylic acid [3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (46.1 mg) as a white solid. LC-MS (Method L) R T =6.43 minutes, 341.28 (M+H) + .

(e) 3-[3-(5-Methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea

By proceeding in a manner similar to Example 258(d) above but using dimethylcarbamyl chloride there was prepared 3-[3-(5-methoxy-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea as a white solid. LC-MS (Method M): R T =7.64 minutes, 301.35 (M+H) + .

(f) Piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 258(d) above but (i) using 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [400 mg, Example 233(d)], 1-piperidinecarbonyl chloride (1.25 ml) and diisopropylethylamine (1.74 ml) with tetrahydrofuran (20 ml) as the solvent and, stirring the reaction mixture at ambient temperature for 48 hours, then at 50° C. for 24 hours, (ii) treating the bis-acylated product with 1M potassium hydroxide in methanol/tetrahydrofuran (1:3, 20 ml) at room temperature, and (iii) subjecting the product to flash column chromatography on silica [eluting with ethyl acetate/hexane (1:1 v/v) to ethyl acetate/hexane (3:1 v/v)], there was prepared piperidine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (425 mg) as a white solid. LC-MS (METHOD L): R T =7.55 minutes, 353.34 (M+H) + .

(g) 3-[3-(5-Fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea

By proceeding in a manner similar to Example 258(f) above but using 3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(h)] and N,N′-dimethylcarbamylchloride there was prepared 3-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea (32 mg) as a white solid. LC-MS (METHOD M): R T =10.40 minutes, 303.34 (M+H) + .

(h) Morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 258(f) above but using 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(j)] and morpholine-1-carbonyl chloride there was prepared morpholine-4-carboxylic acid [3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (131 mg) was prepared as a white solid. MS: 379.08 (M−H) − . HPLC (METHOD E1): R T =10.61 minutes.

(i) 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide

By proceeding in a manner similar to Example 258(f) above, but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine [Example 251(a)] and diethylcarbamyl chloride, and subjecting the reaction product to flash column chromatography eluting with ethyl acetate to ethyl acetate/methanol (49:1, v/v), there was prepared 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide (20.9 mg) as an off-white solid. LC-MS (METHOD J): R T =3.44 minutes, 367 (M+H) + .

›EXAMPLE 258 · 2 of 2

(j) [3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]pyrrolidin-1-yl-methanone

By proceeding in a manner similar to Example 258(i) above, but using 1-pyrollidincarbonyl chloride and triturating the reaction product with ethyl acetate, methanol and dichloromethane, there was prepared [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyrrolidin-1-yl-methanone (68 mg) as an off-white solid. MS: 365 (M+H) + . HPLC (METHOD E1): R T =10.32 minutes.

(k) [3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone

By proceeding in a manner similar to Example 258(f) above, but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine [Example 251(a)] and subjecting the reaction product to flash column chromatography eluting with ethyl acetate/petrol (5:1, v/v) to 100% ethyl acetate to ethyl acetate/methanol (19:1, v/v), there was prepared [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-piperidin-1-yl-methanone (93.3 mg) as an off-white solid. LC-MS (METHOD L): R T =6.77 minutes, 379 (M+H) + .

(l) [3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone

By proceeding in a manner similar to Example 258(k) above, but using 1-morpholinecarbonyl chloride and azeotroping the reaction product with toluene and dichloromethane, there was prepared [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-morpholin-4-yl-methanone (32 mg) as an off-white solid. MS: 381 (M+H) + . HPLC (METHOD E1): R T =9.39 minutes.

(m) 3-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide

By proceeding in a manner similar to Example 258(a) above but (i) using 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine [Example 251(b)] and diethylcarbamyl chloride, and (ii) subjecting the reaction product to flash column chromatography, eluting with ethyl acetate to ethyl acetate/methanol (47:3, v/v) followed by trituration with ethanol, there was prepared 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide (35.6 mg) as a pale yellow solid. MS: 387/389 (M+H) + . HPLC (METHOD E1): R T =11.07 minutes.

(n) Morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 258(p) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(c)] and 1-morpholinecarbonyl chloride there was prepared morpholine-4-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (206 mg) as a white solid. LC-MS (METHOD L): R T =7.36 minutes, 341 (M+H) + .

(o) Piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 258(p) above but using 1-piperidinecarbonyl chloride there was prepared piperidine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (185 mg) as a white solid. LC-MS (METHOD M): R T =10.79 minutes, 339 (M+H) + .

(p) 3-[5-(2-Morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide

By proceeding in a manner similar to Example 258(a) above but using 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine [Example 251 (c)] and diethylcarbamyl chloride there was prepared 3-[5-(2-morpholin-4-yl-ethoxy)-1H-benzoimidazol-2-yl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide (28 mg) as a white solid. MS: 468.30 (M+H) + . HPLC (METHOD E1): R T =9.47 minutes.

(q) 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide

By proceeding in a manner similar to Example 258(a) above but using 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine [Example 251(d)] and diethylcarbamyl chloride there was prepared 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1,4,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid diethylamide (103 mg) as a white solid. MS: 407.17 (M+H) + . HPLC (METHOD E1): R T =10.81 minutes.

(r) 3-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea

By proceeding in a manner similar to Example 258(p) above but using dimethylcarbamyl chloride there was prepared 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-dimethyl-urea. MS: 299 (M+H) + . HPLC (Method E1): R T =8.24 minutes.

›EXAMPLE 259

2-(1H-Indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [2-(2H-tetrazol-5-yl)-ethyl]-amide

A stirred solution of 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (2-cyano-ethyl)-amide [150 mg, Example 246(s)] and azidotributyltin (2 ml) was heated at 95° C. for 24 hours. The reaction was cooled to ambient temperature and stirred for 2 hours with acetonitrile (20 ml), tetrahydrofuran (10 ml) and acetic acid (20 ml). The reaction mixture was washed with iso-hexane (6×80 ml) and concentrated in vacuo. The residue was subjected to preparative HPLC to give 2-(1H-indazol-3-yl)-1H-benzoimidazole-5-carboxylic acid [2-(2H-tetrazol-5-yl)-ethyl]-amide (35.9 mg) as a brown solid.

LC-MS (Method L): R T =9.80 minutes, 374.21 (M+H) + .

›EXAMPLE 260 · 1 of 2

(a) 1-Cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea

To a stirred solution of 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [250 mg, Example 233(d)] in tetrahydrofuran (20 ml) was added 1,1-carbonyldiimidazole (740 mg) and the reaction heated at reflux for 60 hours. The reaction mixture was cooled to ambient temperature and the solvent removed in vacuo. The residue was added 2M cyclopropylamine in tetrahydrofuran (15 ml). The reaction mixture was transferred to a pressure tube and heated at reflux for 48 hours. The reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The aqueous layer was extracted three times with ethyl acetate and the combined organic extracts washed with brine, dried over magnesium sulfate, and concentrated. The residue was subjected to flash column chromatography on silica eluting with ethyl acetate/hexane (1:1 v/v) to 100% ethyl acetate to afford 1-cyclopropyl-3-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea (95 mg) as a white solid. LC-MS (METHOD M): R T =9.40 minutes, 325.32 (M+H) + .

(b) 1-[3-(5-Ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea

By proceeding in a manner similar to Example 260(a) above but using 2M methylamine in tetrahydrofuran there was prepared 1-[3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea (36 mg) as a white solid. LC-MS (METHOD M): R T =7.08 minutes, 299.34 (M+H) + .

By proceeding in a manner similar to Example 260(a) above but using 2M 1-methylpiperazine in tetrahydrofuran there was prepared 4-methyl-piperazine-1-carboxylic acid [3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (247 mg) pared as a white solid. LC-MS (METHOD M): R T =5.21 minutes, 368.32 (M+H) + .

(d) Piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 260(a) above but using 3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(h)] and 2M piperidine in tetrahydrofuran there was prepared piperidine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (140 mg) as a white solid. LC-MS (METHOD L): R T =8.29 minutes, 343.26 (M+H) + .

(e) 1-[3-(5-Fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea

By proceeding in a manner similar to Example 260(d) above but using 2M methylamine in tetrahydrofuran there was prepared 1-[3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea (61 mg) as a white solid. LC-MS (METHOD L): R T =4.85 minutes, 289.26 (M+H) + .

(f) Morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 260(d) above but using 2M morpholine in tetrahydrofuran there was prepared morpholine-4-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (49 mg) as a white solid. LC-MS (METHOD L): R T =6.26 minutes, 345.33 (M+H) + .

(g) 4-Methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 31(d) above but using 2M 1-methylpiperazine in tetrahydrofuran there was prepared 4-methyl-piperazine-1-carboxylic acid [3-(5-fluoro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (58 mg) as a white solid. LC-MS (METHOD P): R T =7.72 minutes, 358.19 (M+H) + .

(h) 1-Methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea

By proceeding in a manner similar to Example 260(a) above but using 3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 2330)] and 2M methylamine in tetrahydrofuran there was prepared 1-methyl-3-[3-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea (99 mg) as a white solid. LC-MS (METHOD L): R T =6.51 minutes, 325 (M+H) + .

(i) 1-[3-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea

By proceeding in a manner similar to Example 260(a) above but using 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 261] and 2M methylamine in tetrahydrofuran there was prepared 1-[3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-methyl-urea (45 mg) as a white solid. LC-MS (METHOD L): R T =5.85 minutes, 305/307 (M+H) + .

(j) 4-Methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 260(i) above but using 2M 1-methylpiperazine in tetrahydrofuran there was prepared 4-methyl-piperazine-1-carboxylic acid [3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (60 mg) as a pale yellow solid. LC-MS (METHOD M): R T =6.35 minutes, 374 (M+H) + .

(k) 1-tert-Butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea

By proceeding in a manner similar to Example 260(a) above but using 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine [Example 233(c)] and tert-butylamine there was prepared 1-tert-butyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea (21 mg) as a white solid. LC-MS (METHOD L): R T =5.38 minutes, 327 (M+H) + .

(l) 1-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea

By proceeding in a manner similar to Example 260(k) above but using 2M ethylamine in tetrahydrofuran there was prepared 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-ethyl-urea (39 mg) as a white solid. LC-MS (METHOD L): R T =3.95 minutes, 299 (M+H) + .

(m) 4-Methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide

By proceeding in a manner similar to Example 260(k) above but using 2M 1-methylpiperazine in tetrahydrofuran there was prepared 4-methyl-piperazine-1-carboxylic acid [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-amide (113 mg) as a white solid. MS: 354 (M+H) + . HPLC (METHOD E1): R T =10.21 minutes.

›EXAMPLE 260 · 2 of 2

(n) 1-Cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea

By proceeding in a manner similar to Example 260(k) above but using cyclopropylamine there was prepared 1-cyclopropyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea (80 mg) as a white solid. MS: 311 (M+H) + . HPLC (METHOD E1): R T =10.36 minutes.

(o) 3-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea

By proceeding in a manner similar to Example 260(k) above but using 2M diethylamine in tetrahydrofuran there was prepared 3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-1,1-diethyl-urea (61 mg) as a white solid. MS: 327 (M+H) + . HPLC (METHOD E1): R T =11.36 minutes.

(p) 1-[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea

By proceeding in a manner similar to Example 2601(k) above but using 2M isobutylamine in tetrahydrofuran, there was prepared 1-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-3-isobutyl-urea (58 mg) as a white solid. MS: 327 (M+H) + . HPLC (METHOD E1): R T =10.95 minutes.

(q) 1-Cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea

By proceeding in a manner similar to Example 260(k) above but using 2M (aminomethyl)cyclopropane in tetrahydrofuran, there was prepared 1-cyclopropylmethyl-3-[3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea (29 mg) as a white solid. MS: 325 (M+H) + . HPLC (METHOD E1): R T =10.63 minutes.

›EXAMPLE 261

3-(5-Chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine

A stirred solution of 5-chloro-6-methyl-2-(4-nitro-1H-pyrazol-3-yl)-1H-benzoimidazole [0.320 g, Example 249(g)] and tin-chloride (1.10 g) in ethanol (5 ml) was heated in a Smith Creator microwave at 140° C. for 10 minutes. The reaction mixture was basified using saturated sodium hydrogen carbonate solution to pH 8 and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to give 3-(5-chloro-6-methyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-ylamine as a pale brown solid. LC-MS (METHOD B): R T =2.28 minutes, 248.13 (M+H) + .

›EXAMPLE 262

3-(5-Ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride

A stirred suspension of 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile [100 mg, Example 235(an)] in acetic acid (1 ml) and concentrated hydrochloric acid (1 ml) was heated at 80° C. for 30 minutes and then at 100° C. for 4 hours. The reaction was cooled to ambient temperature and stirred for 16 hours. The reaction was then heated at 80° C. for 2.5 hours and then at 100° C. for 2 hours. The reaction mixture was cooled to ambient temperature and neutralized with aqueous sodium carbonate solution. The resulting white precipitate was collected by filtration and the aqueous layer was extracted with ethyl acetate, combined with the precipitate and concentrated in vacuo. The residue was taken up in methanol, transferred to a solid phase cartridge containing MP-carbonate resin (100 mg) and shaken for 16 hours. The reaction was then filtered, the resin washed with methanol and the combined organic layers concentrated in vacuo. The residue was triturated with diethyl ether, taken up in methanol and acidified with 4M hydrogen chloride in 1,4-dioxane. The solvent was removed in vacuo to give 3-(5-ethyl-6-methyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid amide dihydrochloride (58 mg) as a pale brown solid. LC-MS (METHOD M): R T =9.40 minutes, 320 (M+H) + .

›EXAMPLE 263

3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid

A stirred suspension of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carbonitrile dihydrochloride [200 mg, Reference Example 6(aq)] in acetic acid/concentrated hydrochloric acid (4 ml, 1:1 v/v) was heated at 100° C. for 16 hours. The reaction mixture was cooled to ambient temperature and filtered. The precipitate was washed with water and dried in vacuo to give 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-1H-indazole-5-carboxylic acid (195 mg) as a white solid. LC-MS (METHOD B): R T =2.52 minutes, 307 (M+H) + .

›EXAMPLE 264

2-(4-Isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid

To a stirred solution of 2-(4-amino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid methyl ester [200 mg, Example 233(k)] in tetrahydrofuran (5 ml) was added diisopropylethylamine (545 μl) and isobutyryl chloride (327 μl) dropwise and the reaction stirred for 30 minutes. The reaction mixture was concentrated in vacuo and the residue was taken up in 1M potassium hydroxide in tetrahydrofuran/methanol (1:3, v/v) (5 ml) and stirred for 1 hour. The reaction mixture was concentrated in vacuo and the residue was taken up in 1M sodium hydroxide in water/methanol (5 ml) and stirred for 1 hour. The solvent was removed in vacuo and the residue was partitioned between ethyl acetate and water and the layers separated. The aqueous layer was acidified to pH 3-4 with 5% citric acid solution, extracted with ethyl acetate and the organic layer washed with brine. The organic layer was then dried over magnesium sulfate, filtered and the filtrate concentrated in vacuo to give 2-(4-isobutyrylamino-1H-pyrazol-3-yl)-1H-benzoimidazole-5-carboxylic acid (140 mg) as a white solid. LC-MS (METHOD C): R T =2.87 minutes, 313.33 (M+H) + .

›EXAMPLE 265 · 1 of 5

2-(1H-Indazol-3-yl)-3H-benzoimidazol-5-amine

A stirred solution of 3-(5-nitro-1H-benzoimidazol-2-yl)-1H-indazole [90.8 mg, Reference Example 233(as)] in methanol (1 ml) was treated with tin chloride (616 mg). The reaction was heated at reflux for 16 hours and then cooled to ambient temperature. The pH of the reaction mixture was adjusted to pH 8 by addition of aqueous sodium bicarbonate and then this mixture was extracted with ethyl acetate. The organic extracts were dried over magnesium sulfate and then evaporated to yield an oil. The crude product was subjected to flash column chromatography on silica eluting with ethyl acetate and 10% triethylamine to give 2-(1H-indazol-3-yl)-3H-benzoimidazol-5-amine (826 mg). MS: 250.31 (M+H) + , 248.31 (M−H) − . HPLC (Method B): R T =2.03 minutes.

REFERENCE EXAMPLE 1

(a) 5,6-Dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl-1H-benzoimidazole

A mixture of 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone [318 mg, Reference Example 2(a)], hydrazine (2 mL) and ethanol (12 mL) was heated at reflux temperature for 1 hour. The reaction mixture was then cooled to room temperature, then stirred at room temperature overnight, then heated at 60° C. for 2 hours, then heated at reflux temperature for 3 hours, then stood at room temperature for 3 days and then evaporated. The residue was dissolved in dichloromethane and this solution was washed with water plus a little brine to facilitate separation and the aqueous phase was washed with dichloromethane and then with ethyl acetate. The combined organics were dried over magnesium sulfate and then evaporated to give 5,6-dimethyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole (90 mg) as a colourless solid.

(b) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone [Reference Example 2(b)] there was prepared 6-chloro-5-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(c) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-ethylsulfanyl-propenone [Reference Example 2(c)] there was prepared 6-chloro-5-methyl-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole

(d) By proceeding in a similar manner to Reference Example 1(a) above but using 3,3-bis-methylsulfanyl-1-[5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone [Reference Example 2(d)] there was prepared 2-(5-methylsulfanyl-1H-pyrazol-3-yl)-5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole

(e) By proceeding in a similar manner to Reference Example 1(a) above but using 3,3-bis-cyclopropylmethylsulfanyl-1-[5,6-dimethyl-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone [Reference Example 2(e)] there was prepared 2-(5-cyclopropylmethylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(f) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-ethylsulfanyl propenone [Reference Example 2(f)] there was prepared 5,6-dimethyl-2-(5-ethylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(g) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-(pyridin-3-ylmethylsulfanyl)-propenone [Reference Example 2(g)] there was prepared 5,6-dimethyl-2-(5-(pyridin-3-yl)methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(h) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[5-fluoro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone [Reference Example 2(h)] there was prepared 5-fluoro-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(i) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-phenethylsulfanyl-propenone [Reference Example 2(i)] there was prepared 5,6-dimethyl-2-(5-phenethylsulfanyl-1H-pyrazol-3-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(j) By proceeding in a similar manner to Reference Example 1(a) above but using 3,3-bis-methylsulfanyl-1-[4-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone [Reference Example 2(k)] there was prepared 4-methyl-2-(5-methylsulfanyl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(k) By proceeding in a similar manner to Reference Example 1(a) above but using 3,3-bis-benzylsulfanyl-1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone [Reference Example 2(o)] there was prepared 2-(5-benzylsulfanyl-1H-pyrazol-3-yl)-5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(l) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3-methylsulfanyl-3-morpholin-1-yl-propenone [Reference Example 13] there was prepared 6-chloro-5-methyl-2-(5-morpholin-4-yl-1H-pyrazol-3-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(m) By proceeding in a similar manner to Reference Example 1(a) above but using 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-(thiophen-2-ylmethylsulfanyl) propenone [Reference Example 2(s)] there was prepared 5,6-dimethyl-2-[5-(thiophen-2-ylmethylsulfanyl)-1H-pyrazol-3-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

REFERENCE EXAMPLE 2

(a) 1-[5,6-Dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone

›EXAMPLE 265 · 2 of 5

A stirred suspension of sodium tert-butoxide (350 mg) in benzene (6 mL), at −5° C., was treated with a solution of 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [240 mg, Reference Example 3(a)] in benzene (5 mL) followed by carbon disulfide (230 μL). The resulting orange solution was stirred for 1 hour at −5° C., then treated with methyl iodide (180 μL), then allowed to warm to room temperature and then stirred at room temperature overnight. An orange precipitate was formed. The reaction mixture was poured into ice-water and this mixture was then extracted with dichloromethane. The combined organic extracts were washed with water, then dried over sodium sulfate and then evaporated to give 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone (318 mg) as an orange oil which was used without further purification.

(b) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 3(b)] there was prepared 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone.

(c) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 3(b)] and ethyl iodide there was prepared 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-ethylsulfanyl-propenone.

(d) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 3(c)] there was prepared 3,3-bis-methylsulfanyl-1-[5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone.

(e) By proceeding in a similar manner to Reference Example 2(a) above but using bromomethylcyclopropane there was prepared 3,3-bis-cyclopropylmethylsulfanyl-1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone.

(f) By proceeding in a similar manner to Reference Example 2(a) above but using ethyl iodide there was prepared 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-ethylsulfanyl-propenone.

(g) By proceeding in a similar manner to Reference Example 2(a) above but using 3-picolyl chloride there was prepared 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-(pyridin-3-ylmethylsulfanyl)-propenone.

(h) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[5-fluoro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 3(d)] there was prepared 1-[5-fluoro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone.

(i) By proceeding in a similar manner to Reference Example 2(a) above but using phenethyl bromide there was prepared 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-phenethylsulfanyl-propenone.

(j) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 4(g)] and ethyl bromide there was prepared 3,3-bis-ethylsulfanyl-1-[5-methoxy-2-(trimethylsilanylethoxymethyl)-1H-benzoimidazol-2-yl]-propenone.

(k) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[4-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 3(e)] there was prepared 3,3-bis-methylsulfanyl-1-[4-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone.

(l) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-pentan-1-one [Reference Example 3(f)] there was prepared 2-(bis-methylsulfanyl-methylene)-1-(5-methyl-1H-benzoimidazol-2-yl)-pentan-1-one.

(m) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-pentan-1-one [Reference Example 3(f)] and 4-methoxybenzyl chloride there was prepared 2-[bis-(4-methoxy-benzylsulfanyl)-methylene]-1-(5-methyl-1H-benzoimidazol-2-yl)-pentan-1-one.

(n) By proceeding in a similar manner to Reference Example 2(a) above but using 3-methyl-1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-butan-1-one [Reference Example 3(g)] and benzyl chloride there was prepared 2-(bis-benzylsulfanyl-methylene)-3-methyl-1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-butan-1-one.

(o) By proceeding in a similar manner to Reference Example 2(a) above but using benzyl chloride there was prepared 3,3-bis-benzylsulfanyl-1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone.

(p) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 4(h)] with tetrahydrofuran as the solvent and carrying out the reaction at room temperature and then subjecting the reaction product to flash chromatography on silica under gradient elution conditions (20 to 33% ethyl acetate in pentane) there was prepared 3,3-bis-methanesulfanyl-1-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propenone as an oil which slowly solidified on standing at room temperature.

(q) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 3(b)] and methyl iodide there was prepared 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-methylsulfanyl-propenone.

(r) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propan-1-one [Reference Example 4(i)] and methyl iodide there was prepared 1-[5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-2-methyl-3-(bis-methanesulfanyl)-1-propenone.

›EXAMPLE 265 · 3 of 5

(s) By proceeding in a similar manner to Reference Example 2(a) above but using of 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone [Reference Example 3(a)] and 2-chloromethylthiophene [Reference Example 14]) there was prepared 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-3,3-bis-(thiophen-2-ylmethylsulfanyl)-propenone.

(t) By proceeding in a similar manner to Reference Example 2(a) above but using 1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propan-1-one [Reference Example 3(h)] there was prepared 1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-2-methyl-3-(bis-methanesulfanyl)-1-propenone.

REFERENCE EXAMPLE 3

(a) 1-[5,6-Dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone

A solution of 5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [5.01 g, Reference Example 4(a)] in dry tetrahydrofuran (55 mL), at −78° C., was treated with a solution of lithium diisopropylamide in a mixture of tetrahydrofuran and heptane (11.9 mL, 2M) over 10 minutes. The mixture was stirred for 15 minutes then treated dropwise with dimethylacetamide (2.15 mL) over 10 minutes. After stirring at −78° C. for a further 30 minutes the reaction mixture was poured into ice (50 g) and then left until all the ice had melted. This mixture was extracted with dichloromethane and the extracts were washed with brine, then with water, then dried over magnesium sulfate and then evaporated. The residual orange oil (5.91 g) was subjected to column chromatography on silica eluting with a mixture of petroleum ether and ethyl acetate (4:1, v/v) to give 1-[5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone (3.93 g) as a yellow crystalline solid.

(b) By proceeding in a similar manner to Reference Example 3(a) above but using 6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 4(b)] there was prepared 1-[6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone.

(c) By proceeding in a similar manner to Reference Example 3(a) above but using 5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 4(c)] there was prepared 1-[5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone.

(d) By proceeding in a similar manner to Reference Example 3(a) above but using 5-fluoro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 4(d)] there was prepared 1-[5-fluoro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone.

(e) By proceeding in a similar manner to Reference Example 3(a) above but using 4-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 4(e)] there was prepared 1-[4-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone.

(f) By proceeding in a similar manner to Reference Example 3(a) above but using 5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 4(f)] and dimethylvaleramide [Reference Example 8(a)] there was prepared 1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-pentan-1-one.

(g) By proceeding in a similar manner to Reference Example 3(a) above but using 5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 4(f)] and dimethylisovalerylamide [Reference Example 8(b)] there was prepared 3-methyl-1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-butan-1-one.

(h) By proceeding in a similar manner to Reference Example 3(a) above but using 5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole [Reference Example 4(f)] and dimethylpropionamide there was prepared 1-[5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propan-1-one.

REFERENCE EXAMPLE 4

(a) 5,6-Dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole

A stirred mixture of sodium hydride (1.08 g) in dimethylformamide (80 mL) was treated with a solution of 5,6-dimethyl-1H-benzoimidazole (4.95 g) in dimethylformamide (50 mL) at room temperature over 10 minutes. After stirring for a further 1 hour the mixture was then treated with 2-(trimethylsilanyl)ethoxymethyl) chloride (6.4 mL) over 15 minutes and then stirring was continued for 18 hours. The reaction mixture was treated with methanol (15 mL) and water (1 mL) and then evaporated. The residue was treated with water (50 mL) and this mixture was then extracted twice with diethyl ether (80 mL then 50 mL). The combined extracts were washed three times with water (50 mL), then dried over magnesium sulfate and then evaporated. The residual brown oil (10.3 g) was purified by Flashmaster using mixtures of ethyl acetate in hexane (20% to 80%) at 40 ml/minute to give 5,6-dimethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole (7.54 g) as an orange oil.

(b) By proceeding in a similar manner to Reference Example 4(a) above but using 6-chloro-5-methyl-1H-benzoimidazole [Reference Example 5(a)] there was prepared 6-chloro-5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(c) By proceeding in a similar manner to Reference Example 4(a) above but using 5-trifluoromethyl-1H-benzoimidazole [Reference Example 5(b)] there was prepared 5-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(d) By proceeding in a similar manner to Reference Example 4(a) above but using 5-fluoro-1H-benzoimidazole [Reference Example 5(c)] there was prepared 5-fluoro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(e) By proceeding in a similar manner to Reference Example 4(a) above but using 4-methyl-1H-benzoimidazole [Reference Example 5(d)] there was prepared 4-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(f) By proceeding in a similar manner to Reference Example 4(a) above but using 5-methyl-1H-benzoimidazole there was prepared 5-methyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazole.

(g) By proceeding in a similar manner to Reference Example 4(a) above but using 1-(5-methoxy-1H-benzoimidazol-2-yl)-ethanone [Reference Example 6(a)] there was prepared 1-[5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone.

›EXAMPLE 265 · 4 of 5

(h) By proceeding in a similar manner to Reference Example 4(a) above but using (1H-benzoimidazol-2-yl)-1-ethanone and carrying out the reaction in tetrahydrofuran there was prepared 1-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-ethanone as a colourless oil.

(i) By proceeding in a similar manner to Reference Example 4(a) above but using 1-(5-methoxy-1H-benzoimidazol-2-yl)-propan-1-one [Reference Example 6(b)] there was prepared 1-[5-methoxy-1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-yl]-propan-1-one

REFERENCE EXAMPLE 5

(a) 6-chloro-5-methyl-1H-benzoimidazole

A solution of 5-chloro-4-methyl-1,2-phenylenediamine (7.8 g) in a mixture of formic acid (35 mL) and hydrochloric acid (300 mL) was heated at 50° C. for 3 hours then treated with ammonium hydroxide solution until the solution was basic. The reaction mixture was then extracted with dichloromethane. The extracts were evaporated to give 6-chloro-5-methyl-1H-benzoimidazole (7 g).

(b) By proceeding in a similar manner to Reference Example 5(a) above but using 4-trifluoromethyl-1,2-phenylenediamine there was prepared 5-trifluoromethyl-1H-benzoimidazole.

(c) By proceeding in a similar manner to Reference Example 5(a) above but using 4-fluoro-o-phenylenediamine there was prepared 5-fluoro-1H-benzoimidazole.

(d) By proceeding in a similar manner to Reference Example 5(a) above but using 2,3-diaminotoluene there was prepared 4-methyl-1H-benzoimidazole.

REFERENCE EXAMPLE 6

(a) 1-(5-Methoxy-1H-benzoimidazol-2-yl)-ethanone

A stirred mixture of 1-(5-methoxy-1-benzoimidazole)-1-ethanol [5.14 g, Reference Example 7(a)] and manganese dioxide (9 g) in chloroform (80 mL) was heated at 60° C. for 18 hours, then cooled to room temperature and then filtered. The filtrate was evaporated to give 1-(5-methoxy-1H-benzoimidazol-2-yl)-ethanone (4.28 g).

(b) 1-(5-Methoxy-1H-benzoimidazol-2-yl)-propan-1-one

By proceeding in a similar manner to Reference Example 6(a) above but using 1-(5-methoxy-1-benzoimidazole)-1-propanol [Reference Example 7(b)] there was prepared 1-(5-methoxy-1H-benzoimidazol-2-yl)-propan-1-one.

By proceeding in a similar manner to Reference Example 6(a) above but using (5-fluoro-1H-indazol-3-yl)-methanol [Reference Example 25(a)] with acetone as the solvent, a reaction temperature of 55° C. and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of 40/60 petrol and ethyl acetate (1:1 v/v) there was prepared 5-fluoro-1H-indazole-3-carbaldehyde as a light brown solid. LC-MS (METHOD B): R T =2.74 minutes, 165 (M+H) + .

(d) 6-Fluoro-1H-indazole-3-carbaldehyde

By proceeding in a manner similar to Reference Example 6(a) above but using (6-fluoro-1H-indazol-3-yl)-methanol [Reference Example 25(b)] with acetone as the solvent, a reaction temperature of 55° C. and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of 40/60 petrol and ethyl acetate (1:1 v/v) there was prepared 6-fluoro-1H-indazole-3-carbaldehyde as a light brown solid. LC-MS (METHOD B): R T =2.74 minutes, 165 (M+H) + .

(e) 5-Methyl-1H-indazole-3-carbaldehyde

By proceeding in a manner similar to Reference Example 6(a) above but using (5-methyl-1H-indazol-3-yl)-methanol [Reference Example 25(c)] with dichloromethane as solvent, a reaction temperature of 40° C. and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of hexane and ethyl acetate (1:1, v/v) there was prepared 5-methyl-1H-indazole-3-carbaldehyde as a pale brown solid. LC-MS (METHOD B): R T =2.79 minutes, 161 (M+H) + .

(f) 6-Methoxy-1H-indazole-3-carbaldehyde

By proceeding in a manner similar to Reference Example 6(a) above but using (6-methoxy-1H-indazol-3-yl)-methanol [Reference Example 25(e)] with acetone as the solvent, a reaction temperature of 55° C. and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of 40/60 petrol and ethyl acetate (1:1 v/v) there was prepared 6-methoxy-1H-indazole-3-carbaldehyde as a light brown solid. LC-MS (METHOD B): R T =2.76 minutes, 177 (M+H) + .

(g) 4-Phenyl-1H-pyrazole-3-carbaldehyde

By proceeding in a similar manner to Reference Example 6(a) above but using (4-phenyl-1H-pyrazol-3-yl)-methanol [Reference Example 25(f)] with acetone as the solvent, a reaction temperature of 60° C. for 2 hours, and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of dichloromethane and methanol (49:1, v/v) there was prepared 4-phenyl-1H-pyrazole-3-carbaldehyde as a white solid. LC-MS (METHOD B): R T 2.76 minutes; 213 (M+H) + .

(h) 5-Chloro-1H-indazole-3-carbaldehyde

By proceeding in a similar manner to Reference Example 6(a) above but using (5-chloro-1H-indazol-3-yl)-methanol [Reference Example 25(d)] with a mixture of dichloromethane and tetrahydrofuran as solvent, heating at reflux temperature and subjecting the reaction product to flash column chromatography on silica eluting with a mixture of hexane and ethyl acetate (1:1, v/v) there was prepared 5-chloro-1H-indazole-3-carbaldehyde as a pale brown solid. LC-MS (METHOD B): R T =2.89 minutes, 181 (M+H) + .

(i) 3-Formyl-pyrazole-4-carboxylic acid ethyl ester

By proceeding in a manner similar to Reference Example 6(a) above but using 3-hydroxymethyl-1H-pyrazole-4-carboxylic acid ethyl ester [Reference Example 41 (a)] there was prepared 3-formyl-pyrazole-4-carboxylic acid ethyl ester as a brown solid. LC-MS (METHOD B): R T =2.65 minutes; 169 (M+H) + .

(j) 3-Formyl-pyrazole-4-carboxylic acid isopropylamide

By proceeding in a manner similar to Reference Example 6(a) above but using 3-hydroxymethyl-1H-pyrazole-4-carboxylic acid isopropylamide [Reference Example 41(b)] there was prepared 3-formyl-pyrazole-4-carboxylic acid isopropylamide as a waxy orange solid. LC-MS (METHOD B): R T =2.73 minutes; 182 (M+H) + .

(k) 3-Formyl-5-methyl-pyrazole-4-carboxylic acid ethyl ester

By proceeding in a manner similar to Reference Example 6(a) above but using 3-hydroxymethyl-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester [Reference Example 41(c)] there was prepared 3-formyl-5-methyl-pyrazole-4-carboxylic acid ethyl ester as a white solid. LC-MS (METHOD B): R T =2.80 minutes; 183 (M+H) + .

›EXAMPLE 265 · 5 of 5

(l) 1H-indazole-3-carbaldehyde

By proceeding in a manner similar to Reference Example 6(a) above but using (1H-indazol-3-yl)-methanol [Reference Example 25(g)] with acetone as the solvent and carrying out the reaction at reflux temperature for 16 hours there was prepared 1H-indazole-3-carbaldehyde as a yellow solid. LC-MS [METHOD B]; R T =2.63 minutes; 147.26 (M+H) + ; 145.26 (M−H) − .

(m) 4-Nitro-1-(tetrahydro-pyran-2-yl)-1H-pyrazole-3-carbaldehyde

By proceeding in a manner similar to Reference Example 6(a) above but (i) using [4-nitro-1-(tetrahydro-pyran-2-yl)-1H-pyrazol-3-yl]-methanol (663 mg, Reference Example 53) and manganese (IV) oxide (2.54 g) with acetone as the solvent, (ii) carrying out the reaction at 65° C. for 2 hours and (iii) subjecting the reaction product to flash silica chromatography eluting with a mixture of pentane and ethyl acetate (70:30, v/v), there was prepared 4-nitro-1-(tetrahydro-pyran-2-yl)-1H-pyrazole-3-carbaldehyde (191 mg) as a pale yellow oil. LC-MS (Method H): R T =2.19 minutes, 248.24 (M+H+Na) + .

(n) 3-Formyl-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide

By proceeding in a manner similar to Reference Example 6(a) above but using 3-hydroxymethyl-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide [Reference Example 41 (d)] there was prepared 3-formyl-1H-pyrazole-4-carboxylic acid (2-methoxy-ethyl)-amide (325 mg) as a yellow oil. LC-MS (METHOD B): R T =2.13 minutes, 198 (M+H) + .

(o) 3-Formyl-1H-pyrazole-4-carboxylic acid propylamide

By proceeding in a manner similar to Reference Example 6(a) above but using 3-hydroxymethyl-1H-pyrazole-4-carboxylic acid propylamide [Reference Exampl

›Tables in the description — 4

A1-B1;	A1-B2;	A1-B3;	A1-B4;	A1-B5;	A1-B6;
A1-B7;	A1-B8;	A1-B9;	A1-B10;	A1-B11;	A1-B12;
A1-B13;	A1-B14;	A1-B15;	A1-B16;	A1-B17;	A1-B18;
A1-B19;	A1-B20;	A1-B21;	A1-B22;	A1-B23;	A1-B24;
A1-B25;	A1-B26;	A1-B27;	A1-B28;	A1-B29;	A1-B30;
A1-B31;	A1-B32;	A1-B33;	A1-B34;	A1-B35;	A1-B36;
A1-B37;	A1-B38;	A1-B39;	A1-B40;	A1-B41;	A1-B42;
A1-B43;	A1-B44;	A1-B45;	A1-B46;	A1-B47;	A1-B48;
A1-B49;	A1-B50;	A1-B51;	A1-B52;	A1-B53;	A1-B54;
A1-B55;	A1-B56;	A1-B57;	A1-B58;	A1-B59;	A1-B60;
A1-B61;	A1-B62;	A1-B63;	A1-B64;	A1-B65;	A1-B66;
A1-B67;	A1-B68;	A1-B69;	A1-B70;	A1-B71;	A1-B72;
A1-B73;	A1-B74;	A1-B75;	A1-B76;	A1-B77;	A1-B78;
A1-B79;	A1-B80;	A1-B81;	A1-B82;	A1-B83;	A1-B84;
A1-B85;	A1-B86;	A1-B87;	A1-B88;	A1-B89;	A1-B90;
A1-B91;	A1-B92;	A1-B93;	A1-B94;	A1-B95;	A1-B96;
A1-B97;	A1-B98;	A1-B99;	A1-B100;	A1-B101;	A1-B102;
A1-B103;	A1-B104;	A1-B105;	A1-B106;	A1-B107;	A1-B108;
A1-B109;	A1-B110;	A1-B111;	A1-B112;	A1-B113;	A1-B114;
A1-B115;	A1-B116;	A1-B117;	A1-B118;	A1-B119;	A1-B120;
A1-B121;	A1-B122;	A1-B123;	A1-B124;	A1-B125;	A1-B126;
A1-B127;	A1-B128;	A1-B129;	A1-B130;	A1-B131;	A1-B132;
A1-B133;	A1-B134;	A1-B135;	A1-B136;	A1-B137;	A1-B138;
A1-B139;	A1-B140;	A1-B141;	A1-B142;	A1-B143;	A1-B144;
A1-B145;	A1-B146;	A1-B147;	A1-B148;	A1-B149;	A1-B150;
A1-B151;	A1-B152;	A1-B153;	A1-B154;	A1-B155;	A1-B156;
A1-B157;	A1-B158;	A1-B159;	A1-B160;	A1-B161;	A1-B162;
A1-B163;	A1-B164;	A1-B165;	A1-B166;	A1-B167;	A1-B168;
A1-B169;	A2-B1;	A2-B2;	A2-B3;	A2-B4;	A2-B5;
A2-B6;	A2-B7;	A2-B8;	A2-B9;	A2-B10;	A2-B11;
A2-B12;	A2-B13;	A2-B14;	A2-B15;	A2-B16;	A2-B17;
A2-B18;	A2-B19;	A2-B20;	A2-B21;	A2-B22;	A2-B23;
A2-B24;	A2-B25;	A2-B26;	A2-B27;	A2-B28;	A2-B29;
A2-B30;	A2-B31;	A2-B32;	A2-B33;	A2-B34;	A2-B35;
A2-B36;	A2-B37;	A2-B38;	A2-B39;	A2-B40;	A2-B41;
A2-B42;	A2-B43;	A2-B44;	A2-B45;	A2-B46;	A2-B47;
A2-B48;	A2-B49;	A2-B50;	A2-B51;	A2-B52;	A2-B53;
A2-B54;	A2-B55;	A2-B56;	A2-B57;	A2-B58;	A2-B59;
A2-B60;	A2-B61;	A2-B62;	A2-B63;	A2-B64;	A2-B65;
A2-B66;	A2-B67;	A2-B68;	A2-B69;	A2-B70;	A2-B71;
A2-B72;	A2-B73;	A2-B74;	A2-B75;	A2-B76;	A2-B77;
A2-B78;	A2-B79;	A2-B80;	A2-B81;	A2-B82;	A2-B83;
A2-B84;	A2-B85;	A2-B86;	A2-B87;	A2-B88;	A2-B89;
A2-B90;	A2-B91;	A2-B92;	A2-B93;	A2-B94;	A2-B95;
A2-B96;	A2-B97;	A2-B98;	A2-B99;	A2-B100;	A2-B101;
A2-B102;	A2-B103;	A2-B104;	A2-B105;	A2-B106;	A2-B107;
A2-B108;	A2-B109;	A2-B110;	A2-B111;	A2-B112;	A2-B113;
A2-B114;	A2-B115;	A2-B116;	A2-B117;	A2-B118;	A2-B119;
A2-B120;	A2-B121;	A2-B122;	A2-B123;	A2-B124;	A2-B125;
A2-B126;	A2-B127;	A2-B128;	A2-B129;	A2-B130;	A2-B131;
A2-B132;	A2-B133;	A2-B134;	A2-B135;	A2-B136;	A2-B137;
A2-B138;	A2-B139;	A2-B140;	A2-B141;	A2-B142;	A2-B143;
A2-B144;	A2-B145;	A2-B146;	A2-B147;	A2-B148;	A2-B149;
A2-B150;	A2-B151;	A2-B152;	A2-B153;	A2-B154;	A2-B155;
A2-B156;	A2-B157;	A2-B158;	A2-B159;	A2-B160;	A2-B161;
A2-B162;	A2-B163;	A2-B164;	A2-B165;	A2-B166;	A2-B167;
A2-B168;	A2-B169;	A3-B1;	A3-B2;	A3-B3;	A3-B4;
A3-B5;	A3-B6;	A3-B7;	A3-B8;	A3-B9;	A3-B10;
A3-B11;	A3-B12;	A3-B13;	A3-B14;	A3-B15;	A3-B16;
A3-B17;	A3-B18;	A3-B19;	A3-B20;	A3-B21;	A3-B22;
A3-B23;	A3-B24;	A3-B25;	A3-B26;	A3-B27;	A3-B28;
A3-B29;	A3-B30;	A3-B31;	A3-B32;	A3-B33;	A3-B34;
A3-B35;	A3-B36;	A3-B37;	A3-B38;	A3-B39;	A3-B40;
A3-B41;	A3-B42;	A3-B43;	A3-B44;	A3-B45;	A3-B46;
A3-B47;	A3-B48;	A3-B49;	A3-B50;	A3-B51;	A3-B52;
A3-B53;	A3-B54;	A3-B55;	A3-B56;	A3-B57;	A3-B58;
A3-B59;	A3-B60;	A3-B61;	A3-B62;	A3-B63;	A3-B64;
A3-B65;	A3-B66;	A3-B67;	A3-B68;	A3-B69;	A3-B70;
A3-B71;	A3-B72;	A3-B73;	A3-B74;	A3-B75;	A3-B76;
A3-B77;	A3-B78;	A3-B79;	A3-B80;	A3-B81;	A3-B82;
A3-B83;	A3-B84;	A3-B85;	A3-B86;	A3-B87;	A3-B88;
A3-B89;	A3-B90;	A3-B91;	A3-B92;	A3-B93;	A3-B94;
A3-B95;	A3-B96;	A3-B97;	A3-B98;	A3-B99;	A3-B100;
A3-B101;	A3-B102;	A3-B103;	A3-B104;	A3-B105;	A3-B106;
A3-B107;	A3-B108;	A3-B109;	A3-B110;	A3-B111;	A3-B112;
A3-B113;	A3-B114;	A3-B115;	A3-B116;	A3-B117;	A3-B118;
A3-B119;	A3-B120;	A3-B121;	A3-B122;	A3-B123;	A3-B124;
A3-B125;	A3-B126;	A3-B127;	A3-B128;	A3-B129;	A3-B130;
A3-B131;	A3-B132;	A3-B133;	A3-B134;	A3-B135;	A3-B136;
A3-B137;	A3-B138;	A3-B139;	A3-B140;	A3-B141;	A3-B142;
A3-B143;	A3-B144;	A3-B145;	A3-B146;	A3-B147;	A3-B148;
A3-B149;	A3-B150;	A3-B151;	A3-B152;	A3-B153;	A3-B154;
A3-B155;	A3-B156;	A3-B157;	A3-B158;	A3-B159;	A3-B160;
A3-B161;	A3-B162;	A3-B163;	A3-B164;	A3-B165;	A3-B166;
A3-B167;	A3-B168;	A3-B169;	A4-B1;	A4-B2;	A4-B3;
A4-B4;	A4-B5;	A4-B6;	A4-B7;	A4-B8;	A4-B9;
A4-B10;	A4-B11;	A4-B12;	A4-B13;	A4-B14;	A4-B15;
A4-B16;	A4-B17;	A4-B18;	A4-B19;	A4-B20;	A4-B21;
A4-B22;	A4-B23;	A4-B24;	A4-B25;	A4-B26;	A4-B27;
A4-B28;	A4-B29;	A4-B30;	A4-B31;	A4-B32;	A4-B33;
A4-B34;	A4-B35;	A4-B36;	A4-B37;	A4-B38;	A4-B39;
A4-B40;	A4-B41;	A4-B42;	A4-B43;	A4-B44;	A4-B45;
A4-B46;	A4-B47;	A4-B48;	A4-B49;	A4-B50;	A4-B51;
A4-B52;	A4-B53;	A4-B54;	A4-B55;	A4-B56;	A4-B57;
A4-B58;	A4-B59;	A4-B60;	A4-B61;	A4-B62;	A4-B63;
A4-B64;	A4-B65;	A4-B66;	A4-B67;	A4-B68;	A4-B69;
A4-B70;	A4-B71;	A4-B72;	A4-B73;	A4-B74;	A4-B75;
A4-B76;	A4-B77;	A4-B78;	A4-B79;	A4-B80;	A4-B81;
A4-B82;	A4-B83;	A4-B84;	A4-B85;	A4-B86;	A4-B87;
A4-B88;	A4-B89;	A4-B90;	A4-B91;	A4-B92;	A4-B93;
A4-B94;	A4-B95;	A4-B96;	A4-B97;	A4-B98;	A4-B99;
A4-B100;	A4-B101;	A4-B102;	A4-B103;	A4-B104;	A4-B105;
A4-B106;	A4-B107;	A4-B108;	A4-B109;	A4-B110;	A4-B111;
A4-B112;	A4-B113;	A4-B114;	A4-B115;	A4-B116;	A4-B117;
A4-B118;	A4-B119;	A4-B120;	A4-B121;	A4-B122;	A4-B123;
A4-B124;	A4-B125;	A4-B126;	A4-B127;	A4-B128;	A4-B129;
A4-B130;	A4-B131;	A4-B132;	A4-B133;	A4-B134;	A4-B135;
A4-B136;	A4-B137;	A4-B138;	A4-B139;	A4-B140;	A4-B141;
A4-B142;	A4-B143;	A4-B144;	A4-B145;	A4-B146;	A4-B147;
A4-B148;	A4-B149;	A4-B150;	A4-B151;	A4-B152;	A4-B153;
A4-B154;	A4-B155;	A4-B156;	A4-B157;	A4-B158;	A4-B159;
A4-B160;	A4-B161;	A4-B162;	A4-B163;	A4-B164;	A4-B165;
A4-B166;	A4-B167;	A4-B168;	A4-B169;	A5-B1;	A5-B2;
A5-B3;	A5-B4;	A5-B5;	A5-B6;	A5-B7;	A5-B8;
A5-B9;	A5-B10;	A5-B11;	A5-B12;	A5-B13;	A5-B14;
A5-B15;	A5-B16;	A5-B17;	A5-B18;	A5-B19;	A5-B20;
A5-B21;	A5-B22;	A5-B23;	A5-B24;	A5-B25;	A5-B26;
A5-B27;	A5-B28;	A5-B29;	A5-B30;	A5-B31;	A5-B32;
A5-B33;	A5-B34;	A5-B35;	A5-B36;	A5-B37;	A5-B38;
A5-B39;	A5-B40;	A5-B41;	A5-B42;	A5-B43;	A5-B44;
A5-B45;	A5-B46;	A5-B47;	A5-B48;	A5-B49;	A5-B50;
A5-B51;	A5-B52;	A5-B53;	A5-B54;	A5-B55;	A5-B56;
A5-B57;	A5-B58;	A5-B59;	A5-B60;	A5-B61;	A5-B62;
A5-B63;	A5-B64;	A5-B65;	A5-B66;	A5-B67;	A5-B68;
A5-B69;	A5-B70;	A5-B71;	A5-B72;	A5-B73;	A5-B74;
A5-B75;	A5-B76;	A5-B77;	A5-B78;	A5-B79;	A5-B80;
A5-B81;	A5-B82;	A5-B83;	A5-B84;	A5-B85;	A5-B86;
A5-B87;	A5-B88;	A5-B89;	A5-B90;	A5-B91;	A5-B92;
A5-B93;	A5-B94;	A5-B95;	A5-B96;	A5-B97;	A5-B98;
A5-B99;	A5-B100;	A5-B101;	A5-B102;	A5-B103;	A5-B104;
A5-B105;	A5-B106;	A5-B107;	A5-B108;	A5-B109;	A5-B110;
A5-B111;	A5-B112;	A5-B113;	A5-B114;	A5-B115;	A5-B116;
A5-B117;	A5-B118;	A5-B119;	A5-B120;	A5-B121;	A5-B122;
A5-B123;	A5-B124;	A5-B125;	A5-B126;	A5-B127;	A5-B128;
A5-B129;	A5-B130;	A5-B131;	A5-B132;	A5-B133;	A5-B134;
A5-B135;	A5-B136;	A5-B137;	A5-B138;	A5-B139;	A5-B140;
A5-B141;	A5-B142;	A5-B143;	A5-B144;	A5-B145;	A5-B146;
A5-B147;	A5-B148;	A5-B149;	A5-B150;	A5-B151;	A5-B152;
A5-B153;	A5-B154;	A5-B155;	A5-B156;	A5-B157;	A5-B158;
A5-B159;	A5-B160;	A5-B161;	A5-B162;	A5-B163;	A5-B164;
A5-B165;	A5-B166;	A5-B167;	A5-B168;	A5-B169;	A6-B1;
A6-B2;	A6-B3;	A6-B4;	A6-B5;	A6-B6;	A6-B7;
A6-B8;	A6-B9;	A6-B10;	A6-B11;	A6-B12;	A6-B13;
A6-B14;	A6-B15;	A6-B16;	A6-B17;	A6-B18;	A6-B19;
A6-B20;	A6-B21;	A6-B22;	A6-B23;	A6-B24;	A6-B25;
A6-B26;	A6-B27;	A6-B28;	A6-B29;	A6-B30;	A6-B31;
A6-B32;	A6-B33;	A6-B34;	A6-B35;	A6-B36;	A6-B37;
A6-B38;	A6-B39;	A6-B40;	A6-B41;	A6-B42;	A6-B43;
A6-B44;	A6-B45;	A6-B46;	A6-B47;	A6-B48;	A6-B49;
A6-B50;	A6-B51;	A6-B52;	A6-B53;	A6-B54;	A6-B55;
A6-B56;	A6-B57;	A6-B58;	A6-B59;	A6-B60;	A6-B61;
A6-B62;	A6-B63;	A6-B64;	A6-B65;	A6-B66;	A6-B67;
A6-B68;	A6-B69;	A6-B70;	A6-B71;	A6-B72;	A6-B73;
A6-B74;	A6-B75;	A6-B76;	A6-B77;	A6-B78;	A6-B79;
A6-B80;	A6-B81;	A6-B82;	A6-B83;	A6-B84;	A6-B85;
A6-B86;	A6-B87;	A6-B88;	A6-B89;	A6-B90;	A6-B91;
A6-B92;	A6-B93;	A6-B94;	A6-B95;	A6-B96;	A6-B97;
A6-B98;	A6-B99;	A6-B100;	A6-B101;	A6-B102;	A6-B103;
A6-B104;	A6-B105;	A6-B106;	A6-B107;	A6-B108;	A6-B109;
A6-B110;	A6-B111;	A6-B112;	A6-B113;	A6-B114;	A6-B115;
A6-B116;	A6-B117;	A6-B118;	A6-B119;	A6-B120;	A6-B121;
A6-B122;	A6-B123;	A6-B124;	A6-B125;	A6-B126;	A6-B127;
A6-B128;	A6-B129;	A6-B130;	A6-B131;	A6-B132;	A6-B133;
A6-B134;	A6-B135;	A6-B136;	A6-B137;	A6-B138;	A6-B139;
A6-B140;	A6-B141;	A6-B142;	A6-B143;	A6-B144;	A6-B145;
A6-B146;	A6-B147;	A6-B148;	A6-B149;	A6-B150;	A6-B151;
A6-B152;	A6-B153;	A6-B154;	A6-B155;	A6-B156;	A6-B157;
A6-B158;	A6-B159;	A6-B160;	A6-B161;	A6-B162;	A6-B163;
A6-B164;	A6-B165;	A6-B166;	A6-B167;	A6-B168;	A6-B169;
A7-B1;	A7-B2;	A7-B3;	A7-B4;	A7-B5;	A7-B6;
A7-B7;	A7-B8;	A7-B9;	A7-B10;	A7-B11;	A7-B12;
A7-B13;	A7-B14;	A7-B15;	A7-B16;	A7-B17;	A7-B18;
A7-B19;	A7-B20;	A7-B21;	A7-B22;	A7-B23;	A7-B24;
A7-B25;	A7-B26;	A7-B27;	A7-B28;	A7-B29;	A7-B30;
A7-B31;	A7-B32;	A7-B33;	A7-B34;	A7-B35;	A7-B36;
A7-B37;	A7-B38;	A7-B39;	A7-B40;	A7-B41;	A7-B42;
A7-B43;	A7-B44;	A7-B45;	A7-B46;	A7-B47;	A7-B48;
A7-B49;	A7-B50;	A7-B51;	A7-B52;	A7-B53;	A7-B54;
A7-B55;	A7-B56;	A7-B57;	A7-B58;	A7-B59;	A7-B60;
A7-B61;	A7-B62;	A7-B63;	A7-B64;	A7-B65;	A7-B66;
A7-B67;	A7-B68;	A7-B69;	A7-B70;	A7-B71;	A7-B72;
A7-B73;	A7-B74;	A7-B75;	A7-B76;	A7-B77;	A7-B78;
A7-B79;	A7-B80;	A7-B81;	A7-B82;	A7-B83;	A7-B84;
A7-B85;	A7-B86;	A7-B87;	A7-B88;	A7-B89;	A7-B90;
A7-B91;	A7-B92;	A7-B93;	A7-B94;	A7-B95;	A7-B96;
A7-B97;	A7-B98;	A7-B99;	A7-B100;	A7-B101;	A7-B102;
A7-B103;	A7-B104;	A7-B105;	A7-B106;	A7-B107;	A7-B108;
A7-B109;	A7-B110;	A7-B111;	A7-B112;	A7-B113;	A7-B114;
A7-B115;	A7-B116;	A7-B117;	A7-B118;	A7-B119;	A7-B120;
A7-B121;	A7-B122;	A7-B123;	A7-B124;	A7-B125;	A7-B126;
A7-B127;	A7-B128;	A7-B129;	A7-B130;	A7-B131;	A7-B132;
A7-B133;	A7-B134;	A7-B135;	A7-B136;	A7-B137;	A7-B138;
A7-B139;	A7-B140;	A7-B141;	A7-B142;	A7-B143;	A7-B144;
A7-B145;	A7-B146;	A7-B147;	A7-B148;	A7-B149;	A7-B150;
A7-B151;	A7-B152;	A7-B153;	A7-B154;	A7-B155;	A7-B156;
A7-B157;	A7-B158;	A7-B159;	A7-B160;	A7-B161;	A7-B162;
A7-B163;	A7-B164;	A7-B165;	A7-B166;	A7-B167;	A7-B168;
A7-B169;	A8-B1;	A8-B2;	A8-B3;	A8-B4;	A8-B5;
A8-B6;	A8-B7;	A8-B8;	A8-B9;	A8-B10;	A8-B11;
A8-B12;	A8-B13;	A8-B14;	A8-B15;	A8-B16;	A8-B17;
A8-B18;	A8-B19;	A8-B20;	A8-B21;	A8-B22;	A8-B23;
A8-B24;	A8-B25;	A8-B26;	A8-B27;	A8-B28;	A8-B29;
A8-B30;	A8-B31;	A8-B32;	A8-B33;	A8-B34;	A8-B35;
A8-B36;	A8-B37;	A8-B38;	A8-B39;	A8-B40;	A8-B41;
A8-B42;	A8-B43;	A8-B44;	A8-B45;	A8-B46;	A8-B47;
A8-B48;	A8-B49;	A8-B50;	A8-B51;	A8-B52;	A8-B53;
A8-B54;	A8-B55;	A8-B56;	A8-B57;	A8-B58;	A8-B59;
A8-B60;	A8-B61;	A8-B62;	A8-B63;	A8-B64;	A8-B65;
A8-B66;	A8-B67;	A8-B68;	A8-B69;	A8-B70;	A8-B71;
A8-B72;	A8-B73;	A8-B74;	A8-B75;	A8-B76;	A8-B77;
A8-B78;	A8-B79;	A8-B80;	A8-B81;	A8-B82;	A8-B83;
A8-B84;	A8-B85;	A8-B86;	A8-B87;	A8-B88;	A8-B89;
A8-B90;	A8-B91;	A8-B92;	A8-B93;	A8-B94;	A8-B95;
A8-B96;	A8-B97;	A8-B98;	A8-B99;	A8-B100;	A8-B101;
A8-B102;	A8-B103;	A8-B104;	A8-B105;	A8-B106;	A8-B107;
A8-B108;	A8-B109;	A8-B110;	A8-B111;	A8-B112;	A8-B113;
A8-B114;	A8-B115;	A8-B116;	A8-B117;	A8-B118;	A8-B119;
A8-B120;	A8-B121;	A8-B122;	A8-B123;	A8-B124;	A8-B125;
A8-B126;	A8-B127;	A8-B128;	A8-B129;	A8-B130;	A8-B131;
A8-B132;	A8-B133;	A8-B134;	A8-B135;	A8-B136;	A8-B137;
A8-B138;	A8-B139;	A8-B140;	A8-B141;	A8-B142;	A8-B143;
A8-B144;	A8-B145;	A8-B146;	A8-B147;	A8-B148;	A8-B149;
A8-B150;	A8-B151;	A8-B152;	A8-B153;	A8-B154;	A8-B155;
A8-B156;	A8-B157;	A8-B158;	A8-B159;	A8-B160;	A8-B161;
A8-B162;	A8-B163;	A8-B164;	A8-B165;	A8-B166;	A8-B167;
A8-B168;	A8-B169;	A9-B1;	A9-B2;	A9-B3;	A9-B4;
A9-B5;	A9-B6;	A9-B7;	A9-B8;	A9-B9;	A9-B10;
A9-B11;	A9-B12;	A9-B13;	A9-B14;	A9-B15;	A9-B16;
A9-B17;	A9-B18;	A9-B19;	A9-B20;	A9-B21;	A9-B22;
A9-B23;	A9-B24;	A9-B25;	A9-B26;	A9-B27;	A9-B28;
A9-B29;	A9-B30;	A9-B31;	A9-B32;	A9-B33;	A9-B34;
A9-B35;	A9-B36;	A9-B37;	A9-B38;	A9-B39;	A9-B40;
A9-B41;	A9-B42;	A9-B43;	A9-B44;	A9-B45;	A9-B46;
A9-B47;	A9-B48;	A9-B49;	A9-B50;	A9-B51;	A9-B52;
A9-B53;	A9-B54;	A9-B55;	A9-B56;	A9-B57;	A9-B58;
A9-B59;	A9-B60;	A9-B61;	A9-B62;	A9-B63;	A9-B64;
A9-B65;	A9-B66;	A9-B67;	A9-B68;	A9-B69;	A9-B70;
A9-B71;	A9-B72;	A9-B73;	A9-B74;	A9-B75;	A9-B76;
A9-B77;	A9-B78;	A9-B79;	A9-B80;	A9-B81;	A9-B82;
A9-B83;	A9-B84;	A9-B85;	A9-B86;	A9-B87;	A9-B88;
A9-B89;	A9-B90;	A9-B91;	A9-B92;	A9-B93;	A9-B94;
A9-B95;	A9-B96;	A9-B97;	A9-B98;	A9-B99;	A9-B100;
A9-B101;	A9-B102;	A9-B103;	A9-B104;	A9-B105;	A9-B106;
A9-B107;	A9-B108;	A9-B109;	A9-B110;	A9-B111;	A9-B112;
A9-B113;	A9-B114;	A9-B115;	A9-B116;	A9-B117;	A9-B118;
A9-B119;	A9-B120;	A9-B121;	A9-B122;	A9-B123;	A9-B124;
A9-B125;	A9-B126;	A9-B127;	A9-B128;	A9-B129;	A9-B130;
A9-B131;	A9-B132;	A9-B133;	A9-B134;	A9-B135;	A9-B136;
A9-B137;	A9-B138;	A9-B139;	A9-B140;	A9-B141;	A9-B142;
A9-B143;	A9-B144;	A9-B145;	A9-B146;	A9-B147;	A9-B148;
A9-B149;	A9-B150;	A9-B151;	A9-B152;	A9-B153;	A9-B154;
A9-B155;	A9-B156;	A9-B157;	A9-B158;	A9-B159;	A9-B160;
A9-B161;	A9-B162;	A9-B163;	A9-B164;	A9-B165;	A9-B166;
A9-B167;	A9-B168;	A9-B169;	A10-B1;	A10-B2;	A10-B3;
A10-B4;	A10-B5;	A10-B6;	A10-B7;	A10-B8;	A10-B9;
A10-B10;	A10-B11;	A10-B12;	A10-B13;	A10-B14;	A10-B15;
A10-B16;	A10-B17;	A10-B18;	A10-B19;	A10-B20;	A10-B21;
A10-B22;	A10-B23;	A10-B24;	A10-B25;	A10-B26;	A10-B27;
A10-B28;	A10-B29;	A10-B30;	A10-B31;	A10-B32;	A10-B33;
A10-B34;	A10-B35;	A10-B36;	A10-B37;	A10-B38;	A10-B39;
A10-B40;	A10-B41;	A10-B42;	A10-B43;	A10-B44;	A10-B45;
A10-B46;	A10-B47;	A10-B48;	A10-B49;	A10-B50;	A10-B51;
A10-B52;	A10-B53;	A10-B54;	A10-B55;	A10-B56;	A10-B57;
A10-B58;	A10-B59;	A10-B60;	A10-B61;	A10-B62;	A10-B63;
A10-B64;	A10-B65;	A10-B66;	A10-B67;	A10-B68;	A10-B69;
A10-B70;	A10-B71;	A10-B72;	A10-B73;	A10-B74;	A10-B75;
A10-B76;	A10-B77;	A10-B78;	A10-B79;	A10-B80;	A10-B81;
A10-B82;	A10-B83;	A10-B84;	A10-B85;	A10-B86;	A10-B87;
A10-B88;	A10-B89;	A10-B90;	A10-B91;	A10-B92;	A10-B93;
A10-B94;	A10-B95;	A10-B96;	A10-B97;	A10-B98;	A10-B99;
A10-B100;	A10-B101;	A10-B102;	A10-B103;	A10-B104;	A10-B105;
A10-B106;	A10-B107;	A10-B108;	A10-B109;	A10-B110;	A10-B111;
A10-B112;	A10-B113;	A10-B114;	A10-B115;	A10-B116;	A10-B117;
A10-B118;	A10-B119;	A10-B120;	A10-B121;	A10-B122;	A10-B123;
A10-B124;	A10-B125;	A10-B126;	A10-B127;	A10-B128;	A10-B129;
A10-B130;	A10-B131;	A10-B132;	A10-B133;	A10-B134;	A10-B135;
A10-B136;	A10-B137;	A10-B138;	A10-B139;	A10-B140;	A10-B141;
A10-B142;	A10-B143;	A10-B144;	A10-B145;	A10-B146;	A10-B147;
A10-B148;	A10-B149;	A10-B150;	A10-B151;	A10-B152;	A10-B153;
A10-B154;	A10-B155;	A10-B156;	A10-B157;	A10-B158;	A10-B159;
A10-B160;	A10-B161;	A10-B162;	A10-B163;	A10-B164;	A10-B165;
A10-B166;	A10-B167;	A10-B168;	A10-B169;	A11-B1;	A11-B2;
A11-B3;	A11-B4;	A11-B5;	A11-B6;	A11-B7;	A11-B8;
A11-B9;	A11-B10;	A11-B11;	A11-B12;	A11-B13;	A11-B14;
A11-B15;	A11-B16;	A11-B17;	A11-B18;	A11-B19;	A11-B20;
A11-B21;	A11-B22;	A11-B23;	A11-B24;	A11-B25;	A11-B26;
A11-B27;	A11-B28;	A11-B29;	A11-B30;	A11-B31;	A11-B32;
A11-B33;	A11-B34;	A11-B35;	A11-B36;	A11-B37;	A11-B38;
A11-B39;	A11-B40;	A11-B41;	A11-B42;	A11-B43;	A11-B44;
A11-B45;	A11-B46;	A11-B47;	A11-B48;	A11-B49;	A11-B50;
A11-B51;	A11-B52;	A11-B53;	A11-B54;	A11-B55;	A11-B56;
A11-B57;	A11-B58;	A11-B59;	A11-B60;	A11-B61;	A11-B62;
A11-B63;	A11-B64;	A11-B65;	A11-B66;	A11-B67;	A11-B68;
A11-B69;	A11-B70;	A11-B71;	A11-B72;	A11-B73;	A11-B74;
A11-B75;	A11-B76;	A11-B77;	A11-B78;	A11-B79;	A11-B80;
A11-B81;	A11-B82;	A11-B83;	A11-B84;	A11-B85;	A11-B86;
A11-B87;	A11-B88;	A11-B89;	A11-B90;	A11-B91;	A11-B92;
A11-B93;	A11-B94;	A11-B95;	A11-B96;	A11-B97;	A11-B98;
A11-B99;	A11-B100;	A11-B101;	A11-B102;	A11-B103;	A11-B104;
A11-B105;	A11-B106;	A11-B107;	A11-B108;	A11-B109;	A11-B110;
A11-B111;	A11-B112;	A11-B113;	A11-B114;	A11-B115;	A11-B116;
A11-B117;	A11-B118;	A11-B119;	A11-B120;	A11-B121;	A11-B122;
A11-B123;	A11-B124;	A11-B125;	A11-B126;	A11-B127;	A11-B128;
A11-B129;	A11-B130;	A11-B131;	A11-B132;	A11-B133;	A11-B134;
A11-B135;	A11-B136;	A11-B137;	A11-B138;	A11-B139;	A11-B140;
A11-B141;	A11-B142;	A11-B143;	A11-B144;	A11-B145;	A11-B146;
A11-B147;	A11-B148;	A11-B149;	A11-B150;	A11-B151;	A11-B152;
A11-B153;	A11-B154;	A11-B155;	A11-B156;	A11-B157;	A11-B158;
A11-B159;	A11-B160;	A11-B161;	A11-B162;	A11-B163;	A11-B164;
A11-B165;	A11-B166;	A11-B167;	A11-B168;	A11-B169;	A12-B1;
A12-B2;	A12-B3;	A12-B4;	A12-B5;	A12-B6;	A12-B7;
A12-B8;	A12-B9;	A12-B10;	A12-B11;	A12-B12;	A12-B13;
A12-B14;	A12-B15;	A12-B16;	A12-B17;	A12-B18;	A12-B19;
A12-B20;	A12-B21;	A12-B22;	A12-B23;	A12-B24;	A12-B25;
A12-B26;	A12-B27;	A12-B28;	A12-B29;	A12-B30;	A12-B31;
A12-B32;	A12-B33;	A12-B34;	A12-B35;	A12-B36;	A12-B37;
A12-B38;	A12-B39;	A12-B40;	A12-B41;	A12-B42;	A12-B43;
A12-B44;	A12-B45;	A12-B46;	A12-B47;	A12-B48;	A12-B49;
A12-B50;	A12-B51;	A12-B52;	A12-B53;	A12-B54;	A12-B55;
A12-B56;	A12-B57;	A12-B58;	A12-B59;	A12-B60;	A12-B61;
A12-B62;	A12-B63;	A12-B64;	A12-B65;	A12-B66;	A12-B67;
A12-B68;	A12-B69;	A12-B70;	A12-B71;	A12-B72;	A12-B73;
A12-B74;	A12-B75;	A12-B76;	A12-B77;	A12-B78;	A12-B79;
A12-B80;	A12-B81;	A12-B82;	A12-B83;	A12-B84;	A12-B85;
A12-B86;	A12-B87;	A12-B88;	A12-B89;	A12-B90;	A12-B91;
A12-B92;	A12-B93;	A12-B94;	A12-B95;	A12-B96;	A12-B97;
A12-B98;	A12-B99;	A12-B100;	A12-B101;	A12-B102;	A12-B103;
A12-B104;	A12-B105;	A12-B106;	A12-B107;	A12-B108;	A12-B109;
A12-B110;	A12-B111;	A12-B112;	A12-B113;	A12-B114;	A12-B115;
A12-B116;	A12-B117;	A12-B118;	A12-B119;	A12-B120;	A12-B121;
A12-B122;	A12-B123;	A12-B124;	A12-B125;	A12-B126;	A12-B127;
A12-B128;	A12-B129;	A12-B130;	A12-B131;	A12-B132;	A12-B133;
A12-B134;	A12-B135;	A12-B136;	A12-B137;	A12-B138;	A12-B139;
A12-B140;	A12-B141;	A12-B142;	A12-B143;	A12-B144;	A12-B145;
A12-B146;	A12-B147;	A12-B148;	A12-B149;	A12-B150;	A12-B151;
A12-B152;	A12-B153;	A12-B154;	A12-B155;	A12-B156;	A12-B157;
A12-B158;	A12-B159;	A12-B160;	A12-B161;	A12-B162;	A12-B163;
A12-B164;	A12-B165;	A12-B166;	A12-B167;	A12-B168;	A12-B169;
A13-B1;	A13-B2;	A13-B3;	A13-B4;	A13-B5;	A13-B6;
A13-B7;	A13-B8;	A13-B9;	A13-B10;	A13-B11;	A13-B12;
A13-B13;	A13-B14;	A13-B15;	A13-B16;	A13-B17;	A13-B18;
A13-B19;	A13-B20;	A13-B21;	A13-B22;	A13-B23;	A13-B24;
A13-B25;	A13-B26;	A13-B27;	A13-B28;	A13-B29;	A13-B30;
A13-B31;	A13-B32;	A13-B33;	A13-B34;	A13-B35;	A13-B36;
A13-B37;	A13-B38;	A13-B39;	A13-B40;	A13-B41;	A13-B42;
A13-B43;	A13-B44;	A13-B45;	A13-B46;	A13-B47;	A13-B48;
A13-B49;	A13-B50;	A13-B51;	A13-B52;	A13-B53;	A13-B54;
A13-B55;	A13-B56;	A13-B57;	A13-B58;	A13-B59;	A13-B60;
A13-B61;	A13-B62;	A13-B63;	A13-B64;	A13-B65;	A13-B66;
A13-B67;	A13-B68;	A13-B69;	A13-B70;	A13-B71;	A13-B72;
A13-B73;	A13-B74;	A13-B75;	A13-B76;	A13-B77;	A13-B78;
A13-B79;	A13-B80;	A13-B81;	A13-B82;	A13-B83;	A13-B84;
A13-B85;	A13-B86;	A13-B87;	A13-B88;	A13-B89;	A13-B90;
A13-B91;	A13-B92;	A13-B93;	A13-B94;	A13-B95;	A13-B96;
A13-B97;	A13-B98;	A13-B99;	A13-B100;	A13-B101;	A13-B102;
A13-B103;	A13-B104;	A13-B105;	A13-B106;	A13-B107;	A13-B108;
A13-B109;	A13-B110;	A13-B111;	A13-B112;	A13-B113;	A13-B114;
A13-B115;	A13-B116;	A13-B117;	A13-B118;	A13-B119;	A13-B120;
A13-B121;	A13-B122;	A13-B123;	A13-B124;	A13-B125;	A13-B126;
A13-B127;	A13-B128;	A13-B129;	A13-B130;	A13-B131;	A13-B132;
A13-B133;	A13-B134;	A13-B135;	A13-B136;	A13-B137;	A13-B138;
A13-B139;	A13-B140;	A13-B141;	A13-B142;	A13-B143;	A13-B144;
A13-B145;	A13-B146;	A13-B147;	A13-B148;	A13-B149;	A13-B150;
A13-B151;	A13-B152;	A13-B153;	A13-B154;	A13-B155;	A13-B156;
A13-B157;	A13-B158;	A13-B159;	A13-B160;	A13-B161;	A13-B162;
A13-B163;	A13-B164;	A13-B165;	A13-B166;	A13-B167;	A13-B168;
A13-B169;	A14-B1;	A14-B2;	A14-B3;	A14-B4;	A14-B5;
A14-B6;	A14-B7;	A14-B8;	A14-B9;	A14-B10;	A14-B11;
A14-B12;	A14-B13;	A14-B14;	A14-B15;	A14-B16;	A14-B17;
A14-B18;	A14-B19;	A14-B20;	A14-B21;	A14-B22;	A14-B23;
A14-B24;	A14-B25;	A14-B26;	A14-B27;	A14-B28;	A14-B29;
A14-B30;	A14-B31;	A14-B32;	A14-B33;	A14-B34;	A14-B35;
A14-B36;	A14-B37;	A14-B38;	A14-B39;	A14-B40;	A14-B41;
A14-B42;	A14-B43;	A14-B44;	A14-B45;	A14-B46;	A14-B47;
A14-B48;	A14-B49;	A14-B50;	A14-B51;	A14-B52;	A14-B53;
A14-B54;	A14-B55;	A14-B56;	A14-B57;	A14-B58;	A14-B59;
A14-B60;	A14-B61;	A14-B62;	A14-B63;	A14-B64;	A14-B65;
A14-B66;	A14-B67;	A14-B68;	A14-B69;	A14-B70;	A14-B71;
A14-B72;	A14-B73;	A14-B74;	A14-B75;	A14-B76;	A14-B77;
A14-B78;	A14-B79;	A14-B80;	A14-B81;	A14-B82;	A14-B83;
A14-B84;	A14-B85;	A14-B86;	A14-B87;	A14-B88;	A14-B89;
A14-B90;	A14-B91;	A14-B92;	A14-B93;	A14-B94;	A14-B95;
A14-B96;	A14-B97;	A14-B98;	A14-B99;	A14-B100;	A14-B101;
A14-B102;	A14-B103;	A14-B104;	A14-B105;	A14-B106;	A14-B107;
A14-B108;	A14-B109;	A14-B110;	A14-B111;	A14-B112;	A14-B113;
A14-B114;	A14-B115;	A14-B116;	A14-B117;	A14-B118;	A14-B119;
A14-B120;	A14-B121;	A14-B122;	A14-B123;	A14-B124;	A14-B125;
A14-B126;	A14-B127;	A14-B128;	A14-B129;	A14-B130;	A14-B131;
A14-B132;	A14-B133;	A14-B134;	A14-B135;	A14-B136;	A14-B137;
A14-B138;	A14-B139;	A14-B140;	A14-B141;	A14-B142;	A14-B143;
A14-B144;	A14-B145;	A14-B146;	A14-B147;	A14-B148;	A14-B149;
A14-B150;	A14-B151;	A14-B152;	A14-B153;	A14-B154;	A14-B155;
A14-B156;	A14-B157;	A14-B158;	A14-B159;	A14-B160;	A14-B161;
A14-B162;	A14-B163;	A14-B164;	A14-B165;	A14-B166;	A14-B167;
A14-B168;	A14-B169;	A15-B1;	A15-B2;	A15-B3;	A15-B4;
A15-B5;	A15-B6;	A15-B7;	A15-B8;	A15-B9;	A15-B10;
A15-B11;	A15-B12;	A15-B13;	A15-B14;	A15-B15;	A15-B16;
A15-B17;	A15-B18;	A15-B19;	A15-B20;	A15-B21;	A15-B22;
A15-B23;	A15-B24;	A15-B25;	A15-B26;	A15-B27;	A15-B28;
A15-B29;	A15-B30;	A15-B31;	A15-B32;	A15-B33;	A15-B34;
A15-B35;	A15-B36;	A15-B37;	A15-B38;	A15-B39;	A15-B40;
A15-B41;	A15-B42;	A15-B43;	A15-B44;	A15-B45;	A15-B46;
A15-B47;	A15-B48;	A15-B49;	A15-B50;	A15-B51;	A15-B52;
A15-B53;	A15-B54;	A15-B55;	A15-B56;	A15-B57;	A15-B58;
A15-B59;	A15-B60;	A15-B61;	A15-B62;	A15-B63;	A15-B64;
A15-B65;	A15-B66;	A15-B67;	A15-B68;	A15-B69;	A15-B70;
A15-B71;	A15-B72;	A15-B73;	A15-B74;	A15-B75;	A15-B76;
A15-B77;	A15-B78;	A15-B79;	A15-B80;	A15-B81;	A15-B82;
A15-B83;	A15-B84;	A15-B85;	A15-B86;	A15-B87;	A15-B88;
A15-B89;	A15-B90;	A15-B91;	A15-B92;	A15-B93;	A15-B94;
A15-B95;	A15-B96;	A15-B97;	A15-B98;	A15-B99;	A15-B100;
A15-B101;	A15-B102;	A15-B103;	A15-B104;	A15-B105;	A15-B106;
A15-B107;	A15-B108;	A15-B109;	A15-B110;	A15-B111;	A15-B112;
A15-B113;	A15-B114;	A15-B115;	A15-B116;	A15-B117;	A15-B118;
A15-B119;	A15-B120;	A15-B121;	A15-B122;	A15-B123;	A15-B124;
A15-B125;	A15-B126;	A15-B127;	A15-B128;	A15-B129;	A15-B130;
A15-B131;	A15-B132;	A15-B133;	A15-B134;	A15-B135;	A15-B136;
A15-B137;	A15-B138;	A15-B139;	A15-B140;	A15-B141;	A15-B142;
A15-B143;	A15-B144;	A15-B145;	A15-B146;	A15-B147;	A15-B148;
A15-B149;	A15-B150;	A15-B151;	A15-B152;	A15-B153;	A15-B154;
A15-B155;	A15-B156;	A15-B157;	A15-B158;	A15-B159;	A15-B160;
A15-B161;	A15-B162;	A15-B163;	A15-B164;	A15-B165;	A15-B166;
A15-B167;	A15-B168;	A15-B169;	A16-B1;	A16-B2;	A16-B3;
A16-B4;	A16-B5;	A16-B6;	A16-B7;	A16-B8;	A16-B9;
A16-B10;	A16-B11;	A16-B12;	A16-B13;	A16-B14;	A16-B15;
A16-B16;	A16-B17;	A16-B18;	A16-B19;	A16-B20;	A16-B21;
A16-B22;	A16-B23;	A16-B24;	A16-B25;	A16-B26;	A16-B27;
A16-B28;	A16-B29;	A16-B30;	A16-B31;	A16-B32;	A16-B33;
A16-B34;	A16-B35;	A16-B36;	A16-B37;	A16-B38;	A16-B39;
A16-B40;	A16-B41;	A16-B42;	A16-B43;	A16-B44;	A16-B45;
A16-B46;	A16-B47;	A16-B48;	A16-B49;	A16-B50;	A16-B51;
A16-B52;	A16-B53;	A16-B54;	A16-B55;	A16-B56;	A16-B57;
A16-B58;	A16-B59;	A16-B60;	A16-B61;	A16-B62;	A16-B63;
A16-B64;	A16-B65;	A16-B66;	A16-B67;	A16-B68;	A16-B69;
A16-B70;	A16-B71;	A16-B72;	A16-B73;	A16-B74;	A16-B75;
A16-B76;	A16-B77;	A16-B78;	A16-B79;	A16-B80;	A16-B81;
A16-B82;	A16-B83;	A16-B84;	A16-B85;	A16-B86;	A16-B87;
A16-B88;	A16-B89;	A16-B90;	A16-B91;	A16-B92;	A16-B93;
A16-B94;	A16-B95;	A16-B96;	A16-B97;	A16-B98;	A16-B99;
A16-B100;	A16-B101;	A16-B102;	A16-B103;	A16-B104;	A16-B105;
A16-B106;	A16-B107;	A16-B108;	A16-B109;	A16-B110;	A16-B111;
A16-B112;	A16-B113;	A16-B114;	A16-B115;	A16-B116;	A16-B117;
A16-B118;	A16-B119;	A16-B120;	A16-B121;	A16-B122;	A16-B123;
A16-B124;	A16-B125;	A16-B126;	A16-B127;	A16-B128;	A16-B129;
A16-B130;	A16-B131;	A16-B132;	A16-B133;	A16-B134;	A16-B135;
A16-B136;	A16-B137;	A16-B138;	A16-B139;	A16-B140;	A16-B141;
A16-B142;	A16-B143;	A16-B144;	A16-B145;	A16-B146;	A16-B147;
A16-B148;	A16-B149;	A16-B150;	A16-B151;	A16-B152;	A16-B153;
A16-B154;	A16-B155;	A16-B156;	A16-B157;	A16-B158;	A16-B159;
A16-B160;	A16-B161;	A16-B162;	A16-B163;	A16-B164;	A16-B165;
A16-B166;	A16-B167;	A16-B168;	A16-B169;	A17-B1;	A17-B2;
A17-B3;	A17-B4;	A17-B5;	A17-B6;	A17-B7;	A17-B8;
A17-B9;	A17-B10;	A17-B11;	A17-B12;	A17-B13;	A17-B14;
A17-B15;	A17-B16;	A17-B17;	A17-B18;	A17-B19;	A17-B20;
A17-B21;	A17-B22;	A17-B23;	A17-B24;	A17-B25;	A17-B26;
A17-B27;	A17-B28;	A17-B29;	A17-B30;	A17-B31;	A17-B32;
A17-B33;	A17-B34;	A17-B35;	A17-B36;	A17-B37;	A17-B38;
A17-B39;	A17-B40;	A17-B41;	A17-B42;	A17-B43;	A17-B44;
A17-B45;	A17-B46;	A17-B47;	A17-B48;	A17-B49;	A17-B50;
A17-B51;	A17-B52;	A17-B53;	A17-B54;	A17-B55;	A17-B56;
A17-B57;	A17-B58;	A17-B59;	A17-B60;	A17-B61;	A17-B62;
A17-B63;	A17-B64;	A17-B65;	A17-B66;	A17-B67;	A17-B68;
A17-B69;	A17-B70;	A17-B71;	A17-B72;	A17-B73;	A17-B74;
A17-B75;	A17-B76;	A17-B77;	A17-B78;	A17-B79;	A17-B80;
A17-B81;	A17-B82;	A17-B83;	A17-B84;	A17-B85;	A17-B86;
A17-B87;	A17-B88;	A17-B89;	A17-B90;	A17-B91;	A17-B92;
A17-B93;	A17-B94;	A17-B95;	A17-B96;	A17-B97;	A17-B98;
A17-B99;	A17-B100;	A17-B101;	A17-B102;	A17-B103;	A17-B104;
A17-B105;	A17-B106;	A17-B107;	A17-B108;	A17-B109;	A17-B110;
A17-B111;	A17-B112;	A17-B113;	A17-B114;	A17-B115;	A17-B116;
A17-B117;	A17-B118;	A17-B119;	A17-B120;	A17-B121;	A17-B122;
A17-B123;	A17-B124;	A17-B125;	A17-B126;	A17-B127;	A17-B128;
A17-B129;	A17-B130;	A17-B131;	A17-B132;	A17-B133;	A17-B134;
A17-B135;	A17-B136;	A17-B137;	A17-B138;	A17-B139;	A17-B140;
A17-B141;	A17-B142;	A17-B143;	A17-B144;	A17-B145;	A17-B146;
A17-B147;	A17-B148;	A17-B149;	A17-B150;	A17-B151;	A17-B152;
A17-B153;	A17-B154;	A17-B155;	A17-B156;	A17-B157;	A17-B158;
A17-B159;	A17-B160;	A17-B161;	A17-B162;	A17-B163;	A17-B164;
A17-B165;	A17-B166;	A17-B167;	A17-B168;	A17-B169;	A18-B1;
A18-B2;	A18-B3;	A18-B4;	A18-B5;	A18-B6;	A18-B7;
A18-B8;	A18-B9;	A18-B10;	A18-B11;	A18-B12;	A18-B13;
A18-B14;	A18-B15;	A18-B16;	A18-B17;	A18-B18;	A18-B19;
A18-B20;	A18-B21;	A18-B22;	A18-B23;	A18-B24;	A18-B25;
A18-B26;	A18-B27;	A18-B28;	A18-B29;	A18-B30;	A18-B31;
A18-B32;	A18-B33;	A18-B34;	A18-B35;	A18-B36;	A18-B37;
A18-B38;	A18-B39;	A18-B40;	A18-B41;	A18-B42;	A18-B43;
A18-B44;	A18-B45;	A18-B46;	A18-B47;	A18-B48;	A18-B49;
A18-B50;	A18-B51;	A18-B52;	A18-B53;	A18-B54;	A18-B55;
A18-B56;	A18-B57;	A18-B58;	A18-B59;	A18-B60;	A18-B61;
A18-B62;	A18-B63;	A18-B64;	A18-B65;	A18-B66;	A18-B67;
A18-B68;	A18-B69;	A18-B70;	A18-B71;	A18-B72;	A18-B73;
A18-B74;	A18-B75;	A18-B76;	A18-B77;	A18-B78;	A18-B79;
A18-B80;	A18-B81;	A18-B82;	A18-B83;	A18-B84;	A18-B85;
A18-B86;	A18-B87;	A18-B88;	A18-B89;	A18-B90;	A18-B91;
A18-B92;	A18-B93;	A18-B94;	A18-B95;	A18-B96;	A18-B97;
A18-B98;	A18-B99;	A18-B100;	A18-B101;	A18-B102;	A18-B103;
A18-B104;	A18-B105;	A18-B106;	A18-B107;	A18-B108;	A18-B109;
A18-B110;	A18-B111;	A18-B112;	A18-B113;	A18-B114;	A18-B115;
A18-B116;	A18-B117;	A18-B118;	A18-B119;	A18-B120;	A18-B121;
A18-B122;	A18-B123;	A18-B124;	A18-B125;	A18-B126;	A18-B127;
A18-B128;	A18-B129;	A18-B130;	A18-B131;	A18-B132;	A18-B133;
A18-B134;	A18-B135;	A18-B136;	A18-B137;	A18-B138;	A18-B139;
A18-B140;	A18-B141;	A18-B142;	A18-B143;	A18-B144;	A18-B145;
A18-B146;	A18-B147;	A18-B148;	A18-B149;	A18-B150;	A18-B151;
A18-B152;	A18-B153;	A18-B154;	A18-B155;	A18-B156;	A18-B157;
A18-B158;	A18-B159;	A18-B160;	A18-B161;	A18-B162;	A18-B163;
A18-B164;	A18-B165;	A18-B166;	A18-B167;	A18-B168;	A18-B169;
A19-B1;	A19-B2;	A19-B3;	A19-B4;	A19-B5;	A19-B6;
A19-B7;	A19-B8;	A19-B9;	A19-B10;	A19-B11;	A19-B12;
A19-B13;	A19-B14;	A19-B15;	A19-B16;	A19-B17;	A19-B18;
A19-B19;	A19-B20;	A19-B21;	A19-B22;	A19-B23;	A19-B24;
A19-B25;	A19-B26;	A19-B27;	A19-B28;	A19-B29;	A19-B30;
A19-B31;	A19-B32;	A19-B33;	A19-B34;	A19-B35;	A19-B36;
A19-B37;	A19-B38;	A19-B39;	A19-B40;	A19-B41;	A19-B42;
A19-B43;	A19-B44;	A19-B45;	A19-B46;	A19-B47;	A19-B48;
A19-B49;	A19-B50;	A19-B51;	A19-B52;	A19-B53;	A19-B54;
A19-B55;	A19-B56;	A19-B57;	A19-B58;	A19-B59;	A19-B60;
A19-B61;	A19-B62;	A19-B63;	A19-B64;	A19-B65;	A19-B66;
A19-B67;	A19-B68;	A19-B69;	A19-B70;	A19-B71;	A19-B72;
A19-B73;	A19-B74;	A19-B75;	A19-B76;	A19-B77;	A19-B78;
A19-B79;	A19-B80;	A19-B81;	A19-B82;	A19-B83;	A19-B84;
A19-B85;	A19-B86;	A19-B87;	A19-B88;	A19-B89;	A19-B90;
A19-B91;	A19-B92;	A19-B93;	A19-B94;	A19-B95;	A19-B96;
A19-B97;	A19-B98;	A19-B99;	A19-B100;	A19-B101;	A19-B102;
A19-B103;	A19-B104;	A19-B105;	A19-B106;	A19-B107;	A19-B108;
A19-B109;	A19-B110;	A19-B111;	A19-B112;	A19-B113;	A19-B114;
A19-B115;	A19-B116;	A19-B117;	A19-B118;	A19-B119;	A19-B120;
A19-B121;	A19-B122;	A19-B123;	A19-B124;	A19-B125;	A19-B126;
A19-B127;	A19-B128;	A19-B129;	A19-B130;	A19-B131;	A19-B132;
A19-B133;	A19-B134;	A19-B135;	A19-B136;	A19-B137;	A19-B138;
A19-B139;	A19-B140;	A19-B141;	A19-B142;	A19-B143;	A19-B144;
A19-B145;	A19-B146;	A19-B147;	A19-B148;	A19-B149;	A19-B150;
A19-B151;	A19-B152;	A19-B153;	A19-B154;	A19-B155;	A19-B156;
A19-B157;	A19-B158;	A19-B159;	A19-B160;	A19-B161;	A19-B162;
A19-B163;	A19-B164;	A19-B165;	A19-B166;	A19-B167;	A19-B168;
A19-B169;	A20-B1;	A20-B2;	A20-B3;	A20-B4;	A20-B5;
A20-B6;	A20-B7;	A20-B8;	A20-B9;	A20-B10;	A20-B11;
A20-B12;	A20-B13;	A20-B14;	A20-B15;	A20-B16;	A20-B17;
A20-B18;	A20-B19;	A20-B20;	A20-B21;	A20-B22;	A20-B23;
A20-B24;	A20-B25;	A20-B26;	A20-B27;	A20-B28;	A20-B29;
A20-B30;	A20-B31;	A20-B32;	A20-B33;	A20-B34;	A20-B35;
A20-B36;	A20-B37;	A20-B38;	A20-B39;	A20-B40;	A20-B41;
A20-B42;	A20-B43;	A20-B44;	A20-B45;	A20-B46;	A20-B47;
A20-B48;	A20-B49;	A20-B50;	A20-B51;	A20-B52;	A20-B53;
A20-B54;	A20-B55;	A20-B56;	A20-B57;	A20-B58;	A20-B59;
A20-B60;	A20-B61;	A20-B62;	A20-B63;	A20-B64;	A20-B65;
A20-B66;	A20-B67;	A20-B68;	A20-B69;	A20-B70;	A20-B71;
A20-B72;	A20-B73;	A20-B74;	A20-B75;	A20-B76;	A20-B77;
A20-B78;	A20-B79;	A20-B80;	A20-B81;	A20-B82;	A20-B83;
A20-B84;	A20-B85;	A20-B86;	A20-B87;	A20-B88;	A20-B89;
A20-B90;	A20-B91;	A20-B92;	A20-B93;	A20-B94;	A20-B95;
A20-B96;	A20-B97;	A20-B98;	A20-B99;	A20-B100;	A20-B101;
A20-B102;	A20-B103;	A20-B104;	A20-B105;	A20-B106;	A20-B107;
A20-B108;	A20-B109;	A20-B110;	A20-B111;	A20-B112;	A20-B113;
A20-B114;	A20-B115;	A20-B116;	A20-B117;	A20-B118;	A20-B119;
A20-B120;	A20-B121;	A20-B122;	A20-B123;	A20-B124;	A20-B125;
A20-B126;	A20-B127;	A20-B128;	A20-B129;	A20-B130;	A20-B131;
A20-B132;	A20-B133;	A20-B134;	A20-B135;	A20-B136;	A20-B137;
A20-B138;	A20-B139;	A20-B140;	A20-B141;	A20-B142;	A20-B143;
A20-B144;	A20-B145;	A20-B146;	A20-B147;	A20-B148;	A20-B149;
A20-B150;	A20-B151;	A20-B152;	A20-B153;	A20-B154;	A20-B155;
A20-B156;	A20-B157;	A20-B158;	A20-B159;	A20-B160;	A20-B161;
A20-B162;	A20-B163;	A20-B164;	A20-B165;	A20-B166;	A20-B167;
A20-B168;	A20-B169;	A21-B1;	A21-B2;	A21-B3;	A21-B4;
A21-B5;	A21-B6;	A21-B7;	A21-B8;	A21-B9;	A21-B10;
A21-B11;	A21-B12;	A21-B13;	A21-B14;	A21-B15;	A21-B16;
A21-B17;	A21-B18;	A21-B19;	A21-B20;	A21-B21;	A21-B22;
A21-B23;	A21-B24;	A21-B25;	A21-B26;	A21-B27;	A21-B28;
A21-B29;	A21-B30;	A21-B31;	A21-B32;	A21-B33;	A21-B34;
A21-B35;	A21-B36;	A21-B37;	A21-B38;	A21-B39;	A21-B40;
A21-B41;	A21-B42;	A21-B43;	A21-B44;	A21-B45;	A21-B46;
A21-B47;	A21-B48;	A21-B49;	A21-B50;	A21-B51;	A21-B52;
A21-B53;	A21-B54;	A21-B55;	A21-B56;	A21-B57;	A21-B58;
A21-B59;	A21-B60;	A21-B61;	A21-B62;	A21-B63;	A21-B64;
A21-B65;	A21-B66;	A21-B67;	A21-B68;	A21-B69;	A21-B70;
A21-B71;	A21-B72;	A21-B73;	A21-B74;	A21-B75;	A21-B76;
A21-B77;	A21-B78;	A21-B79;	A21-B80;	A21-B81;	A21-B82;
A21-B83;	A21-B84;	A21-B85;	A21-B86;	A21-B87;	A21-B88;
A21-B89;	A21-B90;	A21-B91;	A21-B92;	A21-B93;	A21-B94;
A21-B95;	A21-B96;	A21-B97;	A21-B98;	A21-B99;	A21-B100;
A21-B101;	A21-B102;	A21-B103;	A21-B104;	A21-B105;	A21-B106;
A21-B107;	A21-B108;	A21-B109;	A21-B110;	A21-B111;	A21-B112;
A21-B113;	A21-B114;	A21-B115;	A21-B116;	A21-B117;	A21-B118;
A21-B119;	A21-B120;	A21-B121;	A21-B122;	A21-B123;	A21-B124;
A21-B125;	A21-B126;	A21-B127;	A21-B128;	A21-B129;	A21-B130;
A21-B131;	A21-B132;	A21-B133;	A21-B134;	A21-B135;	A21-B136;
A21-B137;	A21-B138;	A21-B139;	A21-B140;	A21-B141;	A21-B142;
A21-B143;	A21-B144;	A21-B145;	A21-B146;	A21-B147;	A21-B148;
A21-B149;	A21-B150;	A21-B151;	A21-B152;	A21-B153;	A21-B154;
A21-B155;	A21-B156;	A21-B157;	A21-B158;	A21-B159;	A21-B160;
A21-B161;	A21-B162;	A21-B163;	A21-B164;	A21-B165;	A21-B166;
A21-B167;	A21-B168;	A21-B169;	A22-B1;	A22-B2;	A22-B3;
A22-B4;	A22-B5;	A22-B6;	A22-B7;	A22-B8;	A22-B9;
A22-B10;	A22-B11;	A22-B12;	A22-B13;	A22-B14;	A22-B15;
A22-B16;	A22-B17;	A22-B18;	A22-B19;	A22-B20;	A22-B21;
A22-B22;	A22-B23;	A22-B24;	A22-B25;	A22-B26;	A22-B27;
A22-B28;	A22-B29;	A22-B30;	A22-B31;	A22-B32;	A22-B33;
A22-B34;	A22-B35;	A22-B36;	A22-B37;	A22-B38;	A22-B39;
A22-B40;	A22-B41;	A22-B42;	A22-B43;	A22-B44;	A22-B45;
A22-B46;	A22-B47;	A22-B48;	A22-B49;	A22-B50;	A22-B51;
A22-B52;	A22-B53;	A22-B54;	A22-B55;	A22-B56;	A22-B57;
A22-B58;	A22-B59;	A22-B60;	A22-B61;	A22-B62;	A22-B63;
A22-B64;	A22-B65;	A22-B66;	A22-B67;	A22-B68;	A22-B69;
A22-B70;	A22-B71;	A22-B72;	A22-B73;	A22-B74;	A22-B75;
A22-B76;	A22-B77;	A22-B78;	A22-B79;	A22-B80;	A22-B81;
A22-B82;	A22-B83;	A22-B84;	A22-B85;	A22-B86;	A22-B87;
A22-B88;	A22-B89;	A22-B90;	A22-B91;	A22-B92;	A22-B93;
A22-B94;	A22-B95;	A22-B96;	A22-B97;	A22-B98;	A22-B99;
A22-B100;	A22-B101;	A22-B102;	A22-B103;	A22-B104;	A22-B105;
A22-B106;	A22-B107;	A22-B108;	A22-B109;	A22-B110;	A22-B111;
A22-B112;	A22-B113;	A22-B114;	A22-B115;	A22-B116;	A22-B117;
A22-B118;	A22-B119;	A22-B120;	A22-B121;	A22-B122;	A22-B123;
A22-B124;	A22-B125;	A22-B126;	A22-B127;	A22-B128;	A22-B129;
A22-B130;	A22-B131;	A22-B132;	A22-B133;	A22-B134;	A22-B135;
A22-B136;	A22-B137;	A22-B138;	A22-B139;	A22-B140;	A22-B141;
A22-B142;	A22-B143;	A22-B144;	A22-B145;	A22-B146;	A22-B147;
A22-B148;	A22-B149;	A22-B150;	A22-B151;	A22-B152;	A22-B153;
A22-B154;	A22-B155;	A22-B156;	A22-B157;	A22-B158;	A22-B159;
A22-B160;	A22-B161;	A22-B162;	A22-B163;	A22-B164;	A22-B165;
A22-B166;	A22-B167;	A22-B168;	A22-B169;	A23-B1;	A23-B2;
A23-B3;	A23-B4;	A23-B5;	A23-B6;	A23-B7;	A23-B8;
A23-B9;	A23-B10;	A23-B11;	A23-B12;	A23-B13;	A23-B14;
A23-B15;	A23-B16;	A23-B17;	A23-B18;	A23-B19;	A23-B20;
A23-B21;	A23-B22;	A23-B23;	A23-B24;	A23-B25;	A23-B26;
A23-B27;	A23-B28;	A23-B29;	A23-B30;	A23-B31;	A23-B32;
A23-B33;	A23-B34;	A23-B35;	A23-B36;	A23-B37;	A23-B38;
A23-B39;	A23-B40;	A23-B41;	A23-B42;	A23-B43;	A23-B44;
A23-B45;	A23-B46;	A23-B47;	A23-B48;	A23-B49;	A23-B50;
A23-B51;	A23-B52;	A23-B53;	A23-B54;	A23-B55;	A23-B56;
A23-B57;	A23-B58;	A23-B59;	A23-B60;	A23-B61;	A23-B62;
A23-B63;	A23-B64;	A23-B65;	A23-B66;	A23-B67;	A23-B68;
A23-B69;	A23-B70;	A23-B71;	A23-B72;	A23-B73;	A23-B74;
A23-B75;	A23-B76;	A23-B77;	A23-B78;	A23-B79;	A23-B80;
A23-B81;	A23-B82;	A23-B83;	A23-B84;	A23-B85;	A23-B86;
A23-B87;	A23-B88;	A23-B89;	A23-B90;	A23-B91;	A23-B92;
A23-B93;	A23-B94;	A23-B95;	A23-B96;	A23-B97;	A23-B98;
A23-B99;	A23-B100;	A23-B101;	A23-B102;	A23-B103;	A23-B104;
A23-B105;	A23-B106;	A23-B107;	A23-B108;	A23-B109;	A23-B110;
A23-B111;	A23-B112;	A23-B113;	A23-B114;	A23-B115;	A23-B116;
A23-B117;	A23-B118;	A23-B119;	A23-B120;	A23-B121;	A23-B122;
A23-B123;	A23-B124;	A23-B125;	A23-B126;	A23-B127;	A23-B128;
A23-B129;	A23-B130;	A23-B131;	A23-B132;	A23-B133;	A23-B134;
A23-B135;	A23-B136;	A23-B137;	A23-B138;	A23-B139;	A23-B140;
A23-B141;	A23-B142;	A23-B143;	A23-B144;	A23-B145;	A23-B146;
A23-B147;	A23-B148;	A23-B149;	A23-B150;	A23-B151;	A23-B152;
A23-B153;	A23-B154;	A23-B155;	A23-B156;	A23-B157;	A23-B158;
A23-B159;	A23-B160;	A23-B161;	A23-B162;	A23-B163;	A23-B164;
A23-B165;	A23-B166;	A23-B167;	A23-B168;	A23-B169;	A24-B1;
A24-B2;	A24-B3;	A24-B4;	A24-B5;	A24-B6;	A24-B7;
A24-B8;	A24-B9;	A24-B10;	A24-B11;	A24-B12;	A24-B13;
A24-B14;	A24-B15;	A24-B16;	A24-B17;	A24-B18;	A24-B19;
A24-B20;	A24-B21;	A24-B22;	A24-B23;	A24-B24;	A24-B25;
A24-B26;	A24-B27;	A24-B28;	A24-B29;	A24-B30;	A24-B31;
A24-B32;	A24-B33;	A24-B34;	A24-B35;	A24-B36;	A24-B37;
A24-B38;	A24-B39;	A24-B40;	A24-B41;	A24-B42;	A24-B43;
A24-B44;	A24-B45;	A24-B46;	A24-B47;	A24-B48;	A24-B49;
A24-B50;	A24-B51;	A24-B52;	A24-B53;	A24-B54;	A24-B55;
A24-B56;	A24-B57;	A24-B58;	A24-B59;	A24-B60;	A24-B61;
A24-B62;	A24-B63;	A24-B64;	A24-B65;	A24-B66;	A24-B67;
A24-B68;	A24-B69;	A24-B70;	A24-B71;	A24-B72;	A24-B73;
A24-B74;	A24-B75;	A24-B76;	A24-B77;	A24-B78;	A24-B79;
A24-B80;	A24-B81;	A24-B82;	A24-B83;	A24-B84;	A24-B85;
A24-B86;	A24-B87;	A24-B88;	A24-B89;	A24-B90;	A24-B91;
A24-B92;	A24-B93;	A24-B94;	A24-B95;	A24-B96;	A24-B97;
A24-B98;	A24-B99;	A24-B100;	A24-B101;	A24-B102;	A24-B103;
A24-B104;	A24-B105;	A24-B106;	A24-B107;	A24-B108;	A24-B109;
A24-B110;	A24-B111;	A24-B112;	A24-B113;	A24-B114;	A24-B115;
A24-B116;	A24-B117;	A24-B118;	A24-B119;	A24-B120;	A24-B121;
A24-B122;	A24-B123;	A24-B124;	A24-B125;	A24-B126;	A24-B127;
A24-B128;	A24-B129;	A24-B130;	A24-B131;	A24-B132;	A24-B133;
A24-B134;	A24-B135;	A24-B136;	A24-B137;	A24-B138;	A24-B139;
A24-B140;	A24-B141;	A24-B142;	A24-B143;	A24-B144;	A24-B145;
A24-B146;	A24-B147;	A24-B148;	A24-B149;	A24-B150;	A24-B151;
A24-B152;	A24-B153;	A24-B154;	A24-B155;	A24-B156;	A24-B157;
A24-B158;	A24-B159;	A24-B160;	A24-B161;	A24-B162;	A24-B163;
A24-B164;	A24-B165;	A24-B166;	A24-B167;	A24-B168;	A24-B169;
A25-B1;	A25-B2;	A25-B3;	A25-B4;	A25-B5;	A25-B6;
A25-B7;	A25-B8;	A25-B9;	A25-B10;	A25-B11;	A25-B12;
A25-B13;	A25-B14;	A25-B15;	A25-B16;	A25-B17;	A25-B18;
A25-B19;	A25-B20;	A25-B21;	A25-B22;	A25-B23;	A25-B24;
A25-B25;	A25-B26;	A25-B27;	A25-B28;	A25-B29;	A25-B30;
A25-B31;	A25-B32;	A25-B33;	A25-B34;	A25-B35;	A25-B36;
A25-B37;	A25-B38;	A25-B39;	A25-B40;	A25-B41;	A25-B42;
A25-B43;	A25-B44;	A25-B45;	A25-B46;	A25-B47;	A25-B48;
A25-B49;	A25-B50;	A25-B51;	A25-B52;	A25-B53;	A25-B54;
A25-B55;	A25-B56;	A25-B57;	A25-B58;	A25-B59;	A25-B60;
A25-B61;	A25-B62;	A25-B63;	A25-B64;	A25-B65;	A25-B66;
A25-B67;	A25-B68;	A25-B69;	A25-B70;	A25-B71;	A25-B72;
A25-B73;	A25-B74;	A25-B75;	A25-B76;	A25-B77;	A25-B78;
A25-B79;	A25-B80;	A25-B81;	A25-B82;	A25-B83;	A25-B84;
A25-B85;	A25-B86;	A25-B87;	A25-B88;	A25-B89;	A25-B90;
A25-B91;	A25-B92;	A25-B93;	A25-B94;	A25-B95;	A25-B96;
A25-B97;	A25-B98;	A25-B99;	A25-B100;	A25-B101;	A25-B102;
A25-B103;	A25-B104;	A25-B105;	A25-B106;	A25-B107;	A25-B108;
A25-B109;	A25-B110;	A25-B111;	A25-B112;	A25-B113;	A25-B114;
A25-B115;	A25-B116;	A25-B117;	A25-B118;	A25-B119;	A25-B120;
A25-B121;	A25-B122;	A25-B123;	A25-B124;	A25-B125;	A25-B126;
A25-B127;	A25-B128;	A25-B129;	A25-B130;	A25-B131;	A25-B132;
A25-B133;	A25-B134;	A25-B135;	A25-B136;	A25-B137;	A25-B138;
A25-B139;	A25-B140;	A25-B141;	A25-B142;	A25-B143;	A25-B144;
A25-B145;	A25-B146;	A25-B147;	A25-B148;	A25-B149;	A25-B150;
A25-B151;	A25-B152;	A25-B153;	A25-B154;	A25-B155;	A25-B156;
A25-B157;	A25-B158;	A25-B159;	A25-B160;	A25-B161;	A25-B162;
A25-B163;	A25-B164;	A25-B165;	A25-B166;	A25-B167;	A25-B168;
A25-B169;	A26-B1;	A26-B2;	A26-B3;	A26-B4;	A26-B5;
A26-B6;	A26-B7;	A26-B8;	A26-B9;	A26-B10;	A26-B11;
A26-B12;	A26-B13;	A26-B14;	A26-B15;	A26-B16;	A26-B17;
A26-B18;	A26-B19;	A26-B20;	A26-B21;	A26-B22;	A26-B23;
A26-B24;	A26-B25;	A26-B26;	A26-B27;	A26-B28;	A26-B29;
A26-B30;	A26-B31;	A26-B32;	A26-B33;	A26-B34;	A26-B35;
A26-B36;	A26-B37;	A26-B38;	A26-B39;	A26-B40;	A26-B41;
A26-B42;	A26-B43;	A26-B44;	A26-B45;	A26-B46;	A26-B47;
A26-B48;	A26-B49;	A26-B50;	A26-B51;	A26-B52;	A26-B53;
A26-B54;	A26-B55;	A26-B56;	A26-B57;	A26-B58;	A26-B59;
A26-B60;	A26-B61;	A26-B62;	A26-B63;	A26-B64;	A26-B65;
A26-B66;	A26-B67;	A26-B68;	A26-B69;	A26-B70;	A26-B71;
A26-B72;	A26-B73;	A26-B74;	A26-B75;	A26-B76;	A26-B77;
A26-B78;	A26-B79;	A26-B80;	A26-B81;	A26-B82;	A26-B83;
A26-B84;	A26-B85;	A26-B86;	A26-B87;	A26-B88;	A26-B89;
A26-B90;	A26-B91;	A26-B92;	A26-B93;	A26-B94;	A26-B95;
A26-B96;	A26-B97;	A26-B98;	A26-B99;	A26-B100;	A26-B101;
A26-B102;	A26-B103;	A26-B104;	A26-B105;	A26-B106;	A26-B107;
A26-B108;	A26-B109;	A26-B110;	A26-B111;	A26-B112;	A26-B113;
A26-B114;	A26-B115;	A26-B116;	A26-B117;	A26-B118;	A26-B119;
A26-B120;	A26-B121;	A26-B122;	A26-B123;	A26-B124;	A26-B125;
A26-B126;	A26-B127;	A26-B128;	A26-B129;	A26-B130;	A26-B131;
A26-B132;	A26-B133;	A26-B134;	A26-B135;	A26-B136;	A26-B137;
A26-B138;	A26-B139;	A26-B140;	A26-B141;	A26-B142;	A26-B143;
A26-B144;	A26-B145;	A26-B146;	A26-B147;	A26-B148;	A26-B149;
A26-B150;	A26-B151;	A26-B152;	A26-B153;	A26-B154;	A26-B155;
A26-B156;	A26-B157;	A26-B158;	A26-B159;	A26-B160;	A26-B161;
A26-B162;	A26-B163;	A26-B164;	A26-B165;	A26-B166;	A26-B167;
A26-B168;	A26-B169;	A27-B1;	A27-B2;	A27-B3;	A27-B4;
A27-B5;	A27-B6;	A27-B7;	A27-B8;	A27-B9;	A27-B10;
A27-B11;	A27-B12;	A27-B13;	A27-B14;	A27-B15;	A27-B16;
A27-B17;	A27-B18;	A27-B19;	A27-B20;	A27-B21;	A27-B22;
A27-B23;	A27-B24;	A27-B25;	A27-B26;	A27-B27;	A27-B28;
A27-B29;	A27-B30;	A27-B31;	A27-B32;	A27-B33;	A27-B34;
A27-B35;	A27-B36;	A27-B37;	A27-B38;	A27-B39;	A27-B40;
A27-B41;	A27-B42;	A27-B43;	A27-B44;	A27-B45;	A27-B46;
A27-B47;	A27-B48;	A27-B49;	A27-B50;	A27-B51;	A27-B52;
A27-B53;	A27-B54;	A27-B55;	A27-B56;	A27-B57;	A27-B58;
A27-B59;	A27-B60;	A27-B61;	A27-B62;	A27-B63;	A27-B64;
A27-B65;	A27-B66;	A27-B67;	A27-B68;	A27-B69;	A27-B70;
A27-B71;	A27-B72;	A27-B73;	A27-B74;	A27-B75;	A27-B76;
A27-B77;	A27-B78;	A27-B79;	A27-B80;	A27-B81;	A27-B82;
A27-B83;	A27-B84;	A27-B85;	A27-B86;	A27-B87;	A27-B88;
A27-B89;	A27-B90;	A27-B91;	A27-B92;	A27-B93;	A27-B94;
A27-B95;	A27-B96;	A27-B97;	A27-B98;	A27-B99;	A27-B100;
A27-B101;	A27-B102;	A27-B103;	A27-B104;	A27-B105;	A27-B106;
A27-B107;	A27-B108;	A27-B109;	A27-B110;	A27-B111;	A27-B112;
A27-B113;	A27-B114;	A27-B115;	A27-B116;	A27-B117;	A27-B118;
A27-B119;	A27-B120;	A27-B121;	A27-B122;	A27-B123;	A27-B124;
A27-B125;	A27-B126;	A27-B127;	A27-B128;	A27-B129;	A27-B130;
A27-B131;	A27-B132;	A27-B133;	A27-B134;	A27-B135;	A27-B136;
A27-B137;	A27-B138;	A27-B139;	A27-B140;	A27-B141;	A27-B142;
A27-B143;	A27-B144;	A27-B145;	A27-B146;	A27-B147;	A27-B148;
A27-B149;	A27-B150;	A27-B151;	A27-B152;	A27-B153;	A27-B154;
A27-B155;	A27-B156;	A27-B157;	A27-B158;	A27-B159;	A27-B160;
A27-B161;	A27-B162;	A27-B163;	A27-B164;	A27-B165;	A27-B166;
A27-B167;	A27-B168;	A27-B169;	A28-B1;	A28-B2;	A28-B3;
A28-B4;	A28-B5;	A28-B6;	A28-B7;	A28-B8;	A28-B9;
A28-B10;	A28-B11;	A28-B12;	A28-B13;	A28-B14;	A28-B15;
A28-B16;	A28-B17;	A28-B18;	A28-B19;	A28-B20;	A28-B21;
A28-B22;	A28-B23;	A28-B24;	A28-B25;	A28-B26;	A28-B27;
A28-B28;	A28-B29;	A28-B30;	A28-B31;	A28-B32;	A28-B33;
A28-B34;	A28-B35;	A28-B36;	A28-B37;	A28-B38;	A28-B39;
A28-B40;	A28-B41;	A28-B42;	A28-B43;	A28-B44;	A28-B45;
A28-B46;	A28-B47;	A28-B48;	A28-B49;	A28-B50;	A28-B51;
A28-B52;	A28-B53;	A28-B54;	A28-B55;	A28-B56;	A28-B57;
A28-B58;	A28-B59;	A28-B60;	A28-B61;	A28-B62;	A28-B63;
A28-B64;	A28-B65;	A28-B66;	A28-B67;	A28-B68;	A28-B69;
A28-B70;	A28-B71;	A28-B72;	A28-B73;	A28-B74;	A28-B75;
A28-B76;	A28-B77;	A28-B78;	A28-B79;	A28-B80;	A28-B81;
A28-B82;	A28-B83;	A28-B84;	A28-B85;	A28-B86;	A28-B87;
A28-B88;	A28-B89;	A28-B90;	A28-B91;	A28-B92;	A28-B93;
A28-B94;	A28-B95;	A28-B96;	A28-B97;	A28-B98;	A28-B99;
A28-B100;	A28-B101;	A28-B102;	A28-B103;	A28-B104;	A28-B105;
A28-B106;	A28-B107;	A28-B108;	A28-B109;	A28-B110;	A28-B111;
A28-B112;	A28-B113;	A28-B114;	A28-B115;	A28-B116;	A28-B117;
A28-B118;	A28-B119;	A28-B120;	A28-B121;	A28-B122;	A28-B123;
A28-B124;	A28-B125;	A28-B126;	A28-B127;	A28-B128;	A28-B129;
A28-B130;	A28-B131;	A28-B132;	A28-B133;	A28-B134;	A28-B135;
A28-B136;	A28-B137;	A28-B138;	A28-B139;	A28-B140;	A28-B141;
A28-B142;	A28-B143;	A28-B144;	A28-B145;	A28-B146;	A28-B147;
A28-B148;	A28-B149;	A28-B150;	A28-B151;	A28-B152;	A28-B153;
A28-B154;	A28-B155;	A28-B156;	A28-B157;	A28-B158;	A28-B159;
A28-B160;	A28-B161;	A28-B162;	A28-B163;	A28-B164;	A28-B165;
A28-B166;	A28-B167;	A28-B168;	A28-B169;	A29-B1;	A29-B2;
A29-B3;	A29-B4;	A29-B5;	A29-B6;	A29-B7;	A29-B8;
A29-B9;	A29-B10;	A29-B11;	A29-B12;	A29-B13;	A29-B14;
A29-B15;	A29-B16;	A29-B17;	A29-B18;	A29-B19;	A29-B20;
A29-B21;	A29-B22;	A29-B23;	A29-B24;	A29-B25;	A29-B26;
A29-B27;	A29-B28;	A29-B29;	A29-B30;	A29-B31;	A29-B32;
A29-B33;	A29-B34;	A29-B35;	A29-B36;	A29-B37;	A29-B38;
A29-B39;	A29-B40;	A29-B41;	A29-B42;	A29-B43;	A29-B44;
A29-B45;	A29-B46;	A29-B47;	A29-B48;	A29-B49;	A29-B50;
A29-B51;	A29-B52;	A29-B53;	A29-B54;	A29-B55;	A29-B56;
A29-B57;	A29-B58;	A29-B59;	A29-B60;	A29-B61;	A29-B62;
A29-B63;	A29-B64;	A29-B65;	A29-B66;	A29-B67;	A29-B68;
A29-B69;	A29-B70;	A29-B71;	A29-B72;	A29-B73;	A29-B74;
A29-B75;	A29-B76;	A29-B77;	A29-B78;	A29-B79;	A29-B80;
A29-B81;	A29-B82;	A29-B83;	A29-B84;	A29-B85;	A29-B86;
A29-B87;	A29-B88;	A29-B89;	A29-B90;	A29-B91;	A29-B92;
A29-B93;	A29-B94;	A29-B95;	A29-B96;	A29-B97;	A29-B98;
A29-B99;	A29-B100;	A29-B101;	A29-B102;	A29-B103;	A29-B104;
A29-B105;	A29-B106;	A29-B107;	A29-B108;	A29-B109;	A29-B110;
A29-B111;	A29-B112;	A29-B113;	A29-B114;	A29-B115;	A29-B116;
A29-B117;	A29-B118;	A29-B119;	A29-B120;	A29-B121;	A29-B122;
A29-B123;	A29-B124;	A29-B125;	A29-B126;	A29-B127;	A29-B128;
A29-B129;	A29-B130;	A29-B131;	A29-B132;	A29-B133;	A29-B134;
A29-B135;	A29-B136;	A29-B137;	A29-B138;	A29-B139;	A29-B140;
A29-B141;	A29-B142;	A29-B143;	A29-B144;	A29-B145;	A29-B146;
A29-B147;	A29-B148;	A29-B149;	A29-B150;	A29-B151;	A29-B152;
A29-B153;	A29-B154;	A29-B155;	A29-B156;	A29-B157;	A29-B158;
A29-B159;	A29-B160;	A29-B161;	A29-B162;	A29-B163;	A29-B164;
A29-B165;	A29-B166;	A29-B167;	A29-B168;	A29-B169;	A30-B1;
A30-B2;	A30-B3;	A30-B4;	A30-B5;	A30-B6;	A30-B7;
A30-B8;	A30-B9;	A30-B10;	A30-B11;	A30-B12;	A30-B13;
A30-B14;	A30-B15;	A30-B16;	A30-B17;	A30-B18;	A30-B19;
A30-B20;	A30-B21;	A30-B22;	A30-B23;	A30-B24;	A30-B25;
A30-B26;	A30-B27;	A30-B28;	A30-B29;	A30-B30;	A30-B31;
A30-B32;	A30-B33;	A30-B34;	A30-B35;	A30-B36;	A30-B37;
A30-B38;	A30-B39;	A30-B40;	A30-B41;	A30-B42;	A30-B43;
A30-B44;	A30-B45;	A30-B46;	A30-B47;	A30-B48;	A30-B49;
A30-B50;	A30-B51;	A30-B52;	A30-B53;	A30-B54;	A30-B55;
A30-B56;	A30-B57;	A30-B58;	A30-B59;	A30-B60;	A30-B61;
A30-B62;	A30-B63;	A30-B64;	A30-B65;	A30-B66;	A30-B67;
A30-B68;	A30-B69;	A30-B70;	A30-B71;	A30-B72;	A30-B73;
A30-B74;	A30-B75;	A30-B76;	A30-B77;	A30-B78;	A30-B79;
A30-B80;	A30-B81;	A30-B82;	A30-B83;	A30-B84;	A30-B85;
A30-B86;	A30-B87;	A30-B88;	A30-B89;	A30-B90;	A30-B91;
A30-B92;	A30-B93;	A30-B94;	A30-B95;	A30-B96;	A30-B97;
A30-B98;	A30-B99;	A30-B100;	A30-B101;	A30-B102;	A30-B103;
A30-B104;	A30-B105;	A30-B106;	A30-B107;	A30-B108;	A30-B109;
A30-B110;	A30-B111;	A30-B112;	A30-B113;	A30-B114;	A30-B115;
A30-B116;	A30-B117;	A30-B118;	A30-B119;	A30-B120;	A30-B121;
A30-B122;	A30-B123;	A30-B124;	A30-B125;	A30-B126;	A30-B127;
A30-B128;	A30-B129;	A30-B130;	A30-B131;	A30-B132;	A30-B133;
A30-B134;	A30-B135;	A30-B136;	A30-B137;	A30-B138;	A30-B139;
A30-B140;	A30-B141;	A30-B142;	A30-B143;	A30-B144;	A30-B145;
A30-B146;	A30-B147;	A30-B148;	A30-B149;	A30-B150;	A30-B151;
A30-B152;	A30-B153;	A30-B154;	A30-B155;	A30-B156;	A30-B157;
A30-B158;	A30-B159;	A30-B160;	A30-B161;	A30-B162;	A30-B163;
A30-B164;	A30-B165;	A30-B166;	A30-B167;	A30-B168;	A30-B169;
A31-B1;	A31-B2;	A31-B3;	A31-B4;	A31-B5;	A31-B6;
A31-B7;	A31-B8;	A31-B9;	A31-B10;	A31-B11;	A31-B12;
A31-B13;	A31-B14;	A31-B15;	A31-B16;	A31-B17;	A31-B18;
A31-B19;	A31-B20;	A31-B21;	A31-B22;	A31-B23;	A31-B24;
A31-B25;	A31-B26;	A31-B27;	A31-B28;	A31-B29;	A31-B30;
A31-B31;	A31-B32;	A31-B33;	A31-B34;	A31-B35;	A31-B36;
A31-B37;	A31-B38;	A31-B39;	A31-B40;	A31-B41;	A31-B42;
A31-B43;	A31-B44;	A31-B45;	A31-B46;	A31-B47;	A31-B48;
A31-B49;	A31-B50;	A31-B51;	A31-B52;	A31-B53;	A31-B54;
A31-B55;	A31-B56;	A31-B57;	A31-B58;	A31-B59;	A31-B60;
A31-B61;	A31-B62;	A31-B63;	A31-B64;	A31-B65;	A31-B66;
A31-B67;	A31-B68;	A31-B69;	A31-B70;	A31-B71;	A31-B72;
A31-B73;	A31-B74;	A31-B75;	A31-B76;	A31-B77;	A31-B78;
A31-B79;	A31-B80;	A31-B81;	A31-B82;	A31-B83;	A31-B84;
A31-B85;	A31-B86;	A31-B87;	A31-B88;	A31-B89;	A31-B90;
A31-B91;	A31-B92;	A31-B93;	A31-B94;	A31-B95;	A31-B96;
A31-B97;	A31-B98;	A31-B99;	A31-B100;	A31-B101;	A31-B102;
A31-B103;	A31-B104;	A31-B105;	A31-B106;	A31-B107;	A31-B108;
A31-B109;	A31-B110;	A31-B111;	A31-B112;	A31-B113;	A31-B114;
A31-B115;	A31-B116;	A31-B117;	A31-B118;	A31-B119;	A31-B120;
A31-B121;	A31-B122;	A31-B123;	A31-B124;	A31-B125;	A31-B126;
A31-B127;	A31-B128;	A31-B129;	A31-B130;	A31-B131;	A31-B132;
A31-B133;	A31-B134;	A31-B135;	A31-B136;	A31-B137;	A31-B138;
A31-B139;	A31-B140;	A31-B141;	A31-B142;	A31-B143;	A31-B144;
A31-B145;	A31-B146;	A31-B147;	A31-B148;	A31-B149;	A31-B150;
A31-B151;	A31-B152;	A31-B153;	A31-B154;	A31-B155;	A31-B156;
A31-B157;	A31-B158;	A31-B159;	A31-B160;	A31-B161;	A31-B162;
A31-B163;	A31-B164;	A31-B165;	A31-B166;	A31-B167;	A31-B168;
A31-B169;	A32-B1;	A32-B2;	A32-B3;	A32-B4;	A32-B5;
A32-B6;	A32-B7;	A32-B8;	A32-B9;	A32-B10;	A32-B11;
A32-B12;	A32-B13;	A32-B14;	A32-B15;	A32-B16;	A32-B17;
A32-B18;	A32-B19;	A32-B20;	A32-B21;	A32-B22;	A32-B23;
A32-B24;	A32-B25;	A32-B26;	A32-B27;	A32-B28;	A32-B29;
A32-B30;	A32-B31;	A32-B32;	A32-B33;	A32-B34;	A32-B35;
A32-B36;	A32-B37;	A32-B38;	A32-B39;	A32-B40;	A32-B41;
A32-B42;	A32-B43;	A32-B44;	A32-B45;	A32-B46;	A32-B47;
A32-B48;	A32-B49;	A32-B50;	A32-B51;	A32-B52;	A32-B53;
A32-B54;	A32-B55;	A32-B56;	A32-B57;	A32-B58;	A32-B59;
A32-B60;	A32-B61;	A32-B62;	A32-B63;	A32-B64;	A32-B65;
A32-B66;	A32-B67;	A32-B68;	A32-B69;	A32-B70;	A32-B71;
A32-B72;	A32-B73;	A32-B74;	A32-B75;	A32-B76;	A32-B77;
A32-B78;	A32-B79;	A32-B80;	A32-B81;	A32-B82;	A32-B83;
A32-B84;	A32-B85;	A32-B86;	A32-B87;	A32-B88;	A32-B89;
A32-B90;	A32-B91;	A32-B92;	A32-B93;	A32-B94;	A32-B95;
A32-B96;	A32-B97;	A32-B98;	A32-B99;	A32-B100;	A32-B101;
A32-B102;	A32-B103;	A32-B104;	A32-B105;	A32-B106;	A32-B107;
A32-B108;	A32-B109;	A32-B110;	A32-B111;	A32-B112;	A32-B113;
A32-B114;	A32-B115;	A32-B116;	A32-B117;	A32-B118;	A32-B119;
A32-B120;	A32-B121;	A32-B122;	A32-B123;	A32-B124;	A32-B125;
A32-B126;	A32-B127;	A32-B128;	A32-B129;	A32-B130;	A32-B131;
A32-B132;	A32-B133;	A32-B134;	A32-B135;	A32-B136;	A32-B137;
A32-B138;	A32-B139;	A32-B140;	A32-B141;	A32-B142;	A32-B143;
A32-B144;	A32-B145;	A32-B146;	A32-B147;	A32-B148;	A32-B149;
A32-B150;	A32-B151;	A32-B152;	A32-B153;	A32-B154;	A32-B155;
A32-B156;	A32-B157;	A32-B158;	A32-B159;	A32-B160;	A32-B161;
A32-B162;	A32-B163;	A32-B164;	A32-B165;	A32-B166;	A32-B167;
A32-B168;	A32-B169;	A33-B1;	A33-B2;	A33-B3;	A33-B4;
A33-B5;	A33-B6;	A33-B7;	A33-B8;	A33-B9;	A33-B10;
A33-B11;	A33-B12;	A33-B13;	A33-B14;	A33-B15;	A33-B16;
A33-B17;	A33-B18;	A33-B19;	A33-B20;	A33-B21;	A33-B22;
A33-B23;	A33-B24;	A33-B25;	A33-B26;	A33-B27;	A33-B28;
A33-B29;	A33-B30;	A33-B31;	A33-B32;	A33-B33;	A33-B34;
A33-B35;	A33-B36;	A33-B37;	A33-B38;	A33-B39;	A33-B40;
A33-B41;	A33-B42;	A33-B43;	A33-B44;	A33-B45;	A33-B46;
A33-B47;	A33-B48;	A33-B49;	A33-B50;	A33-B51;	A33-B52;
A33-B53;	A33-B54;	A33-B55;	A33-B56;	A33-B57;	A33-B58;
A33-B59;	A33-B60;	A33-B61;	A33-B62;	A33-B63;	A33-B64;
A33-B65;	A33-B66;	A33-B67;	A33-B68;	A33-B69;	A33-B70;
A33-B71;	A33-B72;	A33-B73;	A33-B74;	A33-B75;	A33-B76;
A33-B77;	A33-B78;	A33-B79;	A33-B80;	A33-B81;	A33-B82;
A33-B83;	A33-B84;	A33-B85;	A33-B86;	A33-B87;	A33-B88;
A33-B89;	A33-B90;	A33-B91;	A33-B92;	A33-B93;	A33-B94;
A33-B95;	A33-B96;	A33-B97;	A33-B98;	A33-B99;	A33-B100;
A33-B101;	A33-B102;	A33-B103;	A33-B104;	A33-B105;	A33-B106;
A33-B107;	A33-B108;	A33-B109;	A33-B110;	A33-B111;	A33-B112;
A33-B113;	A33-B114;	A33-B115;	A33-B116;	A33-B117;	A33-B118;
A33-B119;	A33-B120;	A33-B121;	A33-B122;	A33-B123;	A33-B124;
A33-B125;	A33-B126;	A33-B127;	A33-B128;	A33-B129;	A33-B130;
A33-B131;	A33-B132;	A33-B133;	A33-B134;	A33-B135;	A33-B136;
A33-B137;	A33-B138;	A33-B139;	A33-B140;	A33-B141;	A33-B142;
A33-B143;	A33-B144;	A33-B145;	A33-B146;	A33-B147;	A33-B148;
A33-B149;	A33-B150;	A33-B151;	A33-B152;	A33-B153;	A33-B154;
A33-B155;	A33-B156;	A33-B157;	A33-B158;	A33-B159;	A33-B160;
A33-B161;	A33-B162;	A33-B163;	A33-B164;	A33-B165;	A33-B166;
A33-B167;	A33-B168;	A33-B169;	A34-B1;	A34-B2;	A34-B3;
A34-B4;	A34-B5;	A34-B6;	A34-B7;	A34-B8;	A34-B9;
A34-B10;	A34-B11;	A34-B12;	A34-B13;	A34-B14;	A34-B15;
A34-B16;	A34-B17;	A34-B18;	A34-B19;	A34-B20;	A34-B21;
A34-B22;	A34-B23;	A34-B24;	A34-B25;	A34-B26;	A34-B27;
A34-B28;	A34-B29;	A34-B30;	A34-B31;	A34-B32;	A34-B33;
A34-B34;	A34-B35;	A34-B36;	A34-B37;	A34-B38;	A34-B39;
A34-B40;	A34-B41;	A34-B42;	A34-B43;	A34-B44;	A34-B45;
A34-B46;	A34-B47;	A34-B48;	A34-B49;	A34-B50;	A34-B51;
A34-B52;	A34-B53;	A34-B54;	A34-B55;	A34-B56;	A34-B57;
A34-B58;	A34-B59;	A34-B60;	A34-B61;	A34-B62;	A34-B63;
A34-B64;	A34-B65;	A34-B66;	A34-B67;	A34-B68;	A34-B69;
A34-B70;	A34-B71;	A34-B72;	A34-B73;	A34-B74;	A34-B75;
A34-B76;	A34-B77;	A34-B78;	A34-B79;	A34-B80;	A34-B81;
A34-B82;	A34-B83;	A34-B84;	A34-B85;	A34-B86;	A34-B87;
A34-B88;	A34-B89;	A34-B90;	A34-B91;	A34-B92;	A34-B93;
A34-B94;	A34-B95;	A34-B96;	A34-B97;	A34-B98;	A34-B99;
A34-B100;	A34-B101;	A34-B102;	A34-B103;	A34-B104;	A34-B105;
A34-B106;	A34-B107;	A34-B108;	A34-B109;	A34-B110;	A34-B111;
A34-B112;	A34-B113;	A34-B114;	A34-B115;	A34-B116;	A34-B117;
A34-B118;	A34-B119;	A34-B120;	A34-B121;	A34-B122;	A34-B123;
A34-B124;	A34-B125;	A34-B126;	A34-B127;	A34-B128;	A34-B129;
A34-B130;	A34-B131;	A34-B132;	A34-B133;	A34-B134;	A34-B135;
A34-B136;	A34-B137;	A34-B138;	A34-B139;	A34-B140;	A34-B141;
A34-B142;	A34-B143;	A34-B144;	A34-B145;	A34-B146;	A34-B147;
A34-B148;	A34-B149;	A34-B150;	A34-B151;	A34-B152;	A34-B153;
A34-B154;	A34-B155;	A34-B156;	A34-B157;	A34-B158;	A34-B159;
A34-B160;	A34-B161;	A34-B162;	A34-B163;	A34-B164;	A34-B165;
A34-B166;	A34-B167;	A34-B168;	A34-B169;	A35-B1;	A35-B2;
A35-B3;	A35-B4;	A35-B5;	A35-B6;	A35-B7;	A35-B8;
A35-B9;	A35-B10;	A35-B11;	A35-B12;	A35-B13;	A35-B14;
A35-B15;	A35-B16;	A35-B17;	A35-B18;	A35-B19;	A35-B20;
A35-B21;	A35-B22;	A35-B23;	A35-B24;	A35-B25;	A35-B26;
A35-B27;	A35-B28;	A35-B29;	A35-B30;	A35-B31;	A35-B32;
A35-B33;	A35-B34;	A35-B35;	A35-B36;	A35-B37;	A35-B38;
A35-B39;	A35-B40;	A35-B41;	A35-B42;	A35-B43;	A35-B44;
A35-B45;	A35-B46;	A35-B47;	A35-B48;	A35-B49;	A35-B50;
A35-B51;	A35-B52;	A35-B53;	A35-B54;	A35-B55;	A35-B56;
A35-B57;	A35-B58;	A35-B59;	A35-B60;	A35-B61;	A35-B62;
A35-B63;	A35-B64;	A35-B65;	A35-B66;	A35-B67;	A35-B68;
A35-B69;	A35-B70;	A35-B71;	A35-B72;	A35-B73;	A35-B74;
A35-B75;	A35-B76;	A35-B77;	A35-B78;	A35-B79;	A35-B80;
A35-B81;	A35-B82;	A35-B83;	A35-B84;	A35-B85;	A35-B86;
A35-B87;	A35-B88;	A35-B89;	A35-B90;	A35-B91;	A35-B92;
A35-B93;	A35-B94;	A35-B95;	A35-B96;	A35-B97;	A35-B98;
A35-B99;	A35-B100;	A35-B101;	A35-B102;	A35-B103;	A35-B104;
A35-B105;	A35-B106;	A35-B107;	A35-B108;	A35-B109;	A35-B110;
A35-B111;	A35-B112;	A35-B113;	A35-B114;	A35-B115;	A35-B116;
A35-B117;	A35-B118;	A35-B119;	A35-B120;	A35-B121;	A35-B122;
A35-B123;	A35-B124;	A35-B125;	A35-B126;	A35-B127;	A35-B128;
A35-B129;	A35-B130;	A35-B131;	A35-B132;	A35-B133;	A35-B134;
A35-B135;	A35-B136;	A35-B137;	A35-B138;	A35-B139;	A35-B140;
A35-B141;	A35-B142;	A35-B143;	A35-B144;	A35-B145;	A35-B146;
A35-B147;	A35-B148;	A35-B149;	A35-B150;	A35-B151;	A35-B152;
A35-B153;	A35-B154;	A35-B155;	A35-B156;	A35-B157;	A35-B158;
A35-B159;	A35-B160;	A35-B161;	A35-B162;	A35-B163;	A35-B164;
A35-B165;	A35-B166;	A35-B167;	A35-B168;	A35-B169;	A36-B1;
A36-B2;	A36-B3;	A36-B4;	A36-B5;	A36-B6;	A36-B7;
A36-B8;	A36-B9;	A36-B10;	A36-B11;	A36-B12;	A36-B13;
A36-B14;	A36-B15;	A36-B16;	A36-B17;	A36-B18;	A36-B19;
A36-B20;	A36-B21;	A36-B22;	A36-B23;	A36-B24;	A36-B25;
A36-B26;	A36-B27;	A36-B28;	A36-B29;	A36-B30;	A36-B31;
A36-B32;	A36-B33;	A36-B34;	A36-B35;	A36-B36;	A36-B37;
A36-B38;	A36-B39;	A36-B40;	A36-B41;	A36-B42;	A36-B43;
A36-B44;	A36-B45;	A36-B46;	A36-B47;	A36-B48;	A36-B49;
A36-B50;	A36-B51;	A36-B52;	A36-B53;	A36-B54;	A36-B55;
A36-B56;	A36-B57;	A36-B58;	A36-B59;	A36-B60;	A36-B61;
A36-B62;	A36-B63;	A36-B64;	A36-B65;	A36-B66;	A36-B67;
A36-B68;	A36-B69;	A36-B70;	A36-B71;	A36-B72;	A36-B73;
A36-B74;	A36-B75;	A36-B76;	A36-B77;	A36-B78;	A36-B79;
A36-B80;	A36-B81;	A36-B82;	A36-B83;	A36-B84;	A36-B85;
A36-B86;	A36-B87;	A36-B88;	A36-B89;	A36-B90;	A36-B91;
A36-B92;	A36-B93;	A36-B94;	A36-B95;	A36-B96;	A36-B97;
A36-B98;	A36-B99;	A36-B100;	A36-B101;	A36-B102;	A36-B103;
A36-B104;	A36-B105;	A36-B106;	A36-B107;	A36-B108;	A36-B109;
A36-B110;	A36-B111;	A36-B112;	A36-B113;	A36-B114;	A36-B115;
A36-B116;	A36-B117;	A36-B118;	A36-B119;	A36-B120;	A36-B121;
A36-B122;	A36-B123;	A36-B124;	A36-B125;	A36-B126;	A36-B127;
A36-B128;	A36-B129;	A36-B130;	A36-B131;	A36-B132;	A36-B133;
A36-B134;	A36-B135;	A36-B136;	A36-B137;	A36-B138;	A36-B139;
A36-B140;	A36-B141;	A36-B142;	A36-B143;	A36-B144;	A36-B145;
A36-B146;	A36-B147;	A36-B148;	A36-B149;	A36-B150;	A36-B151;
A36-B152;	A36-B153;	A36-B154;	A36-B155;	A36-B156;	A36-B157;
A36-B158;	A36-B159;	A36-B160;	A36-B161;	A36-B162;	A36-B163;
A36-B164;	A36-B165;	A36-B166;	A36-B167;	A36-B168;	A36-B169;
A37-B1;	A37-B2;	A37-B3;	A37-B4;	A37-B5;	A37-B6;
A37-B7;	A37-B8;	A37-B9;	A37-B10;	A37-B11;	A37-B12;
A37-B13;	A37-B14;	A37-B15;	A37-B16;	A37-B17;	A37-B18;
A37-B19;	A37-B20;	A37-B21;	A37-B22;	A37-B23;	A37-B24;
A37-B25;	A37-B26;	A37-B27;	A37-B28;	A37-B29;	A37-B30;
A37-B31;	A37-B32;	A37-B33;	A37-B34;	A37-B35;	A37-B36;
A37-B37;	A37-B38;	A37-B39;	A37-B40;	A37-B41;	A37-B42;
A37-B43;	A37-B44;	A37-B45;	A37-B46;	A37-B47;	A37-B48;
A37-B49;	A37-B50;	A37-B51;	A37-B52;	A37-B53;	A37-B54;
A37-B55;	A37-B56;	A37-B57;	A37-B58;	A37-B59;	A37-B60;
A37-B61;	A37-B62;	A37-B63;	A37-B64;	A37-B65;	A37-B66;
A37-B67;	A37-B68;	A37-B69;	A37-B70;	A37-B71;	A37-B72;
A37-B73;	A37-B74;	A37-B75;	A37-B76;	A37-B77;	A37-B78;
A37-B79;	A37-B80;	A37-B81;	A37-B82;	A37-B83;	A37-B84;
A37-B85;	A37-B86;	A37-B87;	A37-B88;	A37-B89;	A37-B90;
A37-B91;	A37-B92;	A37-B93;	A37-B94;	A37-B95;	A37-B96;
A37-B97;	A37-B98;	A37-B99;	A37-B100;	A37-B101;	A37-B102;
A37-B103;	A37-B104;	A37-B105;	A37-B106;	A37-B107;	A37-B108;
A37-B109;	A37-B110;	A37-B111;	A37-B112;	A37-B113;	A37-B114;
A37-B115;	A37-B116;	A37-B117;	A37-B118;	A37-B119;	A37-B120;
A37-B121;	A37-B122;	A37-B123;	A37-B124;	A37-B125;	A37-B126;
A37-B127;	A37-B128;	A37-B129;	A37-B130;	A37-B131;	A37-B132;
A37-B133;	A37-B134;	A37-B135;	A37-B136;	A37-B137;	A37-B138;
A37-B139;	A37-B140;	A37-B141;	A37-B142;	A37-B143;	A37-B144;
A37-B145;	A37-B146;	A37-B147;	A37-B148;	A37-B149;	A37-B150;
A37-B151;	A37-B152;	A37-B153;	A37-B154;	A37-B155;	A37-B156;
A37-B157;	A37-B158;	A37-B159;	A37-B160;	A37-B161;	A37-B162;
A37-B163;	A37-B164;	A37-B165;	A37-B166;	A37-B167;	A37-B168;
A37-B169;	A38-B1;	A38-B2;	A38-B3;	A38-B4;	A38-B5;
A38-B6;	A38-B7;	A38-B8;	A38-B9;	A38-B10;	A38-B11;
A38-B12;	A38-B13;	A38-B14;	A38-B15;	A38-B16;	A38-B17;
A38-B18;	A38-B19;	A38-B20;	A38-B21;	A38-B22;	A38-B23;
A38-B24;	A38-B25;	A38-B26;	A38-B27;	A38-B28;	A38-B29;
A38-B30;	A38-B31;	A38-B32;	A38-B33;	A38-B34;	A38-B35;
A38-B36;	A38-B37;	A38-B38;	A38-B39;	A38-B40;	A38-B41;
A38-B42;	A38-B43;	A38-B44;	A38-B45;	A38-B46;	A38-B47;
A38-B48;	A38-B49;	A38-B50;	A38-B51;	A38-B52;	A38-B53;
A38-B54;	A38-B55;	A38-B56;	A38-B57;	A38-B58;	A38-B59;
A38-B60;	A38-B61;	A38-B62;	A38-B63;	A38-B64;	A38-B65;
A38-B66;	A38-B67;	A38-B68;	A38-B69;	A38-B70;	A38-B71;
A38-B72;	A38-B73;	A38-B74;	A38-B75;	A38-B76;	A38-B77;
A38-B78;	A38-B79;	A38-B80;	A38-B81;	A38-B82;	A38-B83;
A38-B84;	A38-B85;	A38-B86;	A38-B87;	A38-B88;	A38-B89;
A38-B90;	A38-B91;	A38-B92;	A38-B93;	A38-B94;	A38-B95;
A38-B96;	A38-B97;	A38-B98;	A38-B99;	A38-B100;	A38-B101;
A38-B102;	A38-B103;	A38-B104;	A38-B105;	A38-B106;	A38-B107;
A38-B108;	A38-B109;	A38-B110;	A38-B111;	A38-B112;	A38-B113;
A38-B114;	A38-B115;	A38-B116;	A38-B117;	A38-B118;	A38-B119;
A38-B120;	A38-B121;	A38-B122;	A38-B123;	A38-B124;	A38-B125;
A38-B126;	A38-B127;	A38-B128;	A38-B129;	A38-B130;	A38-B131;
A38-B132;	A38-B133;	A38-B134;	A38-B135;	A38-B136;	A38-B137;
A38-B138;	A38-B139;	A38-B140;	A38-B141;	A38-B142;	A38-B143;
A38-B144;	A38-B145;	A38-B146;	A38-B147;	A38-B148;	A38-B149;
A38-B150;	A38-B151;	A38-B152;	A38-B153;	A38-B154;	A38-B155;
A38-B156;	A38-B157;	A38-B158;	A38-B159;	A38-B160;	A38-B161;
A38-B162;	A38-B163;	A38-B164;	A38-B165;	A38-B166;	A38-B167;
A38-B168;	A38-B169;	A39-B1;	A39-B2;	A39-B3;	A39-B4;
A39-B5;	A39-B6;	A39-B7;	A39-B8;	A39-B9;	A39-B10;
A39-B11;	A39-B12;	A39-B13;	A39-B14;	A39-B15;	A39-B16;
A39-B17;	A39-B18;	A39-B19;	A39-B20;	A39-B21;	A39-B22;
A39-B23;	A39-B24;	A39-B25;	A39-B26;	A39-B27;	A39-B28;
A39-B29;	A39-B30;	A39-B31;	A39-B32;	A39-B33;	A39-B34;
A39-B35;	A39-B36;	A39-B37;	A39-B38;	A39-B39;	A39-B40;
A39-B41;	A39-B42;	A39-B43;	A39-B44;	A39-B45;	A39-B46;
A39-B47;	A39-B48;	A39-B49;	A39-B50;	A39-B51;	A39-B52;
A39-B53;	A39-B54;	A39-B55;	A39-B56;	A39-B57;	A39-B58;
A39-B59;	A39-B60;	A39-B61;	A39-B62;	A39-B63;	A39-B64;
A39-B65;	A39-B66;	A39-B67;	A39-B68;	A39-B69;	A39-B70;
A39-B71;	A39-B72;	A39-B73;	A39-B74;	A39-B75;	A39-B76;
A39-B77;	A39-B78;	A39-B79;	A39-B80;	A39-B81;	A39-B82;
A39-B83;	A39-B84;	A39-B85;	A39-B86;	A39-B87;	A39-B88;
A39-B89;	A39-B90;	A39-B91;	A39-B92;	A39-B93;	A39-B94;
A39-B95;	A39-B96;	A39-B97;	A39-B98;	A39-B99;	A39-B100;
A39-B101;	A39-B102;	A39-B103;	A39-B104;	A39-B105;	A39-B106;
A39-B107;	A39-B108;	A39-B109;	A39-B110;	A39-B111;	A39-B112;
A39-B113;	A39-B114;	A39-B115;	A39-B116;	A39-B117;	A39-B118;
A39-B119;	A39-B120;	A39-B121;	A39-B122;	A39-B123;	A39-B124;
A39-B125;	A39-B126;	A39-B127;	A39-B128;	A39-B129;	A39-B130;
A39-B131;	A39-B132;	A39-B133;	A39-B134;	A39-B135;	A39-B136;
A39-B137;	A39-B138;	A39-B139;	A39-B140;	A39-B141;	A39-B142;
A39-B143;	A39-B144;	A39-B145;	A39-B146;	A39-B147;	A39-B148;
A39-B149;	A39-B150;	A39-B151;	A39-B152;	A39-B153;	A39-B154;
A39-B155;	A39-B156;	A39-B157;	A39-B158;	A39-B159;	A39-B160;
A39-B161;	A39-B162;	A39-B163;	A39-B164;	A39-B165;	A39-B166;
A39-B167;	A39-B168;	A39-B169;	A40-B1;	A40-B2;	A40-B3;
A40-B4;	A40-B5;	A40-B6;	A40-B7;	A40-B8;	A40-B9;
A40-B10;	A40-B11;	A40-B12;	A40-B13;	A40-B14;	A40-B15;
A40-B16;	A40-B17;	A40-B18;	A40-B19;	A40-B20;	A40-B21;
A40-B22;	A40-B23;	A40-B24;	A40-B25;	A40-B26;	A40-B27;
A40-B28;	A40-B29;	A40-B30;	A40-B31;	A40-B32;	A40-B33;
A40-B34;	A40-B35;	A40-B36;	A40-B37;	A40-B38;	A40-B39;
A40-B40;	A40-B41;	A40-B42;	A40-B43;	A40-B44;	A40-B45;
A40-B46;	A40-B47;	A40-B48;	A40-B49;	A40-B50;	A40-B51;
A40-B52;	A40-B53;	A40-B54;	A40-B55;	A40-B56;	A40-B57;
A40-B58;	A40-B59;	A40-B60;	A40-B61;	A40-B62;	A40-B63;
A40-B64;	A40-B65;	A40-B66;	A40-B67;	A40-B68;	A40-B69;
A40-B70;	A40-B71;	A40-B72;	A40-B73;	A40-B74;	A40-B75;
A40-B76;	A40-B77;	A40-B78;	A40-B79;	A40-B80;	A40-B81;
A40-B82;	A40-B83;	A40-B84;	A40-B85;	A40-B86;	A40-B87;
A40-B88;	A40-B89;	A40-B90;	A40-B91;	A40-B92;	A40-B93;
A40-B94;	A40-B95;	A40-B96;	A40-B97;	A40-B98;	A40-B99;
A40-B100;	A40-B101;	A40-B102;	A40-B103;	A40-B104;	A40-B105;
A40-B106;	A40-B107;	A40-B108;	A40-B109;	A40-B110;	A40-B111;
A40-B112;	A40-B113;	A40-B114;	A40-B115;	A40-B116;	A40-B117;
A40-B118;	A40-B119;	A40-B120;	A40-B121;	A40-B122;	A40-B123;
A40-B124;	A40-B125;	A40-B126;	A40-B127;	A40-B128;	A40-B129;
A40-B130;	A40-B131;	A40-B132;	A40-B133;	A40-B134;	A40-B135;
A40-B136;	A40-B137;	A40-B138;	A40-B139;	A40-B140;	A40-B141;
A40-B142;	A40-B143;	A40-B144;	A40-B145;	A40-B146;	A40-B147;
A40-B148;	A40-B149;	A40-B150;	A40-B151;	A40-B152;	A40-B153;
A40-B154;	A40-B155;	A40-B156;	A40-B157;	A40-B158;	A40-B159;
A40-B160;	A40-B161;	A40-B162;	A40-B163;	A40-B164;	A40-B165;
A40-B166;	A40-B167;	A40-B168;	A40-B169;	A41-B1;	A41-B2;
A41-B3;	A41-B4;	A41-B5;	A41-B6;	A41-B7;	A41-B8;
A41-B9;	A41-B10;	A41-B11;	A41-B12;	A41-B13;	A41-B14;
A41-B15;	A41-B16;	A41-B17;	A41-B18;	A41-B19;	A41-B20;
A41-B21;	A41-B22;	A41-B23;	A41-B24;	A41-B25;	A41-B26;
A41-B27;	A41-B28;	A41-B29;	A41-B30;	A41-B31;	A41-B32;
A41-B33;	A41-B34;	A41-B35;	A41-B36;	A41-B37;	A41-B38;
A41-B39;	A41-B40;	A41-B41;	A41-B42;	A41-B43;	A41-B44;
A41-B45;	A41-B46;	A41-B47;	A41-B48;	A41-B49;	A41-B50;
A41-B51;	A41-B52;	A41-B53;	A41-B54;	A41-B55;	A41-B56;
A41-B57;	A41-B58;	A41-B59;	A41-B60;	A41-B61;	A41-B62;
A41-B63;	A41-B64;	A41-B65;	A41-B66;	A41-B67;	A41-B68;
A41-B69;	A41-B70;	A41-B71;	A41-B72;	A41-B73;	A41-B74;
A41-B75;	A41-B76;	A41-B77;	A41-B78;	A41-B79;	A41-B80;
A41-B81;	A41-B82;	A41-B83;	A41-B84;	A41-B85;	A41-B86;
A41-B87;	A41-B88;	A41-B89;	A41-B90;	A41-B91;	A41-B92;
A41-B93;	A41-B94;	A41-B95;	A41-B96;	A41-B97;	A41-B98;
A41-B99;	A41-B100;	A41-B101;	A41-B102;	A41-B103;	A41-B104;
A41-B105;	A41-B106;	A41-B107;	A41-B108;	A41-B109;	A41-B110;
A41-B111;	A41-B112;	A41-B113;	A41-B114;	A41-B115;	A41-B116;
A41-B117;	A41-B118;	A41-B119;	A41-B120;	A41-B121;	A41-B122;
A41-B123;	A41-B124;	A41-B125;	A41-B126;	A41-B127;	A41-B128;
A41-B129;	A41-B130;	A41-B131;	A41-B132;	A41-B133;	A41-B134;
A41-B135;	A41-B136;	A41-B137;	A41-B138;	A41-B139;	A41-B140;
A41-B141;	A41-B142;	A41-B143;	A41-B144;	A41-B145;	A41-B146;
A41-B147;	A41-B148;	A41-B149;	A41-B150;	A41-B151;	A41-B152;
A41-B153;	A41-B154;	A41-B155;	A41-B156;	A41-B157;	A41-B158;
A41-B159;	A41-B160;	A41-B161;	A41-B162;	A41-B163;	A41-B164;
A41-B165;	A41-B166;	A41-B167;	A41-B168;	A41-B169;	A42-B1;
A42-B2;	A42-B3;	A42-B4;	A42-B5;	A42-B6;	A42-B7;
A42-B8;	A42-B9;	A42-B10;	A42-B11;	A42-B12;	A42-B13;
A42-B14;	A42-B15;	A42-B16;	A42-B17;	A42-B18;	A42-B19;
A42-B20;	A42-B21;	A42-B22;	A42-B23;	A42-B24;	A42-B25;
A42-B26;	A42-B27;	A42-B28;	A42-B29;	A42-B30;	A42-B31;
A42-B32;	A42-B33;	A42-B34;	A42-B35;	A42-B36;	A42-B37;
A42-B38;	A42-B39;	A42-B40;	A42-B41;	A42-B42;	A42-B43;
A42-B44;	A42-B45;	A42-B46;	A42-B47;	A42-B48;	A42-B49;
A42-B50;	A42-B51;	A42-B52;	A42-B53;	A42-B54;	A42-B55;
A42-B56;	A42-B57;	A42-B58;	A42-B59;	A42-B60;	A42-B61;
A42-B62;	A42-B63;	A42-B64;	A42-B65;	A42-B66;	A42-B67;
A42-B68;	A42-B69;	A42-B70;	A42-B71;	A42-B72;	A42-B73;
A42-B74;	A42-B75;	A42-B76;	A42-B77;	A42-B78;	A42-B79;
A42-B80;	A42-B81;	A42-B82;	A42-B83;	A42-B84;	A42-B85;
A42-B86;	A42-B87;	A42-B88;	A42-B89;	A42-B90;	A42-B91;
A42-B92;	A42-B93;	A42-B94;	A42-B95;	A42-B96;	A42-B97;
A42-B98;	A42-B99;	A42-B100;	A42-B101;	A42-B102;	A42-B103;
A42-B104;	A42-B105;	A42-B106;	A42-B107;	A42-B108;	A42-B109;
A42-B110;	A42-B111;	A42-B112;	A42-B113;	A42-B114;	A42-B115;
A42-B116;	A42-B117;	A42-B118;	A42-B119;	A42-B120;	A42-B121;
A42-B122;	A42-B123;	A42-B124;	A42-B125;	A42-B126;	A42-B127;
A42-B128;	A42-B129;	A42-B130;	A42-B131;	A42-B132;	A42-B133;
A42-B134;	A42-B135;	A42-B136;	A42-B137;	A42-B138;	A42-B139;
A42-B140;	A42-B141;	A42-B142;	A42-B143;	A42-B144;	A42-B145;
A42-B146;	A42-B147;	A42-B148;	A42-B149;	A42-B150;	A42-B151;
A42-B152;	A42-B153;	A42-B154;	A42-B155;	A42-B156;	A42-B157;
A42-B158;	A42-B159;	A42-B160;	A42-B161;	A42-B162;	A42-B163;
A42-B164;	A42-B165;	A42-B166;	A42-B167;	A42-B168;	A42-B169;
A43-B1;	A43-B2;	A43-B3;	A43-B4;	A43-B5;	A43-B6;
A43-B7;	A43-B8;	A43-B9;	A43-B10;	A43-B11;	A43-B12;
A43-B13;	A43-B14;	A43-B15;	A43-B16;	A43-B17;	A43-B18;
A43-B19;	A43-B20;	A43-B21;	A43-B22;	A43-B23;	A43-B24;
A43-B25;	A43-B26;	A43-B27;	A43-B28;	A43-B29;	A43-B30;
A43-B31;	A43-B32;	A43-B33;	A43-B34;	A43-B35;	A43-B36;
A43-B37;	A43-B38;	A43-B39;	A43-B40;	A43-B41;	A43-B42;
A43-B43;	A43-B44;	A43-B45;	A43-B46;	A43-B47;	A43-B48;
A43-B49;	A43-B50;	A43-B51;	A43-B52;	A43-B53;	A43-B54;
A43-B55;	A43-B56;	A43-B57;	A43-B58;	A43-B59;	A43-B60;
A43-B61;	A43-B62;	A43-B63;	A43-B64;	A43-B65;	A43-B66;
A43-B67;	A43-B68;	A43-B69;	A43-B70;	A43-B71;	A43-B72;
A43-B73;	A43-B74;	A43-B75;	A43-B76;	A43-B77;	A43-B78;
A43-B79;	A43-B80;	A43-B81;	A43-B82;	A43-B83;	A43-B84;
A43-B85;	A43-B86;	A43-B87;	A43-B88;	A43-B89;	A43-B90;
A43-B91;	A43-B92;	A43-B93;	A43-B94;	A43-B95;	A43-B96;
A43-B97;	A43-B98;	A43-B99;	A43-B100;	A43-B101;	A43-B102;
A43-B103;	A43-B104;	A43-B105;	A43-B106;	A43-B107;	A43-B108;
A43-B109;	A43-B110;	A43-B111;	A43-B112;	A43-B113;	A43-B114;
A43-B115;	A43-B116;	A43-B117;	A43-B118;	A43-B119;	A43-B120;
A43-B121;	A43-B122;	A43-B123;	A43-B124;	A43-B125;	A43-B126;
A43-B127;	A43-B128;	A43-B129;	A43-B130;	A43-B131;	A43-B132;
A43-B133;	A43-B134;	A43-B135;	A43-B136;	A43-B137;	A43-B138;
A43-B139;	A43-B140;	A43-B141;	A43-B142;	A43-B143;	A43-B144;
A43-B145;	A43-B146;	A43-B147;	A43-B148;	A43-B149;	A43-B150;
A43-B151;	A43-B152;	A43-B153;	A43-B154;	A43-B155;	A43-B156;
A43-B157;	A43-B158;	A43-B159;	A43-B160;	A43-B161;	A43-B162;
A43-B163;	A43-B164;	A43-B165;	A43-B166;	A43-B167;	A43-B168;
A43-B169;	A44-B1;	A44-B2;	A44-B3;	A44-B4;	A44-B5;
A44-B6;	A44-B7;	A44-B8;	A44-B9;	A44-B10;	A44-B11;
A44-B12;	A44-B13;	A44-B14;	A44-B15;	A44-B16;	A44-B17;
A44-B18;	A44-B19;	A44-B20;	A44-B21;	A44-B22;	A44-B23;
A44-B24;	A44-B25;	A44-B26;	A44-B27;	A44-B28;	A44-B29;
A44-B30;	A44-B31;	A44-B32;	A44-B33;	A44-B34;	A44-B35;
A44-B36;	A44-B37;	A44-B38;	A44-B39;	A44-B40;	A44-B41;
A44-B42;	A44-B43;	A44-B44;	A44-B45;	A44-B46;	A44-B47;
A44-B48;	A44-B49;	A44-B50;	A44-B51;	A44-B52;	A44-B53;
A44-B54;	A44-B55;	A44-B56;	A44-B57;	A44-B58;	A44-B59;
A44-B60;	A44-B61;	A44-B62;	A44-B63;	A44-B64;	A44-B65;
A44-B66;	A44-B67;	A44-B68;	A44-B69;	A44-B70;	A44-B71;
A44-B72;	A44-B73;	A44-B74;	A44-B75;	A44-B76;	A44-B77;
A44-B78;	A44-B79;	A44-B80;	A44-B81;	A44-B82;	A44-B83;
A44-B84;	A44-B85;	A44-B86;	A44-B87;	A44-B88;	A44-B89;
A44-B90;	A44-B91;	A44-B92;	A44-B93;	A44-B94;	A44-B95;
A44-B96;	A44-B97;	A44-B98;	A44-B99;	A44-B100;	A44-B101;
A44-B102;	A44-B103;	A44-B104;	A44-B105;	A44-B106;	A44-B107;
A44-B108;	A44-B109;	A44-B110;	A44-B111;	A44-B112;	A44-B113;
A44-B114;	A44-B115;	A44-B116;	A44-B117;	A44-B118;	A44-B119;
A44-B120;	A44-B121;	A44-B122;	A44-B123;	A44-B124;	A44-B125;
A44-B126;	A44-B127;	A44-B128;	A44-B129;	A44-B130;	A44-B131;
A44-B132;	A44-B133;	A44-B134;	A44-B135;	A44-B136;	A44-B137;
A44-B138;	A44-B139;	A44-B140;	A44-B141;	A44-B142;	A44-B143;
A44-B144;	A44-B145;	A44-B146;	A44-B147;	A44-B148;	A44-B149;
A44-B150;	A44-B151;	A44-B152;	A44-B153;	A44-B154;	A44-B155;
A44-B156;	A44-B157;	A44-B158;	A44-B159;	A44-B160;	A44-B161;
A44-B162;	A44-B163;	A44-B164;	A44-B165;	A44-B166;	A44-B167;
A44-B168;	A44-B169;	A45-B1;	A45-B2;	A45-B3;	A45-B4;
A45-B5;	A45-B6;	A45-B7;	A45-B8;	A45-B9;	A45-B10;
A45-B11;	A45-B12;	A45-B13;	A45-B14;	A45-B15;	A45-B16;
A45-B17;	A45-B18;	A45-B19;	A45-B20;	A45-B21;	A45-B22;
A45-B23;	A45-B24;	A45-B25;	A45-B26;	A45-B27;	A45-B28;
A45-B29;	A45-B30;	A45-B31;	A45-B32;	A45-B33;	A45-B34;
A45-B35;	A45-B36;	A45-B37;	A45-B38;	A45-B39;	A45-B40;
A45-B41;	A45-B42;	A45-B43;	A45-B44;	A45-B45;	A45-B46;
A45-B47;	A45-B48;	A45-B49;	A45-B50;	A45-B51;	A45-B52;
A45-B53;	A45-B54;	A45-B55;	A45-B56;	A45-B57;	A45-B58;
A45-B59;	A45-B60;	A45-B61;	A45-B62;	A45-B63;	A45-B64;
A45-B65;	A45-B66;	A45-B67;	A45-B68;	A45-B69;	A45-B70;
A45-B71;	A45-B72;	A45-B73;	A45-B74;	A45-B75;	A45-B76;
A45-B77;	A45-B78;	A45-B79;	A45-B80;	A45-B81;	A45-B82;
A45-B83;	A45-B84;	A45-B85;	A45-B86;	A45-B87;	A45-B88;
A45-B89;	A45-B90;	A45-B91;	A45-B92;	A45-B93;	A45-B94;
A45-B95;	A45-B96;	A45-B97;	A45-B98;	A45-B99;	A45-B100;
A45-B101;	A45-B102;	A45-B103;	A45-B104;	A45-B105;	A45-B106;
A45-B107;	A45-B108;	A45-B109;	A45-B110;	A45-B111;	A45-B112;
A45-B113;	A45-B114;	A45-B115;	A45-B116;	A45-B117;	A45-B118;
A45-B119;	A45-B120;	A45-B121;	A45-B122;	A45-B123;	A45-B124;
A45-B125;	A45-B126;	A45-B127;	A45-B128;	A45-B129;	A45-B130;
A45-B131;	A45-B132;	A45-B133;	A45-B134;	A45-B135;	A45-B136;
A45-B137;	A45-B138;	A45-B139;	A45-B140;	A45-B141;	A45-B142;
A45-B143;	A45-B144;	A45-B145;	A45-B146;	A45-B147;	A45-B148;
A45-B149;	A45-B150;	A45-B151;	A45-B152;	A45-B153;	A45-B154;
A45-B155;	A45-B156;	A45-B157;	A45-B158;	A45-B159;	A45-B160;
A45-B161;	A45-B162;	A45-B163;	A45-B164;	A45-B165;	A45-B166;
A45-B167;	A45-B168;	A45-B169;	A46-B1;	A46-B2;	A46-B3;
A46-B4;	A46-B5;	A46-B6;	A46-B7;	A46-B8;	A46-B9;
A46-B10;	A46-B11;	A46-B12;	A46-B13;	A46-B14;	A46-B15;
A46-B16;	A46-B17;	A46-B18;	A46-B19;	A46-B20;	A46-B21;
A46-B22;	A46-B23;	A46-B24;	A46-B25;	A46-B26;	A46-B27;
A46-B28;	A46-B29;	A46-B30;	A46-B31;	A46-B32;	A46-B33;
A46-B34;	A46-B35;	A46-B36;	A46-B37;	A46-B38;	A46-B39;
A46-B40;	A46-B41;	A46-B42;	A46-B43;	A46-B44;	A46-B45;
A46-B46;	A46-B47;	A46-B48;	A46-B49;	A46-B50;	A46-B51;
A46-B52;	A46-B53;	A46-B54;	A46-B55;	A46-B56;	A46-B57;
A46-B58;	A46-B59;	A46-B60;	A46-B61;	A46-B62;	A46-B63;
A46-B64;	A46-B65;	A46-B66;	A46-B67;	A46-B68;	A46-B69;
A46-B70;	A46-B71;	A46-B72;	A46-B73;	A46-B74;	A46-B75;
A46-B76;	A46-B77;	A46-B78;	A46-B79;	A46-B80;	A46-B81;
A46-B82;	A46-B83;	A46-B84;	A46-B85;	A46-B86;	A46-B87;
A46-B88;	A46-B89;	A46-B90;	A46-B91;	A46-B92;	A46-B93;
A46-B94;	A46-B95;	A46-B96;	A46-B97;	A46-B98;	A46-B99;
A46-B100;	A46-B101;	A46-B102;	A46-B103;	A46-B104;	A46-B105;
A46-B106;	A46-B107;	A46-B108;	A46-B109;	A46-B110;	A46-B111;
A46-B112;	A46-B113;	A46-B114;	A46-B115;	A46-B116;	A46-B117;
A46-B118;	A46-B119;	A46-B120;	A46-B121;	A46-B122;	A46-B123;
A46-B124;	A46-B125;	A46-B126;	A46-B127;	A46-B128;	A46-B129;
A46-B130;	A46-B131;	A46-B132;	A46-B133;	A46-B134;	A46-B135;
A46-B136;	A46-B137;	A46-B138;	A46-B139;	A46-B140;	A46-B141;
A46-B142;	A46-B143;	A46-B144;	A46-B145;	A46-B146;	A46-B147;
A46-B148;	A46-B149;	A46-B150;	A46-B151;	A46-B152;	A46-B153;
A46-B154;	A46-B155;	A46-B156;	A46-B157;	A46-B158;	A46-B159;
A46-B160;	A46-B161;	A46-B162;	A46-B163;	A46-B164;	A46-B165;
A46-B166;	A46-B167;	A46-B168;	A46-B169;	A47-B1;	A47-B2;
A47-B3;	A47-B4;	A47-B5;	A47-B6;	A47-B7;	A47-B8;
A47-B9;	A47-B10;	A47-B11;	A47-B12;	A47-B13;	A47-B14;
A47-B15;	A47-B16;	A47-B17;	A47-B18;	A47-B19;	A47-B20;
A47-B21;	A47-B22;	A47-B23;	A47-B24;	A47-B25;	A47-B26;
A47-B27;	A47-B28;	A47-B29;	A47-B30;	A47-B31;	A47-B32;
A47-B33;	A47-B34;	A47-B35;	A47-B36;	A47-B37;	A47-B38;
A47-B39;	A47-B40;	A47-B41;	A47-B42;	A47-B43;	A47-B44;
A47-B45;	A47-B46;	A47-B47;	A47-B48;	A47-B49;	A47-B50;
A47-B51;	A47-B52;	A47-B53;	A47-B54;	A47-B55;	A47-B56;
A47-B57;	A47-B58;	A47-B59;	A47-B60;	A47-B61;	A47-B62;
A47-B63;	A47-B64;	A47-B65;	A47-B66;	A47-B67;	A47-B68;
A47-B69;	A47-B70;	A47-B71;	A47-B72;	A47-B73;	A47-B74;
A47-B75;	A47-B76;	A47-B77;	A47-B78;	A47-B79;	A47-B80;
A47-B81;	A47-B82;	A47-B83;	A47-B84;	A47-B85;	A47-B86;
A47-B87;	A47-B88;	A47-B89;	A47-B90;	A47-B91;	A47-B92;
A47-B93;	A47-B94;	A47-B95;	A47-B96;	A47-B97;	A47-B98;
A47-B99;	A47-B100;	A47-B101;	A47-B102;	A47-B103;	A47-B104;
A47-B105;	A47-B106;	A47-B107;	A47-B108;	A47-B109;	A47-B110;
A47-B111;	A47-B112;	A47-B113;	A47-B114;	A47-B115;	A47-B116;
A47-B117;	A47-B118;	A47-B119;	A47-B120;	A47-B121;	A47-B122;
A47-B123;	A47-B124;	A47-B125;	A47-B126;	A47-B127;	A47-B128;
A47-B129;	A47-B130;	A47-B131;	A47-B132;	A47-B133;	A47-B134;
A47-B135;	A47-B136;	A47-B137;	A47-B138;	A47-B139;	A47-B140;
A47-B141;	A47-B142;	A47-B143;	A47-B144;	A47-B145;	A47-B146;
A47-B147;	A47-B148;	A47-B149;	A47-B150;	A47-B151;	A47-B152;
A47-B153;	A47-B154;	A47-B155;	A47-B156;	A47-B157;	A47-B158;
A47-B159;	A47-B160;	A47-B161;	A47-B162;	A47-B163;	A47-B164;
A47-B165;	A47-B166;	A47-B167;	A47-B168;	A47-B169;	A48-B1;
A48-B2;	A48-B3;	A48-B4;	A48-B5;	A48-B6;	A48-B7;
A48-B8;	A48-B9;	A48-B10;	A48-B11;	A48-B12;	A48-B13;
A48-B14;	A48-B15;	A48-B16;	A48-B17;	A48-B18;	A48-B19;
A48-B20;	A48-B21;	A48-B22;	A48-B23;	A48-B24;	A48-B25;
A48-B26;	A48-B27;	A48-B28;	A48-B29;	A48-B30;	A48-B31;
A48-B32;	A48-B33;	A48-B34;	A48-B35;	A48-B36;	A48-B37;
A48-B38;	A48-B39;	A48-B40;	A48-B41;	A48-B42;	A48-B43;
A48-B44;	A48-B45;	A48-B46;	A48-B47;	A48-B48;	A48-B49;
A48-B50;	A48-B51;	A48-B52;	A48-B53;	A48-B54;	A48-B55;
A48-B56;	A48-B57;	A48-B58;	A48-B59;	A48-B60;	A48-B61;
A48-B62;	A48-B63;	A48-B64;	A48-B65;	A48-B66;	A48-B67;
A48-B68;	A48-B69;	A48-B70;	A48-B71;	A48-B72;	A48-B73;
A48-B74;	A48-B75;	A48-B76;	A48-B77;	A48-B78;	A48-B79;
A48-B80;	A48-B81;	A48-B82;	A48-B83;	A48-B84;	A48-B85;
A48-B86;	A48-B87;	A48-B88;	A48-B89;	A48-B90;	A48-B91;
A48-B92;	A48-B93;	A48-B94;	A48-B95;	A48-B96;	A48-B97;
A48-B98;	A48-B99;	A48-B100;	A48-B101;	A48-B102;	A48-B103;
A48-B104;	A48-B105;	A48-B106;	A48-B107;	A48-B108;	A48-B109;
A48-B110;	A48-B111;	A48-B112;	A48-B113;	A48-B114;	A48-B115;
A48-B116;	A48-B117;	A48-B118;	A48-B119;	A48-B120;	A48-B121;
A48-B122;	A48-B123;	A48-B124;	A48-B125;	A48-B126;	A48-B127;
A48-B128;	A48-B129;	A48-B130;	A48-B131;	A48-B132;	A48-B133;
A48-B134;	A48-B135;	A48-B136;	A48-B137;	A48-B138;	A48-B139;
A48-B140;	A48-B141;	A48-B142;	A48-B143;	A48-B144;	A48-B145;
A48-B146;	A48-B147;	A48-B148;	A48-B149;	A48-B150;	A48-B151;
A48-B152;	A48-B153;	A48-B154;	A48-B155;	A48-B156;	A48-B157;
A48-B158;	A48-B159;	A48-B160;	A48-B161;	A48-B162;	A48-B163;
A48-B164;	A48-B165;	A48-B166;	A48-B167;	A48-B168;	A48-B169;
A49-B1;	A49-B2;	A49-B3;	A49-B4;	A49-B5;	A49-B6;
A49-B7;	A49-B8;	A49-B9;	A49-B10;	A49-B11;	A49-B12;
A49-B13;	A49-B14;	A49-B15;	A49-B16;	A49-B17;	A49-B18;
A49-B19;	A49-B20;	A49-B21;	A49-B22;	A49-B23;	A49-B24;
A49-B25;	A49-B26;	A49-B27;	A49-B28;	A49-B29;	A49-B30;
A49-B31;	A49-B32;	A49-B33;	A49-B34;	A49-B35;	A49-B36;
A49-B37;	A49-B38;	A49-B39;	A49-B40;	A49-B41;	A49-B42;
A49-B43;	A49-B44;	A49-B45;	A49-B46;	A49-B47;	A49-B48;
A49-B49;	A49-B50;	A49-B51;	A49-B52;	A49-B53;	A49-B54;
A49-B55;	A49-B56;	A49-B57;	A49-B58;	A49-B59;	A49-B60;
A49-B61;	A49-B62;	A49-B63;	A49-B64;	A49-B65;	A49-B66;
A49-B67;	A49-B68;	A49-B69;	A49-B70;	A49-B71;	A49-B72;
A49-B73;	A49-B74;	A49-B75;	A49-B76;	A49-B77;	A49-B78;
A49-B79;	A49-B80;	A49-B81;	A49-B82;	A49-B83;	A49-B84;
A49-B85;	A49-B86;	A49-B87;	A49-B88;	A49-B89;	A49-B90;
A49-B91;	A49-B92;	A49-B93;	A49-B94;	A49-B95;	A49-B96;
A49-B97;	A49-B98;	A49-B99;	A49-B100;	A49-B101;	A49-B102;
A49-B103;	A49-B104;	A49-B105;	A49-B106;	A49-B107;	A49-B108;
A49-B109;	A49-B110;	A49-B111;	A49-B112;	A49-B113;	A49-B114;
A49-B115;	A49-B116;	A49-B117;	A49-B118;	A49-B119;	A49-B120;
A49-B121;	A49-B122;	A49-B123;	A49-B124;	A49-B125;	A49-B126;
A49-B127;	A49-B128;	A49-B129;	A49-B130;	A49-B131;	A49-B132;
A49-B133;	A49-B134;	A49-B135;	A49-B136;	A49-B137;	A49-B138;
A49-B139;	A49-B140;	A49-B141;	A49-B142;	A49-B143;	A49-B144;
A49-B145;	A49-B146;	A49-B147;	A49-B148;	A49-B149;	A49-B150;
A49-B151;	A49-B152;	A49-B153;	A49-B154;	A49-B155;	A49-B156;
A49-B157;	A49-B158;	A49-B159;	A49-B160;	A49-B161;	A49-B162;
A49-B163;	A49-B164;	A49-B165;	A49-B166;	A49-B167;	A49-B168;
A49-B169;	A50-B1;	A50-B2;	A50-B3;	A50-B4;	A50-B5;
A50-B6;	A50-B7;	A50-B8;	A50-B9;	A50-B10;	A50-B11;
A50-B12;	A50-B13;	A50-B14;	A50-B15;	A50-B16;	A50-B17;
A50-B18;	A50-B19;	A50-B20;	A50-B21;	A50-B22;	A50-B23;
A50-B24;	A50-B25;	A50-B26;	A50-B27;	A50-B28;	A50-B29;
A50-B30;	A50-B31;	A50-B32;	A50-B33;	A50-B34;	A50-B35;
A50-B36;	A50-B37;	A50-B38;	A50-B39;	A50-B40;	A50-B41;
A50-B42;	A50-B43;	A50-B44;	A50-B45;	A50-B46;	A50-B47;
A50-B48;	A50-B49;	A50-B50;	A50-B51;	A50-B52;	A50-B53;
A50-B54;	A50-B55;	A50-B56;	A50-B57;	A50-B58;	A50-B59;
A50-B60;	A50-B61;	A50-B62;	A50-B63;	A50-B64;	A50-B65;
A50-B66;	A50-B67;	A50-B68;	A50-B69;	A50-B70;	A50-B71;
A50-B72;	A50-B73;	A50-B74;	A50-B75;	A50-B76;	A50-B77;
A50-B78;	A50-B79;	A50-B80;	A50-B81;	A50-B82;	A50-B83;
A50-B84;	A50-B85;	A50-B86;	A50-B87;	A50-B88;	A50-B89;
A50-B90;	A50-B91;	A50-B92;	A50-B93;	A50-B94;	A50-B95;
A50-B96;	A50-B97;	A50-B98;	A50-B99;	A50-B100;	A50-B101;
A50-B102;	A50-B103;	A50-B104;	A50-B105;	A50-B106;	A50-B107;
A50-B108;	A50-B109;	A50-B110;	A50-B111;	A50-B112;	A50-B113;
A50-B114;	A50-B115;	A50-B116;	A50-B117;	A50-B118;	A50-B119;
A50-B120;	A50-B121;	A50-B122;	A50-B123;	A50-B124;	A50-B125;
A50-B126;	A50-B127;	A50-B128;	A50-B129;	A50-B130;	A50-B131;
A50-B132;	A50-B133;	A50-B134;	A50-B135;	A50-B136;	A50-B137;
A50-B138;	A50-B139;	A50-B140;	A50-B141;	A50-B142;	A50-B143;
A50-B144;	A50-B145;	A50-B146;	A50-B147;	A50-B148;	A50-B149;
A50-B150;	A50-B151;	A50-B152;	A50-B153;	A50-B154;	A50-B155;
A50-B156;	A50-B157;	A50-B158;	A50-B159;	A50-B160;	A50-B161;
A50-B162;	A50-B163;	A50-B164;	A50-B165;	A50-B166;	A50-B167;
A50-B168;	A50-B169;	A51-B1;	A51-B2;	A51-B3;	A51-B4;
A51-B5;	A51-B6;	A51-B7;	A51-B8;	A51-B9;	A51-B10;
A51-B11;	A51-B12;	A51-B13;	A51-B14;	A51-B15;	A51-B16;
A51-B17;	A51-B18;	A51-B19;	A51-B20;	A51-B21;	A51-B22;
A51-B23;	A51-B24;	A51-B25;	A51-B26;	A51-B27;	A51-B28;
A51-B29;	A51-B30;	A51-B31;	A51-B32;	A51-B33;	A51-B34;
A51-B35;	A51-B36;	A51-B37;	A51-B38;	A51-B39;	A51-B40;
A51-B41;	A51-B42;	A51-B43;	A51-B44;	A51-B45;	A51-B46;
A51-B47;	A51-B48;	A51-B49;	A51-B50;	A51-B51;	A51-B52;
A51-B53;	A51-B54;	A51-B55;	A51-B56;	A51-B57;	A51-B58;
A51-B59;	A51-B60;	A51-B61;	A51-B62;	A51-B63;	A51-B64;
A51-B65;	A51-B66;	A51-B67;	A51-B68;	A51-B69;	A51-B70;
A51-B71;	A51-B72;	A51-B73;	A51-B74;	A51-B75;	A51-B76;
A51-B77;	A51-B78;	A51-B79;	A51-B80;	A51-B81;	A51-B82;
A51-B83;	A51-B84;	A51-B85;	A51-B86;	A51-B87;	A51-B88;
A51-B89;	A51-B90;	A51-B91;	A51-B92;	A51-B93;	A51-B94;
A51-B95;	A51-B96;	A51-B97;	A51-B98;	A51-B99;	A51-B100;
A51-B101;	A51-B102;	A51-B103;	A51-B104;	A51-B105;	A51-B106;
A51-B107;	A51-B108;	A51-B109;	A51-B110;	A51-B111;	A51-B112;
A51-B113;	A51-B114;	A51-B115;	A51-B116;	A51-B117;	A51-B118;
A51-B119;	A51-B120;	A51-B121;	A51-B122;	A51-B123;	A51-B124;
A51-B125;	A51-B126;	A51-B127;	A51-B128;	A51-B129;	A51-B130;
A51-B131;	A51-B132;	A51-B133;	A51-B134;	A51-B135;	A51-B136;
A51-B137;	A51-B138;	A51-B139;	A51-B140;	A51-B141;	A51-B142;
A51-B143;	A51-B144;	A51-B145;	A51-B146;	A51-B147;	A51-B148;
A51-B149;	A51-B150;	A51-B151;	A51-B152;	A51-B153;	A51-B154;
A51-B155;	A51-B156;	A51-B157;	A51-B158;	A51-B159;	A51-B160;
A51-B161;	A51-B162;	A51-B163;	A51-B164;	A51-B165;	A51-B166;
A51-B167;	A51-B168;	A51-B169;	A52-B1;	A52-B2;	A52-B3;
A52-B4;	A52-B5;	A52-B6;	A52-B7;	A52-B8;	A52-B9;
A52-B10;	A52-B11;	A52-B12;	A52-B13;	A52-B14;	A52-B15;
A52-B16;	A52-B17;	A52-B18;	A52-B19;	A52-B20;	A52-B21;
A52-B22;	A52-B23;	A52-B24;	A52-B25;	A52-B26;	A52-B27;
A52-B28;	A52-B29;	A52-B30;	A52-B31;	A52-B32;	A52-B33;
A52-B34;	A52-B35;	A52-B36;	A52-B37;	A52-B38;	A52-B39;
A52-B40;	A52-B41;	A52-B42;	A52-B43;	A52-B44;	A52-B45;
A52-B46;	A52-B47;	A52-B48;	A52-B49;	A52-B50;	A52-B51;
A52-B52;	A52-B53;	A52-B54;	A52-B55;	A52-B56;	A52-B57;
A52-B58;	A52-B59;	A52-B60;	A52-B61;	A52-B62;	A52-B63;
A52-B64;	A52-B65;	A52-B66;	A52-B67;	A52-B68;	A52-B69;
A52-B70;	A52-B71;	A52-B72;	A52-B73;	A52-B74;	A52-B75;
A52-B76;	A52-B77;	A52-B78;	A52-B79;	A52-B80;	A52-B81;
A52-B82;	A52-B83;	A52-B84;	A52-B85;	A52-B86;	A52-B87;
A52-B88;	A52-B89;	A52-B90;	A52-B91;	A52-B92;	A52-B93;
A52-B94;	A52-B95;	A52-B96;	A52-B97;	A52-B98;	A52-B99;
A52-B100;	A52-B101;	A52-B102;	A52-B103;	A52-B104;	A52-B105;
A52-B106;	A52-B107;	A52-B108;	A52-B109;	A52-B110;	A52-B111;
A52-B112;	A52-B113;	A52-B114;	A52-B115;	A52-B116;	A52-B117;
A52-B118;	A52-B119;	A52-B120;	A52-B121;	A52-B122;	A52-B123;
A52-B124;	A52-B125;	A52-B126;	A52-B127;	A52-B128;	A52-B129;
A52-B130;	A52-B131;	A52-B132;	A52-B133;	A52-B134;	A52-B135;
A52-B136;	A52-B137;	A52-B138;	A52-B139;	A52-B140;	A52-B141;
A52-B142;	A52-B143;	A52-B144;	A52-B145;	A52-B146;	A52-B147;
A52-B148;	A52-B149;	A52-B150;	A52-B151;	A52-B152;	A52-B153;
A52-B154;	A52-B155;	A52-B156;	A52-B157;	A52-B158;	A52-B159;
A52-B160;	A52-B161;	A52-B162;	A52-B163;	A52-B164;	A52-B165;
A52-B166;	A52-B167;	A52-B168;	A52-B169;	A53-B1;	A53-B2;
A53-B3;	A53-B4;	A53-B5;	A53-B6;	A53-B7;	A53-B8;
A53-B9;	A53-B10;	A53-B11;	A53-B12;	A53-B13;	A53-B14;
A53-B15;	A53-B16;	A53-B17;	A53-B18;	A53-B19;	A53-B20;
A53-B21;	A53-B22;	A53-B23;	A53-B24;	A53-B25;	A53-B26;
A53-B27;	A53-B28;	A53-B29;	A53-B30;	A53-B31;	A53-B32;
A53-B33;	A53-B34;	A53-B35;	A53-B36;	A53-B37;	A53-B38;
A53-B39;	A53-B40;	A53-B41;	A53-B42;	A53-B43;	A53-B44;
A53-B45;	A53-B46;	A53-B47;	A53-B48;	A53-B49;	A53-B50;
A53-B51;	A53-B52;	A53-B53;	A53-B54;	A53-B55;	A53-B56;
A53-B57;	A53-B58;	A53-B59;	A53-B60;	A53-B61;	A53-B62;
A53-B63;	A53-B64;	A53-B65;	A53-B66;	A53-B67;	A53-B68;
A53-B69;	A53-B70;	A53-B71;	A53-B72;	A53-B73;	A53-B74;
A53-B75;	A53-B76;	A53-B77;	A53-B78;	A53-B79;	A53-B80;
A53-B81;	A53-B82;	A53-B83;	A53-B84;	A53-B85;	A53-B86;
A53-B87;	A53-B88;	A53-B89;	A53-B90;	A53-B91;	A53-B92;
A53-B93;	A53-B94;	A53-B95;	A53-B96;	A53-B97;	A53-B98;
A53-B99;	A53-B100;	A53-B101;	A53-B102;	A53-B103;	A53-B104;
A53-B105;	A53-B106;	A53-B107;	A53-B108;	A53-B109;	A53-B110;
A53-B111;	A53-B112;	A53-B113;	A53-B114;	A53-B115;	A53-B116;
A53-B117;	A53-B118;	A53-B119;	A53-B120;	A53-B121;	A53-B122;
A53-B123;	A53-B124;	A53-B125;	A53-B126;	A53-B127;	A53-B128;
A53-B129;	A53-B130;	A53-B131;	A53-B132;	A53-B133;	A53-B134;
A53-B135;	A53-B136;	A53-B137;	A53-B138;	A53-B139;	A53-B140;
A53-B141;	A53-B142;	A53-B143;	A53-B144;	A53-B145;	A53-B146;
A53-B147;	A53-B148;	A53-B149;	A53-B150;	A53-B151;	A53-B152;
A53-B153;	A53-B154;	A53-B155;	A53-B156;	A53-B157;	A53-B158;
A53-B159;	A53-B160;	A53-B161;	A53-B162;	A53-B163;	A53-B164;
A53-B165;	A53-B166;	A53-B167;	A53-B168;	A53-B169;	A54-B1;
A54-B2;	A54-B3;	A54-B4;	A54-B5;	A54-B6;	A54-B7;
A54-B8;	A54-B9;	A54-B10;	A54-B11;	A54-B12;	A54-B13;
A54-B14;	A54-B15;	A54-B16;	A54-B17;	A54-B18;	A54-B19;
A54-B20;	A54-B21;	A54-B22;	A54-B23;	A54-B24;	A54-B25;
A54-B26;	A54-B27;	A54-B28;	A54-B29;	A54-B30;	A54-B31;
A54-B32;	A54-B33;	A54-B34;	A54-B35;	A54-B36;	A54-B37;
A54-B38;	A54-B39;	A54-B40;	A54-B41;	A54-B42;	A54-B43;
A54-B44;	A54-B45;	A54-B46;	A54-B47;	A54-B48;	A54-B49;
A54-B50;	A54-B51;	A54-B52;	A54-B53;	A54-B54;	A54-B55;
A54-B56;	A54-B57;	A54-B58;	A54-B59;	A54-B60;	A54-B61;
A54-B62;	A54-B63;	A54-B64;	A54-B65;	A54-B66;	A54-B67;
A54-B68;	A54-B69;	A54-B70;	A54-B71;	A54-B72;	A54-B73;
A54-B74;	A54-B75;	A54-B76;	A54-B77;	A54-B78;	A54-B79;
A54-B80;	A54-B81;	A54-B82;	A54-B83;	A54-B84;	A54-B85;
A54-B86;	A54-B87;	A54-B88;	A54-B89;	A54-B90;	A54-B91;
A54-B92;	A54-B93;	A54-B94;	A54-B95;	A54-B96;	A54-B97;
A54-B98;	A54-B99;	A54-B100;	A54-B101;	A54-B102;	A54-B103;
A54-B104;	A54-B105;	A54-B106;	A54-B107;	A54-B108;	A54-B109;
A54-B110;	A54-B111;	A54-B112;	A54-B113;	A54-B114;	A54-B115;
A54-B116;	A54-B117;	A54-B118;	A54-B119;	A54-B120;	A54-B121;
A54-B122;	A54-B123;	A54-B124;	A54-B125;	A54-B126;	A54-B127;
A54-B128;	A54-B129;	A54-B130;	A54-B131;	A54-B132;	A54-B133;
A54-B134;	A54-B135;	A54-B136;	A54-B137;	A54-B138;	A54-B139;
A54-B140;	A54-B141;	A54-B142;	A54-B143;	A54-B144;	A54-B145;
A54-B146;	A54-B147;	A54-B148;	A54-B149;	A54-B150;	A54-B151;
A54-B152;	A54-B153;	A54-B154;	A54-B155;	A54-B156;	A54-B157;
A54-B158;	A54-B159;	A54-B160;	A54-B161;	A54-B162;	A54-B163;
A54-B164;	A54-B165;	A54-B166;	A54-B167;	A54-B168;	A54-B169;
A55-B1;	A55-B2;	A55-B3;	A55-B4;	A55-B5;	A55-B6;
A55-B7;	A55-B8;	A55-B9;	A55-B10;	A55-B11;	A55-B12;
A55-B13;	A55-B14;	A55-B15;	A55-B16;	A55-B17;	A55-B18;
A55-B19;	A55-B20;	A55-B21;	A55-B22;	A55-B23;	A55-B24;
A55-B25;	A55-B26;	A55-B27;	A55-B28;	A55-B29;	A55-B30;
A55-B31;	A55-B32;	A55-B33;	A55-B34;	A55-B35;	A55-B36;
A55-B37;	A55-B38;	A55-B39;	A55-B40;	A55-B41;	A55-B42;
A55-B43;	A55-B44;	A55-B45;	A55-B46;	A55-B47;	A55-B48;
A55-B49;	A55-B50;	A55-B51;	A55-B52;	A55-B53;	A55-B54;
A55-B55;	A55-B56;	A55-B57;	A55-B58;	A55-B59;	A55-B60;
A55-B61;	A55-B62;	A55-B63;	A55-B64;	A55-B65;	A55-B66;
A55-B67;	A55-B68;	A55-B69;	A55-B70;	A55-B71;	A55-B72;
A55-B73;	A55-B74;	A55-B75;	A55-B76;	A55-B77;	A55-B78;
A55-B79;	A55-B80;	A55-B81;	A55-B82;	A55-B83;	A55-B84;
A55-B85;	A55-B86;	A55-B87;	A55-B88;	A55-B89;	A55-B90;
A55-B91;	A55-B92;	A55-B93;	A55-B94;	A55-B95;	A55-B96;
A55-B97;	A55-B98;	A55-B99;	A55-B100;	A55-B101;	A55-B102;
A55-B103;	A55-B104;	A55-B105;	A55-B106;	A55-B107;	A55-B108;
A55-B109;	A55-B110;	A55-B111;	A55-B112;	A55-B113;	A55-B114;
A55-B115;	A55-B116;	A55-B117;	A55-B118;	A55-B119;	A55-B120;
A55-B121;	A55-B122;	A55-B123;	A55-B124;	A55-B125;	A55-B126;
A55-B127;	A55-B128;	A55-B129;	A55-B130;	A55-B131;	A55-B132;
A55-B133;	A55-B134;	A55-B135;	A55-B136;	A55-B137;	A55-B138;
A55-B139;	A55-B140;	A55-B141;	A55-B142;	A55-B143;	A55-B144;
A55-B145;	A55-B146;	A55-B147;	A55-B148;	A55-B149;	A55-B150;
A55-B151;	A55-B152;	A55-B153;	A55-B154;	A55-B155;	A55-B156;
A55-B157;	A55-B158;	A55-B159;	A55-B160;	A55-B161;	A55-B162;
A55-B163;	A55-B164;	A55-B165;	A55-B166;	A55-B167;	A55-B168;
A55-B169;	A56-B1;	A56-B2;	A56-B3;	A56-B4;	A56-B5;
A56-B6;	A56-B7;	A56-B8;	A56-B9;	A56-B10;	A56-B11;
A56-B12;	A56-B13;	A56-B14;	A56-B15;	A56-B16;	A56-B17;
A56-B18;	A56-B19;	A56-B20;	A56-B21;	A56-B22;	A56-B23;
A56-B24;	A56-B25;	A56-B26;	A56-B27;	A56-B28;	A56-B29;
A56-B30;	A56-B31;	A56-B32;	A56-B33;	A56-B34;	A56-B35;
A56-B36;	A56-B37;	A56-B38;	A56-B39;	A56-B40;	A56-B41;
A56-B42;	A56-B43;	A56-B44;	A56-B45;	A56-B46;	A56-B47;
A56-B48;	A56-B49;	A56-B50;	A56-B51;	A56-B52;	A56-B53;
A56-B54;	A56-B55;	A56-B56;	A56-B57;	A56-B58;	A56-B59;
A56-B60;	A56-B61;	A56-B62;	A56-B63;	A56-B64;	A56-B65;
A56-B66;	A56-B67;	A56-B68;	A56-B69;	A56-B70;	A56-B71;
A56-B72;	A56-B73;	A56-B74;	A56-B75;	A56-B76;	A56-B77;
A56-B78;	A56-B79;	A56-B80;	A56-B81;	A56-B82;	A56-B83;
A56-B84;	A56-B85;	A56-B86;	A56-B87;	A56-B88;	A56-B89;
A56-B90;	A56-B91;	A56-B92;	A56-B93;	A56-B94;	A56-B95;
A56-B96;	A56-B97;	A56-B98;	A56-B99;	A56-B100;	A56-B101;
A56-B102;	A56-B103;	A56-B104;	A56-B105;	A56-B106;	A56-B107;
A56-B108;	A56-B109;	A56-B110;	A56-B111;	A56-B112;	A56-B113;
A56-B114;	A56-B115;	A56-B116;	A56-B117;	A56-B118;	A56-B119;
A56-B120;	A56-B121;	A56-B122;	A56-B123;	A56-B124;	A56-B125;
A56-B126;	A56-B127;	A56-B128;	A56-B129;	A56-B130;	A56-B131;
A56-B132;	A56-B133;	A56-B134;	A56-B135;	A56-B136;	A56-B137;
A56-B138;	A56-B139;	A56-B140;	A56-B141;	A56-B142;	A56-B143;
A56-B144;	A56-B145;	A56-B146;	A56-B147;	A56-B148;	A56-B149;
A56-B150;	A56-B151;	A56-B152;	A56-B153;	A56-B154;	A56-B155;
A56-B156;	A56-B157;	A56-B158;	A56-B159;	A56-B160;	A56-B161;
A56-B162;	A56-B163;	A56-B164;	A56-B165;	A56-B166;	A56-B167;
A56-B168;	A56-B169;	A57-B1;	A57-B2;	A57-B3;	A57-B4;
A57-B5;	A57-B6;	A57-B7;	A57-B8;	A57-B9;	A57-B10;
A57-B11;	A57-B12;	A57-B13;	A57-B14;	A57-B15;	A57-B16;
A57-B17;	A57-B18;	A57-B19;	A57-B20;	A57-B21;	A57-B22;
A57-B23;	A57-B24;	A57-B25;	A57-B26;	A57-B27;	A57-B28;
A57-B29;	A57-B30;	A57-B31;	A57-B32;	A57-B33;	A57-B34;
A57-B35;	A57-B36;	A57-B37;	A57-B38;	A57-B39;	A57-B40;
A57-B41;	A57-B42;	A57-B43;	A57-B44;	A57-B45;	A57-B46;
A57-B47;	A57-B48;	A57-B49;	A57-B50;	A57-B51;	A57-B52;
A57-B53;	A57-B54;	A57-B55;	A57-B56;	A57-B57;	A57-B58;
A57-B59;	A57-B60;	A57-B61;	A57-B62;	A57-B63;	A57-B64;
A57-B65;	A57-B66;	A57-B67;	A57-B68;	A57-B69;	A57-B70;
A57-B71;	A57-B72;	A57-B73;	A57-B74;	A57-B75;	A57-B76;
A57-B77;	A57-B78;	A57-B79;	A57-B80;	A57-B81;	A57-B82;
A57-B83;	A57-B84;	A57-B85;	A57-B86;	A57-B87;	A57-B88;
A57-B89;	A57-B90;	A57-B91;	A57-B92;	A57-B93;	A57-B94;
A57-B95;	A57-B96;	A57-B97;	A57-B98;	A57-B99;	A57-B100;
A57-B101;	A57-B102;	A57-B103;	A57-B104;	A57-B105;	A57-B106;
A57-B107;	A57-B108;	A57-B109;	A57-B110;	A57-B111;	A57-B112;
A57-B113;	A57-B114;	A57-B115;	A57-B116;	A57-B117;	A57-B118;
A57-B119;	A57-B120;	A57-B121;	A57-B122;	A57-B123;	A57-B124;
A57-B125;	A57-B126;	A57-B127;	A57-B128;	A57-B129;	A57-B130;
A57-B131;	A57-B132;	A57-B133;	A57-B134;	A57-B135;	A57-B136;
A57-B137;	A57-B138;	A57-B139;	A57-B140;	A57-B141;	A57-B142;
A57-B143;	A57-B144;	A57-B145;	A57-B146;	A57-B147;	A57-B148;
A57-B149;	A57-B150;	A57-B151;	A57-B152;	A57-B153;	A57-B154;
A57-B155;	A57-B156;	A57-B157;	A57-B158;	A57-B159;	A57-B160;
A57-B161;	A57-B162;	A57-B163;	A57-B164;	A57-B165;	A57-B166;
A57-B167;	A57-B168;	A57-B169;	A58-B1;	A58-B2;	A58-B3;
A58-B4;	A58-B5;	A58-B6;	A58-B7;	A58-B8;	A58-B9;
A58-B10;	A58-B11;	A58-B12;	A58-B13;	A58-B14;	A58-B15;
A58-B16;	A58-B17;	A58-B18;	A58-B19;	A58-B20;	A58-B21;
A58-B22;	A58-B23;	A58-B24;	A58-B25;	A58-B26;	A58-B27;
A58-B28;	A58-B29;	A58-B30;	A58-B31;	A58-B32;	A58-B33;
A58-B34;	A58-B35;	A58-B36;	A58-B37;	A58-B38;	A58-B39;
A58-B40;	A58-B41;	A58-B42;	A58-B43;	A58-B44;	A58-B45;
A58-B46;	A58-B47;	A58-B48;	A58-B49;	A58-B50;	A58-B51;
A58-B52;	A58-B53;	A58-B54;	A58-B55;	A58-B56;	A58-B57;
A58-B58;	A58-B59;	A58-B60;	A58-B61;	A58-B62;	A58-B63;
A58-B64;	A58-B65;	A58-B66;	A58-B67;	A58-B68;	A58-B69;
A58-B70;	A58-B71;	A58-B72;	A58-B73;	A58-B74;	A58-B75;
A58-B76;	A58-B77;	A58-B78;	A58-B79;	A58-B80;	A58-B81;
A58-B82;	A58-B83;	A58-B84;	A58-B85;	A58-B86;	A58-B87;
A58-B88;	A58-B89;	A58-B90;	A58-B91;	A58-B92;	A58-B93;
A58-B94;	A58-B95;	A58-B96;	A58-B97;	A58-B98;	A58-B99;
A58-B100;	A58-B101;	A58-B102;	A58-B103;	A58-B104;	A58-B105;
A58-B106;	A58-B107;	A58-B108;	A58-B109;	A58-B110;	A58-B111;
A58-B112;	A58-B113;	A58-B114;	A58-B115;	A58-B116;	A58-B117;
A58-B118;	A58-B119;	A58-B120;	A58-B121;	A58-B122;	A58-B123;
A58-B124;	A58-B125;	A58-B126;	A58-B127;	A58-B128;	A58-B129;
A58-B130;	A58-B131;	A58-B132;	A58-B133;	A58-B134;	A58-B135;
A58-B136;	A58-B137;	A58-B138;	A58-B139;	A58-B140;	A58-B141;
A58-B142;	A58-B143;	A58-B144;	A58-B145;	A58-B146;	A58-B147;
A58-B148;	A58-B149;	A58-B150;	A58-B151;	A58-B152;	A58-B153;
A58-B154;	A58-B155;	A58-B156;	A58-B157;	A58-B158;	A58-B159;
A58-B160;	A58-B161;	A58-B162;	A58-B163;	A58-B164;	A58-B165;
A58-B166;	A58-B167;	A58-B168;	A58-B169;	A59-B1;	A59-B2;
A59-B3;	A59-B4;	A59-B5;	A59-B6;	A59-B7;	A59-B8;
A59-B9;	A59-B10;	A59-B11;	A59-B12;	A59-B13;	A59-B14;
A59-B15;	A59-B16;	A59-B17;	A59-B18;	A59-B19;	A59-B20;
A59-B21;	A59-B22;	A59-B23;	A59-B24;	A59-B25;	A59-B26;
A59-B27;	A59-B28;	A59-B29;	A59-B30;	A59-B31;	A59-B32;
A59-B33;	A59-B34;	A59-B35;	A59-B36;	A59-B37;	A59-B38;
A59-B39;	A59-B40;	A59-B41;	A59-B42;	A59-B43;	A59-B44;
A59-B45;	A59-B46;	A59-B47;	A59-B48;	A59-B49;	A59-B50;
A59-B51;	A59-B52;	A59-B53;	A59-B54;	A59-B55;	A59-B56;
A59-B57;	A59-B58;	A59-B59;	A59-B60;	A59-B61;	A59-B62;
A59-B63;	A59-B64;	A59-B65;	A59-B66;	A59-B67;	A59-B68;
A59-B69;	A59-B70;	A59-B71;	A59-B72;	A59-B73;	A59-B74;
A59-B75;	A59-B76;	A59-B77;	A59-B78;	A59-B79;	A59-B80;
A59-B81;	A59-B82;	A59-B83;	A59-B84;	A59-B85;	A59-B86;
A59-B87;	A59-B88;	A59-B89;	A59-B90;	A59-B91;	A59-B92;
A59-B93;	A59-B94;	A59-B95;	A59-B96;	A59-B97;	A59-B98;
A59-B99;	A59-B100;	A59-B101;	A59-B102;	A59-B103;	A59-B104;
A59-B105;	A59-B106;	A59-B107;	A59-B108;	A59-B109;	A59-B110;
A59-B111;	A59-B112;	A59-B113;	A59-B114;	A59-B115;	A59-B116;
A59-B117;	A59-B118;	A59-B119;	A59-B120;	A59-B121;	A59-B122;
A59-B123;	A59-B124;	A59-B125;	A59-B126;	A59-B127;	A59-B128;
A59-B129;	A59-B130;	A59-B131;	A59-B132;	A59-B133;	A59-B134;
A59-B135;	A59-B136;	A59-B137;	A59-B138;	A59-B139;	A59-B140;
A59-B141;	A59-B142;	A59-B143;	A59-B144;	A59-B145;	A59-B146;
A59-B147;	A59-B148;	A59-B149;	A59-B150;	A59-B151;	A59-B152;
A59-B153;	A59-B154;	A59-B155;	A59-B156;	A59-B157;	A59-B158;
A59-B159;	A59-B160;	A59-B161;	A59-B162;	A59-B163;	A59-B164;
A59-B165;	A59-B166;	A59-B167;	A59-B168;	A59-B169;	A60-B1;
A60-B2;	A60-B3;	A60-B4;	A60-B5;	A60-B6;	A60-B7;
A60-B8;	A60-B9;	A60-B10;	A60-B11;	A60-B12;	A60-B13;
A60-B14;	A60-B15;	A60-B16;	A60-B17;	A60-B18;	A60-B19;
A60-B20;	A60-B21;	A60-B22;	A60-B23;	A60-B24;	A60-B25;
A60-B26;	A60-B27;	A60-B28;	A60-B29;	A60-B30;	A60-B31;
A60-B32;	A60-B33;	A60-B34;	A60-B35;	A60-B36;	A60-B37;
A60-B38;	A60-B39;	A60-B40;	A60-B41;	A60-B42;	A60-B43;
A60-B44;	A60-B45;	A60-B46;	A60-B47;	A60-B48;	A60-B49;
A60-B50;	A60-B51;	A60-B52;	A60-B53;	A60-B54;	A60-B55;
A60-B56;	A60-B57;	A60-B58;	A60-B59;	A60-B60;	A60-B61;
A60-B62;	A60-B63;	A60-B64;	A60-B65;	A60-B66;	A60-B67;
A60-B68;	A60-B69;	A60-B70;	A60-B71;	A60-B72;	A60-B73;
A60-B74;	A60-B75;	A60-B76;	A60-B77;	A60-B78;	A60-B79;
A60-B80;	A60-B81;	A60-B82;	A60-B83;	A60-B84;	A60-B85;
A60-B86;	A60-B87;	A60-B88;	A60-B89;	A60-B90;	A60-B91;
A60-B92;	A60-B93;	A60-B94;	A60-B95;	A60-B96;	A60-B97;
A60-B98;	A60-B99;	A60-B100;	A60-B101;	A60-B102;	A60-B103;
A60-B104;	A60-B105;	A60-B106;	A60-B107;	A60-B108;	A60-B109;
A60-B110;	A60-B111;	A60-B112;	A60-B113;	A60-B114;	A60-B115;
A60-B116;	A60-B117;	A60-B118;	A60-B119;	A60-B120;	A60-B121;
A60-B122;	A60-B123;	A60-B124;	A60-B125;	A60-B126;	A60-B127;
A60-B128;	A60-B129;	A60-B130;	A60-B131;	A60-B132;	A60-B133;
A60-B134;	A60-B135;	A60-B136;	A60-B137;	A60-B138;	A60-B139;
A60-B140;	A60-B141;	A60-B142;	A60-B143;	A60-B144;	A60-B145;
A60-B146;	A60-B147;	A60-B148;	A60-B149;	A60-B150;	A60-B151;
A60-B152;	A60-B153;	A60-B154;	A60-B155;	A60-B156;	A60-B157;
A60-B158;	A60-B159;	A60-B160;	A60-B161;	A60-B162;	A60-B163;
A60-B164;	A60-B165;	A60-B166;	A60-B167;	A60-B168;	A60-B169;
A61-B1;	A61-B2;	A61-B3;	A61-B4;	A61-B5;	A61-B6;
A61-B7;	A61-B8;	A61-B9;	A61-B10;	A61-B11;	A61-B12;
A61-B13;	A61-B14;	A61-B15;	A61-B16;	A61-B17;	A61-B18;
A61-B19;	A61-B20;	A61-B21;	A61-B22;	A61-B23;	A61-B24;
A61-B25;	A61-B26;	A61-B27;	A61-B28;	A61-B29;	A61-B30;
A61-B31;	A61-B32;	A61-B33;	A61-B34;	A61-B35;	A61-B36;
A61-B37;	A61-B38;	A61-B39;	A61-B40;	A61-B41;	A61-B42;
A61-B43;	A61-B44;	A61-B45;	A61-B46;	A61-B47;	A61-B48;
A61-B49;	A61-B50;	A61-B51;	A61-B52;	A61-B53;	A61-B54;
A61-B55;	A61-B56;	A61-B57;	A61-B58;	A61-B59;	A61-B60;
A61-B61;	A61-B62;	A61-B63;	A61-B64;	A61-B65;	A61-B66;
A61-B67;	A61-B68;	A61-B69;	A61-B70;	A61-B71;	A61-B72;
A61-B73;	A61-B74;	A61-B75;	A61-B76;	A61-B77;	A61-B78;
A61-B79;	A61-B80;	A61-B81;	A61-B82;	A61-B83;	A61-B84;
A61-B85;	A61-B86;	A61-B87;	A61-B88;	A61-B89;	A61-B90;
A61-B91;	A61-B92;	A61-B93;	A61-B94;	A61-B95;	A61-B96;
A61-B97;	A61-B98;	A61-B99;	A61-B100;	A61-B101;	A61-B102;
A61-B103;	A61-B104;	A61-B105;	A61-B106;	A61-B107;	A61-B108;
A61-B109;	A61-B110;	A61-B111;	A61-B112;	A61-B113;	A61-B114;
A61-B115;	A61-B116;	A61-B117;	A61-B118;	A61-B119;	A61-B120;
A61-B121;	A61-B122;	A61-B123;	A61-B124;	A61-B125;	A61-B126;
A61-B127;	A61-B128;	A61-B129;	A61-B130;	A61-B131;	A61-B132;
A61-B133;	A61-B134;	A61-B135;	A61-B136;	A61-B137;	A61-B138;
A61-B139;	A61-B140;	A61-B141;	A61-B142;	A61-B143;	A61-B144;
A61-B145;	A61-B146;	A61-B147;	A61-B148;	A61-B149;	A61-B150;
A61-B151;	A61-B152;	A61-B153;	A61-B154;	A61-B155;	A61-B156;
A61-B157;	A61-B158;	A61-B159;	A61-B160;	A61-B161;	A61-B162;
A61-B163;	A61-B164;	A61-B165;	A61-B166;	A61-B167;	A61-B168;
A61-B169;	A62-B1;	A62-B2;	A62-B3;	A62-B4;	A62-B5;
A62-B6;	A62-B7;	A62-B8;	A62-B9;	A62-B10;	A62-B11;
A62-B12;	A62-B13;	A62-B14;	A62-B15;	A62-B16;	A62-B17;
A62-B18;	A62-B19;	A62-B20;	A62-B21;	A62-B22;	A62-B23;
A62-B24;	A62-B25;	A62-B26;	A62-B27;	A62-B28;	A62-B29;
A62-B30;	A62-B31;	A62-B32;	A62-B33;	A62-B34;	A62-B35;
A62-B36;	A62-B37;	A62-B38;	A62-B39;	A62-B40;	A62-B41;
A62-B42;	A62-B43;	A62-B44;	A62-B45;	A62-B46;	A62-B47;
A62-B48;	A62-B49;	A62-B50;	A62-B51;	A62-B52;	A62-B53;
A62-B54;	A62-B55;	A62-B56;	A62-B57;	A62-B58;	A62-B59;
A62-B60;	A62-B61;	A62-B62;	A62-B63;	A62-B64;	A62-B65;
A62-B66;	A62-B67;	A62-B68;	A62-B69;	A62-B70;	A62-B71;
A62-B72;	A62-B73;	A62-B74;	A62-B75;	A62-B76;	A62-B77;
A62-B78;	A62-B79;	A62-B80;	A62-B81;	A62-B82;	A62-B83;
A62-B84;	A62-B85;	A62-B86;	A62-B87;	A62-B88;	A62-B89;
A62-B90;	A62-B91;	A62-B92;	A62-B93;	A62-B94;	A62-B95;
A62-B96;	A62-B97;	A62-B98;	A62-B99;	A62-B100;	A62-B101;
A62-B102;	A62-B103;	A62-B104;	A62-B105;	A62-B106;	A62-B107;
A62-B108;	A62-B109;	A62-B110;	A62-B111;	A62-B112;	A62-B113;
A62-B114;	A62-B115;	A62-B116;	A62-B117;	A62-B118;	A62-B119;
A62-B120;	A62-B121;	A62-B122;	A62-B123;	A62-B124;	A62-B125;
A62-B126;	A62-B127;	A62-B128;	A62-B129;	A62-B130;	A62-B131;
A62-B132;	A62-B133;	A62-B134;	A62-B135;	A62-B136;	A62-B137;
A62-B138;	A62-B139;	A62-B140;	A62-B141;	A62-B142;	A62-B143;
A62-B144;	A62-B145;	A62-B146;	A62-B147;	A62-B148;	A62-B149;
A62-B150;	A62-B151;	A62-B152;	A62-B153;	A62-B154;	A62-B155;
A62-B156;	A62-B157;	A62-B158;	A62-B159;	A62-B160;	A62-B161;
A62-B162;	A62-B163;	A62-B164;	A62-B165;	A62-B166;	A62-B167;
A62-B168;	A62-B169;	A63-B1;	A63-B2;	A63-B3;	A63-B4;
A63-B5;	A63-B6;	A63-B7;	A63-B8;	A63-B9;	A63-B10;
A63-B11;	A63-B12;	A63-B13;	A63-B14;	A63-B15;	A63-B16;
A63-B17;	A63-B18;	A63-B19;	A63-B20;	A63-B21;	A63-B22;
A63-B23;	A63-B24;	A63-B25;	A63-B26;	A63-B27;	A63-B28;
A63-B29;	A63-B30;	A63-B31;	A63-B32;	A63-B33;	A63-B34;
A63-B35;	A63-B36;	A63-B37;	A63-B38;	A63-B39;	A63-B40;
A63-B41;	A63-B42;	A63-B43;	A63-B44;	A63-B45;	A63-B46;
A63-B47;	A63-B48;	A63-B49;	A63-B50;	A63-B51;	A63-B52;
A63-B53;	A63-B54;	A63-B55;	A63-B56;	A63-B57;	A63-B58;
A63-B59;	A63-B60;	A63-B61;	A63-B62;	A63-B63;	A63-B64;
A63-B65;	A63-B66;	A63-B67;	A63-B68;	A63-B69;	A63-B70;
A63-B71;	A63-B72;	A63-B73;	A63-B74;	A63-B75;	A63-B76;
A63-B77;	A63-B78;	A63-B79;	A63-B80;	A63-B81;	A63-B82;
A63-B83;	A63-B84;	A63-B85;	A63-B86;	A63-B87;	A63-B88;
A63-B89;	A63-B90;	A63-B91;	A63-B92;	A63-B93;	A63-B94;
A63-B95;	A63-B96;	A63-B97;	A63-B98;	A63-B99;	A63-B100;
A63-B101;	A63-B102;	A63-B103;	A63-B104;	A63-B105;	A63-B106;
A63-B107;	A63-B108;	A63-B109;	A63-B110;	A63-B111;	A63-B112;
A63-B113;	A63-B114;	A63-B115;	A63-B116;	A63-B117;	A63-B118;
A63-B119;	A63-B120;	A63-B121;	A63-B122;	A63-B123;	A63-B124;
A63-B125;	A63-B126;	A63-B127;	A63-B128;	A63-B129;	A63-B130;
A63-B131;	A63-B132;	A63-B133;	A63-B134;	A63-B135;	A63-B136;
A63-B137;	A63-B138;	A63-B139;	A63-B140;	A63-B141;	A63-B142;
A63-B143;	A63-B144;	A63-B145;	A63-B146;	A63-B147;	A63-B148;
A63-B149;	A63-B150;	A63-B151;	A63-B152;	A63-B153;	A63-B154;
A63-B155;	A63-B156;	A63-B157;	A63-B158;	A63-B159;	A63-B160;
A63-B161;	A63-B162;	A63-B163;	A63-B164;	A63-B165;	A63-B166;
A63-B167;	A63-B168;	A63-B169;	A64-B1;	A64-B2;	A64-B3;
A64-B4;	A64-B5;	A64-B6;	A64-B7;	A64-B8;	A64-B9;
A64-B10;	A64-B11;	A64-B12;	A64-B13;	A64-B14;	A64-B15;
A64-B16;	A64-B17;	A64-B18;	A64-B19;	A64-B20;	A64-B21;
A64-B22;	A64-B23;	A64-B24;	A64-B25;	A64-B26;	A64-B27;
A64-B28;	A64-B29;	A64-B30;	A64-B31;	A64-B32;	A64-B33;
A64-B34;	A64-B35;	A64-B36;	A64-B37;	A64-B38;	A64-B39;
A64-B40;	A64-B41;	A64-B42;	A64-B43;	A64-B44;	A64-B45;
A64-B46;	A64-B47;	A64-B48;	A64-B49;	A64-B50;	A64-B51;
A64-B52;	A64-B53;	A64-B54;	A64-B55;	A64-B56;	A64-B57;
A64-B58;	A64-B59;	A64-B60;	A64-B61;	A64-B62;	A64-B63;
A64-B64;	A64-B65;	A64-B66;	A64-B67;	A64-B68;	A64-B69;
A64-B70;	A64-B71;	A64-B72;	A64-B73;	A64-B74;	A64-B75;
A64-B76;	A64-B77;	A64-B78;	A64-B79;	A64-B80;	A64-B81;
A64-B82;	A64-B83;	A64-B84;	A64-B85;	A64-B86;	A64-B87;
A64-B88;	A64-B89;	A64-B90;	A64-B91;	A64-B92;	A64-B93;
A64-B94;	A64-B95;	A64-B96;	A64-B97;	A64-B98;	A64-B99;
A64-B100;	A64-B101;	A64-B102;	A64-B103;	A64-B104;	A64-B105;
A64-B106;	A64-B107;	A64-B108;	A64-B109;	A64-B110;	A64-B111;
A64-B112;	A64-B113;	A64-B114;	A64-B115;	A64-B116;	A64-B117;
A64-B118;	A64-B119;	A64-B120;	A64-B121;	A64-B122;	A64-B123;
A64-B124;	A64-B125;	A64-B126;	A64-B127;	A64-B128;	A64-B129;
A64-B130;	A64-B131;	A64-B132;	A64-B133;	A64-B134;	A64-B135;
A64-B136;	A64-B137;	A64-B138;	A64-B139;	A64-B140;	A64-B141;
A64-B142;	A64-B143;	A64-B144;	A64-B145;	A64-B146;	A64-B147;
A64-B148;	A64-B149;	A64-B150;	A64-B151;	A64-B152;	A64-B153;
A64-B154;	A64-B155;	A64-B156;	A64-B157;	A64-B158;	A64-B159;
A64-B160;	A64-B161;	A64-B162;	A64-B163;	A64-B164;	A64-B165;
A64-B166;	A64-B167;	A64-B168;	A64-B169;	A65-B1;	A65-B2;
A65-B3;	A65-B4;	A65-B5;	A65-B6;	A65-B7;	A65-B8;
A65-B9;	A65-B10;	A65-B11;	A65-B12;	A65-B13;	A65-B14;
A65-B15;	A65-B16;	A65-B17;	A65-B18;	A65-B19;	A65-B20;
A65-B21;	A65-B22;	A65-B23;	A65-B24;	A65-B25;	A65-B26;
A65-B27;	A65-B28;	A65-B29;	A65-B30;	A65-B31;	A65-B32;
A65-B33;	A65-B34;	A65-B35;	A65-B36;	A65-B37;	A65-B38;
A65-B39;	A65-B40;	A65-B41;	A65-B42;	A65-B43;	A65-B44;
A65-B45;	A65-B46;	A65-B47;	A65-B48;	A65-B49;	A65-B50;
A65-B51;	A65-B52;	A65-B53;	A65-B54;	A65-B55;	A65-B56;
A65-B57;	A65-B58;	A65-B59;	A65-B60;	A65-B61;	A65-B62;
A65-B63;	A65-B64;	A65-B65;	A65-B66;	A65-B67;	A65-B68;
A65-B69;	A65-B70;	A65-B71;	A65-B72;	A65-B73;	A65-B74;
A65-B75;	A65-B76;	A65-B77;	A65-B78;	A65-B79;	A65-B80;
A65-B81;	A65-B82;	A65-B83;	A65-B84;	A65-B85;	A65-B86;
A65-B87;	A65-B88;	A65-B89;	A65-B90;	A65-B91;	A65-B92;
A65-B93;	A65-B94;	A65-B95;	A65-B96;	A65-B97;	A65-B98;
A65-B99;	A65-B100;	A65-B101;	A65-B102;	A65-B103;	A65-B104;
A65-B105;	A65-B106;	A65-B107;	A65-B108;	A65-B109;	A65-B110;
A65-B111;	A65-B112;	A65-B113;	A65-B114;	A65-B115;	A65-B116;
A65-B117;	A65-B118;	A65-B119;	A65-B120;	A65-B121;	A65-B122;
A65-B123;	A65-B124;	A65-B125;	A65-B126;	A65-B127;	A65-B128;
A65-B129;	A65-B130;	A65-B131;	A65-B132;	A65-B133;	A65-B134;
A65-B135;	A65-B136;	A65-B137;	A65-B138;	A65-B139;	A65-B140;
A65-B141;	A65-B142;	A65-B143;	A65-B144;	A65-B145;	A65-B146;
A65-B147;	A65-B148;	A65-B149;	A65-B150;	A65-B151;	A65-B152;
A65-B153;	A65-B154;	A65-B155;	A65-B156;	A65-B157;	A65-B158;
A65-B159;	A65-B160;	A65-B161;	A65-B162;	A65-B163;	A65-B164;
A65-B165;	A65-B166;	A65-B167;	A65-B168;	A65-B169;	A66-B1;
A66-B2;	A66-B3;	A66-B4;	A66-B5;	A66-B6;	A66-B7;
A66-B8;	A66-B9;	A66-B10;	A66-B11;	A66-B12;	A66-B13;
A66-B14;	A66-B15;	A66-B16;	A66-B17;	A66-B18;	A66-B19;
A66-B20;	A66-B21;	A66-B22;	A66-B23;	A66-B24;	A66-B25;
A66-B26;	A66-B27;	A66-B28;	A66-B29;	A66-B30;	A66-B31;
A66-B32;	A66-B33;	A66-B34;	A66-B35;	A66-B36;	A66-B37;
A66-B38;	A66-B39;	A66-B40;	A66-B41;	A66-B42;	A66-B43;
A66-B44;	A66-B45;	A66-B46;	A66-B47;	A66-B48;	A66-B49;
A66-B50;	A66-B51;	A66-B52;	A66-B53;	A66-B54;	A66-B55;
A66-B56;	A66-B57;	A66-B58;	A66-B59;	A66-B60;	A66-B61;
A66-B62;	A66-B63;	A66-B64;	A66-B65;	A66-B66;	A66-B67;
A66-B68;	A66-B69;	A66-B70;	A66-B71;	A66-B72;	A66-B73;
A66-B74;	A66-B75;	A66-B76;	A66-B77;	A66-B78;	A66-B79;
A66-B80;	A66-B81;	A66-B82;	A66-B83;	A66-B84;	A66-B85;
A66-B86;	A66-B87;	A66-B88;	A66-B89;	A66-B90;	A66-B91;
A66-B92;	A66-B93;	A66-B94;	A66-B95;	A66-B96;	A66-B97;
A66-B98;	A66-B99;	A66-B100;	A66-B101;	A66-B102;	A66-B103;
A66-B104;	A66-B105;	A66-B106;	A66-B107;	A66-B108;	A66-B109;
A66-B110;	A66-B111;	A66-B112;	A66-B113;	A66-B114;	A66-B115;
A66-B116;	A66-B117;	A66-B118;	A66-B119;	A66-B120;	A66-B121;
A66-B122;	A66-B123;	A66-B124;	A66-B125;	A66-B126;	A66-B127;
A66-B128;	A66-B129;	A66-B130;	A66-B131;	A66-B132;	A66-B133;
A66-B134;	A66-B135;	A66-B136;	A66-B137;	A66-B138;	A66-B139;
A66-B140;	A66-B141;	A66-B142;	A66-B143;	A66-B144;	A66-B145;
A66-B146;	A66-B147;	A66-B148;	A66-B149;	A66-B150;	A66-B151;
A66-B152;	A66-B153;	A66-B154;	A66-B155;	A66-B156;	A66-B157;
A66-B158;	A66-B159;	A66-B160;	A66-B161;	A66-B162;	A66-B163;
A66-B164;	A66-B165;	A66-B166;	A66-B167;	A66-B168;	A66-B169;
A67-B1;	A67-B2;	A67-B3;	A67-B4;	A67-B5;	A67-B6;
A67-B7;	A67-B8;	A67-B9;	A67-B10;	A67-B11;	A67-B12;
A67-B13;	A67-B14;	A67-B15;	A67-B16;	A67-B17;	A67-B18;
A67-B19;	A67-B20;	A67-B21;	A67-B22;	A67-B23;	A67-B24;
A67-B25;	A67-B26;	A67-B27;	A67-B28;	A67-B29;	A67-B30;
A67-B31;	A67-B32;	A67-B33;	A67-B34;	A67-B35;	A67-B36;
A67-B37;	A67-B38;	A67-B39;	A67-B40;	A67-B41;	A67-B42;
A67-B43;	A67-B44;	A67-B45;	A67-B46;	A67-B47;	A67-B48;
A67-B49;	A67-B50;	A67-B51;	A67-B52;	A67-B53;	A67-B54;
A67-B55;	A67-B56;	A67-B57;	A67-B58;	A67-B59;	A67-B60;
A67-B61;	A67-B62;	A67-B63;	A67-B64;	A67-B65;	A67-B66;
A67-B67;	A67-B68;	A67-B69;	A67-B70;	A67-B71;	A67-B72;
A67-B73;	A67-B74;	A67-B75;	A67-B76;	A67-B77;	A67-B78;
A67-B79;	A67-B80;	A67-B81;	A67-B82;	A67-B83;	A67-B84;
A67-B85;	A67-B86;	A67-B87;	A67-B88;	A67-B89;	A67-B90;
A67-B91;	A67-B92;	A67-B93;	A67-B94;	A67-B95;	A67-B96;
A67-B97;	A67-B98;	A67-B99;	A67-B100;	A67-B101;	A67-B102;
A67-B103;	A67-B104;	A67-B105;	A67-B106;	A67-B107;	A67-B108;
A67-B109;	A67-B110;	A67-B111;	A67-B112;	A67-B113;	A67-B114;
A67-B115;	A67-B116;	A67-B117;	A67-B118;	A67-B119;	A67-B120;
A67-B121;	A67-B122;	A67-B123;	A67-B124;	A67-B125;	A67-B126;
A67-B127;	A67-B128;	A67-B129;	A67-B130;	A67-B131;	A67-B132;
A67-B133;	A67-B134;	A67-B135;	A67-B136;	A67-B137;	A67-B138;
A67-B139;	A67-B140;	A67-B141;	A67-B142;	A67-B143;	A67-B144;
A67-B145;	A67-B146;	A67-B147;	A67-B148;	A67-B149;	A67-B150;
A67-B151;	A67-B152;	A67-B153;	A67-B154;	A67-B155;	A67-B156;
A67-B157;	A67-B158;	A67-B159;	A67-B160;	A67-B161;	A67-B162;
A67-B163;	A67-B164;	A67-B165;	A67-B166;	A67-B167;	A67-B168;
A67-B169;	A68-B1;	A68-B2;	A68-B3;	A68-B4;	A68-B5;
A68-B6;	A68-B7;	A68-B8;	A68-B9;	A68-B10;	A68-B11;
A68-B12;	A68-B13;	A68-B14;	A68-B15;	A68-B16;	A68-B17;
A68-B18;	A68-B19;	A68-B20;	A68-B21;	A68-B22;	A68-B23;
A68-B24;	A68-B25;	A68-B26;	A68-B27;	A68-B28;	A68-B29;
A68-B30;	A68-B31;	A68-B32;	A68-B33;	A68-B34;	A68-B35;
A68-B36;	A68-B37;	A68-B38;	A68-B39;	A68-B40;	A68-B41;
A68-B42;	A68-B43;	A68-B44;	A68-B45;	A68-B46;	A68-B47;
A68-B48;	A68-B49;	A68-B50;	A68-B51;	A68-B52;	A68-B53;
A68-B54;	A68-B55;	A68-B56;	A68-B57;	A68-B58;	A68-B59;
A68-B60;	A68-B61;	A68-B62;	A68-B63;	A68-B64;	A68-B65;
A68-B66;	A68-B67;	A68-B68;	A68-B69;	A68-B70;	A68-B71;
A68-B72;	A68-B73;	A68-B74;	A68-B75;	A68-B76;	A68-B77;
A68-B78;	A68-B79;	A68-B80;	A68-B81;	A68-B82;	A68-B83;
A68-B84;	A68-B85;	A68-B86;	A68-B87;	A68-B88;	A68-B89;
A68-B90;	A68-B91;	A68-B92;	A68-B93;	A68-B94;	A68-B95;
A68-B96;	A68-B97;	A68-B98;	A68-B99;	A68-B100;	A68-B101;
A68-B102;	A68-B103;	A68-B104;	A68-B105;	A68-B106;	A68-B107;
A68-B108;	A68-B109;	A68-B110;	A68-B111;	A68-B112;	A68-B113;
A68-B114;	A68-B115;	A68-B116;	A68-B117;	A68-B118;	A68-B119;
A68-B120;	A68-B121;	A68-B122;	A68-B123;	A68-B124;	A68-B125;
A68-B126;	A68-B127;	A68-B128;	A68-B129;	A68-B130;	A68-B131;
A68-B132;	A68-B133;	A68-B134;	A68-B135;	A68-B136;	A68-B137;
A68-B138;	A68-B139;	A68-B140;	A68-B141;	A68-B142;	A68-B143;
A68-B144;	A68-B145;	A68-B146;	A68-B147;	A68-B148;	A68-B149;
A68-B150;	A68-B151;	A68-B152;	A68-B153;	A68-B154;	A68-B155;
A68-B156;	A68-B157;	A68-B158;	A68-B159;	A68-B160;	A68-B161;
A68-B162;	A68-B163;	A68-B164;	A68-B165;	A68-B166;	A68-B167;
A68-B168;	A68-B169;	A69-B1;	A69-B2;	A69-B3;	A69-B4;
A69-B5;	A69-B6;	A69-B7;	A69-B8;	A69-B9;	A69-B10;
A69-B11;	A69-B12;	A69-B13;	A69-B14;	A69-B15;	A69-B16;
A69-B17;	A69-B18;	A69-B19;	A69-B20;	A69-B21;	A69-B22;
A69-B23;	A69-B24;	A69-B25;	A69-B26;	A69-B27;	A69-B28;
A69-B29;	A69-B30;	A69-B31;	A69-B32;	A69-B33;	A69-B34;
A69-B35;	A69-B36;	A69-B37;	A69-B38;	A69-B39;	A69-B40;
A69-B41;	A69-B42;	A69-B43;	A69-B44;	A69-B45;	A69-B46;
A69-B47;	A69-B48;	A69-B49;	A69-B50;	A69-B51;	A69-B52;
A69-B53;	A69-B54;	A69-B55;	A69-B56;	A69-B57;	A69-B58;
A69-B59;	A69-B60;	A69-B61;	A69-B62;	A69-B63;	A69-B64;
A69-B65;	A69-B66;	A69-B67;	A69-B68;	A69-B69;	A69-B70;
A69-B71;	A69-B72;	A69-B73;	A69-B74;	A69-B75;	A69-B76;
A69-B77;	A69-B78;	A69-B79;	A69-B80;	A69-B81;	A69-B82;
A69-B83;	A69-B84;	A69-B85;	A69-B86;	A69-B87;	A69-B88;
A69-B89;	A69-B90;	A69-B91;	A69-B92;	A69-B93;	A69-B94;
A69-B95;	A69-B96;	A69-B97;	A69-B98;	A69-B99;	A69-B100;
A69-B101;	A69-B102;	A69-B103;	A69-B104;	A69-B105;	A69-B106;
A69-B107;	A69-B108;	A69-B109;	A69-B110;	A69-B111;	A69-B112;
A69-B113;	A69-B114;	A69-B115;	A69-B116;	A69-B117;	A69-B118;
A69-B119;	A69-B120;	A69-B121;	A69-B122;	A69-B123;	A69-B124;
A69-B125;	A69-B126;	A69-B127;	A69-B128;	A69-B129;	A69-B130;
A69-B131;	A69-B132;	A69-B133;	A69-B134;	A69-B135;	A69-B136;
A69-B137;	A69-B138;	A69-B139;	A69-B140;	A69-B141;	A69-B142;
A69-B143;	A69-B144;	A69-B145;	A69-B146;	A69-B147;	A69-B148;
A69-B149;	A69-B150;	A69-B151;	A69-B152;	A69-B153;	A69-B154;
A69-B155;	A69-B156;	A69-B157;	A69-B158;	A69-B159;	A69-B160;
A69-B161;	A69-B162;	A69-B163;	A69-B164;	A69-B165;	A69-B166;
A69-B167;	A69-B168;	A69-B169;	A70-B1;	A70-B2;	A70-B3;
A70-B4;	A70-B5;	A70-B6;	A70-B7;	A70-B8;	A70-B9;
A70-B10;	A70-B11;	A70-B12;	A70-B13;	A70-B14;	A70-B15;
A70-B16;	A70-B17;	A70-B18;	A70-B19;	A70-B20;	A70-B21;
A70-B22;	A70-B23;	A70-B24;	A70-B25;	A70-B26;	A70-B27;
A70-B28;	A70-B29;	A70-B30;	A70-B31;	A70-B32;	A70-B33;
A70-B34;	A70-B35;	A70-B36;	A70-B37;	A70-B38;	A70-B39;
A70-B40;	A70-B41;	A70-B42;	A70-B43;	A70-B44;	A70-B45;
A70-B46;	A70-B47;	A70-B48;	A70-B49;	A70-B50;	A70-B51;
A70-B52;	A70-B53;	A70-B54;	A70-B55;	A70-B56;	A70-B57;
A70-B58;	A70-B59;	A70-B60;	A70-B61;	A70-B62;	A70-B63;
A70-B64;	A70-B65;	A70-B66;	A70-B67;	A70-B68;	A70-B69;
A70-B70;	A70-B71;	A70-B72;	A70-B73;	A70-B74;	A70-B75;
A70-B76;	A70-B77;	A70-B78;	A70-B79;	A70-B80;	A70-B81;
A70-B82;	A70-B83;	A70-B84;	A70-B85;	A70-B86;	A70-B87;
A70-B88;	A70-B89;	A70-B90;	A70-B91;	A70-B92;	A70-B93;
A70-B94;	A70-B95;	A70-B96;	A70-B97;	A70-B98;	A70-B99;
A70-B100;	A70-B101;	A70-B102;	A70-B103;	A70-B104;	A70-B105;
A70-B106;	A70-B107;	A70-B108;	A70-B109;	A70-B110;	A70-B111;
A70-B112;	A70-B113;	A70-B114;	A70-B115;	A70-B116;	A70-B117;
A70-B118;	A70-B119;	A70-B120;	A70-B121;	A70-B122;	A70-B123;
A70-B124;	A70-B125;	A70-B126;	A70-B127;	A70-B128;	A70-B129;
A70-B130;	A70-B131;	A70-B132;	A70-B133;	A70-B134;	A70-B135;
A70-B136;	A70-B137;	A70-B138;	A70-B139;	A70-B140;	A70-B141;
A70-B142;	A70-B143;	A70-B144;	A70-B145;	A70-B146;	A70-B147;
A70-B148;	A70-B149;	A70-B150;	A70-B151;	A70-B152;	A70-B153;
A70-B154;	A70-B155;	A70-B156;	A70-B157;	A70-B158;	A70-B159;
A70-B160;	A70-B161;	A70-B162;	A70-B163;	A70-B164;	A70-B165;
A70-B166;	A70-B167;	A70-B168;	A70-B169;	A71-B1;	A71-B2;
A71-B3;	A71-B4;	A71-B5;	A71-B6;	A71-B7;	A71-B8;
A71-B9;	A71-B10;	A71-B11;	A71-B12;	A71-B13;	A71-B14;
A71-B15;	A71-B16;	A71-B17;	A71-B18;	A71-B19;	A71-B20;
A71-B21;	A71-B22;	A71-B23;	A71-B24;	A71-B25;	A71-B26;
A71-B27;	A71-B28;	A71-B29;	A71-B30;	A71-B31;	A71-B32;
A71-B33;	A71-B34;	A71-B35;	A71-B36;	A71-B37;	A71-B38;
A71-B39;	A71-B40;	A71-B41;	A71-B42;	A71-B43;	A71-B44;
A71-B45;	A71-B46;	A71-B47;	A71-B48;	A71-B49;	A71-B50;
A71-B51;	A71-B52;	A71-B53;	A71-B54;	A71-B55;	A71-B56;
A71-B57;	A71-B58;	A71-B59;	A71-B60;	A71-B61;	A71-B62;
A71-B63;	A71-B64;	A71-B65;	A71-B66;	A71-B67;	A71-B68;
A71-B69;	A71-B70;	A71-B71;	A71-B72;	A71-B73;	A71-B74;
A71-B75;	A71-B76;	A71-B77;	A71-B78;	A71-B79;	A71-B80;
A71-B81;	A71-B82;	A71-B83;	A71-B84;	A71-B85;	A71-B86;
A71-B87;	A71-B88;	A71-B89;	A71-B90;	A71-B91;	A71-B92;
A71-B93;	A71-B94;	A71-B95;	A71-B96;	A71-B97;	A71-B98;
A71-B99;	A71-B100;	A71-B101;	A71-B102;	A71-B103;	A71-B104;
A71-B105;	A71-B106;	A71-B107;	A71-B108;	A71-B109;	A71-B110;
A71-B111;	A71-B112;	A71-B113;	A71-B114;	A71-B115;	A71-B116;
A71-B117;	A71-B118;	A71-B119;	A71-B120;	A71-B121;	A71-B122;
A71-B123;	A71-B124;	A71-B125;	A71-B126;	A71-B127;	A71-B128;
A71-B129;	A71-B130;	A71-B131;	A71-B132;	A71-B133;	A71-B134;
A71-B135;	A71-B136;	A71-B137;	A71-B138;	A71-B139;	A71-B140;
A71-B141;	A71-B142;	A71-B143;	A71-B144;	A71-B145;	A71-B146;
A71-B147;	A71-B148;	A71-B149;	A71-B150;	A71-B151;	A71-B152;
A71-B153;	A71-B154;	A71-B155;	A71-B156;	A71-B157;	A71-B158;
A71-B159;	A71-B160;	A71-B161;	A71-B162;	A71-B163;	A71-B164;
A71-B165;	A71-B166;	A71-B167;	A71-B168;	A71-B169;	A72-B1;
A72-B2;	A72-B3;	A72-B4;	A72-B5;	A72-B6;	A72-B7;
A72-B8;	A72-B9;	A72-B10;	A72-B11;	A72-B12;	A72-B13;
A72-B14;	A72-B15;	A72-B16;	A72-B17;	A72-B18;	A72-B19;
A72-B20;	A72-B21;	A72-B22;	A72-B23;	A72-B24;	A72-B25;
A72-B26;	A72-B27;	A72-B28;	A72-B29;	A72-B30;	A72-B31;
A72-B32;	A72-B33;	A72-B34;	A72-B35;	A72-B36;	A72-B37;
A72-B38;	A72-B39;	A72-B40;	A72-B41;	A72-B42;	A72-B43;
A72-B44;	A72-B45;	A72-B46;	A72-B47;	A72-B48;	A72-B49;
A72-B50;	A72-B51;	A72-B52;	A72-B53;	A72-B54;	A72-B55;
A72-B56;	A72-B57;	A72-B58;	A72-B59;	A72-B60;	A72-B61;
A72-B62;	A72-B63;	A72-B64;	A72-B65;	A72-B66;	A72-B67;
A72-B68;	A72-B69;	A72-B70;	A72-B71;	A72-B72;	A72-B73;
A72-B74;	A72-B75;	A72-B76;	A72-B77;	A72-B78;	A72-B79;
A72-B80;	A72-B81;	A72-B82;	A72-B83;	A72-B84;	A72-B85;
A72-B86;	A72-B87;	A72-B88;	A72-B89;	A72-B90;	A72-B91;
A72-B92;	A72-B93;	A72-B94;	A72-B95;	A72-B96;	A72-B97;
A72-B98;	A72-B99;	A72-B100;	A72-B101;	A72-B102;	A72-B103;
A72-B104;	A72-B105;	A72-B106;	A72-B107;	A72-B108;	A72-B109;
A72-B110;	A72-B111;	A72-B112;	A72-B113;	A72-B114;	A72-B115;
A72-B116;	A72-B117;	A72-B118;	A72-B119;	A72-B120;	A72-B121;
A72-B122;	A72-B123;	A72-B124;	A72-B125;	A72-B126;	A72-B127;
A72-B128;	A72-B129;	A72-B130;	A72-B131;	A72-B132;	A72-B133;
A72-B134;	A72-B135;	A72-B136;	A72-B137;	A72-B138;	A72-B139;
A72-B140;	A72-B141;	A72-B142;	A72-B143;	A72-B144;	A72-B145;
A72-B146;	A72-B147;	A72-B148;	A72-B149;	A72-B150;	A72-B151;
A72-B152;	A72-B153;	A72-B154;	A72-B155;	A72-B156;	A72-B157;
A72-B158;	A72-B159;	A72-B160;	A72-B161;	A72-B162;	A72-B163;
A72-B164;	A72-B165;	A72-B166;	A72-B167;	A72-B168;	A72-B169;
A73-B1;	A73-B2;	A73-B3;	A73-B4;	A73-B5;	A73-B6;
A73-B7;	A73-B8;	A73-B9;	A73-B10;	A73-B11;	A73-B12;
A73-B13;	A73-B14;	A73-B15;	A73-B16;	A73-B17;	A73-B18;
A73-B19;	A73-B20;	A73-B21;	A73-B22;	A73-B23;	A73-B24;
A73-B25;	A73-B26;	A73-B27;	A73-B28;	A73-B29;	A73-B30;
A73-B31;	A73-B32;	A73-B33;	A73-B34;	A73-B35;	A73-B36;
A73-B37;	A73-B38;	A73-B39;	A73-B40;	A73-B41;	A73-B42;
A73-B43;	A73-B44;	A73-B45;	A73-B46;	A73-B47;	A73-B48;
A73-B49;	A73-B50;	A73-B51;	A73-B52;	A73-B53;	A73-B54;
A73-B55;	A73-B56;	A73-B57;	A73-B58;	A73-B59;	A73-B60;
A73-B61;	A73-B62;	A73-B63;	A73-B64;	A73-B65;	A73-B66;
A73-B67;	A73-B68;	A73-B69;	A73-B70;	A73-B71;	A73-B72;
A73-B73;	A73-B74;	A73-B75;	A73-B76;	A73-B77;	A73-B78;
A73-B79;	A73-B80;	A73-B81;	A73-B82;	A73-B83;	A73-B84;
A73-B85;	A73-B86;	A73-B87;	A73-B88;	A73-B89;	A73-B90;
A73-B91;	A73-B92;	A73-B93;	A73-B94;	A73-B95;	A73-B96;
A73-B97;	A73-B98;	A73-B99;	A73-B100;	A73-B101;	A73-B102;
A73-B103;	A73-B104;	A73-B105;	A73-B106;	A73-B107;	A73-B108;
A73-B109;	A73-B110;	A73-B111;	A73-B112;	A73-B113;	A73-B114;
A73-B115;	A73-B116;	A73-B117;	A73-B118;	A73-B119;	A73-B120;
A73-B121;	A73-B122;	A73-B123;	A73-B124;	A73-B125;	A73-B126;
A73-B127;	A73-B128;	A73-B129;	A73-B130;	A73-B131;	A73-B132;
A73-B133;	A73-B134;	A73-B135;	A73-B136;	A73-B137;	A73-B138;
A73-B139;	A73-B140;	A73-B141;	A73-B142;	A73-B143;	A73-B144;
A73-B145;	A73-B146;	A73-B147;	A73-B148;	A73-B149;	A73-B150;
A73-B151;	A73-B152;	A73-B153;	A73-B154;	A73-B155;	A73-B156;
A73-B157;	A73-B158;	A73-B159;	A73-B160;	A73-B161;	A73-B162;
A73-B163;	A73-B164;	A73-B165;	A73-B166;	A73-B167;	A73-B168;
A73-B169;	A74-B1;	A74-B2;	A74-B3;	A74-B4;	A74-B5;
A74-B6;	A74-B7;	A74-B8;	A74-B9;	A74-B10;	A74-B11;
A74-B12;	A74-B13;	A74-B14;	A74-B15;	A74-B16;	A74-B17;
A74-B18;	A74-B19;	A74-B20;	A74-B21;	A74-B22;	A74-B23;
A74-B24;	A74-B25;	A74-B26;	A74-B27;	A74-B28;	A74-B29;
A74-B30;	A74-B31;	A74-B32;	A74-B33;	A74-B34;	A74-B35;
A74-B36;	A74-B37;	A74-B38;	A74-B39;	A74-B40;	A74-B41;
A74-B42;	A74-B43;	A74-B44;	A74-B45;	A74-B46;	A74-B47;
A74-B48;	A74-B49;	A74-B50;	A74-B51;	A74-B52;	A74-B53;
A74-B54;	A74-B55;	A74-B56;	A74-B57;	A74-B58;	A74-B59;
A74-B60;	A74-B61;	A74-B62;	A74-B63;	A74-B64;	A74-B65;
A74-B66;	A74-B67;	A74-B68;	A74-B69;	A74-B70;	A74-B71;
A74-B72;	A74-B73;	A74-B74;	A74-B75;	A74-B76;	A74-B77;
A74-B78;	A74-B79;	A74-B80;	A74-B81;	A74-B82;	A74-B83;
A74-B84;	A74-B85;	A74-B86;	A74-B87;	A74-B88;	A74-B89;
A74-B90;	A74-B91;	A74-B92;	A74-B93;	A74-B94;	A74-B95;
A74-B96;	A74-B97;	A74-B98;	A74-B99;	A74-B100;	A74-B101;
A74-B102;	A74-B103;	A74-B104;	A74-B105;	A74-B106;	A74-B107;
A74-B108;	A74-B109;	A74-B110;	A74-B111;	A74-B112;	A74-B113;
A74-B114;	A74-B115;	A74-B116;	A74-B117;	A74-B118;	A74-B119;
A74-B120;	A74-B121;	A74-B122;	A74-B123;	A74-B124;	A74-B125;
A74-B126;	A74-B127;	A74-B128;	A74-B129;	A74-B130;	A74-B131;
A74-B132;	A74-B133;	A74-B134;	A74-B135;	A74-B136;	A74-B137;
A74-B138;	A74-B139;	A74-B140;	A74-B141;	A74-B142;	A74-B143;
A74-B144;	A74-B145;	A74-B146;	A74-B147;	A74-B148;	A74-B149;
A74-B150;	A74-B151;	A74-B152;	A74-B153;	A74-B154;	A74-B155;
A74-B156;	A74-B157;	A74-B158;	A74-B159;	A74-B160;	A74-B161;
A74-B162;	A74-B163;	A74-B164;	A74-B165;	A74-B166;	A74-B167;
A74-B168;	A74-B169;	A75-B1;	A75-B2;	A75-B3;	A75-B4;
A75-B5;	A75-B6;	A75-B7;	A75-B8;	A75-B9;	A75-B10;
A75-B11;	A75-B12;	A75-B13;	A75-B14;	A75-B15;	A75-B16;
A75-B17;	A75-B18;	A75-B19;	A75-B20;	A75-B21;	A75-B22;
A75-B23;	A75-B24;	A75-B25;	A75-B26;	A75-B27;	A75-B28;
A75-B29;	A75-B30;	A75-B31;	A75-B32;	A75-B33;	A75-B34;
A75-B35;	A75-B36;	A75-B37;	A75-B38;	A75-B39;	A75-B40;
A75-B41;	A75-B42;	A75-B43;	A75-B44;	A75-B45;	A75-B46;
A75-B47;	A75-B48;	A75-B49;	A75-B50;	A75-B51;	A75-B52;
A75-B53;	A75-B54;	A75-B55;	A75-B56;	A75-B57;	A75-B58;
A75-B59;	A75-B60;	A75-B61;	A75-B62;	A75-B63;	A75-B64;
A75-B65;	A75-B66;	A75-B67;	A75-B68;	A75-B69;	A75-B70;
A75-B71;	A75-B72;	A75-B73;	A75-B74;	A75-B75;	A75-B76;
A75-B77;	A75-B78;	A75-B79;	A75-B80;	A75-B81;	A75-B82;
A75-B83;	A75-B84;	A75-B85;	A75-B86;	A75-B87;	A75-B88;
A75-B89;	A75-B90;	A75-B91;	A75-B92;	A75-B93;	A75-B94;
A75-B95;	A75-B96;	A75-B97;	A75-B98;	A75-B99;	A75-B100;
A75-B101;	A75-B102;	A75-B103;	A75-B104;	A75-B105;	A75-B106;
A75-B107;	A75-B108;	A75-B109;	A75-B110;	A75-B111;	A75-B112;
A75-B113;	A75-B114;	A75-B115;	A75-B116;	A75-B117;	A75-B118;
A75-B119;	A75-B120;	A75-B121;	A75-B122;	A75-B123;	A75-B124;
A75-B125;	A75-B126;	A75-B127;	A75-B128;	A75-B129;	A75-B130;
A75-B131;	A75-B132;	A75-B133;	A75-B134;	A75-B135;	A75-B136;
A75-B137;	A75-B138;	A75-B139;	A75-B140;	A75-B141;	A75-B142;
A75-B143;	A75-B144;	A75-B145;	A75-B146;	A75-B147;	A75-B148;
A75-B149;	A75-B150;	A75-B151;	A75-B152;	A75-B153;	A75-B154;
A75-B155;	A75-B156;	A75-B157;	A75-B158;	A75-B159;	A75-B160;
A75-B161;	A75-B162;	A75-B163;	A75-B164;	A75-B165;	A75-B166;
A75-B167;	A75-B168;	A75-B169;	A76-B1;	A76-B2;	A76-B3;
A76-B4;	A76-B5;	A76-B6;	A76-B7;	A76-B8;	A76-B9;
A76-B10;	A76-B11;	A76-B12;	A76-B13;	A76-B14;	A76-B15;
A76-B16;	A76-B17;	A76-B18;	A76-B19;	A76-B20;	A76-B21;
A76-B22;	A76-B23;	A76-B24;	A76-B25;	A76-B26;	A76-B27;
A76-B28;	A76-B29;	A76-B30;	A76-B31;	A76-B32;	A76-B33;
A76-B34;	A76-B35;	A76-B36;	A76-B37;	A76-B38;	A76-B39;
A76-B40;	A76-B41;	A76-B42;	A76-B43;	A76-B44;	A76-B45;
A76-B46;	A76-B47;	A76-B48;	A76-B49;	A76-B50;	A76-B51;
A76-B52;	A76-B53;	A76-B54;	A76-B55;	A76-B56;	A76-B57;
A76-B58;	A76-B59;	A76-B60;	A76-B61;	A76-B62;	A76-B63;
A76-B64;	A76-B65;	A76-B66;	A76-B67;	A76-B68;	A76-B69;
A76-B70;	A76-B71;	A76-B72;	A76-B73;	A76-B74;	A76-B75;
A76-B76;	A76-B77;	A76-B78;	A76-B79;	A76-B80;	A76-B81;
A76-B82;	A76-B83;	A76-B84;	A76-B85;	A76-B86;	A76-B87;
A76-B88;	A76-B89;	A76-B90;	A76-B91;	A76-B92;	A76-B93;
A76-B94;	A76-B95;	A76-B96;	A76-B97;	A76-B98;	A76-B99;
A76-B100;	A76-B101;	A76-B102;	A76-B103;	A76-B104;	A76-B105;
A76-B106;	A76-B107;	A76-B108;	A76-B109;	A76-B110;	A76-B111;
A76-B112;	A76-B113;	A76-B114;	A76-B115;	A76-B116;	A76-B117;
A76-B118;	A76-B119;	A76-B120;	A76-B121;	A76-B122;	A76-B123;
A76-B124;	A76-B125;	A76-B126;	A76-B127;	A76-B128;	A76-B129;
A76-B130;	A76-B131;	A76-B132;	A76-B133;	A76-B134;	A76-B135;
A76-B136;	A76-B137;	A76-B138;	A76-B139;	A76-B140;	A76-B141;
A76-B142;	A76-B143;	A76-B144;	A76-B145;	A76-B146;	A76-B147;
A76-B148;	A76-B149;	A76-B150;	A76-B151;	A76-B152;	A76-B153;
A76-B154;	A76-B155;	A76-B156;	A76-B157;	A76-B158;	A76-B159;
A76-B160;	A76-B161;	A76-B162;	A76-B163;	A76-B164;	A76-B165;
A76-B166;	A76-B167;	A76-B168;	A76-B169;	A77-B1;	A77-B2;
A77-B3;	A77-B4;	A77-B5;	A77-B6;	A77-B7;	A77-B8;
A77-B9;	A77-B10;	A77-B11;	A77-B12;	A77-B13;	A77-B14;
A77-B15;	A77-B16;	A77-B17;	A77-B18;	A77-B19;	A77-B20;
A77-B21;	A77-B22;	A77-B23;	A77-B24;	A77-B25;	A77-B26;
A77-B27;	A77-B28;	A77-B29;	A77-B30;	A77-B31;	A77-B32;
A77-B33;	A77-B34;	A77-B35;	A77-B36;	A77-B37;	A77-B38;
A77-B39;	A77-B40;	A77-B41;	A77-B42;	A77-B43;	A77-B44;
A77-B45;	A77-B46;	A77-B47;	A77-B48;	A77-B49;	A77-B50;
A77-B51;	A77-B52;	A77-B53;	A77-B54;	A77-B55;	A77-B56;
A77-B57;	A77-B58;	A77-B59;	A77-B60;	A77-B61;	A77-B62;
A77-B63;	A77-B64;	A77-B65;	A77-B66;	A77-B67;	A77-B68;
A77-B69;	A77-B70;	A77-B71;	A77-B72;	A77-B73;	A77-B74;
A77-B75;	A77-B76;	A77-B77;	A77-B78;	A77-B79;	A77-B80;
A77-B81;	A77-B82;	A77-B83;	A77-B84;	A77-B85;	A77-B86;
A77-B87;	A77-B88;	A77-B89;	A77-B90;	A77-B91;	A77-B92;
A77-B93;	A77-B94;	A77-B95;	A77-B96;	A77-B97;	A77-B98;
A77-B99;	A77-B100;	A77-B101;	A77-B102;	A77-B103;	A77-B104;
A77-B105;	A77-B106;	A77-B107;	A77-B108;	A77-B109;	A77-B110;
A77-B111;	A77-B112;	A77-B113;	A77-B114;	A77-B115;	A77-B116;
A77-B117;	A77-B118;	A77-B119;	A77-B120;	A77-B121;	A77-B122;
A77-B123;	A77-B124;	A77-B125;	A77-B126;	A77-B127;	A77-B128;
A77-B129;	A77-B130;	A77-B131;	A77-B132;	A77-B133;	A77-B134;
A77-B135;	A77-B136;	A77-B137;	A77-B138;	A77-B139;	A77-B140;
A77-B141;	A77-B142;	A77-B143;	A77-B144;	A77-B145;	A77-B146;
A77-B147;	A77-B148;	A77-B149;	A77-B150;	A77-B151;	A77-B152;
A77-B153;	A77-B154;	A77-B155;	A77-B156;	A77-B157;	A77-B158;
A77-B159;	A77-B160;	A77-B161;	A77-B162;	A77-B163;	A77-B164;
A77-B165;	A77-B166;	A77-B167;	A77-B168;	A77-B169;	A78-B1;
A78-B2;	A78-B3;	A78-B4;	A78-B5;	A78-B6;	A78-B7;
A78-B8;	A78-B9;	A78-B10;	A78-B11;	A78-B12;	A78-B13;
A78-B14;	A78-B15;	A78-B16;	A78-B17;	A78-B18;	A78-B19;
A78-B20;	A78-B21;	A78-B22;	A78-B23;	A78-B24;	A78-B25;
A78-B26;	A78-B27;	A78-B28;	A78-B29;	A78-B30;	A78-B31;
A78-B32;	A78-B33;	A78-B34;	A78-B35;	A78-B36;	A78-B37;
A78-B38;	A78-B39;	A78-B40;	A78-B41;	A78-B42;	A78-B43;
A78-B44;	A78-B45;	A78-B46;	A78-B47;	A78-B48;	A78-B49;
A78-B50;	A78-B51;	A78-B52;	A78-B53;	A78-B54;	A78-B55;
A78-B56;	A78-B57;	A78-B58;	A78-B59;	A78-B60;	A78-B61;
A78-B62;	A78-B63;	A78-B64;	A78-B65;	A78-B66;	A78-B67;
A78-B68;	A78-B69;	A78-B70;	A78-B71;	A78-B72;	A78-B73;
A78-B74;	A78-B75;	A78-B76;	A78-B77;	A78-B78;	A78-B79;
A78-B80;	A78-B81;	A78-B82;	A78-B83;	A78-B84;	A78-B85;
A78-B86;	A78-B87;	A78-B88;	A78-B89;	A78-B90;	A78-B91;
A78-B92;	A78-B93;	A78-B94;	A78-B95;	A78-B96;	A78-B97;
A78-B98;	A78-B99;	A78-B100;	A78-B101;	A78-B102;	A78-B103;
A78-B104;	A78-B105;	A78-B106;	A78-B107;	A78-B108;	A78-B109;
A78-B110;	A78-B111;	A78-B112;	A78-B113;	A78-B114;	A78-B115;
A78-B116;	A78-B117;	A78-B118;	A78-B119;	A78-B120;	A78-B121;
A78-B122;	A78-B123;	A78-B124;	A78-B125;	A78-B126;	A78-B127;
A78-B128;	A78-B129;	A78-B130;	A78-B131;	A78-B132;	A78-B133;
A78-B134;	A78-B135;	A78-B136;	A78-B137;	A78-B138;	A78-B139;
A78-B140;	A78-B141;	A78-B142;	A78-B143;	A78-B144;	A78-B145;
A78-B146;	A78-B147;	A78-B148;	A78-B149;	A78-B150;	A78-B151;
A78-B152;	A78-B153;	A78-B154;	A78-B155;	A78-B156;	A78-B157;
A78-B158;	A78-B159;	A78-B160;	A78-B161;	A78-B162;	A78-B163;
A78-B164;	A78-B165;	A78-B166;	A78-B167;	A78-B168;	A78-B169;
A79-B1;	A79-B2;	A79-B3;	A79-B4;	A79-B5;	A79-B6;
A79-B7;	A79-B8;	A79-B9;	A79-B10;	A79-B11;	A79-B12;
A79-B13;	A79-B14;	A79-B15;	A79-B16;	A79-B17;	A79-B18;
A79-B19;	A79-B20;	A79-B21;	A79-B22;	A79-B23;	A79-B24;
A79-B25;	A79-B26;	A79-B27;	A79-B28;	A79-B29;	A79-B30;
A79-B31;	A79-B32;	A79-B33;	A79-B34;	A79-B35;	A79-B36;
A79-B37;	A79-B38;	A79-B39;	A79-B40;	A79-B41;	A79-B42;
A79-B43;	A79-B44;	A79-B45;	A79-B46;	A79-B47;	A79-B48;
A79-B49;	A79-B50;	A79-B51;	A79-B52;	A79-B53;	A79-B54;
A79-B55;	A79-B56;	A79-B57;	A79-B58;	A79-B59;	A79-B60;
A79-B61;	A79-B62;	A79-B63;	A79-B64;	A79-B65;	A79-B66;
A79-B67;	A79-B68;	A79-B69;	A79-B70;	A79-B71;	A79-B72;
A79-B73;	A79-B74;	A79-B75;	A79-B76;	A79-B77;	A79-B78;
A79-B79;	A79-B80;	A79-B81;	A79-B82;	A79-B83;	A79-B84;
A79-B85;	A79-B86;	A79-B87;	A79-B88;	A79-B89;	A79-B90;
A79-B91;	A79-B92;	A79-B93;	A79-B94;	A79-B95;	A79-B96;
A79-B97;	A79-B98;	A79-B99;	A79-B100;	A79-B101;	A79-B102;
A79-B103;	A79-B104;	A79-B105;	A79-B106;	A79-B107;	A79-B108;
A79-B109;	A79-B110;	A79-B111;	A79-B112;	A79-B113;	A79-B114;
A79-B115;	A79-B116;	A79-B117;	A79-B118;	A79-B119;	A79-B120;
A79-B121;	A79-B122;	A79-B123;	A79-B124;	A79-B125;	A79-B126;
A79-B127;	A79-B128;	A79-B129;	A79-B130;	A79-B131;	A79-B132;
A79-B133;	A79-B134;	A79-B135;	A79-B136;	A79-B137;	A79-B138;
A79-B139;	A79-B140;	A79-B141;	A79-B142;	A79-B143;	A79-B144;
A79-B145;	A79-B146;	A79-B147;	A79-B148;	A79-B149;	A79-B150;
A79-B151;	A79-B152;	A79-B153;	A79-B154;	A79-B155;	A79-B156;
A79-B157;	A79-B158;	A79-B159;	A79-B160;	A79-B161;	A79-B162;
A79-B163;	A79-B164;	A79-B165;	A79-B166;	A79-B167;	A79-B168;
A79-B169;	A80-B1;	A80-B2;	A80-B3;	A80-B4;	A80-B5;
A80-B6;	A80-B7;	A80-B8;	A80-B9;	A80-B10;	A80-B11;
A80-B12;	A80-B13;	A80-B14;	A80-B15;	A80-B16;	A80-B17;
A80-B18;	A80-B19;	A80-B20;	A80-B21;	A80-B22;	A80-B23;
A80-B24;	A80-B25;	A80-B26;	A80-B27;	A80-B28;	A80-B29;
A80-B30;	A80-B31;	A80-B32;	A80-B33;	A80-B34;	A80-B35;
A80-B36;	A80-B37;	A80-B38;	A80-B39;	A80-B40;	A80-B41;
A80-B42;	A80-B43;	A80-B44;	A80-B45;	A80-B46;	A80-B47;
A80-B48;	A80-B49;	A80-B50;	A80-B51;	A80-B52;	A80-B53;
A80-B54;	A80-B55;	A80-B56;	A80-B57;	A80-B58;	A80-B59;
A80-B60;	A80-B61;	A80-B62;	A80-B63;	A80-B64;	A80-B65;
A80-B66;	A80-B67;	A80-B68;	A80-B69;	A80-B70;	A80-B71;
A80-B72;	A80-B73;	A80-B74;	A80-B75;	A80-B76;	A80-B77;
A80-B78;	A80-B79;	A80-B80;	A80-B81;	A80-B82;	A80-B83;
A80-B84;	A80-B85;	A80-B86;	A80-B87;	A80-B88;	A80-B89;
A80-B90;	A80-B91;	A80-B92;	A80-B93;	A80-B94;	A80-B95;
A80-B96;	A80-B97;	A80-B98;	A80-B99;	A80-B100;	A80-B101;
A80-B102;	A80-B103;	A80-B104;	A80-B105;	A80-B106;	A80-B107;
A80-B108;	A80-B109;	A80-B110;	A80-B111;	A80-B112;	A80-B113;
A80-B114;	A80-B115;	A80-B116;	A80-B117;	A80-B118;	A80-B119;
A80-B120;	A80-B121;	A80-B122;	A80-B123;	A80-B124;	A80-B125;
A80-B126;	A80-B127;	A80-B128;	A80-B129;	A80-B130;	A80-B131;
A80-B132;	A80-B133;	A80-B134;	A80-B135;	A80-B136;	A80-B137;
A80-B138;	A80-B139;	A80-B140;	A80-B141;	A80-B142;	A80-B143;
A80-B144;	A80-B145;	A80-B146;	A80-B147;	A80-B148;	A80-B149;
A80-B150;	A80-B151;	A80-B152;	A80-B153;	A80-B154;	A80-B155;
A80-B156;	A80-B157;	A80-B158;	A80-B159;	A80-B160;	A80-B161;
A80-B162;	A80-B163;	A80-B164;	A80-B165;	A80-B166;	A80-B167;
A80-B168;	A80-B169;	A81-B1;	A81-B2;	A81-B3;	A81-B4;
A81-B5;	A81-B6;	A81-B7;	A81-B8;	A81-B9;	A81-B10;
A81-B11;	A81-B12;	A81-B13;	A81-B14;	A81-B15;	A81-B16;
A81-B17;	A81-B18;	A81-B19;	A81-B20;	A81-B21;	A81-B22;
A81-B23;	A81-B24;	A81-B25;	A81-B26;	A81-B27;	A81-B28;
A81-B29;	A81-B30;	A81-B31;	A81-B32;	A81-B33;	A81-B34;
A81-B35;	A81-B36;	A81-B37;	A81-B38;	A81-B39;	A81-B40;
A81-B41;	A81-B42;	A81-B43;	A81-B44;	A81-B45;	A81-B46;
A81-B47;	A81-B48;	A81-B49;	A81-B50;	A81-B51;	A81-B52;
A81-B53;	A81-B54;	A81-B55;	A81-B56;	A81-B57;	A81-B58;
A81-B59;	A81-B60;	A81-B61;	A81-B62;	A81-B63;	A81-B64;
A81-B65;	A81-B66;	A81-B67;	A81-B68;	A81-B69;	A81-B70;
A81-B71;	A81-B72;	A81-B73;	A81-B74;	A81-B75;	A81-B76;
A81-B77;	A81-B78;	A81-B79;	A81-B80;	A81-B81;	A81-B82;
A81-B83;	A81-B84;	A81-B85;	A81-B86;	A81-B87;	A81-B88;
A81-B89;	A81-B90;	A81-B91;	A81-B92;	A81-B93;	A81-B94;
A81-B95;	A81-B96;	A81-B97;	A81-B98;	A81-B99;	A81-B100;
A81-B101;	A81-B102;	A81-B103;	A81-B104;	A81-B105;	A81-B106;
A81-B107;	A81-B108;	A81-B109;	A81-B110;	A81-B111;	A81-B112;
A81-B113;	A81-B114;	A81-B115;	A81-B116;	A81-B117;	A81-B118;
A81-B119;	A81-B120;	A81-B121;	A81-B122;	A81-B123;	A81-B124;
A81-B125;	A81-B126;	A81-B127;	A81-B128;	A81-B129;	A81-B130;
A81-B131;	A81-B132;	A81-B133;	A81-B134;	A81-B135;	A81-B136;
A81-B137;	A81-B138;	A81-B139;	A81-B140;	A81-B141;	A81-B142;
A81-B143;	A81-B144;	A81-B145;	A81-B146;	A81-B147;	A81-B148;
A81-B149;	A81-B150;	A81-B151;	A81-B152;	A81-B153;	A81-B154;
A81-B155;	A81-B156;	A81-B157;	A81-B158;	A81-B159;	A81-B160;
A81-B161;	A81-B162;	A81-B163;	A81-B164;	A81-B165;	A81-B166;
A81-B167;	A81-B168;	A81-B169;	A82-B1;	A82-B2;	A82-B3;
A82-B4;	A82-B5;	A82-B6;	A82-B7;	A82-B8;	A82-B9;
A82-B10;	A82-B11;	A82-B12;	A82-B13;	A82-B14;	A82-B15;
A82-B16;	A82-B17;	A82-B18;	A82-B19;	A82-B20;	A82-B21;
A82-B22;	A82-B23;	A82-B24;	A82-B25;	A82-B26;	A82-B27;
A82-B28;	A82-B29;	A82-B30;	A82-B31;	A82-B32;	A82-B33;
A82-B34;	A82-B35;	A82-B36;	A82-B37;	A82-B38;	A82-B39;
A82-B40;	A82-B41;	A82-B42;	A82-B43;	A82-B44;	A82-B45;
A82-B46;	A82-B47;	A82-B48;	A82-B49;	A82-B50;	A82-B51;
A82-B52;	A82-B53;	A82-B54;	A82-B55;	A82-B56;	A82-B57;
A82-B58;	A82-B59;	A82-B60;	A82-B61;	A82-B62;	A82-B63;
A82-B64;	A82-B65;	A82-B66;	A82-B67;	A82-B68;	A82-B69;
A82-B70;	A82-B71;	A82-B72;	A82-B73;	A82-B74;	A82-B75;
A82-B76;	A82-B77;	A82-B78;	A82-B79;	A82-B80;	A82-B81;
A82-B82;	A82-B83;	A82-B84;	A82-B85;	A82-B86;	A82-B87;
A82-B88;	A82-B89;	A82-B90;	A82-B91;	A82-B92;	A82-B93;
A82-B94;	A82-B95;	A82-B96;	A82-B97;	A82-B98;	A82-B99;
A82-B100;	A82-B101;	A82-B102;	A82-B103;	A82-B104;	A82-B105;
A82-B106;	A82-B107;	A82-B108;	A82-B109;	A82-B110;	A82-B111;
A82-B112;	A82-B113;	A82-B114;	A82-B115;	A82-B116;	A82-B117;
A82-B118;	A82-B119;	A82-B120;	A82-B121;	A82-B122;	A82-B123;
A82-B124;	A82-B125;	A82-B126;	A82-B127;	A82-B128;	A82-B129;
A82-B130;	A82-B131;	A82-B132;	A82-B133;	A82-B134;	A82-B135;
A82-B136;	A82-B137;	A82-B138;	A82-B139;	A82-B140;	A82-B141;
A82-B142;	A82-B143;	A82-B144;	A82-B145;	A82-B146;	A82-B147;
A82-B148;	A82-B149;	A82-B150;	A82-B151;	A82-B152;	A82-B153;
A82-B154;	A82-B155;	A82-B156;	A82-B157;	A82-B158;	A82-B159;
A82-B160;	A82-B161;	A82-B162;	A82-B163;	A82-B164;	A82-B165;
A82-B166;	A82-B167;	A82-B168;	A82-B169;	A83-B1;	A83-B2;
A83-B3;	A83-B4;	A83-B5;	A83-B6;	A83-B7;	A83-B8;
A83-B9;	A83-B10;	A83-B11;	A83-B12;	A83-B13;	A83-B14;
A83-B15;	A83-B16;	A83-B17;	A83-B18;	A83-B19;	A83-B20;
A83-B21;	A83-B22;	A83-B23;	A83-B24;	A83-B25;	A83-B26;
A83-B27;	A83-B28;	A83-B29;	A83-B30;	A83-B31;	A83-B32;
A83-B33;	A83-B34;	A83-B35;	A83-B36;	A83-B37;	A83-B38;
A83-B39;	A83-B40;	A83-B41;	A83-B42;	A83-B43;	A83-B44;
A83-B45;	A83-B46;	A83-B47;	A83-B48;	A83-B49;	A83-B50;
A83-B51;	A83-B52;	A83-B53;	A83-B54;	A83-B55;	A83-B56;
A83-B57;	A83-B58;	A83-B59;	A83-B60;	A83-B61;	A83-B62;
A83-B63;	A83-B64;	A83-B65;	A83-B66;	A83-B67;	A83-B68;
A83-B69;	A83-B70;	A83-B71;	A83-B72;	A83-B73;	A83-B74;
A83-B75;	A83-B76;	A83-B77;	A83-B78;	A83-B79;	A83-B80;
A83-B81;	A83-B82;	A83-B83;	A83-B84;	A83-B85;	A83-B86;
A83-B87;	A83-B88;	A83-B89;	A83-B90;	A83-B91;	A83-B92;
A83-B93;	A83-B94;	A83-B95;	A83-B96;	A83-B97;	A83-B98;
A83-B99;	A83-B100;	A83-B101;	A83-B102;	A83-B103;	A83-B104;
A83-B105;	A83-B106;	A83-B107;	A83-B108;	A83-B109;	A83-B110;
A83-B111;	A83-B112;	A83-B113;	A83-B114;	A83-B115;	A83-B116;
A83-B117;	A83-B118;	A83-B119;	A83-B120;	A83-B121;	A83-B122;
A83-B123;	A83-B124;	A83-B125;	A83-B126;	A83-B127;	A83-B128;
A83-B129;	A83-B130;	A83-B131;	A83-B132;	A83-B133;	A83-B134;
A83-B135;	A83-B136;	A83-B137;	A83-B138;	A83-B139;	A83-B140;
A83-B141;	A83-B142;	A83-B143;	A83-B144;	A83-B145;	A83-B146;
A83-B147;	A83-B148;	A83-B149;	A83-B150;	A83-B151;	A83-B152;
A83-B153;	A83-B154;	A83-B155;	A83-B156;	A83-B157;	A83-B158;
A83-B159;	A83-B160;	A83-B161;	A83-B162;	A83-B163;	A83-B164;
A83-B165;	A83-B166;	A83-B167;	A83-B168;	A83-B169;	A84-B1;
A84-B2;	A84-B3;	A84-B4;	A84-B5;	A84-B6;	A84-B7;
A84-B8;	A84-B9;	A84-B10;	A84-B11;	A84-B12;	A84-B13;
A84-B14;	A84-B15;	A84-B16;	A84-B17;	A84-B18;	A84-B19;
A84-B20;	A84-B21;	A84-B22;	A84-B23;	A84-B24;	A84-B25;
A84-B26;	A84-B27;	A84-B28;	A84-B29;	A84-B30;	A84-B31;
A84-B32;	A84-B33;	A84-B34;	A84-B35;	A84-B36;	A84-B37;
A84-B38;	A84-B39;	A84-B40;	A84-B41;	A84-B42;	A84-B43;
A84-B44;	A84-B45;	A84-B46;	A84-B47;	A84-B48;	A84-B49;
A84-B50;	A84-B51;	A84-B52;	A84-B53;	A84-B54;	A84-B55;
A84-B56;	A84-B57;	A84-B58;	A84-B59;	A84-B60;	A84-B61;
A84-B62;	A84-B63;	A84-B64;	A84-B65;	A84-B66;	A84-B67;
A84-B68;	A84-B69;	A84-B70;	A84-B71;	A84-B72;	A84-B73;
A84-B74;	A84-B75;	A84-B76;	A84-B77;	A84-B78;	A84-B79;
A84-B80;	A84-B81;	A84-B82;	A84-B83;	A84-B84;	A84-B85;
A84-B86;	A84-B87;	A84-B88;	A84-B89;	A84-B90;	A84-B91;
A84-B92;	A84-B93;	A84-B94;	A84-B95;	A84-B96;	A84-B97;
A84-B98;	A84-B99;	A84-B100;	A84-B101;	A84-B102;	A84-B103;
A84-B104;	A84-B105;	A84-B106;	A84-B107;	A84-B108;	A84-B109;
A84-B110;	A84-B111;	A84-B112;	A84-B113;	A84-B114;	A84-B115;
A84-B116;	A84-B117;	A84-B118;	A84-B119;	A84-B120;	A84-B121;
A84-B122;	A84-B123;	A84-B124;	A84-B125;	A84-B126;	A84-B127;
A84-B128;	A84-B129;	A84-B130;	A84-B131;	A84-B132;	A84-B133;
A84-B134;	A84-B135;	A84-B136;	A84-B137;	A84-B138;	A84-B139;
A84-B140;	A84-B141;	A84-B142;	A84-B143;	A84-B144;	A84-B145;
A84-B146;	A84-B147;	A84-B148;	A84-B149;	A84-B150;	A84-B151;
A84-B152;	A84-B153;	A84-B154;	A84-B155;	A84-B156;	A84-B157;
A84-B158;	A84-B159;	A84-B160;	A84-B161;	A84-B162;	A84-B163;
A84-B164;	A84-B165;	A84-B166;	A84-B167;	A84-B168;	A84-B169;
A85-B1;	A85-B2;	A85-B3;	A85-B4;	A85-B5;	A85-B6;
A85-B7;	A85-B8;	A85-B9;	A85-B10;	A85-B11;	A85-B12;
A85-B13;	A85-B14;	A85-B15;	A85-B16;	A85-B17;	A85-B18;
A85-B19;	A85-B20;	A85-B21;	A85-B22;	A85-B23;	A85-B24;
A85-B25;	A85-B26;	A85-B27;	A85-B28;	A85-B29;	A85-B30;
A85-B31;	A85-B32;	A85-B33;	A85-B34;	A85-B35;	A85-B36;
A85-B37;	A85-B38;	A85-B39;	A85-B40;	A85-B41;	A85-B42;
A85-B43;	A85-B44;	A85-B45;	A85-B46;	A85-B47;	A85-B48;
A85-B49;	A85-B50;	A85-B51;	A85-B52;	A85-B53;	A85-B54;
A85-B55;	A85-B56;	A85-B57;	A85-B58;	A85-B59;	A85-B60;
A85-B61;	A85-B62;	A85-B63;	A85-B64;	A85-B65;	A85-B66;
A85-B67;	A85-B68;	A85-B69;	A85-B70;	A85-B71;	A85-B72;
A85-B73;	A85-B74;	A85-B75;	A85-B76;	A85-B77;	A85-B78;
A85-B79;	A85-B80;	A85-B81;	A85-B82;	A85-B83;	A85-B84;
A85-B85;	A85-B86;	A85-B87;	A85-B88;	A85-B89;	A85-B90;
A85-B91;	A85-B92;	A85-B93;	A85-B94;	A85-B95;	A85-B96;
A85-B97;	A85-B98;	A85-B99;	A85-B100;	A85-B101;	A85-B102;
A85-B103;	A85-B104;	A85-B105;	A85-B106;	A85-B107;	A85-B108;
A85-B109;	A85-B110;	A85-B111;	A85-B112;	A85-B113;	A85-B114;
A85-B115;	A85-B116;	A85-B117;	A85-B118;	A85-B119;	A85-B120;
A85-B121;	A85-B122;	A85-B123;	A85-B124;	A85-B125;	A85-B126;
A85-B127;	A85-B128;	A85-B129;	A85-B130;	A85-B131;	A85-B132;
A85-B133;	A85-B134;	A85-B135;	A85-B136;	A85-B137;	A85-B138;
A85-B139;	A85-B140;	A85-B141;	A85-B142;	A85-B143;	A85-B144;
A85-B145;	A85-B146;	A85-B147;	A85-B148;	A85-B149;	A85-B150;
A85-B151;	A85-B152;	A85-B153;	A85-B154;	A85-B155;	A85-B156;
A85-B157;	A85-B158;	A85-B159;	A85-B160;	A85-B161;	A85-B162;
A85-B163;	A85-B164;	A85-B165;	A85-B166;	A85-B167;	A85-B168;
A85-B169;	A86-B1;	A86-B2;	A86-B3;	A86-B4;	A86-B5;
A86-B6;	A86-B7;	A86-B8;	A86-B9;	A86-B10;	A86-B11;
A86-B12;	A86-B13;	A86-B14;	A86-B15;	A86-B16;	A86-B17;
A86-B18;	A86-B19;	A86-B20;	A86-B21;	A86-B22;	A86-B23;
A86-B24;	A86-B25;	A86-B26;	A86-B27;	A86-B28;	A86-B29;
A86-B30;	A86-B31;	A86-B32;	A86-B33;	A86-B34;	A86-B35;
A86-B36;	A86-B37;	A86-B38;	A86-B39;	A86-B40;	A86-B41;
A86-B42;	A86-B43;	A86-B44;	A86-B45;	A86-B46;	A86-B47;
A86-B48;	A86-B49;	A86-B50;	A86-B51;	A86-B52;	A86-B53;
A86-B54;	A86-B55;	A86-B56;	A86-B57;	A86-B58;	A86-B59;
A86-B60;	A86-B61;	A86-B62;	A86-B63;	A86-B64;	A86-B65;
A86-B66;	A86-B67;	A86-B68;	A86-B69;	A86-B70;	A86-B71;
A86-B72;	A86-B73;	A86-B74;	A86-B75;	A86-B76;	A86-B77;
A86-B78;	A86-B79;	A86-B80;	A86-B81;	A86-B82;	A86-B83;
A86-B84;	A86-B85;	A86-B86;	A86-B87;	A86-B88;	A86-B89;
A86-B90;	A86-B91;	A86-B92;	A86-B93;	A86-B94;	A86-B95;
A86-B96;	A86-B97;	A86-B98;	A86-B99;	A86-B100;	A86-B101;
A86-B102;	A86-B103;	A86-B104;	A86-B105;	A86-B106;	A86-B107;
A86-B108;	A86-B109;	A86-B110;	A86-B111;	A86-B112;	A86-B113;
A86-B114;	A86-B115;	A86-B116;	A86-B117;	A86-B118;	A86-B119;
A86-B120;	A86-B121;	A86-B122;	A86-B123;	A86-B124;	A86-B125;
A86-B126;	A86-B127;	A86-B128;	A86-B129;	A86-B130;	A86-B131;
A86-B132;	A86-B133;	A86-B134;	A86-B135;	A86-B136;	A86-B137;
A86-B138;	A86-B139;	A86-B140;	A86-B141;	A86-B142;	A86-B143;
A86-B144;	A86-B145;	A86-B146;	A86-B147;	A86-B148;	A86-B149;
A86-B150;	A86-B151;	A86-B152;	A86-B153;	A86-B154;	A86-B155;
A86-B156;	A86-B157;	A86-B158;	A86-B159;	A86-B160;	A86-B161;
A86-B162;	A86-B163;	A86-B164;	A86-B165;	A86-B166;	A86-B167;
A86-B168;	A86-B169;	A87-B1;	A87-B2;	A87-B3;	A87-B4;
A87-B5;	A87-B6;	A87-B7;	A87-B8;	A87-B9;	A87-B10;
A87-B11;	A87-B12;	A87-B13;	A87-B14;	A87-B15;	A87-B16;
A87-B17;	A87-B18;	A87-B19;	A87-B20;	A87-B21;	A87-B22;
A87-B23;	A87-B24;	A87-B25;	A87-B26;	A87-B27;	A87-B28;
A87-B29;	A87-B30;	A87-B31;	A87-B32;	A87-B33;	A87-B34;
A87-B35;	A87-B36;	A87-B37;	A87-B38;	A87-B39;	A87-B40;
A87-B41;	A87-B42;	A87-B43;	A87-B44;	A87-B45;	A87-B46;
A87-B47;	A87-B48;	A87-B49;	A87-B50;	A87-B51;	A87-B52;
A87-B53;	A87-B54;	A87-B55;	A87-B56;	A87-B57;	A87-B58;
A87-B59;	A87-B60;	A87-B61;	A87-B62;	A87-B63;	A87-B64;
A87-B65;	A87-B66;	A87-B67;	A87-B68;	A87-B69;	A87-B70;
A87-B71;	A87-B72;	A87-B73;	A87-B74;	A87-B75;	A87-B76;
A87-B77;	A87-B78;	A87-B79;	A87-B80;	A87-B81;	A87-B82;
A87-B83;	A87-B84;	A87-B85;	A87-B86;	A87-B87;	A87-B88;
A87-B89;	A87-B90;	A87-B91;	A87-B92;	A87-B93;	A87-B94;
A87-B95;	A87-B96;	A87-B97;	A87-B98;	A87-B99;	A87-B100;
A87-B101;	A87-B102;	A87-B103;	A87-B104;	A87-B105;	A87-B106;
A87-B107;	A87-B108;	A87-B109;	A87-B110;	A87-B111;	A87-B112;
A87-B113;	A87-B114;	A87-B115;	A87-B116;	A87-B117;	A87-B118;
A87-B119;	A87-B120;	A87-B121;	A87-B122;	A87-B123;	A87-B124;
A87-B125;	A87-B126;	A87-B127;	A87-B128;	A87-B129;	A87-B130;
A87-B131;	A87-B132;	A87-B133;	A87-B134;	A87-B135;	A87-B136;
A87-B137;	A87-B138;	A87-B139;	A87-B140;	A87-B141;	A87-B142;
A87-B143;	A87-B144;	A87-B145;	A87-B146;	A87-B147;	A87-B148;
A87-B149;	A87-B150;	A87-B151;	A87-B152;	A87-B153;	A87-B154;
A87-B155;	A87-B156;	A87-B157;	A87-B158;	A87-B159;	A87-B160;
A87-B161;	A87-B162;	A87-B163;	A87-B164;	A87-B165;	A87-B166;
A87-B167;	A87-B168;	A87-B169;	A88-B1;	A88-B2;	A88-B3;
A88-B4;	A88-B5;	A88-B6;	A88-B7;	A88-B8;	A88-B9;
A88-B10;	A88-B11;	A88-B12;	A88-B13;	A88-B14;	A88-B15;
A88-B16;	A88-B17;	A88-B18;	A88-B19;	A88-B20;	A88-B21;
A88-B22;	A88-B23;	A88-B24;	A88-B25;	A88-B26;	A88-B27;
A88-B28;	A88-B29;	A88-B30;	A88-B31;	A88-B32;	A88-B33;
A88-B34;	A88-B35;	A88-B36;	A88-B37;	A88-B38;	A88-B39;
A88-B40;	A88-B41;	A88-B42;	A88-B43;	A88-B44;	A88-B45;
A88-B46;	A88-B47;	A88-B48;	A88-B49;	A88-B50;	A88-B51;
A88-B52;	A88-B53;	A88-B54;	A88-B55;	A88-B56;	A88-B57;
A88-B58;	A88-B59;	A88-B60;	A88-B61;	A88-B62;	A88-B63;
A88-B64;	A88-B65;	A88-B66;	A88-B67;	A88-B68;	A88-B69;
A88-B70;	A88-B71;	A88-B72;	A88-B73;	A88-B74;	A88-B75;
A88-B76;	A88-B77;	A88-B78;	A88-B79;	A88-B80;	A88-B81;
A88-B82;	A88-B83;	A88-B84;	A88-B85;	A88-B86;	A88-B87;
A88-B88;	A88-B89;	A88-B90;	A88-B91;	A88-B92;	A88-B93;
A88-B94;	A88-B95;	A88-B96;	A88-B97;	A88-B98;	A88-B99;
A88-B100;	A88-B101;	A88-B102;	A88-B103;	A88-B104;	A88-B105;
A88-B106;	A88-B107;	A88-B108;	A88-B109;	A88-B110;	A88-B111;
A88-B112;	A88-B113;	A88-B114;	A88-B115;	A88-B116;	A88-B117;
A88-B118;	A88-B119;	A88-B120;	A88-B121;	A88-B122;	A88-B123;
A88-B124;	A88-B125;	A88-B126;	A88-B127;	A88-B128;	A88-B129;
A88-B130;	A88-B131;	A88-B132;	A88-B133;	A88-B134;	A88-B135;
A88-B136;	A88-B137;	A88-B138;	A88-B139;	A88-B140;	A88-B141;
A88-B142;	A88-B143;	A88-B144;	A88-B145;	A88-B146;	A88-B147;
A88-B148;	A88-B149;	A88-B150;	A88-B151;	A88-B152;	A88-B153;
A88-B154;	A88-B155;	A88-B156;	A88-B157;	A88-B158;	A88-B159;
A88-B160;	A88-B161;	A88-B162;	A88-B163;	A88-B164;	A88-B165;
A88-B166;	A88-B167;	A88-B168;	A88-B169;	A89-B1;	A89-B2;
A89-B3;	A89-B4;	A89-B5;	A89-B6;	A89-B7;	A89-B8;
A89-B9;	A89-B10;	A89-B11;	A89-B12;	A89-B13;	A89-B14;
A89-B15;	A89-B16;	A89-B17;	A89-B18;	A89-B19;	A89-B20;
A89-B21;	A89-B22;	A89-B23;	A89-B24;	A89-B25;	A89-B26;
A89-B27;	A89-B28;	A89-B29;	A89-B30;	A89-B31;	A89-B32;
A89-B33;	A89-B34;	A89-B35;	A89-B36;	A89-B37;	A89-B38;
A89-B39;	A89-B40;	A89-B41;	A89-B42;	A89-B43;	A89-B44;
A89-B45;	A89-B46;	A89-B47;	A89-B48;	A89-B49;	A89-B50;
A89-B51;	A89-B52;	A89-B53;	A89-B54;	A89-B55;	A89-B56;
A89-B57;	A89-B58;	A89-B59;	A89-B60;	A89-B61;	A89-B62;
A89-B63;	A89-B64;	A89-B65;	A89-B66;	A89-B67;	A89-B68;
A89-B69;	A89-B70;	A89-B71;	A89-B72;	A89-B73;	A89-B74;
A89-B75;	A89-B76;	A89-B77;	A89-B78;	A89-B79;	A89-B80;
A89-B81;	A89-B82;	A89-B83;	A89-B84;	A89-B85;	A89-B86;
A89-B87;	A89-B88;	A89-B89;	A89-B90;	A89-B91;	A89-B92;
A89-B93;	A89-B94;	A89-B95;	A89-B96;	A89-B97;	A89-B98;
A89-B99;	A89-B100;	A89-B101;	A89-B102;	A89-B103;	A89-B104;
A89-B105;	A89-B106;	A89-B107;	A89-B108;	A89-B109;	A89-B110;
A89-B111;	A89-B112;	A89-B113;	A89-B114;	A89-B115;	A89-B116;
A89-B117;	A89-B118;	A89-B119;	A89-B120;	A89-B121;	A89-B122;
A89-B123;	A89-B124;	A89-B125;	A89-B126;	A89-B127;	A89-B128;
A89-B129;	A89-B130;	A89-B131;	A89-B132;	A89-B133;	A89-B134;
A89-B135;	A89-B136;	A89-B137;	A89-B138;	A89-B139;	A89-B140;
A89-B141;	A89-B142;	A89-B143;	A89-B144;	A89-B145;	A89-B146;
A89-B147;	A89-B148;	A89-B149;	A89-B150;	A89-B151;	A89-B152;
A89-B153;	A89-B154;	A89-B155;	A89-B156;	A89-B157;	A89-B158;
A89-B159;	A89-B160;	A89-B161;	A89-B162;	A89-B163;	A89-B164;
A89-B165;	A89-B166;	A89-B167;	A89-B168;	A89-B169;	A90-B1;
A90-B2;	A90-B3;	A90-B4;	A90-B5;	A90-B6;	A90-B7;
A90-B8;	A90-B9;	A90-B10;	A90-B11;	A90-B12;	A90-B13;
A90-B14;	A90-B15;	A90-B16;	A90-B17;	A90-B18;	A90-B19;
A90-B20;	A90-B21;	A90-B22;	A90-B23;	A90-B24;	A90-B25;
A90-B26;	A90-B27;	A90-B28;	A90-B29;	A90-B30;	A90-B31;
A90-B32;	A90-B33;	A90-B34;	A90-B35;	A90-B36;	A90-B37;
A90-B38;	A90-B39;	A90-B40;	A90-B41;	A90-B42;	A90-B43;
A90-B44;	A90-B45;	A90-B46;	A90-B47;	A90-B48;	A90-B49;
A90-B50;	A90-B51;	A90-B52;	A90-B53;	A90-B54;	A90-B55;
A90-B56;	A90-B57;	A90-B58;	A90-B59;	A90-B60;	A90-B61;
A90-B62;	A90-B63;	A90-B64;	A90-B65;	A90-B66;	A90-B67;
A90-B68;	A90-B69;	A90-B70;	A90-B71;	A90-B72;	A90-B73;
A90-B74;	A90-B75;	A90-B76;	A90-B77;	A90-B78;	A90-B79;
A90-B80;	A90-B81;	A90-B82;	A90-B83;	A90-B84;	A90-B85;
A90-B86;	A90-B87;	A90-B88;	A90-B89;	A90-B90;	A90-B91;
A90-B92;	A90-B93;	A90-B94;	A90-B95;	A90-B96;	A90-B97;
A90-B98;	A90-B99;	A90-B100;	A90-B101;	A90-B102;	A90-B103;
A90-B104;	A90-B105;	A90-B106;	A90-B107;	A90-B108;	A90-B109;
A90-B110;	A90-B111;	A90-B112;	A90-B113;	A90-B114;	A90-B115;
A90-B116;	A90-B117;	A90-B118;	A90-B119;	A90-B120;	A90-B121;
A90-B122;	A90-B123;	A90-B124;	A90-B125;	A90-B126;	A90-B127;
A90-B128;	A90-B129;	A90-B130;	A90-B131;	A90-B132;	A90-B133;
A90-B134;	A90-B135;	A90-B136;	A90-B137;	A90-B138;	A90-B139;
A90-B140;	A90-B141;	A90-B142;	A90-B143;	A90-B144;	A90-B145;
A90-B146;	A90-B147;	A90-B148;	A90-B149;	A90-B150;	A90-B151;
A90-B152;	A90-B153;	A90-B154;	A90-B155;	A90-B156;	A90-B157;
A90-B158;	A90-B159;	A90-B160;	A90-B161;	A90-B162;	A90-B163;
A90-B164;	A90-B165;	A90-B166;	A90-B167;	A90-B168;	A90-B169;
A91-B1;	A91-B2;	A91-B3;	A91-B4;	A91-B5;	A91-B6;
A91-B7;	A91-B8;	A91-B9;	A91-B10;	A91-B11;	A91-B12;
A91-B13;	A91-B14;	A91-B15;	A91-B16;	A91-B17;	A91-B18;
A91-B19;	A91-B20;	A91-B21;	A91-B22;	A91-B23;	A91-B24;
A91-B25;	A91-B26;	A91-B27;	A91-B28;	A91-B29;	A91-B30;
A91-B31;	A91-B32;	A91-B33;	A91-B34;	A91-B35;	A91-B36;
A91-B37;	A91-B38;	A91-B39;	A91-B40;	A91-B41;	A91-B42;
A91-B43;	A91-B44;	A91-B45;	A91-B46;	A91-B47;	A91-B48;
A91-B49;	A91-B50;	A91-B51;	A91-B52;	A91-B53;	A91-B54;
A91-B55;	A91-B56;	A91-B57;	A91-B58;	A91-B59;	A91-B60;
A91-B61;	A91-B62;	A91-B63;	A91-B64;	A91-B65;	A91-B66;
A91-B67;	A91-B68;	A91-B69;	A91-B70;	A91-B71;	A91-B72;
A91-B73;	A91-B74;	A91-B75;	A91-B76;	A91-B77;	A91-B78;
A91-B79;	A91-B80;	A91-B81;	A91-B82;	A91-B83;	A91-B84;
A91-B85;	A91-B86;	A91-B87;	A91-B88;	A91-B89;	A91-B90;
A91-B91;	A91-B92;	A91-B93;	A91-B94;	A91-B95;	A91-B96;
A91-B97;	A91-B98;	A91-B99;	A91-B100;	A91-B101;	A91-B102;
A91-B103;	A91-B104;	A91-B105;	A91-B106;	A91-B107;	A91-B108;
A91-B109;	A91-B110;	A91-B111;	A91-B112;	A91-B113;	A91-B114;
A91-B115;	A91-B116;	A91-B117;	A91-B118;	A91-B119;	A91-B120;
A91-B121;	A91-B122;	A91-B123;	A91-B124;	A91-B125;	A91-B126;
A91-B127;	A91-B128;	A91-B129;	A91-B130;	A91-B131;	A91-B132;
A91-B133;	A91-B134;	A91-B135;	A91-B136;	A91-B137;	A91-B138;
A91-B139;	A91-B140;	A91-B141;	A91-B142;	A91-B143;	A91-B144;
A91-B145;	A91-B146;	A91-B147;	A91-B148;	A91-B149;	A91-B150;
A91-B151;	A91-B152;	A91-B153;	A91-B154;	A91-B155;	A91-B156;
A91-B157;	A91-B158;	A91-B159;	A91-B160;	A91-B161;	A91-B162;
A91-B163;	A91-B164;	A91-B165;	A91-B166;	A91-B167;	A91-B168;
A91-B169;	A92-B1;	A92-B2;	A92-B3;	A92-B4;	A92-B5;
A92-B6;	A92-B7;	A92-B8;	A92-B9;	A92-B10;	A92-B11;
A92-B12;	A92-B13;	A92-B14;	A92-B15;	A92-B16;	A92-B17;
A92-B18;	A92-B19;	A92-B20;	A92-B21;	A92-B22;	A92-B23;
A92-B24;	A92-B25;	A92-B26;	A92-B27;	A92-B28;	A92-B29;
A92-B30;	A92-B31;	A92-B32;	A92-B33;	A92-B34;	A92-B35;
A92-B36;	A92-B37;	A92-B38;	A92-B39;	A92-B40;	A92-B41;
A92-B42;	A92-B43;	A92-B44;	A92-B45;	A92-B46;	A92-B47;
A92-B48;	A92-B49;	A92-B50;	A92-B51;	A92-B52;	A92-B53;
A92-B54;	A92-B55;	A92-B56;	A92-B57;	A92-B58;	A92-B59;
A92-B60;	A92-B61;	A92-B62;	A92-B63;	A92-B64;	A92-B65;
A92-B66;	A92-B67;	A92-B68;	A92-B69;	A92-B70;	A92-B71;
A92-B72;	A92-B73;	A92-B74;	A92-B75;	A92-B76;	A92-B77;
A92-B78;	A92-B79;	A92-B80;	A92-B81;	A92-B82;	A92-B83;
A92-B84;	A92-B85;	A92-B86;	A92-B87;	A92-B88;	A92-B89;
A92-B90;	A92-B91;	A92-B92;	A92-B93;	A92-B94;	A92-B95;
A92-B96;	A92-B97;	A92-B98;	A92-B99;	A92-B100;	A92-B101;
A92-B102;	A92-B103;	A92-B104;	A92-B105;	A92-B106;	A92-B107;
A92-B108;	A92-B109;	A92-B110;	A92-B111;	A92-B112;	A92-B113;
A92-B114;	A92-B115;	A92-B116;	A92-B117;	A92-B118;	A92-B119;
A92-B120;	A92-B121;	A92-B122;	A92-B123;	A92-B124;	A92-B125;
A92-B126;	A92-B127;	A92-B128;	A92-B129;	A92-B130;	A92-B131;
A92-B132;	A92-B133;	A92-B134;	A92-B135;	A92-B136;	A92-B137;
A92-B138;	A92-B139;	A92-B140;	A92-B141;	A92-B142;	A92-B143;
A92-B144;	A92-B145;	A92-B146;	A92-B147;	A92-B148;	A92-B149;
A92-B150;	A92-B151;	A92-B152;	A92-B153;	A92-B154;	A92-B155;
A92-B156;	A92-B157;	A92-B158;	A92-B159;	A92-B160;	A92-B161;
A92-B162;	A92-B163;	A92-B164;	A92-B165;	A92-B166;	A92-B167;
A92-B168;	A92-B169;	A93-B1;	A93-B2;	A93-B3;	A93-B4;
A93-B5;	A93-B6;	A93-B7;	A93-B8;	A93-B9;	A93-B10;
A93-B11;	A93-B12;	A93-B13;	A93-B14;	A93-B15;	A93-B16;
A93-B17;	A93-B18;	A93-B19;	A93-B20;	A93-B21;	A93-B22;
A93-B23;	A93-B24;	A93-B25;	A93-B26;	A93-B27;	A93-B28;
A93-B29;	A93-B30;	A93-B31;	A93-B32;	A93-B33;	A93-B34;
A93-B35;	A93-B36;	A93-B37;	A93-B38;	A93-B39;	A93-B40;
A93-B41;	A93-B42;	A93-B43;	A93-B44;	A93-B45;	A93-B46;
A93-B47;	A93-B48;	A93-B49;	A93-B50;	A93-B51;	A93-B52;
A93-B53;	A93-B54;	A93-B55;	A93-B56;	A93-B57;	A93-B58;
A93-B59;	A93-B60;	A93-B61;	A93-B62;	A93-B63;	A93-B64;
A93-B65;	A93-B66;	A93-B67;	A93-B68;	A93-B69;	A93-B70;
A93-B71;	A93-B72;	A93-B73;	A93-B74;	A93-B75;	A93-B76;
A93-B77;	A93-B78;	A93-B79;	A93-B80;	A93-B81;	A93-B82;
A93-B83;	A93-B84;	A93-B85;	A93-B86;	A93-B87;	A93-B88;
A93-B89;	A93-B90;	A93-B91;	A93-B92;	A93-B93;	A93-B94;
A93-B95;	A93-B96;	A93-B97;	A93-B98;	A93-B99;	A93-B100;
A93-B101;	A93-B102;	A93-B103;	A93-B104;	A93-B105;	A93-B106;
A93-B107;	A93-B108;	A93-B109;	A93-B110;	A93-B111;	A93-B112;
A93-B113;	A93-B114;	A93-B115;	A93-B116;	A93-B117;	A93-B118;
A93-B119;	A93-B120;	A93-B121;	A93-B122;	A93-B123;	A93-B124;
A93-B125;	A93-B126;	A93-B127;	A93-B128;	A93-B129;	A93-B130;
A93-B131;	A93-B132;	A93-B133;	A93-B134;	A93-B135;	A93-B136;
A93-B137;	A93-B138;	A93-B139;	A93-B140;	A93-B141;	A93-B142;
A93-B143;	A93-B144;	A93-B145;	A93-B146;	A93-B147;	A93-B148;
A93-B149;	A93-B150;	A93-B151;	A93-B152;	A93-B153;	A93-B154;
A93-B155;	A93-B156;	A93-B157;	A93-B158;	A93-B159;	A93-B160;
A93-B161;	A93-B162;	A93-B163;	A93-B164;	A93-B165;	A93-B166;
A93-B167;	A93-B168;	A93-B169;	A94-B1;	A94-B2;	A94-B3;
A94-B4;	A94-B5;	A94-B6;	A94-B7;	A94-B8;	A94-B9;
A94-B10;	A94-B11;	A94-B12;	A94-B13;	A94-B14;	A94-B15;
A94-B16;	A94-B17;	A94-B18;	A94-B19;	A94-B20;	A94-B21;
A94-B22;	A94-B23;	A94-B24;	A94-B25;	A94-B26;	A94-B27;
A94-B28;	A94-B29;	A94-B30;	A94-B31;	A94-B32;	A94-B33;
A94-B34;	A94-B35;	A94-B36;	A94-B37;	A94-B38;	A94-B39;
A94-B40;	A94-B41;	A94-B42;	A94-B43;	A94-B44;	A94-B45;
A94-B46;	A94-B47;	A94-B48;	A94-B49;	A94-B50;	A94-B51;
A94-B52;	A94-B53;	A94-B54;	A94-B55;	A94-B56;	A94-B57;
A94-B58;	A94-B59;	A94-B60;	A94-B61;	A94-B62;	A94-B63;
A94-B64;	A94-B65;	A94-B66;	A94-B67;	A94-B68;	A94-B69;
A94-B70;	A94-B71;	A94-B72;	A94-B73;	A94-B74;	A94-B75;
A94-B76;	A94-B77;	A94-B78;	A94-B79;	A94-B80;	A94-B81;
A94-B82;	A94-B83;	A94-B84;	A94-B85;	A94-B86;	A94-B87;
A94-B88;	A94-B89;	A94-B90;	A94-B91;	A94-B92;	A94-B93;
A94-B94;	A94-B95;	A94-B96;	A94-B97;	A94-B98;	A94-B99;
A94-B100;	A94-B101;	A94-B102;	A94-B103;	A94-B104;	A94-B105;
A94-B106;	A94-B107;	A94-B108;	A94-B109;	A94-B110;	A94-B111;
A94-B112;	A94-B113;	A94-B114;	A94-B115;	A94-B116;	A94-B117;
A94-B118;	A94-B119;	A94-B120;	A94-B121;	A94-B122;	A94-B123;
A94-B124;	A94-B125;	A94-B126;	A94-B127;	A94-B128;	A94-B129;
A94-B130;	A94-B131;	A94-B132;	A94-B133;	A94-B134;	A94-B135;
A94-B136;	A94-B137;	A94-B138;	A94-B139;	A94-B140;	A94-B141;
A94-B142;	A94-B143;	A94-B144;	A94-B145;	A94-B146;	A94-B147;
A94-B148;	A94-B149;	A94-B150;	A94-B151;	A94-B152;	A94-B153;
A94-B154;	A94-B155;	A94-B156;	A94-B157;	A94-B158;	A94-B159;
A94-B160;	A94-B161;	A94-B162;	A94-B163;	A94-B164;	A94-B165;
A94-B166;	A94-B167;	A94-B168;	A94-B169;	A95-B1;	A95-B2;
A95-B3;	A95-B4;	A95-B5;	A95-B6;	A95-B7;	A95-B8;
A95-B9;	A95-B10;	A95-B11;	A95-B12;	A95-B13;	A95-B14;
A95-B15;	A95-B16;	A95-B17;	A95-B18;	A95-B19;	A95-B20;
A95-B21;	A95-B22;	A95-B23;	A95-B24;	A95-B25;	A95-B26;
A95-B27;	A95-B28;	A95-B29;	A95-B30;	A95-B31;	A95-B32;
A95-B33;	A95-B34;	A95-B35;	A95-B36;	A95-B37;	A95-B38;
A95-B39;	A95-B40;	A95-B41;	A95-B42;	A95-B43;	A95-B44;
A95-B45;	A95-B46;	A95-B47;	A95-B48;	A95-B49;	A95-B50;
A95-B51;	A95-B52;	A95-B53;	A95-B54;	A95-B55;	A95-B56;
A95-B57;	A95-B58;	A95-B59;	A95-B60;	A95-B61;	A95-B62;
A95-B63;	A95-B64;	A95-B65;	A95-B66;	A95-B67;	A95-B68;
A95-B69;	A95-B70;	A95-B71;	A95-B72;	A95-B73;	A95-B74;
A95-B75;	A95-B76;	A95-B77;	A95-B78;	A95-B79;	A95-B80;
A95-B81;	A95-B82;	A95-B83;	A95-B84;	A95-B85;	A95-B86;
A95-B87;	A95-B88;	A95-B89;	A95-B90;	A95-B91;	A95-B92;
A95-B93;	A95-B94;	A95-B95;	A95-B96;	A95-B97;	A95-B98;
A95-B99;	A95-B100;	A95-B101;	A95-B102;	A95-B103;	A95-B104;
A95-B105;	A95-B106;	A95-B107;	A95-B108;	A95-B109;	A95-B110;
A95-B111;	A95-B112;	A95-B113;	A95-B114;	A95-B115;	A95-B116;
A95-B117;	A95-B118;	A95-B119;	A95-B120;	A95-B121;	A95-B122;
A95-B123;	A95-B124;	A95-B125;	A95-B126;	A95-B127;	A95-B128;
A95-B129;	A95-B130;	A95-B131;	A95-B132;	A95-B133;	A95-B134;
A95-B135;	A95-B136;	A95-B137;	A95-B138;	A95-B139;	A95-B140;
A95-B141;	A95-B142;	A95-B143;	A95-B144;	A95-B145;	A95-B146;
A95-B147;	A95-B148;	A95-B149;	A95-B150;	A95-B151;	A95-B152;
A95-B153;	A95-B154;	A95-B155;	A95-B156;	A95-B157;	A95-B158;
A95-B159;	A95-B160;	A95-B161;	A95-B162;	A95-B163;	A95-B164;
A95-B165;	A95-B166;	A95-B167;	A95-B168;	A95-B169;	A96-B1;
A96-B2;	A96-B3;	A96-B4;	A96-B5;	A96-B6;	A96-B7;
A96-B8;	A96-B9;	A96-B10;	A96-B11;	A96-B12;	A96-B13;
A96-B14;	A96-B15;	A96-B16;	A96-B17;	A96-B18;	A96-B19;
A96-B20;	A96-B21;	A96-B22;	A96-B23;	A96-B24;	A96-B25;
A96-B26;	A96-B27;	A96-B28;	A96-B29;	A96-B30;	A96-B31;
A96-B32;	A96-B33;	A96-B34;	A96-B35;	A96-B36;	A96-B37;
A96-B38;	A96-B39;	A96-B40;	A96-B41;	A96-B42;	A96-B43;
A96-B44;	A96-B45;	A96-B46;	A96-B47;	A96-B48;	A96-B49;
A96-B50;	A96-B51;	A96-B52;	A96-B53;	A96-B54;	A96-B55;
A96-B56;	A96-B57;	A96-B58;	A96-B59;	A96-B60;	A96-B61;
A96-B62;	A96-B63;	A96-B64;	A96-B65;	A96-B66;	A96-B67;
A96-B68;	A96-B69;	A96-B70;	A96-B71;	A96-B72;	A96-B73;
A96-B74;	A96-B75;	A96-B76;	A96-B77;	A96-B78;	A96-B79;
A96-B80;	A96-B81;	A96-B82;	A96-B83;	A96-B84;	A96-B85;
A96-B86;	A96-B87;	A96-B88;	A96-B89;	A96-B90;	A96-B91;
A96-B92;	A96-B93;	A96-B94;	A96-B95;	A96-B96;	A96-B97;
A96-B98;	A96-B99;	A96-B100;	A96-B101;	A96-B102;	A96-B103;
A96-B104;	A96-B105;	A96-B106;	A96-B107;	A96-B108;	A96-B109;
A96-B110;	A96-B111;	A96-B112;	A96-B113;	A96-B114;	A96-B115;
A96-B116;	A96-B117;	A96-B118;	A96-B119;	A96-B120;	A96-B121;
A96-B122;	A96-B123;	A96-B124;	A96-B125;	A96-B126;	A96-B127;
A96-B128;	A96-B129;	A96-B130;	A96-B131;	A96-B132;	A96-B133;
A96-B134;	A96-B135;	A96-B136;	A96-B137;	A96-B138;	A96-B139;
A96-B140;	A96-B141;	A96-B142;	A96-B143;	A96-B144;	A96-B145;
A96-B146;	A96-B147;	A96-B148;	A96-B149;	A96-B150;	A96-B151;
A96-B152;	A96-B153;	A96-B154;	A96-B155;	A96-B156;	A96-B157;
A96-B158;	A96-B159;	A96-B160;	A96-B161;	A96-B162;	A96-B163;
A96-B164;	A96-B165;	A96-B166;	A96-B167;	A96-B168;	A96-B169;
A97-B1;	A97-B2;	A97-B3;	A97-B4;	A97-B5;	A97-B6;
A97-B7;	A97-B8;	A97-B9;	A97-B10;	A97-B11;	A97-B12;
A97-B13;	A97-B14;	A97-B15;	A97-B16;	A97-B17;	A97-B18;
A97-B19;	A97-B20;	A97-B21;	A97-B22;	A97-B23;	A97-B24;
A97-B25;	A97-B26;	A97-B27;	A97-B28;	A97-B29;	A97-B30;
A97-B31;	A97-B32;	A97-B33;	A97-B34;	A97-B35;	A97-B36;
A97-B37;	A97-B38;	A97-B39;	A97-B40;	A97-B41;	A97-B42;
A97-B43;	A97-B44;	A97-B45;	A97-B46;	A97-B47;	A97-B48;
A97-B49;	A97-B50;	A97-B51;	A97-B52;	A97-B53;	A97-B54;
A97-B55;	A97-B56;	A97-B57;	A97-B58;	A97-B59;	A97-B60;
A97-B61;	A97-B62;	A97-B63;	A97-B64;	A97-B65;	A97-B66;
A97-B67;	A97-B68;	A97-B69;	A97-B70;	A97-B71;	A97-B72;
A97-B73;	A97-B74;	A97-B75;	A97-B76;	A97-B77;	A97-B78;
A97-B79;	A97-B80;	A97-B81;	A97-B82;	A97-B83;	A97-B84;
A97-B85;	A97-B86;	A97-B87;	A97-B88;	A97-B89;	A97-B90;
A97-B91;	A97-B92;	A97-B93;	A97-B94;	A97-B95;	A97-B96;
A97-B97;	A97-B98;	A97-B99;	A97-B100;	A97-B101;	A97-B102;
A97-B103;	A97-B104;	A97-B105;	A97-B106;	A97-B107;	A97-B108;
A97-B109;	A97-B110;	A97-B111;	A97-B112;	A97-B113;	A97-B114;
A97-B115;	A97-B116;	A97-B117;	A97-B118;	A97-B119;	A97-B120;
A97-B121;	A97-B122;	A97-B123;	A97-B124;	A97-B125;	A97-B126;
A97-B127;	A97-B128;	A97-B129;	A97-B130;	A97-B131;	A97-B132;
A97-B133;	A97-B134;	A97-B135;	A97-B136;	A97-B137;	A97-B138;
A97-B139;	A97-B140;	A97-B141;	A97-B142;	A97-B143;	A97-B144;
A97-B145;	A97-B146;	A97-B147;	A97-B148;	A97-B149;	A97-B150;
A97-B151;	A97-B152;	A97-B153;	A97-B154;	A97-B155;	A97-B156;
A97-B157;	A97-B158;	A97-B159;	A97-B160;	A97-B161;	A97-B162;
A97-B163;	A97-B164;	A97-B165;	A97-B166;	A97-B167;	A97-B168;
A97-B169;	A98-B1;	A98-B2;	A98-B3;	A98-B4;	A98-B5;
A98-B6;	A98-B7;	A98-B8;	A98-B9;	A98-B10;	A98-B11;
A98-B12;	A98-B13;	A98-B14;	A98-B15;	A98-B16;	A98-B17;
A98-B18;	A98-B19;	A98-B20;	A98-B21;	A98-B22;	A98-B23;
A98-B24;	A98-B25;	A98-B26;	A98-B27;	A98-B28;	A98-B29;
A98-B30;	A98-B31;	A98-B32;	A98-B33;	A98-B34;	A98-B35;
A98-B36;	A98-B37;	A98-B38;	A98-B39;	A98-B40;	A98-B41;
A98-B42;	A98-B43;	A98-B44;	A98-B45;	A98-B46;	A98-B47;
A98-B48;	A98-B49;	A98-B50;	A98-B51;	A98-B52;	A98-B53;
A98-B54;	A98-B55;	A98-B56;	A98-B57;	A98-B58;	A98-B59;
A98-B60;	A98-B61;	A98-B62;	A98-B63;	A98-B64;	A98-B65;
A98-B66;	A98-B67;	A98-B68;	A98-B69;	A98-B70;	A98-B71;
A98-B72;	A98-B73;	A98-B74;	A98-B75;	A98-B76;	A98-B77;
A98-B78;	A98-B79;	A98-B80;	A98-B81;	A98-B82;	A98-B83;
A98-B84;	A98-B85;	A98-B86;	A98-B87;	A98-B88;	A98-B89;
A98-B90;	A98-B91;	A98-B92;	A98-B93;	A98-B94;	A98-B95;
A98-B96;	A98-B97;	A98-B98;	A98-B99;	A98-B100;	A98-B101;
A98-B102;	A98-B103;	A98-B104;	A98-B105;	A98-B106;	A98-B107;
A98-B108;	A98-B109;	A98-B110;	A98-B111;	A98-B112;	A98-B113;
A98-B114;	A98-B115;	A98-B116;	A98-B117;	A98-B118;	A98-B119;
A98-B120;	A98-B121;	A98-B122;	A98-B123;	A98-B124;	A98-B125;
A98-B126;	A98-B127;	A98-B128;	A98-B129;	A98-B130;	A98-B131;
A98-B132;	A98-B133;	A98-B134;	A98-B135;	A98-B136;	A98-B137;
A98-B138;	A98-B139;	A98-B140;	A98-B141;	A98-B142;	A98-B143;
A98-B144;	A98-B145;	A98-B146;	A98-B147;	A98-B148;	A98-B149;
A98-B150;	A98-B151;	A98-B152;	A98-B153;	A98-B154;	A98-B155;
A98-B156;	A98-B157;	A98-B158;	A98-B159;	A98-B160;	A98-B161;
A98-B162;	A98-B163;	A98-B164;	A98-B165;	A98-B166;	A98-B167;
A98-B168;	A98-B169;	A99-B1;	A99-B2;	A99-B3;	A99-B4;
A99-B5;	A99-B6;	A99-B7;	A99-B8;	A99-B9;	A99-B10;
A99-B11;	A99-B12;	A99-B13;	A99-B14;	A99-B15;	A99-B16;
A99-B17;	A99-B18;	A99-B19;	A99-B20;	A99-B21;	A99-B22;
A99-B23;	A99-B24;	A99-B25;	A99-B26;	A99-B27;	A99-B28;
A99-B29;	A99-B30;	A99-B31;	A99-B32;	A99-B33;	A99-B34;
A99-B35;	A99-B36;	A99-B37;	A99-B38;	A99-B39;	A99-B40;
A99-B41;	A99-B42;	A99-B43;	A99-B44;	A99-B45;	A99-B46;
A99-B47;	A99-B48;	A99-B49;	A99-B50;	A99-B51;	A99-B52;
A99-B53;	A99-B54;	A99-B55;	A99-B56;	A99-B57;	A99-B58;
A99-B59;	A99-B60;	A99-B61;	A99-B62;	A99-B63;	A99-B64;
A99-B65;	A99-B66;	A99-B67;	A99-B68;	A99-B69;	A99-B70;
A99-B71;	A99-B72;	A99-B73;	A99-B74;	A99-B75;	A99-B76;
A99-B77;	A99-B78;	A99-B79;	A99-B80;	A99-B81;	A99-B82;
A99-B83;	A99-B84;	A99-B85;	A99-B86;	A99-B87;	A99-B88;
A99-B89;	A99-B90;	A99-B91;	A99-B92;	A99-B93;	A99-B94;
A99-B95;	A99-B96;	A99-B97;	A99-B98;	A99-B99;	A99-B100;
A99-B101;	A99-B102;	A99-B103;	A99-B104;	A99-B105;	A99-B106;
A99-B107;	A99-B108;	A99-B109;	A99-B110;	A99-B111;	A99-B112;
A99-B113;	A99-B114;	A99-B115;	A99-B116;	A99-B117;	A99-B118;
A99-B119;	A99-B120;	A99-B121;	A99-B122;	A99-B123;	A99-B124;
A99-B125;	A99-B126;	A99-B127;	A99-B128;	A99-B129;	A99-B130;
A99-B131;	A99-B132;	A99-B133;	A99-B134;	A99-B135;	A99-B136;
A99-B137;	A99-B138;	A99-B139;	A99-B140;	A99-B141;	A99-B142;
A99-B143;	A99-B144;	A99-B145;	A99-B146;	A99-B147;	A99-B148;
A99-B149;	A99-B150;	A99-B151;	A99-B152;	A99-B153;	A99-B154;
A99-B155;	A99-B156;	A99-B157;	A99-B158;	A99-B159;	A99-B160;
A99-B161;	A99-B162;	A99-B163;	A99-B164;	A99-B165;	A99-B166;
A99-B167;	A99-B168;	A99-B169;	A100-B1;	A100-B2;	A100-B3;
A100-B4;	A100-B5;	A100-B6;	A100-B7;	A100-B8;	A100-B9;
A100-B10;	A100-B11;	A100-B12;	A100-B13;	A100-B14;	A100-B15;
A100-B16;	A100-B17;	A100-B18;	A100-B19;	A100-B20;	A100-B21;
A100-B22;	A100-B23;	A100-B24;	A100-B25;	A100-B26;	A100-B27;
A100-B28;	A100-B29;	A100-B30;	A100-B31;	A100-B32;	A100-B33;
A100-B34;	A100-B35;	A100-B36;	A100-B37;	A100-B38;	A100-B39;
A100-B40;	A100-B41;	A100-B42;	A100-B43;	A100-B44;	A100-B45;
A100-B46;	A100-B47;	A100-B48;	A100-B49;	A100-B50;	A100-B51;
A100-B52;	A100-B53;	A100-B54;	A100-B55;	A100-B56;	A100-B57;
A100-B58;	A100-B59;	A100-B60;	A100-B61;	A100-B62;	A100-B63;
A100-B64;	A100-B65;	A100-B66;	A100-B67;	A100-B68;	A100-B69;
A100-B70;	A100-B71;	A100-B72;	A100-B73;	A100-B74;	A100-B75;
A100-B76;	A100-B77;	A100-B78;	A100-B79;	A100-B80;	A100-B81;
A100-B82;	A100-B83;	A100-B84;	A100-B85;	A100-B86;	A100-B87;
A100-B88;	A100-B89;	A100-B90;	A100-B91;	A100-B92;	A100-B93;
A100-B94;	A100-B95;	A100-B96;	A100-B97;	A100-B98;	A100-B99;
A100-B100;	A100-B101;	A100-B102;	A100-B103;	A100-B104;	A100-B105;
A100-B106;	A100-B107;	A100-B108;	A100-B109;	A100-B110;	A100-B111;
A100-B112;	A100-B113;	A100-B114;	A100-B115;	A100-B116;	A100-B117;
A100-B118;	A100-B119;	A100-B120;	A100-B121;	A100-B122;	A100-B123;
A100-B124;	A100-B125;	A100-B126;	A100-B127;	A100-B128;	A100-B129;
A100-B130;	A100-B131;	A100-B132;	A100-B133;	A100-B134;	A100-B135;
A100-B136;	A100-B137;	A100-B138;	A100-B139;	A100-B140;	A100-B141;
A100-B142;	A100-B143;	A100-B144;	A100-B145;	A100-B146;	A100-B147;
A100-B148;	A100-B149;	A100-B150;	A100-B151;	A100-B152;	A100-B153;
A100-B154;	A100-B155;	A100-B156;	A100-B157;	A100-B158;	A100-B159;
A100-B160;	A100-B161;	A100-B162;	A100-B163;	A100-B164;	A100-B165;
A100-B166;	A100-B167;	A100-B168;	A100-B169;	A101-B1;	A101-B2;
A101-B3;	A101-B4;	A101-B5;	A101-B6;	A101-B7;	A101-B8;
A101-B9;	A101-B10;	A101-B11;	A101-B12;	A101-B13;	A101-B14;
A101-B15;	A101-B16;	A101-B17;	A101-B18;	A101-B19;	A101-B20;
A101-B21;	A101-B22;	A101-B23;	A101-B24;	A101-B25;	A101-B26;
A101-B27;	A101-B28;	A101-B29;	A101-B30;	A101-B31;	A101-B32;
A101-B33;	A101-B34;	A101-B35;	A101-B36;	A101-B37;	A101-B38;
A101-B39;	A101-B40;	A101-B41;	A101-B42;	A101-B43;	A101-B44;
A101-B45;	A101-B46;	A101-B47;	A101-B48;	A101-B49;	A101-B50;
A101-B51;	A101-B52;	A101-B53;	A101-B54;	A101-B55;	A101-B56;
A101-B57;	A101-B58;	A101-B59;	A101-B60;	A101-B61;	A101-B62;
A101-B63;	A101-B64;	A101-B65;	A101-B66;	A101-B67;	A101-B68;
A101-B69;	A101-B70;	A101-B71;	A101-B72;	A101-B73;	A101-B74;
A101-B75;	A101-B76;	A101-B77;	A101-B78;	A101-B79;	A101-B80;
A101-B81;	A101-B82;	A101-B83;	A101-B84;	A101-B85;	A101-B86;
A101-B87;	A101-B88;	A101-B89;	A101-B90;	A101-B91;	A101-B92;
A101-B93;	A101-B94;	A101-B95;	A101-B96;	A101-B97;	A101-B98;
A101-B99;	A101-B100;	A101-B101;	A101-B102;	A101-B103;	A101-B104;
A101-B105;	A101-B106;	A101-B107;	A101-B108;	A101-B109;	A101-B110;
A101-B111;	A101-B112;	A101-B113;	A101-B114;	A101-B115;	A101-B116;
A101-B117;	A101-B118;	A101-B119;	A101-B120;	A101-B121;	A101-B122;
A101-B123;	A101-B124;	A101-B125;	A101-B126;	A101-B127;	A101-B128;
A101-B129;	A101-B130;	A101-B131;	A101-B132;	A101-B133;	A101-B134;
A101-B135;	A101-B136;	A101-B137;	A101-B138;	A101-B139;	A101-B140;
A101-B141;	A101-B142;	A101-B143;	A101-B144;	A101-B145;	A101-B146;
A101-B147;	A101-B148;	A101-B149;	A101-B150;	A101-B151;	A101-B152;
A101-B153;	A101-B154;	A101-B155;	A101-B156;	A101-B157;	A101-B158;
A101-B159;	A101-B160;	A101-B161;	A101-B162;	A101-B163;	A101-B164;
A101-B165;	A101-B166;	A101-B167;	A101-B168;	A101-B169;	A102-B1;
A102-B2;	A102-B3;	A102-B4;	A102-B5;	A102-B6;	A102-B7;
A102-B8;	A102-B9;	A102-B10;	A102-B11;	A102-B12;	A102-B13;
A102-B14;	A102-B15;	A102-B16;	A102-B17;	A102-B18;	A102-B19;
A102-B20;	A102-B21;	A102-B22;	A102-B23;	A102-B24;	A102-B25;
A102-B26;	A102-B27;	A102-B28;	A102-B29;	A102-B30;	A102-B31;
A102-B32;	A102-B33;	A102-B34;	A102-B35;	A102-B36;	A102-B37;
A102-B38;	A102-B39;	A102-B40;	A102-B41;	A102-B42;	A102-B43;
A102-B44;	A102-B45;	A102-B46;	A102-B47;	A102-B48;	A102-B49;
A102-B50;	A102-B51;	A102-B52;	A102-B53;	A102-B54;	A102-B55;
A102-B56;	A102-B57;	A102-B58;	A102-B59;	A102-B60;	A102-B61;
A102-B62;	A102-B63;	A102-B64;	A102-B65;	A102-B66;	A102-B67;
A102-B68;	A102-B69;	A102-B70;	A102-B71;	A102-B72;	A102-B73;
A102-B74;	A102-B75;	A102-B76;	A102-B77;	A102-B78;	A102-B79;
A102-B80;	A102-B81;	A102-B82;	A102-B83;	A102-B84;	A102-B85;
A102-B86;	A102-B87;	A102-B88;	A102-B89;	A102-B90;	A102-B91;
A102-B92;	A102-B93;	A102-B94;	A102-B95;	A102-B96;	A102-B97;
A102-B98;	A102-B99;	A102-B100;	A102-B101;	A102-B102;	A102-B103;
A102-B104;	A102-B105;	A102-B106;	A102-B107;	A102-B108;	A102-B109;
A102-B110;	A102-B111;	A102-B112;	A102-B113;	A102-B114;	A102-B115;
A102-B116;	A102-B117;	A102-B118;	A102-B119;	A102-B120;	A102-B121;
A102-B122;	A102-B123;	A102-B124;	A102-B125;	A102-B126;	A102-B127;
A102-B128;	A102-B129;	A102-B130;	A102-B131;	A102-B132;	A102-B133;
A102-B134;	A102-B135;	A102-B136;	A102-B137;	A102-B138;	A102-B139;
A102-B140;	A102-B141;	A102-B142;	A102-B143;	A102-B144;	A102-B145;
A102-B146;	A102-B147;	A102-B148;	A102-B149;	A102-B150;	A102-B151;
A102-B152;	A102-B153;	A102-B154;	A102-B155;	A102-B156;	A102-B157;
A102-B158;	A102-B159;	A102-B160;	A102-B161;	A102-B162;	A102-B163;
A102-B164;	A102-B165;	A102-B166;	A102-B167;	A102-B168;	A102-B169;
A103-B1;	A103-B2;	A103-B3;	A103-B4;	A103-B5;	A103-B6;
A103-B7;	A103-B8;	A103-B9;	A103-B10;	A103-B11;	A103-B12;
A103-B13;	A103-B14;	A103-B15;	A103-B16;	A103-B17;	A103-B18;
A103-B19;	A103-B20;	A103-B21;	A103-B22;	A103-B23;	A103-B24;
A103-B25;	A103-B26;	A103-B27;	A103-B28;	A103-B29;	A103-B30;
A103-B31;	A103-B32;	A103-B33;	A103-B34;	A103-B35;	A103-B36;
A103-B37;	A103-B38;	A103-B39;	A103-B40;	A103-B41;	A103-B42;
A103-B43;	A103-B44;	A103-B45;	A103-B46;	A103-B47;	A103-B48;
A103-B49;	A103-B50;	A103-B51;	A103-B52;	A103-B53;	A103-B54;
A103-B55;	A103-B56;	A103-B57;	A103-B58;	A103-B59;	A103-B60;
A103-B61;	A103-B62;	A103-B63;	A103-B64;	A103-B65;	A103-B66;
A103-B67;	A103-B68;	A103-B69;	A103-B70;	A103-B71;	A103-B72;
A103-B73;	A103-B74;	A103-B75;	A103-B76;	A103-B77;	A103-B78;
A103-B79;	A103-B80;	A103-B81;	A103-B82;	A103-B83;	A103-B84;
A103-B85;	A103-B86;	A103-B87;	A103-B88;	A103-B89;	A103-B90;
A103-B91;	A103-B92;	A103-B93;	A103-B94;	A103-B95;	A103-B96;
A103-B97;	A103-B98;	A103-B99;	A103-B100;	A103-B101;	A103-B102;
A103-B103;	A103-B104;	A103-B105;	A103-B106;	A103-B107;	A103-B108;
A103-B109;	A103-B110;	A103-B111;	A103-B112;	A103-B113;	A103-B114;
A103-B115;	A103-B116;	A103-B117;	A103-B118;	A103-B119;	A103-B120;
A103-B121;	A103-B122;	A103-B123;	A103-B124;	A103-B125;	A103-B126;
A103-B127;	A103-B128;	A103-B129;	A103-B130;	A103-B131;	A103-B132;
A103-B133;	A103-B134;	A103-B135;	A103-B136;	A103-B137;	A103-B138;
A103-B139;	A103-B140;	A103-B141;	A103-B142;	A103-B143;	A103-B144;
A103-B145;	A103-B146;	A103-B147;	A103-B148;	A103-B149;	A103-B150;
A103-B151;	A103-B152;	A103-B153;	A103-B154;	A103-B155;	A103-B156;
A103-B157;	A103-B158;	A103-B159;	A103-B160;	A103-B161;	A103-B162;
A103-B163;	A103-B164;	A103-B165;	A103-B166;	A103-B167;	A103-B168;
A103-B169;	A104-B1;	A104-B2;	A104-B3;	A104-B4;	A104-B5;
A104-B6;	A104-B7;	A104-B8;	A104-B9;	A104-B10;	A104-B11;
A104-B12;	A104-B13;	A104-B14;	A104-B15;	A104-B16;	A104-B17;
A104-B18;	A104-B19;	A104-B20;	A104-B21;	A104-B22;	A104-B23;
A104-B24;	A104-B25;	A104-B26;	A104-B27;	A104-B28;	A104-B29;
A104-B30;	A104-B31;	A104-B32;	A104-B33;	A104-B34;	A104-B35;
A104-B36;	A104-B37;	A104-B38;	A104-B39;	A104-B40;	A104-B41;
A104-B42;	A104-B43;	A104-B44;	A104-B45;	A104-B46;	A104-B47;
A104-B48;	A104-B49;	A104-B50;	A104-B51;	A104-B52;	A104-B53;
A104-B54;	A104-B55;	A104-B56;	A104-B57;	A104-B58;	A104-B59;
A104-B60;	A104-B61;	A104-B62;	A104-B63;	A104-B64;	A104-B65;
A104-B66;	A104-B67;	A104-B68;	A104-B69;	A104-B70;	A104-B71;
A104-B72;	A104-B73;	A104-B74;	A104-B75;	A104-B76;	A104-B77;
A104-B78;	A104-B79;	A104-B80;	A104-B81;	A104-B82;	A104-B83;
A104-B84;	A104-B85;	A104-B86;	A104-B87;	A104-B88;	A104-B89;
A104-B90;	A104-B91;	A104-B92;	A104-B93;	A104-B94;	A104-B95;
A104-B96;	A104-B97;	A104-B98;	A104-B99;	A104-B100;	A104-B101;
A104-B102;	A104-B103;	A104-B104;	A104-B105;	A104-B106;	A104-B107;
A104-B108;	A104-B109;	A104-B110;	A104-B111;	A104-B112;	A104-B113;
A104-B114;	A104-B115;	A104-B116;	A104-B117;	A104-B118;	A104-B119;
A104-B120;	A104-B121;	A104-B122;	A104-B123;	A104-B124;	A104-B125;
A104-B126;	A104-B127;	A104-B128;	A104-B129;	A104-B130;	A104-B131;
A104-B132;	A104-B133;	A104-B134;	A104-B135;	A104-B136;	A104-B137;
A104-B138;	A104-B139;	A104-B140;	A104-B141;	A104-B142;	A104-B143;
A104-B144;	A104-B145;	A104-B146;	A104-B147;	A104-B148;	A104-B149;
A104-B150;	A104-B151;	A104-B152;	A104-B153;	A104-B154;	A104-B155;
A104-B156;	A104-B157;	A104-B158;	A104-B159;	A104-B160;	A104-B161;
A104-B162;	A104-B163;	A104-B164;	A104-B165;	A104-B166;	A104-B167;
A104-B168;	A104-B169;	A105-B1;	A105-B2;	A105-B3;	A105-B4;
A105-B5;	A105-B6;	A105-B7;	A105-B8;	A105-B9;	A105-B10;
A105-B11;	A105-B12;	A105-B13;	A105-B14;	A105-B15;	A105-B16;
A105-B17;	A105-B18;	A105-B19;	A105-B20;	A105-B21;	A105-B22;
A105-B23;	A105-B24;	A105-B25;	A105-B26;	A105-B27;	A105-B28;
A105-B29;	A105-B30;	A105-B31;	A105-B32;	A105-B33;	A105-B34;
A105-B35;	A105-B36;	A105-B37;	A105-B38;	A105-B39;	A105-B40;
A105-B41;	A105-B42;	A105-B43;	A105-B44;	A105-B45;	A105-B46;
A105-B47;	A105-B48;	A105-B49;	A105-B50;	A105-B51;	A105-B52;
A105-B53;	A105-B54;	A105-B55;	A105-B56;	A105-B57;	A105-B58;
A105-B59;	A105-B60;	A105-B61;	A105-B62;	A105-B63;	A105-B64;
A105-B65;	A105-B66;	A105-B67;	A105-B68;	A105-B69;	A105-B70;
A105-B71;	A105-B72;	A105-B73;	A105-B74;	A105-B75;	A105-B76;
A105-B77;	A105-B78;	A105-B79;	A105-B80;	A105-B81;	A105-B82;
A105-B83;	A105-B84;	A105-B85;	A105-B86;	A105-B87;	A105-B88;
A105-B89;	A105-B90;	A105-B91;	A105-B92;	A105-B93;	A105-B94;
A105-B95;	A105-B96;	A105-B97;	A105-B98;	A105-B99;	A105-B100;
A105-B101;	A105-B102;	A105-B103;	A105-B104;	A105-B105;	A105-B106;
A105-B107;	A105-B108;	A105-B109;	A105-B110;	A105-B111;	A105-B112;
A105-B113;	A105-B114;	A105-B115;	A105-B116;	A105-B117;	A105-B118;
A105-B119;	A105-B120;	A105-B121;	A105-B122;	A105-B123;	A105-B124;
A105-B125;	A105-B126;	A105-B127;	A105-B128;	A105-B129;	A105-B130;
A105-B131;	A105-B132;	A105-B133;	A105-B134;	A105-B135;	A105-B136;
A105-B137;	A105-B138;	A105-B139;	A105-B140;	A105-B141;	A105-B142;
A105-B143;	A105-B144;	A105-B145;	A105-B146;	A105-B147;	A105-B148;
A105-B149;	A105-B150;	A105-B151;	A105-B152;	A105-B153;	A105-B154;
A105-B155;	A105-B156;	A105-B157;	A105-B158;	A105-B159;	A105-B160;
A105-B161;	A105-B162;	A105-B163;	A105-B164;	A105-B165;	A105-B166;
A105-B167;	A105-B168;	A105-B169;	A106-B1;	A106-B2;	A106-B3;
A106-B4;	A106-B5;	A106-B6;	A106-B7;	A106-B8;	A106-B9;
A106-B10;	A106-B11;	A106-B12;	A106-B13;	A106-B14;	A106-B15;
A106-B16;	A106-B17;	A106-B18;	A106-B19;	A106-B20;	A106-B21;
A106-B22;	A106-B23;	A106-B24;	A106-B25;	A106-B26;	A106-B27;
A106-B28;	A106-B29;	A106-B30;	A106-B31;	A106-B32;	A106-B33;
A106-B34;	A106-B35;	A106-B36;	A106-B37;	A106-B38;	A106-B39;
A106-B40;	A106-B41;	A106-B42;	A106-B43;	A106-B44;	A106-B45;
A106-B46;	A106-B47;	A106-B48;	A106-B49;	A106-B50;	A106-B51;
A106-B52;	A106-B53;	A106-B54;	A106-B55;	A106-B56;	A106-B57;
A106-B58;	A106-B59;	A106-B60;	A106-B61;	A106-B62;	A106-B63;
A106-B64;	A106-B65;	A106-B66;	A106-B67;	A106-B68;	A106-B69;
A106-B70;	A106-B71;	A106-B72;	A106-B73;	A106-B74;	A106-B75;
A106-B76;	A106-B77;	A106-B78;	A106-B79;	A106-B80;	A106-B81;
A106-B82;	A106-B83;	A106-B84;	A106-B85;	A106-B86;	A106-B87;
A106-B88;	A106-B89;	A106-B90;	A106-B91;	A106-B92;	A106-B93;
A106-B94;	A106-B95;	A106-B96;	A106-B97;	A106-B98;	A106-B99;
A106-B100;	A106-B101;	A106-B102;	A106-B103;	A106-B104;	A106-B105;
A106-B106;	A106-B107;	A106-B108;	A106-B109;	A106-B110;	A106-B111;
A106-B112;	A106-B113;	A106-B114;	A106-B115;	A106-B116;	A106-B117;
A106-B118;	A106-B119;	A106-B120;	A106-B121;	A106-B122;	A106-B123;
A106-B124;	A106-B125;	A106-B126;	A106-B127;	A106-B128;	A106-B129;
A106-B130;	A106-B131;	A106-B132;	A106-B133;	A106-B134;	A106-B135;
A106-B136;	A106-B137;	A106-B138;	A106-B139;	A106-B140;	A106-B141;
A106-B142;	A106-B143;	A106-B144;	A106-B145;	A106-B146;	A106-B147;
A106-B148;	A106-B149;	A106-B150;	A106-B151;	A106-B152;	A106-B153;
A106-B154;	A106-B155;	A106-B156;	A106-B157;	A106-B158;	A106-B159;
A106-B160;	A106-B161;	A106-B162;	A106-B163;	A106-B164;	A106-B165;
A106-B166;	A106-B167;	A106-B168;	A106-B169;	A107-B1;	A107-B2;
A107-B3;	A107-B4;	A107-B5;	A107-B6;	A107-B7;	A107-B8;
A107-B9;	A107-B10;	A107-B11;	A107-B12;	A107-B13;	A107-B14;
A107-B15;	A107-B16;	A107-B17;	A107-B18;	A107-B19;	A107-B20;
A107-B21;	A107-B22;	A107-B23;	A107-B24;	A107-B25;	A107-B26;
A107-B27;	A107-B28;	A107-B29;	A107-B30;	A107-B31;	A107-B32;
A107-B33;	A107-B34;	A107-B35;	A107-B36;	A107-B37;	A107-B38;
A107-B39;	A107-B40;	A107-B41;	A107-B42;	A107-B43;	A107-B44;
A107-B45;	A107-B46;	A107-B47;	A107-B48;	A107-B49;	A107-B50;
A107-B51;	A107-B52;	A107-B53;	A107-B54;	A107-B55;	A107-B56;
A107-B57;	A107-B58;	A107-B59;	A107-B60;	A107-B61;	A107-B62;
A107-B63;	A107-B64;	A107-B65;	A107-B66;	A107-B67;	A107-B68;
A107-B69;	A107-B70;	A107-B71;	A107-B72;	A107-B73;	A107-B74;
A107-B75;	A107-B76;	A107-B77;	A107-B78;	A107-B79;	A107-B80;
A107-B81;	A107-B82;	A107-B83;	A107-B84;	A107-B85;	A107-B86;
A107-B87;	A107-B88;	A107-B89;	A107-B90;	A107-B91;	A107-B92;
A107-B93;	A107-B94;	A107-B95;	A107-B96;	A107-B97;	A107-B98;
A107-B99;	A107-B100;	A107-B101;	A107-B102;	A107-B103;	A107-B104;
A107-B105;	A107-B106;	A107-B107;	A107-B108;	A107-B109;	A107-B110;
A107-B111;	A107-B112;	A107-B113;	A107-B114;	A107-B115;	A107-B116;
A107-B117;	A107-B118;	A107-B119;	A107-B120;	A107-B121;	A107-B122;
A107-B123;	A107-B124;	A107-B125;	A107-B126;	A107-B127;	A107-B128;
A107-B129;	A107-B130;	A107-B131;	A107-B132;	A107-B133;	A107-B134;
A107-B135;	A107-B136;	A107-B137;	A107-B138;	A107-B139;	A107-B140;
A107-B141;	A107-B142;	A107-B143;	A107-B144;	A107-B145;	A107-B146;
A107-B147;	A107-B148;	A107-B149;	A107-B150;	A107-B151;	A107-B152;
A107-B153;	A107-B154;	A107-B155;	A107-B156;	A107-B157;	A107-B158;
A107-B159;	A107-B160;	A107-B161;	A107-B162;	A107-B163;	A107-B164;
A107-B165;	A107-B166;	A107-B167;	A107-B168;	A107-B169;	A108-B1;
A108-B2;	A108-B3;	A108-B4;	A108-B5;	A108-B6;	A108-B7;
A108-B8;	A108-B9;	A108-B10;	A108-B11;	A108-B12;	A108-B13;
A108-B14;	A108-B15;	A108-B16;	A108-B17;	A108-B18;	A108-B19;
A108-B20;	A108-B21;	A108-B22;	A108-B23;	A108-B24;	A108-B25;
A108-B26;	A108-B27;	A108-B28;	A108-B29;	A108-B30;	A108-B31;
A108-B32;	A108-B33;	A108-B34;	A108-B35;	A108-B36;	A108-B37;
A108-B38;	A108-B39;	A108-B40;	A108-B41;	A108-B42;	A108-B43;
A108-B44;	A108-B45;	A108-B46;	A108-B47;	A108-B48;	A108-B49;
A108-B50;	A108-B51;	A108-B52;	A108-B53;	A108-B54;	A108-B55;
A108-B56;	A108-B57;	A108-B58;	A108-B59;	A108-B60;	A108-B61;
A108-B62;	A108-B63;	A108-B64;	A108-B65;	A108-B66;	A108-B67;
A108-B68;	A108-B69;	A108-B70;	A108-B71;	A108-B72;	A108-B73;
A108-B74;	A108-B75;	A108-B76;	A108-B77;	A108-B78;	A108-B79;
A108-B80;	A108-B81;	A108-B82;	A108-B83;	A108-B84;	A108-B85;
A108-B86;	A108-B87;	A108-B88;	A108-B89;	A108-B90;	A108-B91;
A108-B92;	A108-B93;	A108-B94;	A108-B95;	A108-B96;	A108-B97;
A108-B98;	A108-B99;	A108-B100;	A108-B101;	A108-B102;	A108-B103;
A108-B104;	A108-B105;	A108-B106;	A108-B107;	A108-B108;	A108-B109;
A108-B110;	A108-B111;	A108-B112;	A108-B113;	A108-B114;	A108-B115;
A108-B116;	A108-B117;	A108-B118;	A108-B119;	A108-B120;	A108-B121;
A108-B122;	A108-B123;	A108-B124;	A108-B125;	A108-B126;	A108-B127;
A108-B128;	A108-B129;	A108-B130;	A108-B131;	A108-B132;	A108-B133;
A108-B134;	A108-B135;	A108-B136;	A108-B137;	A108-B138;	A108-B139;
A108-B140;	A108-B141;	A108-B142;	A108-B143;	A108-B144;	A108-B145;
A108-B146;	A108-B147;	A108-B148;	A108-B149;	A108-B150;	A108-B151;
A108-B152;	A108-B153;	A108-B154;	A108-B155;	A108-B156;	A108-B157;
A108-B158;	A108-B159;	A108-B160;	A108-B161;	A108-B162;	A108-B163;
A108-B164;	A108-B165;	A108-B166;	A108-B167;	A108-B168;	A108-B169;
A109-B1;	A109-B2;	A109-B3;	A109-B4;	A109-B5;	A109-B6;
A109-B7;	A109-B8;	A109-B9;	A109-B10;	A109-B11;	A109-B12;
A109-B13;	A109-B14;	A109-B15;	A109-B16;	A109-B17;	A109-B18;
A109-B19;	A109-B20;	A109-B21;	A109-B22;	A109-B23;	A109-B24;
A109-B25;	A109-B26;	A109-B27;	A109-B28;	A109-B29;	A109-B30;
A109-B31;	A109-B32;	A109-B33;	A109-B34;	A109-B35;	A109-B36;
A109-B37;	A109-B38;	A109-B39;	A109-B40;	A109-B41;	A109-B42;
A109-B43;	A109-B44;	A109-B45;	A109-B46;	A109-B47;	A109-B48;
A109-B49;	A109-B50;	A109-B51;	A109-B52;	A109-B53;	A109-B54;
A109-B55;	A109-B56;	A109-B57;	A109-B58;	A109-B59;	A109-B60;
A109-B61;	A109-B62;	A109-B63;	A109-B64;	A109-B65;	A109-B66;
A109-B67;	A109-B68;	A109-B69;	A109-B70;	A109-B71;	A109-B72;
A109-B73;	A109-B74;	A109-B75;	A109-B76;	A109-B77;	A109-B78;
A109-B79;	A109-B80;	A109-B81;	A109-B82;	A109-B83;	A109-B84;
A109-B85;	A109-B86;	A109-B87;	A109-B88;	A109-B89;	A109-B90;
A109-B91;	A109-B92;	A109-B93;	A109-B94;	A109-B95;	A109-B96;
A109-B97;	A109-B98;	A109-B99;	A109-B100;	A109-B101;	A109-B102;
A109-B103;	A109-B104;	A109-B105;	A109-B106;	A109-B107;	A109-B108;
A109-B109;	A109-B110;	A109-B111;	A109-B112;	A109-B113;	A109-B114;
A109-B115;	A109-B116;	A109-B117;	A109-B118;	A109-B119;	A109-B120;
A109-B121;	A109-B122;	A109-B123;	A109-B124;	A109-B125;	A109-B126;
A109-B127;	A109-B128;	A109-B129;	A109-B130;	A109-B131;	A109-B132;
A109-B133;	A109-B134;	A109-B135;	A109-B136;	A109-B137;	A109-B138;
A109-B139;	A109-B140;	A109-B141;	A109-B142;	A109-B143;	A109-B144;
A109-B145;	A109-B146;	A109-B147;	A109-B148;	A109-B149;	A109-B150;
A109-B151;	A109-B152;	A109-B153;	A109-B154;	A109-B155;	A109-B156;
A109-B157;	A109-B158;	A109-B159;	A109-B160;	A109-B161;	A109-B162;
A109-B163;	A109-B164;	A109-B165;	A109-B166;	A109-B167;	A109-B168;
A109-B169;	A110-B1;	A110-B2;	A110-B3;	A110-B4;	A110-B5;
A110-B6;	A110-B7;	A110-B8;	A110-B9;	A110-B10;	A110-B11;
A110-B12;	A110-B13;	A110-B14;	A110-B15;	A110-B16;	A110-B17;
A110-B18;	A110-B19;	A110-B20;	A110-B21;	A110-B22;	A110-B23;
A110-B24;	A110-B25;	A110-B26;	A110-B27;	A110-B28;	A110-B29;
A110-B30;	A110-B31;	A110-B32;	A110-B33;	A110-B34;	A110-B35;
A110-B36;	A110-B37;	A110-B38;	A110-B39;	A110-B40;	A110-B41;
A110-B42;	A110-B43;	A110-B44;	A110-B45;	A110-B46;	A110-B47;
A110-B48;	A110-B49;	A110-B50;	A110-B51;	A110-B52;	A110-B53;
A110-B54;	A110-B55;	A110-B56;	A110-B57;	A110-B58;	A110-B59;
A110-B60;	A110-B61;	A110-B62;	A110-B63;	A110-B64;	A110-B65;
A110-B66;	A110-B67;	A110-B68;	A110-B69;	A110-B70;	A110-B71;
A110-B72;	A110-B73;	A110-B74;	A110-B75;	A110-B76;	A110-B77;
A110-B78;	A110-B79;	A110-B80;	A110-B81;	A110-B82;	A110-B83;
A110-B84;	A110-B85;	A110-B86;	A110-B87;	A110-B88;	A110-B89;
A110-B90;	A110-B91;	A110-B92;	A110-B93;	A110-B94;	A110-B95;
A110-B96;	A110-B97;	A110-B98;	A110-B99;	A110-B100;	A110-B101;
A110-B102;	A110-B103;	A110-B104;	A110-B105;	A110-B106;	A110-B107;
A110-B108;	A110-B109;	A110-B110;	A110-B111;	A110-B112;	A110-B113;
A110-B114;	A110-B115;	A110-B116;	A110-B117;	A110-B118;	A110-B119;
A110-B120;	A110-B121;	A110-B122;	A110-B123;	A110-B124;	A110-B125;
A110-B126;	A110-B127;	A110-B128;	A110-B129;	A110-B130;	A110-B131;
A110-B132;	A110-B133;	A110-B134;	A110-B135;	A110-B136;	A110-B137;
A110-B138;	A110-B139;	A110-B140;	A110-B141;	A110-B142;	A110-B143;
A110-B144;	A110-B145;	A110-B146;	A110-B147;	A110-B148;	A110-B149;
A110-B150;	A110-B151;	A110-B152;	A110-B153;	A110-B154;	A110-B155;
A110-B156;	A110-B157;	A110-B158;	A110-B159;	A110-B160;	A110-B161;
A110-B162;	A110-B163;	A110-B164;	A110-B165;	A110-B166;	A110-B167;
A110-B168;	A110-B169.

TABLE 3

Ex-					MS
ample			Molecular		Characteristic	time
number	STRUCTURE	RNH 2 or RB(OH) 2	Formula	MW	Method	(minutes)	Nomenclature
28

TABLE 4 — CHEMISTRY

181	2-[5-(benzyloxy)-2H- pyrazol-3-yl]-1H- benzoimidazole
182	2-[5-(3-Phenyl-allyloxy)- 2H-pyrazol-3-yl]-1H- benzoimidazole
183	2-[5-(2-Methyl-allyloxy)- 2H-pyrazol-3-yl]-1H- benzoimidazole
184	2-[5-(3,7-Dimethyl-octa- 2,6-dienyloxy)-2H- pyrazol-3-yl]-1H- benzoimidazole
185	2-[5-(3-Bromo- benzyloxy)-2H-pyrazol-3 yl]-1H-benzoimidazole
186	3-[5-(1H-Benzoimidazol 2-yl)-1H-pyrazol-3- yloxymethyl]-benzonitrile-
187	2-[5-(4-Trifluoromethyl- benzyloxy)-2H-pyrazol-3- yl]-1H-benzoimidazole
188	2-[5-(3,4-Dichloro- benzyloxy)-2H-pyrazol-3- yl]-1H-benzoimidazole
189	2-(5- Pentafluorophenylmethoxy- 2H-pyrazol-3-yl)-1H- benzoimidazole
190	2-[5-(4-tert-Butyl- benzyloxy)-2H-pyrazol-3 yl]-1H-benzoimidazole
191	2-[5-(2- Benzenesulfonylmethyl- benzyloxy)-2H-pyrazol-3 yl]-1H-benzoimidazole
192	4-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3- yloxymethyl]-benzonitrile
193	2-[5-(Biphenyl-4- ylmethoxy)-2H-pyrazol-3 yl]-1H-benzoimidazole
194	2,3-Dichloro- benzenesulfonic acid 5- (1H-benzoimidazol-2-yl)- 1H-pyrazol-3-yl ester
195	2-[5-(2-Morpholin-4-yl- ethoxy)-2H-pyrazol-3-yl] 1H-benzoimidazole
196	2-[5-(2-Piperidin-1 -yl- ethoxy)-2H-pyrazol-3-yl] 1H-benzoimidazole
197	2-[5-(3-Methoxy- benzyloxy)-2H-pyrazol-3 yl]-1H-benzoimidazole
198	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1 -p-tolyl-ethanone
199	1-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 3,3,4,4,4-pentafluoro- butan-2-one
200	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1-biphenyl-4-yl- ethanone
201	1-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] butan-2-one
202	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1-(4-dimethylamino- phenyl)-ethanone
203	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1-(3-phenyl-isoxazol-5- yl)-ethanone
204	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] N-phenyl-acetamide
205	1-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 3,3-dimethyl-butan-2- one
206	1-Adamantan-1-yl-2-[5- (1H-benzoimidazol-2-yl)- 1H-pyrazol-3-yloxy]- ethanone
207	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1-naphthalen-2-yl- ethanone
208	4-{2-[5-(1H- Benzoimidazol-2-yl)-1H- pyrazol-3-yloxy]-acetyl}- benzonitrile
209	6-{2-[5-(1H- Benzoimidazol-2-yl)-1H- pyrazol-3-yloxy]-acetyl}- 3,4-dihydro-1H-quinolin- 2-one
210	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1-(4-trifluoromethoxy- phenyl)-ethanone
211	5-{2-[5-(1H- Benzoimidazol-2-yl)-1H- pyrazol-3-yloxy]- acetyl}-2-chloro benzenesulfonamide
212	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1-(4-methoxy-phenyl)- ethanone
213	2-[5-(1H-Benzoimidazol- 2-yl)-1H-pyrazol-3-yloxy] 1-cyclopropyl-ethanone
214	Isonicotinic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
215	2,2-Dimethyl-propionic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
216	Benzyloxy-acetic acid 5- (1H-benzoimidazol-2-yl)- 1H-pyrazol-3-yl ester
217	Benzoic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
218	4-Methoxy-benzoic acid 5-(1H-benzoimidazol-2- yl)-1H-pyrazol-3-yl ester
219	Phenyl-acetic acid 5-(1H benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
220	2,3,4,5,6-Pentafluoro- benzoic acid 5-(1H benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
221	Cyclopropanecarboxylic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
222	2,2,3,3,4,4,4- Heptafluoro-butyric acid 5-(1H-benzoimidazol-2- yl)-1H-pyrazol-3-yl ester
223	Cyclopentanecarboxylic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
224	3-Phenyl-propionic acid 5-(1H-benzoimidazol-2- yl)-1H-pyrazol-3-yl ester
225	Biphenyl-4-carboxylic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
226	3,5-Bis-trifluoromethyl- benzoic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
227	4-Trifluoromethyl- benzoic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester
228	Thiophene-2-carboxylic acid 5-(1H- benzoimidazol-2-yl)-1H- pyrazol-3-yl ester

TABLE 5

	IC 50 (μM) on	% of inhibition of the
	inhibition of the	phosphorylation of PLCγ by
Example	phosphorylation of	KDR (product tested at a
No.	PLCγ by KDR	concentration of 10 μM)
14	1.2
15	0.8
16	2
20	3.4
21	—	35
1	0.47
2	0.45
3	—	91.8
4	0.45
5	—	91.9
6	0.33
7	0.72
8	0.67
9	0.35
10	0.34
11	0.26
12	0.16
13	0.61
18	—	91.2
23	2

description truncated at 500,000 characters. 19 of 121 part labels are ours — the grant heads the rest

Stored text is truncated at the source; the tail of the description is not held.

Claims as granted

18 claims

Classifications

16 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/4184

Section C — Chemistry; metallurgy

C07D401/14
C07D235/18
C07D413/04
C07D405/14
C07D491/04
C07D413/14
C07D409/14
C07D521/00
C07D403/04
C07D403/14
C07D471/04
C07D487/04

USPC · US Patent Classification

514/397548/304.7548/305.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

7.8 y

2,842 days filing → grant

Office actions

after a restriction

Responses

2 RCE

Examiner

Shawquia Young

art unit 1626 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 47 back · 114 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.